

EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer

N. Mottet (Chair), R.C.N. van den Bergh,
E. Briers (Patient Representative), P. Cornford (Vice-chair),
M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry,
T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel,
O. Rouvière, D. Tilki, T. Wiegel
Guidelines Associates: T. Van den Broeck, M. Cumberbatch,
N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots,
P-P.M. Willemse



European
Association
of Urology



European Society
of Urogenital Radiology



ESTRO
European Society for
RADIOTHERAPY
& ONCOLOGY



BIOMEDICAL
IMAGING AND
THERAPY FOR
PERSONALIZED
HEALTHCARE



INTERNATIONAL SOCIETY
OF GERIATRIC ONCOLOGY

TABLE OF CONTENTS

PAGE

1.	INTRODUCTION	9
1.1	Aims and scope	9
1.2	Panel composition	9
1.2.1	Acknowledgement	9
1.3	Available publications	9
1.4	Publication history and summary of changes	9
1.4.1	Publication history	9
1.4.2	Summary of changes	9
2.	METHODS	12
2.1	Data identification	12
2.2	Review	13
2.3	Future goals	13
3.	EPIDEMIOLOGY AND AETIOLOGY	13
3.1	Epidemiology	13
3.2	Aetiology	14
3.2.1	Family history / genetics	14
3.2.2	Risk factors	14
3.2.2.1	Metabolic syndrome	14
3.2.2.1.1	Diabetes/metformin	14
3.2.2.1.2	Cholesterol/statins	14
3.2.2.1.3	Obesity	14
3.2.2.2	Dietary factors	14
3.2.2.3	Hormonally active medication	15
3.2.2.3.1	5-alpha-reductase inhibitors	15
3.2.2.3.2	Testosterone	15
3.2.2.4	Other potential risk factors	15
3.2.3	Summary of evidence and guidelines for epidemiology and aetiology	16
4.	CLASSIFICATION AND STAGING SYSTEMS	16
4.1	Classification	16
4.2	Gleason score and International Society of Urological Pathology 2014 grade	17
4.3	Prognostic relevance of stratification	17
5.	DIAGNOSTIC EVALUATION	18
5.1	Screening and early detection	18
5.1.1	Screening	18
5.1.2	Early detection	19
5.1.3	Guidelines for screening and early detection	20
5.2	Clinical diagnosis	20
5.2.1	Digital rectal examination	20
5.2.2	Prostate-specific antigen	20
5.2.2.1	PSA density	20
5.2.2.2	PSA velocity and doubling time	21
5.2.2.3	Free/total PSA ratio	21
5.2.2.4	Additional serum testing	21
5.2.2.5	Urine tests: PCA3 marker/SelectMDX/Mi Prostate score (MiPS)/ExoDX	21
5.2.2.6	Guidelines for risk-assessment of asymptomatic men	22
5.2.3	Baseline biopsy	22
5.2.4	The role of imaging in clinical diagnosis	22
5.2.4.1	Transrectal ultrasound (TRUS) and ultrasound-based techniques	22
5.2.4.2	Multiparametric magnetic resonance imaging (mpMRI)	22
5.2.4.2.1	mpMRI performance in detecting ISUP grade > 2 PCa	22
5.2.4.2.2	mpMRI performance in detecting ISUP grade group 1 PCa	22
5.2.4.2.3	Does MRI-TBx improve the detection of ISUP grade > 2 as compared to systematic biopsy?	23

	5.2.4.2.4	Does MRI-TBx reduce the detection of ISUP grade 1 PCa as compared to systematic biopsy?	23
	5.2.4.2.5	The added value of systematic and targeted biopsy	23
	5.2.4.2.6	Number of biopsy procedures potentially avoided in the 'MR pathway'	24
	5.2.4.2.7	Other considerations	24
	5.2.4.2.7.1	mpMRI reproducibility	24
	5.2.4.2.7.2	Targeted biopsy accuracy and reproducibility	24
	5.2.4.2.7.3	Role of risk-stratification	25
	5.2.4.3	Summary of evidence and practical considerations on pre-biopsy mpMRI	25
	5.2.4.4	Summary of evidence and guidelines for imaging	25
5.2.5	Repeat biopsy		26
	5.2.5.1	Repeat biopsy after previously negative biopsy	26
	5.2.5.1.1	Tests to select men for a repeat biopsy	26
	5.2.5.2	Saturation biopsy	26
5.2.6	Prostate biopsy procedure		27
	5.2.6.1	Sampling sites and number of cores	27
	5.2.6.2	Antibiotics prior to biopsy	27
	5.2.6.3	Local anaesthesia prior to biopsy	27
	5.2.6.4	Complications	27
	5.2.6.5	Seminal vesicle biopsy	27
	5.2.6.6	Transition zone biopsy	27
	5.2.6.7	Fine-needle aspiration biopsy	28
5.2.7	Pathology of prostate needle biopsies		28
	5.2.7.1	Processing	28
	5.2.7.2	Microscopy and reporting	28
	5.2.7.3	Tissue-based prognostic biomarker testing	29
	5.2.7.4	Histopathology of radical prostatectomy specimens	29
	5.2.7.4.1	Processing of radical prostatectomy specimens	29
	5.2.7.4.1.1	Guidelines for processing prostatectomy specimens	29
	5.2.7.4.2	Radical prostatectomy specimen report	29
	5.2.7.4.3	ISUP grade in prostatectomy specimens	30
	5.2.7.4.4	Definition of extraprostatic extension	30
	5.2.7.4.5	PCa volume	31
	5.2.7.4.6	Surgical margin status	31
	5.2.8	Guidelines for the clinical diagnosis of prostate cancer	31
5.3	Diagnosis – Clinical Staging		31
	5.3.1	T-staging	31
	5.3.1.1	TRUS	31
	5.3.1.2	mpMRI	32
	5.3.2	N-staging	32
	5.3.2.1	Computed tomography (CT) and magnetic resonance imaging	32
	5.3.2.2	Choline PET/CT	32
	5.3.2.3	Prostate-specific membrane antigen-based PET/CT	32
	5.3.3	M-staging	33
	5.3.3.1	Bone scan	33
	5.3.3.2	Fluoride PET and PET/CT, choline PET/CT and MRI	33
	5.3.3.3	Prostate-specific membrane antigen-based PET/CT	33
	5.3.4	Summary of evidence and practical considerations on initial N/M staging	34
	5.3.5	Guidelines for staging of prostate cancer	34
5.4	Evaluating life expectancy and health status		34
	5.4.1	Introduction	34
	5.4.2	Life expectancy	34
	5.4.3	Health status screening	35
	5.4.3.1	Comorbidity	35
	5.4.3.2	Nutritional status	35
	5.4.3.3	Cognitive function	35
	5.4.3.4	Physical function	35

5.4.4	Conclusion	36
5.4.5	Guidelines for evaluating health status and life expectancy	38
6.	TREATMENT	38
6.1	Treatment modalities	38
6.1.1	Deferred treatment (active surveillance/watchful waiting)	38
6.1.1.1	Definitions	38
6.1.1.2	Active surveillance	39
6.1.1.3	Watchful Waiting	39
6.1.1.3.1	Introduction	39
6.1.1.3.2	Outcome of watchful waiting compared with active treatment	39
6.1.1.4	The ProtecT study	40
6.1.2	Radical prostatectomy	40
6.1.2.1	Surgical techniques	41
6.1.2.1.1	Pelvic lymph node dissection	41
6.1.2.1.2	Sentinel node biopsy analysis	41
6.1.2.1.3	Nerve-sparing surgery	41
6.1.2.1.4	Neoadjuvant androgen deprivation therapy	41
6.1.2.1.5	Lymph-node-positive patients during radical prostatectomy	42
6.1.2.2	Comparing effectiveness of radical prostatectomy vs. other interventions for localised disease	42
6.1.2.2.1	Radical prostatectomy vs. deferred treatment	42
6.1.2.2.2	Radical prostatectomy vs. radiotherapy	42
6.1.2.3	Acute complications of surgery	42
6.1.2.3.1	Early complications of extended lymph node dissection	43
6.1.3	Radiotherapy	43
6.1.3.1	External Beam Radiation Therapy:	43
6.1.3.1.1	Technical aspects: intensity-modulated external-beam radiotherapy and volumetric arc external-beam radiotherapy	43
6.1.3.1.2	Dose escalation	43
6.1.3.1.3	Hypofractionation	44
6.1.3.1.4	Neoadjuvant or adjuvant hormone therapy plus radiotherapy	46
6.1.3.1.5	Combined dose-escalated radiotherapy and androgen-deprivation therapy	47
6.1.3.2	Proton beam therapy	48
6.1.3.3	Brachytherapy	48
6.1.3.3.1	Low-dose rate brachytherapy	48
6.1.3.3.2	High-dose rate brachytherapy	48
6.1.3.4	Acute side-effects of external beam radiotherapy and brachytherapy	49
6.1.4	Hormonal therapy	49
6.1.4.1	Introduction	49
6.1.4.1.1	Different types of hormonal therapy	49
6.1.4.1.1.1	Testosterone-lowering therapy (castration)	49
6.1.4.1.1.1.1	Castration level	49
6.1.4.1.1.1.2	Bilateral orchiectomy	49
6.1.4.1.1.2	Oestrogens	49
6.1.4.1.1.3	Luteinising-hormone-releasing hormone agonists	50
6.1.4.1.1.4	Luteinising-hormone-releasing hormone antagonists	50
6.1.4.1.1.5	Anti-androgens	50
6.1.4.1.1.5.1	Steroidal anti-androgens	50
6.1.4.1.1.5.1.1	Cyproterone acetate	50
6.1.4.1.1.5.2	Non-steroidal anti-androgens	50
6.1.4.1.1.5.2.1	Nilutamide	51
6.1.4.1.1.5.2.2	Flutamide	51
6.1.4.1.1.5.2.3	Bicalutamide	51

	6.1.4.1.1.6	New compounds	51
	6.1.4.1.1.6.1	Abiraterone acetate	51
	6.1.4.1.1.6.2	Enzalutamide	51
	6.1.4.1.1.6.3	Apalutamide	51
6.1.5		Investigational therapies	51
	6.1.5.1	Background	51
	6.1.5.2	Cryotherapy	51
	6.1.5.3	High-intensity focused ultrasound	52
	6.1.5.4	Focal therapy	52
6.1.6		General guidelines for active treatment	53
6.1.7		Discussing treatment options	53
6.2		Treatment by disease stages	53
	6.2.1	Treatment of low-risk disease	53
	6.2.1.1	Active surveillance	53
	6.2.1.1.1	Selection criteria for active surveillance based on clinical and pathological variables	53
	6.2.1.1.2	Biological markers	53
	6.2.1.1.3	Imaging for treatment selection	54
	6.2.1.1.3.1	mpMRI in men eligible for active surveillance based on systematic biopsy findings only	54
	6.2.1.1.3.1.1	Reduction of systematic biopsies in MRI-negative men on active surveillance.	54
	6.2.1.1.3.1.2	Multivariate risk prediction at confirmatory biopsy	54
	6.2.1.1.3.2	Follow-up mpMRI in men eligible for active surveillance based on mpMRI and systematic and targeted-biopsy findings	54
	6.2.1.1.3.3	Guidelines for imaging in men on active surveillance	55
	6.2.1.1.4	Follow up	55
	6.2.1.1.5	Switching to active treatment	55
	6.2.1.2	Active treatment	55
	6.2.1.2.1	Radical prostatectomy	55
	6.2.1.2.2	Radiation therapy treatment policy	56
	6.2.1.3	Other treatments	56
	6.2.1.4	Guidelines for the treatment of low-risk disease	56
6.2.2		Treatment of Intermediate-risk disease	56
	6.2.2.1	Active Surveillance	56
	6.2.2.2	Surgery	57
	6.2.2.3	Radiation therapy	57
	6.2.2.3.1	Recommended external beam radiation therapy for intermediate-risk PCa	57
	6.2.2.3.2	Brachytherapy monotherapy	57
	6.2.2.4	Other options for the primary treatment of intermediate-risk PCa (experimental therapies)	57
	6.2.2.5	Guidelines for the treatment of intermediate-risk disease	58
6.2.3		Treatment of high-risk localised disease	58
	6.2.3.1	Radical prostatectomy	58
	6.2.3.1.1	ISUP grade 4-5	58
	6.2.3.1.2	Prostate-specific antigen > 20 ng/mL	58
	6.2.3.1.3	Radical prostatectomy in cN0 patients who are found to have pathologically confirmed lymph node invasion (pN1)	58
	6.2.3.2	External beam radiation therapy	59
	6.2.3.2.1	Recommended external beam radiation therapy treatment policy for localised high-risk PCa	59
	6.2.3.2.2	Lymph node irradiation in cN0	59
	6.2.3.2.3	Low-dose rate brachytherapy boost	59
	6.2.3.3	Options other than surgery and radiotherapy for the primary treatment of localised prostate cancer.	59
	6.2.3.4	Guidelines for radical treatment of high-risk localised disease	59

6.2.4	Treatment of locally advanced prostate cancer	59
6.2.4.1	Surgery	60
6.2.4.2	Radiotherapy for locally advanced PCa	60
6.2.4.3	Options other than surgery and radiotherapy for primary treatment	60
6.2.4.4	Guidelines for radical treatment of locally-advanced disease	60
6.2.5	Adjuvant treatment after radical prostatectomy	61
6.2.5.1	Introduction	61
6.2.5.2	Risk factors for relapse	61
6.2.5.3	Immediate (adjuvant) post-operative external irradiation after RP (cN0 or pN0)	61
6.2.5.4	Adjuvant androgen ablation	61
6.2.5.4.1	Adjuvant androgen ablation in men with N0 disease	61
6.2.5.4.2	Adjuvant androgen ablation in men with pN1 disease	62
6.2.5.5	Adjuvant radiotherapy combined with ADT in men with pN1 disease	62
6.2.5.6	Adjuvant chemotherapy	62
6.2.5.7	Guidelines for adjuvant treatment options after radical prostatectomy	62
6.2.5.8	Guidelines for non-curative or palliative treatments in prostate cancer	63
6.2.6	Persistent PSA after radical prostatectomy	63
6.2.6.1	Introduction	63
6.2.6.2	Natural history of persistently elevated PSA after RP	63
6.2.6.3	Imaging in patients with persistently elevated PSA after RP	65
6.2.6.4	Impact of post-operative RT and/or ADT in patients with persistent PSA	65
6.2.6.5	Conclusion	65
6.2.6.6	Recommendations for the management of persistent PSA after radical prostatectomy	65
6.3	Management of PSA-only recurrence after treatment with curative intent	66
6.3.1	Background	66
6.3.2	Definitions of clinically relevant PSA relapse	66
6.3.3	Natural history of biochemical recurrence	66
6.3.4	The role of imaging in PSA-only recurrence	67
6.3.4.1	Assessment of metastases	67
6.3.4.1.1	Bone scan and abdominopelvic CT	67
6.3.4.1.2	Choline PET/CT	67
6.3.4.1.3	Fluoride PET and PET/CT	67
6.3.4.1.4	Fluciclovine PET/CT	67
6.3.4.1.5	Prostate-specific membrane antigen positron emission tomography computed tomography	67
6.3.4.1.6	Whole-body and axial MRI	68
6.3.4.2	Assessment of local recurrences	68
6.3.4.2.1	Local recurrence after radical prostatectomy	68
6.3.4.2.2	Local recurrence after radiation therapy	68
6.3.4.3	Summary of evidence on imaging in case of biochemical recurrence	68
6.3.4.4	Guidelines for imaging in patients with biochemical recurrence	69
6.3.5	Treatment of PSA-only recurrences	69
6.3.5.1	Salvage radiotherapy for PSA-only recurrence after radical prostatectomy	69
6.3.5.1.1	Target volume, dose, toxicity	71
6.3.5.1.2	Comparison of adjuvant radiotherapy and salvage radiotherapy	72
6.3.5.1.3	Management of PSA failures after radiation therapy	72
6.3.5.2	Salvage radical prostatectomy	73
6.3.5.2.1	Oncological outcomes	73
6.3.5.2.2	Morbidity	73
6.3.5.2.3	Summary of salvage radical prostatectomy	74
6.3.5.3	Salvage cryoablation of the prostate	74
6.3.5.3.1	Oncological outcomes	74
6.3.5.3.2	Morbidity	74
6.3.5.3.3	Summary of salvage cryoablation of the prostate	74
6.3.5.4	Salvage brachytherapy for radiotherapy failure	75
6.3.5.5	Salvage high-intensity focused ultrasound	75

	6.3.5.5.1	Oncological outcomes	75
	6.3.5.5.2	Morbidity	75
	6.3.5.5.3	Summary of salvage high-intensity focused ultrasound	75
	6.3.6	Salvage lymph node dissection	75
	6.3.7	Hormonal therapy	76
	6.3.8	Observation	76
	6.3.9	Guidelines for second-line therapy after treatment with curative intent	76
6.4		Treatment: Metastatic prostate cancer	77
	6.4.1	Introduction	77
	6.4.2	Prognostic factors	77
	6.4.3	First-line hormonal treatment	77
	6.4.3.1	Non-steroidal anti-androgen monotherapy	77
	6.4.3.2	Intermittent versus continuous androgen deprivation therapy	77
	6.4.3.3	Immediate versus deferred androgen deprivation therapy	78
	6.4.4	Combination therapies	78
	6.4.4.1	Complete androgen blockade	78
	6.4.4.2	Androgen deprivation combined with other agents	79
	6.4.4.2.1	Combination with abiraterone acetate	79
	6.4.4.2.2	Androgen deprivation therapy combined with chemotherapy	79
	6.4.5	Treatment selection and patient selection	80
	6.4.6	Deferred treatment for metastatic PCa (stage M1)	81
	6.4.7	Treatment of the primary tumour in newly diagnosed metastatic disease	81
	6.4.8	Metastasis-directed therapy	81
	6.4.9	Guidelines for the first-line treatment of metastatic disease	82
6.5		Treatment: Castration-resistant PCa (CRPC)	82
	6.5.1	Definition of Castration-resistant PCa	82
	6.5.2	Non-metastatic castration-resistant PCa	82
	6.5.3	Metastatic castration-resistant PCa	83
	6.5.3.1	Conventional androgen deprivation in castration-resistant PCa	83
	6.5.4	First-line treatment of metastatic castration-resistant PCa	84
	6.5.4.1	Abiraterone	84
	6.5.4.2	Enzalutamide	84
	6.5.4.3	Docetaxel	84
	6.5.4.4	Sipuleucel-T	85
	6.5.5	Second-line treatment for mCRPC	85
	6.5.5.1	Cabazitaxel	85
	6.5.5.2	Abiraterone acetate after prior docetaxel	86
	6.5.5.3	Enzalutamide after docetaxel	86
	6.5.5.4	Radium-223	86
	6.5.6	Treatment after docetaxel and one line of hormonal treatment for mCRPC	86
	6.5.7	Monitoring of treatment	87
	6.5.8	When to change treatment	87
	6.5.9	Symptomatic management in metastatic castration-resistant PCa	87
	6.5.9.1	Common complications due to bone metastases	87
	6.5.10	Preventing skeletal-related events	88
	6.5.10.1	Bisphosphonates	88
	6.5.10.2	RANK ligand inhibitors	88
	6.5.11	Summary of evidence and guidelines for life-prolonging treatments of castrate-resistant disease	88
	6.5.12	Guidelines for cytotoxic treatment of castrate-resistant disease	89
	6.5.13	Guidelines for supportive care of castrate-resistant disease	89
	6.5.14	Guidelines for non-metastatic castrate-resistant disease	89
6.6		Summary of guidelines for the treatment of prostate cancer	89
	6.6.1	General guidelines recommendations for active treatment	90
	6.6.2	Guidelines recommendations for the various disease stages	90
	6.6.3	Guidelines for metastatic disease, second-line and palliative treatments	92
7.		FOLLOW-UP	94
	7.1	Follow-up: After local treatment	94
	7.1.1	Definition	94

7.1.2	Why follow-up?	94
7.1.3	How to follow-up?	94
7.1.3.1	Prostate-specific antigen monitoring	94
7.1.3.2	Prostate-specific antigen monitoring after radical prostatectomy	94
7.1.3.3	Prostate-specific antigen monitoring after radiotherapy	95
7.1.3.4	Digital rectal examination	95
7.1.3.5	Transrectal ultrasound, bone scintigraphy, computed tomography, magnetic resonance imaging, and positron emission tomography computed tomography	95
7.1.3.5.1	Transrectal ultrasonography/magnetic resonance imaging guided biopsy.	95
7.1.4	How long to follow-up?	95
7.1.5	Summary of evidence and guidelines for follow-up after treatment with curative intent	95
7.2	Follow-up: during first line hormonal treatment (androgen sensitive period)	96
7.2.1	Introduction	96
7.2.2	Purpose of follow-up	96
7.2.3	Methods of follow-up	96
7.2.3.1	Clinical follow-up	96
7.2.3.1.1	Prostate-specific antigen monitoring	96
7.2.3.1.2	Creatinine, haemoglobin and liver function monitoring	96
7.2.3.1.3	Imaging	96
7.2.3.1.4	Testosterone monitoring	96
7.2.3.1.5	Monitoring of metabolic complications	97
7.2.4	When to follow-up	97
7.2.4.1	Stage M0 - M1 patients	97
7.2.5	Imaging as a marker of response in metastatic prostate cancer	97
7.2.6	Guidelines for follow-up during hormonal treatment	98
8.	QUALITY OF LIFE OUTCOMES IN PROSTATE CANCER	98
8.1	Introduction	98
8.2	Adverse effects of prostate cancer therapies	98
8.2.1	Surgery	98
8.2.2	Radiotherapy	99
8.2.2.1	Side-effects of external beam radiotherapy	99
8.2.2.2	Side-effects from brachytherapy	99
8.2.3	Local primary whole-gland treatments other than surgery or radiotherapy	99
8.2.3.1	Cryosurgery	99
8.2.3.2	High-intensity focused ultrasound	99
8.2.4	Hormonal therapy	99
8.2.4.1	Sexual function	100
8.2.4.2	Hot flushes	100
8.2.4.3	Non-metastatic bone fractures	100
8.2.4.3.1	Hormonal treatment modalities	100
8.2.4.4	Metabolic effects	100
8.2.4.5	Cardiovascular morbidity	101
8.2.4.6	Fatigue	101
8.2.4.7	Neurological side-effects	101
8.3	Overall quality of life in men with prostate cancer	101
8.3.1	Long-term (> 12 months) quality of life outcomes in men with localised disease	102
8.3.1.1	Men undergoing local treatments	102
8.3.1.2	Guidelines for quality of life in men undergoing local treatments	103
8.3.2	Improving quality of life in men who have been diagnosed with prostate cancer	103
8.3.2.1	Guidelines for quality of life in men undergoing systemic treatments	104
9.	REFERENCES	104
10.	CONFLICT OF INTEREST	160
11.	CITATION INFORMATION	161

1. INTRODUCTION

1.1 Aims and scope

The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of PCa.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition

The PCa Guidelines Panel consists of an international multidisciplinary group of urologists, radiation oncologists, medical oncologists, radiologists, a pathologist and a patient representative.

All imaging sections in the text have been developed jointly with the European Society of Urogenital Radiology (ESUR) and the European Association of Nuclear Medicine (EANM). Representatives of the ESUR and the EANM in the PCa Guidelines Panel are (in alphabetical order): Prof.Dr. S. Fanti, Prof.Dr. O Rouvière and Dr. I.G. Schoots.

All radiotherapy sections have been developed jointly with the European Society for Radiotherapy & Oncology (ESTRO). Representatives of ESTRO in the PCa Guidelines Panel are (in alphabetical order): Prof.Dr. A.M. Henry, Prof.Dr. M.D. Mason and Prof.Dr. T. Wiegel.

All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: <http://uroweb.org/guideline/prostatecancer/?type=panel>.

1.2.1 Acknowledgement

The PCa Guidelines Panel gratefully acknowledges the assistance and general guidance provided by Prof.Dr. M. Bolla, honorary member of the PCa Guidelines Panel.

1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text version. Several scientific publications are available [1, 2] as are a number of translations of all versions of the PCa Guidelines. All documents can be accessed on the EAU website: <http://uroweb.org/guideline/prostate-cancer/>.

1.4 Publication history and summary of changes

1.4.1 Publication history

The EAU PCa Guidelines were first published in 2001. This 2019 document presents a full update of the 2018 PCa Guidelines publication.

1.4.2 Summary of changes

The literature for the complete document has been assessed and updated, where relevant. Evidence summaries and recommendations have been amended throughout the current document and several new sections have been added.

- Section 5.2.4 – The role of multiparametric magnetic resonance imaging (mpMRI) in clinical diagnosis, has been completely revised, also including data from a recent Cochrane review [1]. As a result new recommendations for imaging have been provided throughout these guidelines.

5.2.4.8 Summary of evidence and guidelines for diagnostic imaging

Summary of evidence	LE
Systematic biopsy is an acceptable approach if mpMRI is unavailable.	3

Recommendations for all patients	LE	Strength rating
Do not use mpMRI as an initial screening tool.	3	Strong
Adhere to PI-RADS guidelines for mpMRI acquisition and interpretation.	3	Strong

Recommendations in biopsy-naïve patients	LE	Strength rating
Perform mpMRI before prostate biopsy.	1a	Weak
When mpMRI is positive (i.e. PI-RADS \geq 3), combine targeted and systematic biopsy.	2a	Strong
When mpMRI is negative (i.e. PI-RADS \leq 2), and clinical suspicion of prostate cancer is low, omit biopsy based on shared decision making with the patient.	2a	Weak

Recommendations in patients with prior negative biopsy	LE	Strength rating
Perform mpMRI before prostate biopsy.	1a	Strong
When mpMRI is positive (i.e. PI-RADS \geq 3), perform targeted biopsy only.	2a	Weak
When mpMRI is negative (i.e. PI-RADS \leq 2), and clinical suspicion of prostate cancer is high, perform systematic biopsy based on shared decision making with the patient.	2a	Strong

5.3.5 Guidelines for staging of prostate cancer

Any risk group staging	LE	Strength rating
Use pre-biopsy mpMRI for staging information.	2a	Weak

- The literature for Section 5.4 – Evaluation of health status and life expectancy, has been updated, resulting in an additional recommendation.

5.4.5 Guidelines for evaluating health status and life expectancy

Recommendations	Strength rating
Use individual life expectancy, health status, and comorbidity to guide PCa management.	Strong

- Due to the comprehensive revision of all imaging sections, recommendations for imaging for a number of text sections have been changed, or added to.

6.2.1.1.3.3 Guidelines for imaging in men on active surveillance

Recommendations in men on active surveillance	LE	Strength rating
Perform multiparametric magnetic resonance imaging before a confirmatory prostate biopsy, if not done before the first biopsy.	1a	Strong
Perform the combination of targeted biopsy (of any PI-RADS \geq 3 lesion) and systematic biopsy at confirmatory biopsy.	2a	Weak

6.2.1.4 Guidelines for the treatment of low-risk disease

Recommendations	Strength rating
Active surveillance (AS)	
Perform multiparametric magnetic resonance imaging before a confirmatory biopsy, if not done before the first biopsy.	Strong
Perform the combination of targeted biopsy (of any PI-RADS \geq 3 lesion) and systematic biopsy at confirmatory biopsy.	Weak

6.2.2.5 Guidelines for the treatment of intermediate-risk disease

Recommendations	Strength rating
Radiotherapeutic treatment	
For external-beam radiation therapy (EBRT), use a total dose of 76-78 Gy or moderate hypofractionation (60 Gy/20 fx in four weeks or 70 Gy/28 fx in six weeks), in combination with short-term neoadjuvant plus concomitant androgen deprivation therapy (ADT) (four to six months).	Strong
Other therapeutic options	
Do not offer ADT monotherapy to intermediate-risk asymptomatic men unable to receive any local treatment.	Strong

- A new text Section 6.2.6 - Persistent PSA after radical prostatectomy, has been added.

6.2.6.6 Recommendations for the management of persistent PSA after radical prostatectomy

Recommendations	Strength rating
Offer a prostate-specific membrane antigen positron emission tomography (PSMA PET) scan to men with a persistent PSA > 0.2 ng/mL to exclude metastatic disease.	Weak
Treat men with no evidence of metastatic disease with salvage radiotherapy and additional hormonal therapy.	Weak

6.3.4.4 Guidelines for imaging in patients with biochemical recurrence

Prostate-specific antigen (PSA) recurrence after radical prostatectomy	LE	Strength rating
Perform PSMA PET/CT if the PSA level is > 0.2 ng/mL and if the results will influence subsequent treatment decisions.	2b	Weak
In case PSMA PET/CT is not available, and the PSA level is ≥ 1 ng/mL, perform Fluciclovine PET/CT or Choline PET/CT imaging if the results will influence subsequent treatment decisions.		Weak
PSA recurrence after radiotherapy		
Perform prostate multiparametric magnetic resonance imaging to localise abnormal areas and guide biopsies in patients fit for local salvage therapy.	3	Strong
Perform PSMA PET/CT (if available) or fluciclovine PET/CT or choline PET/CT in patients fit for curative salvage treatment.	2b	Strong

- Section 6.3 - Management of PSA-only recurrence after treatment with curative intent, has been completely revised, introducing the concept of patient stratification into EAU low- and high-risk recurrence groups based on the findings of a systematic review (SR). New recommendations have been provided.

6.3.9 Guidelines for second-line therapy after treatment with curative intent

Local salvage treatment	Strength rating
Recommendations for biochemical recurrence after radical prostatectomy	
Offer active surveillance and possibly delayed salvage radiotherapy (SRT) to patients with biochemical recurrence and classified as EAU low-risk group at relapse who may not benefit from intervention.	Strong
Treat patients with a PSA rise from the undetectable range with SRT. Once the decision for SRT has been made, SRT (at least 66 Gy) should be given as soon as possible.	Strong
Offer pN0 patients undergoing SRT hormonal therapy (with bicalutamide 150 mg for two years, or LHRH agonists for up to two years).	Weak
Do not offer hormonal therapy to every pN0 patient treated with SRT.	Strong

- Based on the complete update of Section 6.4 - Metastatic prostate cancer, new recommendations have been included.

6.4.9 Guidelines for the first-line treatment of metastatic disease

Recommendations	Strength rating
Offer surgery and/or local radiotherapy to any patient with M1 disease and evidence of impending complications such as spinal cord compression or pathological fracture.	Strong
Offer castration combined with prostate radiotherapy to patients whose first presentation is M1 disease and who have low volume of disease by CHAARTED criteria.	Weak
Offer castration alone, with or without an anti-androgen, to patients unfit for, or unwilling to consider, castration combined with docetaxel or abiraterone acetate plus prednisone or prostate radiotherapy.	Strong

6.5.14 Guidelines for non-metastatic castrate-resistant disease

Recommendation	Strength rating
Offer apalutamide or enzalutamide to patients with M0 CRPC and a high risk of developing metastasis (PSA-DT \leq 10 months) to prolong time to metastases.	Strong

8.3.2.1 Guidelines for quality of life in men undergoing systemic treatments

Recommendations	Strength rating
Advise men on androgen deprivation therapy to maintain a healthy weight and diet, to stop smoking and have yearly screening for diabetes and hypercholesterolemia. Supplementation with vitamin D and calcium is advised.	Strong

Specific sections of the text have been updated based on SR questions prioritised by the Guidelines Panel. These reviews were performed using standard Cochrane SR methodology; <http://www.cochranelibrary.com/about/about-cochrane-systematic-reviews.html>:

- Section 6.3 - Management of PSA-only recurrence after treatment with curative intent [2].

2. METHODS

2.1 Data identification

For the 2019 PCa Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature.

A broad and comprehensive literature search, covering all sections of the PCa Guidelines was performed. The search was limited to studies representing only high levels of evidence (i.e. SRs with meta-analysis, randomised controlled trials (RCTs), and prospective comparative studies) published in the English language. Databases searched included Medline, EMBASE and the Cochrane Libraries, covering a time frame between May 10th 2017 and May 2nd 2018. After deduplication, a total of 1,124 unique records were identified, retrieved and screened for relevance. A total of 169 new publications were added to the 2019 PCa Guidelines.

Additional searches were done for the 'imaging sections' across the PCa Guidelines, addressing all imaging modalities in use for the diagnosis and follow-up of prostate cancer patients. A total of 1,255 new papers were identified and assessed. Detailed search strategies are available online:

<http://uroweb.org/guideline/prostatecancer/?type=appendices-publications>.

For each recommendation within the guidelines there is an accompanying online strength rating form, the basis of which is a modified GRADE methodology [3, 4]. These forms address a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are graded according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [5];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words 'strong' or 'weak' [6]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be available online.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; <http://www.uroweb.org/guideline/>.

A list of Associations endorsing the EAU Guidelines can also be viewed online at the above address. In addition, the International Society of Geriatric Oncology (SIOG), the European Society for Radiotherapy & Oncology (ESTRO), the European Society for Urogenital Radiology (ESUR) and the European Association of Nuclear Medicine (EANM) have endorsed the PCa Guidelines.

2.2 Review

Publications ensuing from SRs have all been peer-reviewed.

2.3 Future goals

Results of ongoing and new SRs will be included in the 2020 update of the PCa Guidelines:

- A SR of oncological effectiveness and harms of primary local interventions for high-risk localised and locally advanced PCa [7];
- A SR on the deferred treatment with curative intent for localised PCa, explore heterogeneity of definitions, thresholds and criteria [8];
- A SR on progression criteria and quality of life (QoL) of patients diagnosed with PCa;
- A SR on the definition and the prognostic value of PSA persistence after radical prostatectomy (RP) for PCa;
- Care pathways for the various stages of PCa management are being developed. These pathways will, in due time, inform treatment flowcharts and an interactive app.

3. EPIDEMIOLOGY AND AETIOLOGY

3.1 Epidemiology

Prostate cancer is the second most commonly diagnosed cancer in men, with an estimated 1.1 million diagnoses worldwide in 2012, accounting for 15% of all cancers diagnosed [9]. The frequency of autopsy-detected PCa is roughly the same worldwide [10]. A SR of autopsy studies reported a prevalence of PCa at age < 30 years of 5% (95% CI: 3-8%), increasing by an odds ratio (OR) of 1.7 (1.6-1.8) per decade, to a prevalence of 59% (48-71%) by age > 79 years [11].

The incidence of PCa diagnosis varies widely between different geographical areas, being highest in Australia/New Zealand and Northern America (age-standardised rates [ASR] per 100,000 of 111.6 and 97.2, respectively), and in Western and Northern Europe (ASRs of 94.9 and 85, respectively), largely due to the use of prostate-specific antigen (PSA) testing and the aging population. The incidence is low in Eastern and South-Central Asia (ASRs of 10.5 and 4.5, respectively), whilst rates in Eastern and Southern Europe, which were low, have showed a steady increase [9, 10].

There is relatively less variation in mortality rates worldwide, although rates are generally high in populations of African descent (Caribbean: ASR of 29 and Sub-Saharan Africa: ASRs ranging between 19 and 14), intermediate in the USA and very low in Asia (South-Central Asia: ASR of 2.9) [9].

3.2 Aetiology

3.2.1 Family history / genetics

Family history and racial/ethnic background are associated with an increased PCa incidence suggesting a genetic predisposition [12, 13]. For men with relatives with PCa their age-specific increased risk of PCa can be estimated. The probability of high-risk PCa at age 65 was 11.4% (vs. a population risk of 1.4%) in men whose father and two brothers had been diagnosed with PCa in a Swedish population-based study [14]. Prostate-specific antigen testing mainly inflates detection of, less relevant, any-risk PCa.

Only a small subpopulation of men with PCa (~9%) have true hereditary disease. This is defined as three or more affected relatives or at least two relatives who have developed early-onset PCa (< 55 years) [13]. Men with one first-degree relative diagnosed with PCa have a relative risk (RR) of 1.8 of having PCa, whereas men with a father and brother or two brothers diagnosed with PCa have a RR of 5.51 and 7.71, respectively [15].

Hereditary PCa is associated with a six to seven year earlier disease onset but the disease aggressiveness and clinical course does not seem to differ in other ways [13, 16]. Men of African descent show a higher incidence of PCa and generally have a more aggressive course of disease [17].

Specific ancestry-specific risk loci have been identified [18]. Of the underlying determinants of genomic diversity and mechanisms between genetic and environmental factors, much remains unknown. Genome-wide association studies have identified more than 100 common susceptibility loci contributing to the risk for PCa [19-21]. Furthermore, among men with metastatic PCa, an incidence of 11.8% was found for germline mutations in genes mediating DNA-repair processes [22]. Germline mutations in genes such as *BRCA1/2* and *HOXB13* have been associated with an increased risk of PCa and targeted genomic analysis of these genes could offer options to identify families at high risk [23, 24]. Prostate cancer screening trials targeting BRCA mutation carriers are ongoing [25]. BRCA mutation carriers were reported to have worse outcome when compared to non-carriers after local therapy [26].

3.2.2 Risk factors

A wide variety of exogenous/environmental factors have been discussed as being associated with the risk of developing PCa or as being aetiologically important for the progression from latent to clinical PCa [27]. Japanese men have a lower PCa risk compared to men from the Western world. However, as Japanese men move from Japan to California, their risk of PCa increases, approaching that of American men, implying a role of environmental or dietary factors [28]. However, currently there are no effective preventative dietary or pharmacological interventions.

3.2.2.1 Metabolic syndrome (MetS)

The single components of MetS hypertension ($p = 0.035$) and waist circumference > 102 cm ($p = 0.007$) have been associated with a significantly greater risk of PCa, but in contrast, having ≥ 3 components of MetS is associated with a reduced risk (OR: 0.70, 95% CI: 0.60-0.82) [29, 30].

3.2.2.1.1 Diabetes/metformin

On a population level, metformin users (but not other oral hypoglycaemic agents) were found to be at a decreased risk of PCa diagnosis compared with never-users (adjusted OR: 0.84; 95% CI: 0.74-0.96) [31]. In 540 diabetic participants of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study, metformin use was not significantly associated with PCa and therefore not advised as a preventive measure (OR: 1.19, $p = 0.50$) [32]. The ongoing Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial assesses metformin use in advanced PCa [33].

3.2.2.1.2 Cholesterol/statins

A meta-analysis of fourteen large prospective studies did not show an association between blood total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol levels and the risk of either overall PCa or high-grade PCa [34]. Results of the REDUCE study also did not show a preventive effect of statins on PCa risk [32].

3.2.2.1.3 Obesity

Within the REDUCE study, obesity was associated with lower risk of low-grade PCa in multivariable analyses (OR: 0.79, $p = 0.01$), but increased risk of high-grade PCa (OR: 1.28, $p = 0.042$) [35]. This effect seems mainly explained by environmental determinants of height/body mass index (BMI) rather than genetically elevated height or BMI [36].

3.2.2.2 Dietary factors

The association between a wide variety of dietary factors and PCa have been studied (Table 3.1).

Table 3.1: Dietary factors that have been associated with PCa

Alcohol	High alcohol intake, but also total abstinence from alcohol has been associated with a higher risk of PCa and PCa-specific mortality [37]. A meta-analysis shows a dose-response relationship with PCa [38].
Dairy	A weak correlation between high intake of protein from dairy products and the risk of PCa was found [39].
Fat	No association between intake of long-chain omega-3 poly-unsaturated fatty acids and PCa was found [40]. A relation between intake of fried foods and risk of PCa may exist [41].
Tomatoes (lycopenes / carotenes)	A trend towards a favourable effect of tomato intake (mainly cooked) and lycopenes on PCa incidence has been identified in meta-analyses [42, 43]. Randomised controlled trials comparing lycopene with placebo did not identify a significant decrease in the incidence of PCa [44].
Meat	A meta-analysis did not show an association between red meat or processed meat consumption and PCa [45].
Phytoestrogens	Phytoestrogen intake was significantly associated with a reduced risk of PCa in a meta-analysis [46].
Soy (phytoestrogens (isoflavones / coumestans))	Total soy food intake has been associated with reduced risk of PCa, but also with increased risk of advanced disease [47, 48].
Vitamin D	A U-shaped association has been observed, with both low- and high vitamin-D concentrations being associated with an increased risk of PCa, and more strongly for high-grade disease [49, 50].
Vitamin E / Selenium	An inverse association of blood, but mainly nail selenium levels (reflecting long-term exposure) with aggressive PCa have been found [51, 52]. Selenium and Vitamin E supplementation were, however, found not to affect PCa incidence [53].

3.2.2.3 *Hormonally active medication*

3.2.2.3.1 5-alpha-reductase inhibitors (5-ARIs)

Although it seems that 5-ARIs have the potential of preventing or delaying the development of PCa (~25%, for ISUP grade 1 cancer only), this must be weighed against treatment-related side-effects as well as the potential small increased risk of high-grade PCa [54-56]. None of the available 5-ARIs have been approved by the European Medicines Agency (EMA) for chemoprevention.

3.2.2.3.2 Testosterone

Hypogonadal men receiving testosterone supplements do not have an increased risk of PCa [57]. A pooled analysis showed that men with very low concentrations of free testosterone (lowest 10%) have a below average risk (OR: 0.77) of PCa [58].

3.2.2.4 *Other potential risk factors*

Balding was associated with a higher risk of PCa death [59]. Gonorrhoea was significantly associated with an increased incidence of PCa (OR: 1.31; 95% CI: 1.14-1.52) [60]. Occupational exposure may also play a role, based on a meta-analysis which revealed that night-shift work is associated with an increased risk (2.8%, $p = 0.030$) of PCa [61]. Current cigarette smoking was associated with an increased risk of PCa death (relative risk [RR] 1.24; 95% CI: 1.18-1.31) [62]. A meta-analysis on Cadmium (Cd) found a positive association (magnitude of risk unknown due to heterogeneity) between high Cd exposure and risk of PCa for occupational exposure, but not for non-occupational exposure, potentially due to higher Cd levels during occupational exposure [63]. Men positive for human papillomavirus-16 may be at increased risk [64].

A number of other factors previously linked to an increased risk of PCa have been disproved including vasectomy [65] and self-reported acne [66]. There are conflicting data about the use of aspirin or non-steroidal anti-inflammatory drugs and the risk of PCa and mortality [67, 68].

Ultraviolet radiation exposure decreased the risk of PCa (hazard ratio [HR]: 0.91; 95% CI: 0.88-0.95) [69]. A review found a small but protective association of circumcision status with PCa [70]. Higher ejaculation frequency (≥ 21 times a month vs. four to seven times) has been associated with a 20% lower risk of PCa [71].

However, the associations identified to date lack evidence for causality. As a consequence there is no data to suggest effective preventative strategies.

3.2.3 Summary of evidence and guidelines for epidemiology and aetiology

Summary of evidence
Prostate cancer is a major health concern in men, with incidence mainly dependent on age.
Genetic factors are associated with risk of (aggressive) PCa but ongoing trials will need to define the clinical applicability of screening for genetic susceptibility to PCa.
A variety of exogenous/environmental factors may have an impact on PCa incidence and the risk of progression.
Selenium or vitamin-E supplements have no beneficial effect in preventing PCa.
In hypogonadal men, testosterone supplements do not increase the risk of PCa.

Recommendation	Strength rating
No specific preventive or dietary measures are recommended to reduce the risk of developing prostate cancer.	Strong

4. CLASSIFICATION AND STAGING SYSTEMS

4.1 Classification

The objective of a tumour classification system is to combine patients with a similar clinical outcome. This allows for the design of clinical trials on relatively homogeneous patient populations, the comparison of clinical and pathological data obtained from different hospitals across the world, and the development of recommendations for the treatment of these patient populations. Throughout these Guidelines the 2017 Tumour, Node, Metastasis (TNM) classification for staging of PCa (Table 4.1) [72] and the EAU risk group classification, which is essentially based on D'Amico's classification system for PCa, are used (Table 4.3) [73]. The latter classification is based on the grouping of patients with a similar risk of biochemical recurrence after RP or external beam radiotherapy (EBRT).

Table 4.1: Clinical Tumour Node Metastasis (TNM) classification of PCa [72]

T - Primary Tumour (stage based on digital rectal examination [DRE] only)	
TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
T1	Clinically inapparent tumour that is not palpable
T1a	Tumour incidental histological finding in 5% or less of tissue resected
T1b	Tumour incidental histological finding in more than 5% of tissue resected
T1c	Tumour identified by needle biopsy (e.g. because of elevated prostate-specific antigen [PSA])
T2	Tumour that is palpable and confined within the prostate
T2a	Tumour involves one half of one lobe or less
T2b	Tumour involves more than half of one lobe, but not both lobes
T2c	Tumour involves both lobes
T3	Tumour extends through the prostatic capsule
T3a	Extracapsular extension (unilateral or bilateral)
T3b	Tumour invades seminal vesicle(s)
T4	Tumour is fixed or invades adjacent structures other than seminal vesicles: external sphincter, rectum, levator muscles, and/or pelvic wall
N - Regional (pelvic) Lymph Nodes ¹	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Regional lymph node metastasis

M - Distant Metastasis²	
M0	No distant metastasis
M1	Distant metastasis
M1a	Non-regional lymph node(s)
M1b	Bone(s)
M1c	Other site(s)

¹Metastasis no larger than 0.2 cm can be designated pNmi.

²When more than one site of metastasis is present, the most advanced category is used. (p)M1c is the most advanced category.

Clinical T stage only refers to DRE findings; imaging findings are not considered in the TNM classification. Pathological staging (pTNM) is based on histopathological tissue assessment and largely parallels the clinical TNM, except for clinical stage T1c and the T2 substages. All histopathologically confirmed organ-confined PCas after RP are pathological stage T2 and the current Union for International Cancer Control (UICC) no longer recognises pT2 substages [72].

4.2 Gleason score and International Society of Urological Pathology 2014 grade

The 2005 International Society of Urological Pathology (ISUP) modified Gleason score (GS) of biopsy-detected PCa comprises the Gleason grade of the most extensive (primary) pattern, plus the second most common (secondary) pattern, if two are present. If one pattern is present, it needs to be doubled to yield the GS. For three grades, the biopsy GS comprises the most common grade plus the highest grade, irrespective of its extent. When a carcinoma is largely grade 4/5, identification of < 5% of Gleason grade 2 or 3 glands should not be incorporated in the GS. A GS ≤ 5 should not be given based on prostate biopsies [74, 75]. In addition to reporting of the carcinoma features for each biopsy, an overall (or global) GS based on the carcinoma-positive biopsies can be provided. The global GS takes into account the extent of each grade from all prostate biopsies. The 2014 ISUP endorsed grading system [75, 76] limits the number of PCa grades, ranging them from 1 to 5 (see Table 4.2), in order to:

1. align the PCa grading with the grading of other carcinomas;
2. eliminate the anomaly that the most highly differentiated PCas have a GS 6;
3. to further define the clinically highly significant distinction between GS 7(3+4) and 7(4+3) PCa [77].

Table 4.2: International Society of Urological Pathology 2014 grades

Gleason score	ISUP grade
2-6	1
7 (3+4)	2
7 (4+3)	3
8 (4+4 or 3+5 or 5+3)	4
9-10	5

Table 4.3 EAU risk groups for biochemical recurrence of localised and locally advanced prostate cancer

Definition			
Low-risk	Intermediate-risk	High-risk	
PSA < 10 ng/mL and GS < 7 (ISUP grade 1) and cT1-2a	PSA 10-20 ng/mL or GS 7 (ISUP grade 2/3) or cT2b	PSA > 20 ng/mL or GS > 7 (ISUP grade 4/5) or cT2c	any PSA any GS (any ISUP grade) cT3-4 or cN+
Localised			Locally advanced

GS = Gleason score; ISUP = International Society for Urological Pathology; PSA = prostate-specific antigen.

4.3 Prognostic relevance of stratification

A more precise stratification of the clinically heterogeneous subset of intermediate-risk group patients could provide a better framework for their management. The adoption of the current ISUP grading system, defining the split-up of GS 7 cancers into ISUP grade 2 (primary Gleason grade 3) and ISUP grade 3 (primary Gleason grade 4) because of their distinct prognostic impact strengthens such a separation of the intermediate-risk group into a low-intermediate (ISUP grade 2) and high intermediate-risk (ISUP grade 3) group [76].

Emerging clinical data support this distinction between favourable- and unfavourable-risk patient categories within the intermediate-risk group [77, 78].

5. DIAGNOSTIC EVALUATION

5.1 Screening and early detection

5.1.1 Screening

Population or mass screening is defined as the 'systematic examination of asymptomatic men (at risk)' and is usually initiated by health authorities. The co-primary objectives are:

- reduction in mortality due to PCa;
- a maintained QoL as expressed by QoL-adjusted gain in life years (QALYs).

Prostate cancer mortality trends range widely from country to country in the industrialised world [79]. Mortality due to PCa has decreased in most Western nations but the magnitude of the reduction varies between countries. The reduced mortality rate seen recently in the USA is considered to be partly due to a widely adopted aggressive PCa screening policy [80].

Currently, screening for PCa is one of the most controversial topics in the urological literature [81]. Three large prospective RCTs published data on screening in 2009 [82-84] resulting in conflicting positions and policy papers. Some authors argue that following the current American Urological Association (AUA) guidelines [85] or the 2012 US Preventive Services Task Force (USPSTF) recommendations for screening [86-88] may lead to a substantial number of men with aggressive disease being missed [89, 90]. In 2017 the USPSTF issued an updated statement suggesting that men aged 55-69 should be informed about the benefits and harms of PSA-based screening as this might be associated with a small survival benefit. The USPSTF has now upgraded this recommendation to a grade C [91], from a previous grade of 'D' [88, 91, 92]. The grade D recommendation remains in place for men over 70 years old. This represents a major switch from discouraging PSA-based screening (grade D) to offering screening to selected patients depending on individual circumstances.

A comparison of systematic and opportunistic screening suggested over-diagnosis and mortality reduction in the systematic screening group compared to a higher over-diagnosis with a marginal survival benefit, at best, in the opportunistic screening regimen [93]. The potential impact of this topic would necessitate the highest level of evidence produced through a systematic literature search of all published trials or cohorts summarised in a meta-analysis. Subgroup analyses of cohorts that are part of large trials, or mathematical projections alone, cannot provide the quality of evidence needed to appropriately address this clinical question.

A Cochrane review published in 2013 [94], which has since been updated [95], presents the main overview to date. The findings of the updated publication (based on a literature search until April 3, 2013) are almost identical to the 2009 review:

- Screening is associated with an increased diagnosis of PCa (RR: 1.3; 95% CI: 1.02-1.65).
- Screening is associated with detection of more localised disease (RR: 1.79; 95% CI: 1.19-2.70) and less advanced PCa (T3-4, N1, M1) (RR: 0.80, 95% CI: 0.73-0.87).
- From the results of five RCTs, randomising more than 341,000 men, no PCa-specific survival benefit was observed (RR: 1.00, 95% CI: 0.86-1.17). This was the main endpoint in all trials.
- From the results of four available RCTs, no overall survival (OS) benefit was observed (RR: 1.00, 95% CI: 0.96-1.03).

Moreover, screening was associated with minor and major harms such as over-diagnosis and over-treatment. Surprisingly, the diagnostic tool (i.e. biopsy) was not associated with any mortality in the selected papers, which is in contrast with other known data [55, 56].

The impact on the patient's overall QoL is still unclear, although screening has never been shown to be detrimental at population level [96-98]. Nevertheless, all these findings have led to strong advice against systematic population-based screening in all countries, including those in Europe.

Since 2013, the European Randomized Study of Screening for Prostate Cancer (ERSPC) data have been updated with thirteen years of follow up (see Table 5.1) [99]. The key message is that with extended follow up, the mortality reduction remains unchanged (21%, and 29% after non-compliance adjustment). However the

number needed to screen and to treat is decreasing, and is now below the number needed to screen observed in breast cancer trials [100].

Table 5.1: Follow-up data from the ERSPC study [99]

Years of follow-up	Number needed to screen	Number needed to treat
9	1,410	48
11	979	35
13	781	27

5.1.2 Early detection

An individualised risk-adapted strategy for early detection might be offered to a well-informed man with at least ten to fifteen years of life expectancy. It is important to carefully identify the patient taking into account the potential balances and harms involved. However, this approach may still be associated with a substantial risk of over-diagnosis. It is essential to remember that breaking the link between diagnosis and active treatment is the only way to decrease over-treatment, while still maintaining the potential benefit of individual early diagnosis for men requesting it.

Men at elevated risk of having PCa are those > 50 years [101] or at age > 45 years with a family history of PCa (either paternal or maternal [102]), or African-Americans [103]. In addition, men with a PSA > 1 ng/mL at 40 years and > 2 ng/mL at 60 years are also at increased risk of PCa metastasis or death from PCa several decades later [104, 105]. The long-term survival and QoL benefits of such an approach remain to be proven at a population level. In 2014, as for breast cancer, a genetic abnormality associated with an increased risk has been shown prospectively i.e. *BRCA2* [25, 78].

The use of DRE alone in the primary care setting had a sensitivity and specificity below 60%, possibly due to inexperience, and can therefore not be recommended to exclude PCa [106]. Informed men requesting an early diagnosis should be given a PSA test and undergo a DRE [107]. The optimal intervals for PSA testing and DRE follow-up are unknown, as they varied between several prospective trials. A single PSA test in men between 50 and 69 years did not improve ten-year PCa-specific survival compared to standard care in a large RCT in a primary care setting [108]. A risk-adapted strategy might be a consideration, based on the initial PSA level. This could be every two years for those initially at risk, or postponed up to eight to ten years in those not at risk with an initial PSA < 1 ng/mL at 40 years and a PSA < 2 ng/mL at 60 years of age and a negative family history [109]. Data from the Goteborg arm of the ERSPC trial suggest that the age at which early diagnosis should be stopped remains controversial, but an individual's life expectancy must definitely be taken into account. Men who have less than a fifteen-year life expectancy are unlikely to benefit, based on data from the Prostate Cancer Intervention Versus Observation Trial (PIVOT) and the ERSPC trials. Furthermore, although there is no simple tool to evaluate individual life expectancy, comorbidity is at least as important as age. A detailed review can be found in Section 5.4 'Evaluating health status and life expectancy' and in the SIOG Guidelines [110].

Multiple tools are now available to determine the need for a biopsy to establish the diagnosis of a PCa, including imaging by MRI, if available (see Section 5.2.4). New biological markers such as *TMPRSS2-ERG* fusion, PCA3 [111, 112] or kallikreins as incorporated in the Phi or 4Kscore tests [113, 114] have been shown to add sensitivity and specificity on top of PSA, potentially avoiding unnecessary biopsies and lowering over-diagnosis (see Section 5.2.2.4). At this time there is too limited data to implement these markers into routine screening programmes.

Risk calculators may be useful in helping to determine (on an individual basis) what the potential risk of cancer may be, thereby reducing the number of unnecessary biopsies. Several tools developed from cohort studies are available including:

- the PCPT cohort: PCPTRC 2.0 <http://myprostatecancerrisk.com/>;
- the ERSPC cohort: <http://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators>; An updated version was presented in 2017 including prediction of low and high risk now also based on the ISUP grading system and presence of cribriform growth in histology [115].
- a local Canadian cohort: <https://sunnybrook.ca/content/?page=asure-calc> (among others).

Since none of these risk calculators has clearly shown superiority, it remains a personal decision as to which one to use [116].

5.1.3 Guidelines for screening and early detection

Recommendations	LE	Strength rating
Do not subject men to prostate-specific antigen (PSA) testing without counselling them on the potential risks and benefits.	3	Strong
Offer an individualised risk-adapted strategy for early detection to a well-informed man with a good performance status (PS) and a life-expectancy of at least ten to fifteen years.	3	Strong
Offer early PSA testing in well-informed men at elevated risk of having PCa: <ul style="list-style-type: none"> men > 50 years of age; men > 45 years of age and a family history of PCa; African-Americans > 45 years of age. 	2b	Strong
Offer a risk-adapted strategy (based on initial PSA level), with follow-up intervals of two years for those initially at risk: <ul style="list-style-type: none"> men with a PSA level of > 1 ng/mL at 40 years of age; men with a PSA level of > 2 ng/mL at 60 years of age; Postpone follow-up to eight years in those not at risk.	3	Weak
Stop early diagnosis of PCa based on life expectancy and PS; men who have a life-expectancy of < fifteen years are unlikely to benefit.	3	Strong

5.2 Clinical diagnosis

Prostate cancer is usually suspected on the basis of DRE and/or PSA levels. Definitive diagnosis depends on histopathological verification of adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE).

5.2.1 Digital rectal examination

Most PCas are located in the peripheral zone and may be detected by DRE when the volume is ≥ 0.2 mL. In ~18% of cases, PCa is detected by suspect DRE alone, irrespective of PSA level [117]. A suspect DRE in patients with a PSA level ≤ 2 ng/mL has a positive predictive value (PPV) of 5-30% [118]. An abnormal DRE is associated with an increased risk of a higher ISUP grade and is an indication for biopsy [119, 120].

5.2.2 Prostate-specific antigen

The use of PSA as a serum marker has revolutionised PCa diagnosis [121]. Prostate-specific antigen is organ but not cancer specific; therefore, it may be elevated in benign prostatic hypertrophy (BPH), prostatitis and other non-malignant conditions. As an independent variable, PSA is a better predictor of cancer than either DRE or transrectal ultrasound (TRUS) [122].

There are no agreed standards defined for measuring PSA [123]. It is a continuous parameter, with higher levels indicating greater likelihood of PCa. Many men may harbour PCa despite having low serum PSA [124]. Table 5.2.1 demonstrates the occurrence of $GS \geq 7$ (or $ISUP \geq$ grade 2) PCa at low PSA levels, precluding an optimal PSA threshold for detecting non-palpable but clinically significant (cs) PCa. The use of nomograms may help in predicting indolent PCa [125].

Table 5.2.1: Risk of PCa in relation to low PSA values [124]

PSA level (ng/mL)	Risk of PCa (%)	Risk of ISUP grade ≥ 2 PCa (%)
0.0-0.5	6.6	0.8
0.6-1.0	10.1	1.0
1.1-2.0	17.0	2.0
2.1-3.0	23.9	4.6
3.1-4.0	26.9	6.7

5.2.2.1 PSA density

Prostate-specific antigen density is the level of serum PSA divided by the TRUS-determined prostate volume. The higher the PSA density, the more likely it is that the PCa is clinically significant (see Section 6.2.1 – Treatment of low-risk disease).

5.2.2.2 PSA velocity and doubling time

There are two methods of measuring PSA kinetics:

- PSA velocity (PSAV): absolute annual increase in serum PSA (ng/mL/year) [126];
- PSA doubling time (PSA-DT): which measures the exponential increase in serum PSA over time [127].

Prostate specific antigen velocity and PSA-DT may have a prognostic role in treating PCa [128], but have limited diagnostic use because of background noise (total prostate volume, and BPH), different intervals between PSA determinations, and acceleration/deceleration of PSAV and PSA-DT over time. These measurements do not provide additional information compared with PSA alone [129-132].

5.2.2.3 Free/total PSA ratio

Free/total (f/t) PSA must be used cautiously because it may be adversely affected by several pre-analytical and clinical factors (e.g., instability of free PSA at 4°C and room temperature, variable assay characteristics, and concomitant BPH in large prostates) [133]. Prostate cancer was detected in men with a PSA 4-10 ng/mL by biopsy in 56% of men with f/t PSA < 0.10, but in only 8% with f/t PSA > 0.25 ng/mL [134]. A SR including fourteen studies found a pooled sensitivity of 70% in men with a PSA of 4-10 ng/mL [135]. Free/total PSA is of no clinical use if the total serum PSA is > 10 ng/mL or during follow up of known PCa. The clinical value of f/t PSA is limited in the light of novel serum tests.

5.2.2.4 Additional serum testing

A few assays measuring a panel of kallikreins in serum or plasma are now commercially available, including the U.S. Food and Drug Administration (FDA) approved Prostate Health Index (PHI) test, (combining free and total PSA and the [-2]pro-PSA isoform [p2PSA]), and the four kallikrein (4K) score test (measuring free, intact and total PSA and kallikrein-like peptidase 2 [hK2] in addition to age, DRE and prior biopsy status). Both tests are intended to reduce the number of unnecessary prostate biopsies in PSA-tested men. A few prospective multicentre studies demonstrated that both the PHI and 4K score test out-performed f/t PSA PCa detection, with an improved prediction of clinically significant PCa in men with a PSA between 2-10 ng /mL [114, 136-138]. In a head-to-head comparison both tests performed equally [139].

5.2.2.5 Urine tests: PCA3 marker/SelectMDX/Mi Prostate score (MiPS)/ExoDX

Prostate cancer gene 3 (PCA3) is a prostate-specific, non-coding microRNA (mRNA) biomarker that is detectable in urine sediments obtained after three strokes of prostatic massage during DRE. The commercially available ProgenSA urine test for PCA3 is superior to total and percent-free PSA for detection of PCa in men with elevated PSA as it shows significant increases in the area under the receiver-operator characteristic curve for positive biopsies [140-143].

PCA3 score increases with PCa volume, but there are conflicting data about whether it independently predicts the ISUP grade, and its use for monitoring in active surveillance (AS) is, as yet, not confirmed [144]. Currently, the main indication for the ProgenSA test is to determine whether repeat biopsy is needed after an initially negative biopsy, but its clinical effectiveness for this purpose is uncertain [145]. Wei *et al.* showed 42% sensitivity at a cut-off of 60 in the primary biopsy setting with a high specificity (91%) and a PPV of 80% suggesting that the assay may be used in the primary setting [146].

The SelectMDX test is similarly based on mRNA biomarker isolation from urine. The presence of *HOXC6* and *DLX1* mRNA levels is assessed to provide an estimate of the risk of both presence of PCa on biopsy as well as presence of high-risk cancer [147].

TMPRSS2-ERG fusion, a fusion of the trans-membrane protease serine 2 (*TMPRSS2*) and the *ERG* gene can be detected in 50% of PCAs [148]. When detection of *TMPRSS2-ERG* in urine was added to PCA3 expression and serum PSA (Mi(chigan)Prostate Score [MiPS]), cancer prediction improved [149]. Exosomes secreted by cancer cells may contain mRNA diagnostic for high-grade PCa [150, 151]. Use of the ExoDx Prostate IntelliScore urine exosome assay resulted in avoiding 27% of unnecessary biopsies when compared to standard of care. However, currently, both the MiPS-score and ExoDx assay are considered investigational.

In six head-to-head comparison studies of PCA3 and PHI, only Seisen *et al.* found a significant difference; PCA3 detected more cancers, but for the detection of significant disease, defined as ISUP grade ≥ 2 , more than three positive cores, or > 50% cancer involvement in any core, PHI proved superior [152]. In the screening population of the ERSPC study the use of both PCA3 and 4K panel has added value to the risk calculator but the differences in AUC were less than 0.03 [111]. Based on the available evidence, some biomarkers could help in discriminating between aggressive and non-aggressive tumours with an additional value compared to the prognostic parameters currently used by clinicians [153]. Upfront mpMRI may likely affect the utility of above-mentioned biomarkers (see Section 5.2.4)

5.2.2.6 Guidelines for risk-assessment of asymptomatic men

Recommendation	LE	Strength rating
To avoid unnecessary biopsies, offer further risk-assessment to asymptomatic men with a normal digital rectal examination (DRE) and a prostate-specific antigen (PSA) level between 2-10 ng/mL prior to performing a prostate biopsy. Use one of the following tools: <ul style="list-style-type: none"> risk-calculator; imaging; an additional serum or urine-based test. 	3	Strong

5.2.3 Baseline biopsy

The need for prostate biopsy is based on PSA level and/or suspicious DRE and/or imaging (see Section 5.2.4). Age, potential comorbidity, and therapeutic consequences should also be considered and discussed beforehand [154]. Risk stratification is a potential tool for reducing unnecessary biopsies [154].

Limited PSA elevation alone should not prompt immediate biopsy. Prostate specific antigen level should be verified after a few weeks, in the same laboratory, using the same assay under standardised conditions (i.e. no ejaculation, manipulations, and urinary tract infections [UTIs]) [155, 156]. Empiric use of antibiotics in an asymptomatic patient in order to lower the PSA should not be undertaken [157].

Ultrasound (US)-guided biopsy is now the standard of care. Prostate biopsy is performed by either the transrectal or transperineal approach. Cancer detection rates, when performed without prior imaging with magnetic resonance imaging (MRI), are comparable between the two approaches [158], however some evidence suggests reduced infection risk with the transperineal route (see Section 5.2.6.4). Rectal disinfection with povidone-iodine may be considered [159].

Transurethral resection of the prostate should not be used as a tool for cancer detection [160].

5.2.4 The role of imaging in clinical diagnosis

5.2.4.1 Transrectal ultrasound (TRUS) and ultrasound-based techniques

Grey-scale TRUS is not reliable at detecting PCa [161]. Thus, there is no evidence that US-targeted biopsies can replace systematic biopsies. New sonographic modalities such as sonoelastography and contrast-enhanced US are still under investigation and not ready for routine use.

5.2.4.2 Multiparametric magnetic resonance imaging (mpMRI)

5.2.4.2.1 mpMRI performance in detecting ISUP grade ≥ 2 PCa

Correlation with RP specimens shows that mpMRI, associating T2-weighted imaging with at least one functional imaging technique (DWI, DCE, H1-spectroscopy), has good sensitivity for the detection and localisation of ISUP grade ≥ 2 cancers (see Table 5.2.4.1) [162-164]. This was further confirmed in patients who underwent template biopsies. In a recent Cochrane meta-analysis which compared mpMRI to template biopsies (≥ 20 cores) in biopsy-naïve and repeat-biopsy settings, mpMRI had a pooled sensitivity of 0.91 (95% CI: 0.83-0.95) and a pooled specificity of 0.37 (95% CI: 0.29-0.46) for ISUP grade ≥ 2 cancers [1]. For ISUP grade ≥ 3 cancers, mpMRI pooled sensitivity and specificity were 0.95 (95% CI: 0.87-0.99) and 0.35 (95% CI: 0.26-0.46), respectively. As a result, mpMRI is increasingly used to localise suspicious areas that could be targeted by so-called magnetic resonance imaging-targeted biopsies (MRI-TBx).

Table 5.2.4.1: PCa detection rates (%) by mpMRI for tumour volume and ISUP grade group in radical prostatectomy specimen [162]

ISUP grade group	Tumour volume (mL)		
	< 0.5	0.5-2	> 2
ISUP grade 1	21-29%	43-54%	67-75%
ISUP grade 2-3	63%	82-88%	97%
ISUP grade ≥ 4	80%	93%	100%

5.2.4.2.2 mpMRI performance in detecting ISUP grade group 1 PCa

Multiparametric magnetic resonance imaging is less sensitive in identifying ISUP grade 1 PCa. It identifies less than 30% of ISUP grade 1 cancers smaller than 0.5 cc identified on RP specimens by histopathology analysis (see Table 5.2.4.1) [162]. In series using template biopsy findings as the reference standard, mpMRI has a pooled sensitivity of 0.70 (95% CI: 0.59-0.80) and a pooled specificity of 0.27 (95% CI: 0.19-0.37) for identifying ISUP grade 1 cancers [1].

5.2.4.2.3 Does MRI-TBx improve the detection of ISUP grade ≥ 2 as compared to systematic biopsy?

In pooled data of 25 reports on agreement analysis (head-to-head comparisons) between systematic biopsy (median number of cores, 8-15) and MRI-TBx (median number of cores, 2-7), the detection ratio (i.e. the ratio of the detection rates obtained by MRI-TBx alone and by systematic biopsy alone) was 1.12 (95% CI: 1.02-1.23) for ISUP grade ≥ 2 cancers and 1.20 (95% CI: 1.06-1.36) for ISUP grade ≥ 3 cancers, and therefore in favour of MRI-TBx [1]. However, the pooled detection ratios for ISUP grade ≥ 2 cancers and ISUP grade ≥ 3 cancers were 1.44 (95% CI: 1.19-1.75) and 1.64 (95% CI: 1.27-2.11), respectively, in patients with prior negative systematic biopsies, and only 1.05 (95% CI: 0.95-1.16) and 1.09 (95% CI: 0.94-1.26) in biopsy-naïve patients. This confirms previous SRs that suggested that MRI-TBx significantly outperformed systematic biopsy in detecting clinically significant (cs)PCa in patients with prior negative systematic biopsy, but not in biopsy-naïve men [165, 166].

Three prospective multicentre RCTs evaluated MRI-TBx in biopsy-naïve patients. In the PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not? (PRECISION) trial, 500 biopsy-naïve patients were randomised to either MRI-TBx only or TRUS-guided systematic biopsy only. The detection rate of ISUP grade ≥ 2 cancers was significantly higher in men assigned to MRI-TBx (38%) than in those assigned to SBx (26%, $p = 0.005$, detection ratio 1.46) [167]. In the Assessment of Prostate MRI Before Prostate Biopsies (MRI-FIRST) trial, 251 biopsy-naïve patients underwent TRUS-guided systematic biopsy by an operator who was blinded to mpMRI findings, and MRI-TBx by another operator. MRI-TBx detected ISUP grade ≥ 2 cancers in a higher percentage of patients but the difference was not significant (32.3% vs. 29.9%, $p = 0.38$; detection ratio: 1.08) [168]. However, MRI-TBx detected significantly more ISUP grade ≥ 3 cancers than systematic biopsy (19.9% vs. 15.1%, $p = 0.0095$; detection ratio: 1.32). A similar trend for improved detection of ISUP grade ≥ 3 cancers by MRI-TBx was observed in the Cochrane analysis; however, it was not statistically significant (detection ratio 1.11 [0.88-1.40]) [1]. The Met Prostaat MRI Meer Mans (4M) study included 626 biopsy-naïve patients; all patients underwent systematic biopsy, and those with a positive mpMRI (Prostate Imaging Reporting and Data System [PI-RADS] 3-5, 51%) underwent additional in-bore MRI-TBx. The results were close to those of the MRI-FIRST trial with a detection ratio for ISUP grade ≥ 2 cancers of 1.09 (detection rate: 25% for MRI-TBx vs. 23% for systematic biopsy) [169]. However, in this study, MRI-TBx and systematic biopsy detected an equal number of ISUP grade ≥ 3 cancers (11% vs. 12%; detection ratio: 0.92).

Thus, MRI-TBx significantly outperforms systematic biopsy for the detection of ISUP grade ≥ 2 in the repeat-biopsy setting. In biopsy-naïve patients, the difference appears to be less marked; it is not significant in all series, but remains in favour of MRI-TBx in most studies.

5.2.4.2.4 Does MRI-TBx reduce the detection of ISUP grade 1 PCa as compared to systematic biopsy?

In pooled data of 25 reports on agreement analysis (head-to-head comparisons) between systematic biopsy and MRI-TBx, the detection ratio for ISUP grade 1 cancers was 0.62 (95% CI: 0.44-0.88) in patients with prior negative biopsy and 0.63 (95% CI: 0.54-0.74) in biopsy-naïve patients [1]. In the PRECISION and 4M trials, the detection rate of ISUP grade 1 patients was significantly lower in the MRI-TBx group (9% vs. 22%, $p < 0.001$, detection ratio of 0.41 for PRECISION; 14% vs. 25%, $p < 0.001$), detection ratio of 0.56 for 4M [167, 169]. In the MRI-FIRST trial, MRI-TBx detected significantly fewer patients with clinically insignificant PCa (defined as ISUP grade 1 and maximum cancer core length < 6 mm) than systematic biopsy (secondary objective, 5.6% vs. 19.5%, $p < 0.0001$, detection ratio of 0.29) [168]. Consequently, MRI-TBx significantly reduces over-diagnosis of low-risk disease, as compared to systematic biopsy.

5.2.4.2.5 The added value of systematic and targeted biopsy

Magnetic resonance imaging-targeted biopsies can be used in two different diagnostic pathways: 1) the 'combined pathway', in which patients with a positive mpMRI undergo combined systematic and targeted biopsy, and patients with negative mpMRI undergo systematic biopsy; 2) the 'MR pathway', in which patients with a positive mpMRI undergo only MRI-TBx, and patients with negative mpMRI are not biopsied at all.

Many studies evaluated combined systematic and targeted biopsy in the same patients and could therefore assess the added value of each technique (i.e. the percentage of patients diagnosed by only one biopsy technique). Data from a Cochrane meta-analysis of these studies and from the MRI-FIRST and 4M trials suggest that the added value of MRI-TBx for detecting ISUP grade ≥ 2 cancers is higher than that of systematic biopsy (see Table 5.2.4.2).

Table 5.2.4.2: Added values of targeted and systematic biopsies for ISUP grade ≥ 2 and ≥ 3 cancer detection

ISUP grade		ISUP ≥ 2			ISUP ≥ 3		
		Cochrane meta-analysis* [1]	MRI-FIRST trial* [168]	4M trial [169]	Cochrane meta-analysis* [1]	MRI-FIRST trial* [168]	4M trial [169]
Biopsy-naïve	Added value of MRI-TBx	6.3% (4.8-8.2)	7.6% (4.6-11.6)	7.0% (ND)	4.7% (3.5-6.3)	6.0% (3.4-9.7)	3.2% (ND)
	Added value of systematic biopsy	4.3% (2.6-6.9)	5.2% (2.8-8.7)	5.0% (ND)	2.8% (1.7-4.8)	1.2% (0.2-3.5)	4.1% (ND)
	Overall prevalence	27.7% (23.7-32.6)	37.5% (31.4-43.8)	30% (ND)	15.5% (12.6-19.5)	21.1% (16.2-26.7)	15% (ND)
Prior negative biopsy	Added value of MRI-TBx	9.6% (7.7-11.8)	-	-	6.3% (5.2-7.7)	-	-
	Added value of systematic biopsy	2.3% (1.2-4.5)	-	-	1.1% (0.5-2.6)	-	-
	Overall prevalence	22.8% (20.0-26.2)	-	-	12.6% (10.5-15.6)	-	-

* 95% CI.

ISUP = International Society for Urological Pathology (grade); MRI-TBx = magnetic resonance imaging-targeted biopsies; ND = not defined.

In Table 5.2.4.2, the added values refer to the percentage of patients in the entire cohort; if the cancer prevalence is taken into account, the ‘relative’ percentage of additional detected PCa can be computed. Adding MRI-TBx to systematic biopsy in biopsy-naïve patients increases the number of ISUP grade ≥ 2 and grade ≥ 3 PCa by approximately 20% and 30%, respectively. In the repeat-biopsy setting, adding MRI-TBx increases detection of ISUP grade ≥ 2 and grade ≥ 3 PCa by approximately 40% and 50%, respectively. Omitting systematic biopsy in biopsy-naïve patients would miss approximately 16% of ISUP grade ≥ 2 PCa and 18% of ISUP grade ≥ 3 PCa. In the repeat-biopsy setting, approximately 10% of ISUP grade ≥ 2 PCa and 9% of ISUP grade ≥ 3 PCa are missed.

5.2.4.2.6 Number of biopsy procedures potentially avoided in the ‘MR pathway’

The diagnostic yield and number of biopsy procedures potentially avoided by the ‘MR pathway’ depends on the Likert/PI-RADS threshold used to define positive mpMRI. In pooled studies on biopsy-naïve patients and patients with prior negative biopsies, a Likert/PI-RADS threshold of ≥ 3 would have avoided 30% (95% CI: 23-38) of all biopsy procedures while missing 11% (95% CI: 6-18) of all detected ISUP grade ≥ 2 cancers (relative percentage) [1]. Increasing the threshold to ≥ 4 would have avoided 59% (95% CI: 43-78) of all biopsy procedures while missing 28% (95% CI: 14-48) of all detected ISUP grade ≥ 2 cancers [1]. Of note, the percentages of negative mpMRI (Likert/PI-RADS score ≤ 2) in MRI-FIRST, PRECISION and 4M were 21.1%, 28.9% and 49%, respectively [167-169].

5.2.4.2.7 Other considerations

5.2.4.2.7.1 mpMRI reproducibility

Despite the use of the PIRADSV2 scoring system [170], mpMRI inter-reader reproducibility remains moderate at best [171-174], which currently limits its broad use by non-dedicated radiologists. In a community hospital that started a prostate mpMRI programme in 2010, cancer detection rates improved and false positives decreased with the implementation of PIRADSV2 scoring and multidisciplinary meetings using pathological correlation and feedback [175]. It is still too early to predict whether quantitative approaches and computer-aided diagnostic systems will improve the characterisation of lesions seen at mpMRI [176-178].

5.2.4.2.7.2 Targeted biopsy accuracy and reproducibility

Magnetic resonance imaging-targeted biopsies can be obtained through cognitive guidance, US/MR fusion software or direct in-bore guidance. Current literature does not show a clear superiority of one technique over another [179-183]. However, the accuracy of most systems have largely been evaluated on phantoms, and data on the accuracy and reproducibility in real-life patients are limited [183]. One study, using an elastic

US/MR fusion and intraprostatic fiducials, showed a median 3D registration error of 3.8-5.6 mm depending on the operator's experience. The error tended to be higher at the apex and in the anteroposterior direction [184].

Clinically significant PCa not detected by the 'MR pathway' can be missed because of MRI failure (invisible cancer or reader's misinterpretation) or because of targeting failure (target missed or undersampled by MRI-TBx). The PRECISION trial found a marked difference between targeted and systematic biopsies (detection ratio: 1.46), a finding the MRI-FIRST trial could not reproduce (detection ratio: 1.08). PRECISION allowed four targeted cores per lesion, while MRI-FIRST allowed only three, which might explain these findings. In a retrospective study of 211 patients with a unilateral mpMRI lesion, targeted biopsy alone detected 73.5% of all csPCa (ISUP grade ≥ 2); combining targeted biopsy with systematic biopsy of the lobe with the MRI lesion detected 96% of all csPCAs and combined targeted and systematic biopsy of the contralateral lobe only identified 81.6% of csPCAs [185]. The difference may reflect targeting errors leading to undersampling of the tumour. Increasing the number of cores taken per target may partially compensate for guiding imprecision, but there is currently no data on the minimum number of targeted cores to be obtained as a function of the prostate volume, lesion size and location. In addition, the inter-operator reproducibility of MRI-TBx is still unclear.

5.2.4.2.7.3 Role of risk-stratification

The negative predictive value (NPV) of a diagnostic test decreases when the disease prevalence increases, i.e. when the *a priori* risk of the patient increases. Therefore, the excellent NPV reported for mpMRI in the literature may not apply to patients with a risk of disease [186]. Prostate-specific antigen density [187-189] or risk-calculators [190] can select patients with a high risk of csPCa in whom mpMRI NPV is low, and who may still benefit from systematic biopsies even if the mpMRI is negative. Several groups have developed nomograms which combine mpMRI findings with simple clinical data as a tool to predict subsequent biopsy results. These nomograms require further validation, but in due time they may outperform predictors such as the ERSPC calculator in the selection of patients who may benefit from systematic and/or MRI-TBx [191-197].

5.2.4.3 Summary of evidence and practical considerations on pre-biopsy mpMRI

Magnetic resonance imaging-targeted biopsies substantially improve the detection of ISUP grade ≥ 2 PCa. This improvement is most notable in the repeat-biopsy setting, with marginal added value for systematic biopsies. It is less marked in biopsy-naïve patients in whom systematic biopsy retain a higher added value, at least for the detection of ISUP grade 2 cancers. Magnetic resonance imaging-targeted biopsies also detect significantly less ISUP grade 1 cancers than systematic biopsies.

The 'MR pathway' is appealing since it could decrease the number of biopsy procedures, reduce the detection of low-grade PCa while maintaining (or even improving) the detection of csPCa, as compared to systematic biopsy. Limitations of the 'MR pathway' are the moderate inter-reader reproducibility of mpMRI and the lack of standardisation of MRI-TBx, as well as the fact that its inter-operator reproducibility has not been evaluated. These caveats also apply to the systematic biopsy procedure. A substantial proportion of csPCa missed by the 'MR pathway' may be due to the imprecision of current targeting methods [168, 185]. Therefore, there is a crucial need to improve these methods, or at least to define the minimum number of targeted cores that need to be obtained from each lesion, as a function of its size, location and prostate volume. Without standardisation of mpMRI interpretation and of MRI-TBx technique, the 'MR pathway' may lead to suboptimal care outside large-volume (expert) centres.

Finally, it must be emphasised that the 'MR pathway' has only been evaluated in patients in whom the risk of csPCa was judged high enough to deserve biopsy. Pre-biopsy mpMRI must not be used in patients who do not have an indication for prostate biopsy based on their family history and clinical and biochemical data. Because of its low specificity, mpMRI in very low-risk patients would result in an inflation of false-positive findings and subsequent unnecessary biopsies.

5.2.4.4 Summary of evidence and guidelines for imaging

Summary of evidence	LE
Systematic biopsy is an acceptable approach if mpMRI is unavailable.	3

Recommendations for all patients	LE	Strength rating
Do not use mpMRI as an initial screening tool.	3	Strong
Adhere to PI-RADS guidelines for mpMRI acquisition and interpretation.	3	Strong

Recommendations in biopsy naïve patients	LE	Strength rating
Perform mpMRI before prostate biopsy.	1a	Weak
When mpMRI is positive (i.e. PI-RADS \geq 3), combine targeted and systematic biopsy.	2a	Strong
When mpMRI is negative (i.e. PI-RADS \leq 2), and clinical suspicion of prostate cancer is low, omit biopsy based on shared decision making with the patient.	2a	Weak

Recommendations in patients with prior negative biopsy	LE	Strength rating
Perform mpMRI before prostate biopsy.	1a	Strong
When mpMRI is positive (i.e. PI-RADS \geq 3), perform targeted biopsy only.	2a	Weak
When mpMRI is negative (i.e. PI-RADS \leq 2), and clinical suspicion of prostate cancer is high, perform systematic biopsy based on shared decision making with the patient.	2a	Strong

5.2.5 Repeat biopsy

5.2.5.1 Repeat biopsy after previously negative biopsy

The indications for repeat biopsy are:

- rising and/or persistently elevated PSA (see Table 5.2.1 for risk estimates);
- suspicious DRE, 5-30% PCa risk [117, 118];
- atypical small acinar proliferation (i.e. atypical glands suspicious for cancer), 31-40% PCa risk on repeat biopsy [198, 199];
- extensive (multiple biopsy sites, i.e. \geq 3) high-grade prostatic intraepithelial neoplasia (HGPIN), ~30% PCa risk [199, 200];
- a few atypical glands immediately adjacent to high-grade prostatic intraepithelial neoplasia (i.e. PINATYP), ~50% PCa risk [201];
- intraductal carcinoma as a solitary finding, > 90% risk of associated high-grade PCa [202];
- positive multiparametric MRI (mpMRI) findings (see Section 5.2.4.2).

5.2.5.1.1 Tests to select men for a repeat biopsy

In men with an elevated risk of PCa with a prior negative biopsy, additional information may be gained by the ProgenSA-PCA3 and SelectMDX DRE urine tests, the serum 4Kscore and PHI tests or a tissue-based epigenetic test (ConfirmMDx). The role of PHI, ProgenSA PCA3, and SelectMDX in deciding whether to take a repeat biopsy in men who had a previous negative biopsy is uncertain and probably not cost-effective [145]. The ConfirmMDx test is based on the concept that benign prostatic tissue in the vicinity of a PCa focus shows distinct epigenetic alterations. In case PCa is missed at biopsy, demonstration of epigenetic changes in the benign tissue would indicate the presence of carcinoma. The ConfirmMDX test quantifies the methylation level of promoter regions of three genes in benign prostatic tissue. A multicentre study found a NPV of 88% when methylation was absent in all three markers, implying that a repeat biopsy could be avoided in these men [203]. Given the limited available data and the fact that the role of mpMRI in tumour detection was not accounted for, no recommendation can be made regarding the routine application of ConfirmMDX, in particular in the light of the widespread use of mpMRI in the repeat-biopsy setting.

Table 5.2.5.1: Description of additional investigational tests after a negative prostate biopsy*

Name of test	Test substrate	Molecular	FDA approved
ProgenSA	DRE urine	lncRNA PCA3	yes
SelectMDX	DRE urine	mRNA <i>HOXC6</i> , <i>DLX1</i>	no
PHI	Serum	Total, free and p2PSA	yes
4Kscore Test	Serum/plasma	Total, free, intact PSA, hK2	no
ConfirmMDX	Benign prostate biopsy	Methylated <i>APC</i> , <i>RASSF1</i> and <i>GSTP1</i>	no

*Isolated high-grade prostatic intraepithelial neoplasia (PIN) in one or two biopsy sites is no longer an indication for repeat biopsy [204].

5.2.5.2 Saturation biopsy

The incidence of PCa detected by saturation repeat biopsy (> 20 cores) is 30-43% and depends on the number of cores sampled during earlier biopsies [205]. Saturation biopsy may be performed with the transperineal technique, which detects an additional 38% of PCa. The rate of urinary retention (10%) is a drawback [206].

5.2.6 Prostate biopsy procedure

5.2.6.1 Sampling sites and number of cores

On baseline biopsies, where no prior imaging with mpMRI has been performed, or where mpMRI has not shown any suspicious lesion, the sample sites should be bilateral from apex to base, as far posterior and lateral as possible in the peripheral gland. Additional cores should be obtained from suspect areas by DRE/TRUS. Sextant biopsy is no longer considered adequate. At least eight systematic biopsies are recommended in prostates with a size of about 30 cc [207]. Ten to twelve core biopsies are recommended in larger prostates, with > twelve cores not being significantly more conclusive [208, 209].

5.2.6.2 Antibiotics prior to biopsy

Oral or intravenous antibiotics are recommended. For transrectal biopsy, quinolones are the drugs of choice, with ciprofloxacin being superior to ofloxacin [210]. Increased quinolone resistance is associated with a rise in severe post-biopsy infection [211, 212]. Risk factors for quinolone resistance include previous TRUS biopsy, a current indwelling catheter, and any of: urogenital infection, international travel or hospital admission within the previous six months. To minimise risk of severe infection due to quinolone resistant rectal flora, patients with any of these risk factors should be offered either TRUS biopsy with prior rectal swab culture or targeted antibiotic prophylaxis [159]. For transperineal biopsy, which avoids rectal flora, a single dose of intravenous cephazolin only is sufficient [213, 214].

5.2.6.3 Local anaesthesia prior to biopsy

Ultrasound-guided periprostatic block is recommended [215]. It is not important whether the depot is apical or basal. Intrarectal instillation of local anaesthesia is inferior to periprostatic infiltration [216]. Local anaesthesia can also be used effectively for mpMRI-targeted transperineal biopsy [217]. Patients are placed in the lithotomy position. Bupivacaine is injected into the perineal skin and subcutaneous tissues, followed two minutes later by a peri-prostatic block. Targeted biopsies can then be taken via a brachytherapy grid or a freehand needle-guiding device [217-219].

5.2.6.4 Complications

Complications of TRUS biopsy are listed in Table 5.2.3 [220]. Severe post-procedural infections were initially reported in < 1% of cases, but have increased as a consequence of antibiotic resistance [221]. Low-dose aspirin is no longer an absolute contraindication [222]. A SR found favourable infection rates for transperineal compared to TRUS biopsies with similar rates of haematuria, haematospermia and urinary retention [223]. A meta-analysis of 4,280 men randomised between transperineal vs. TRUS biopsies in thirteen studies found no significant differences in complication rates, however, data on sepsis compared only 497 men undergoing TRUS biopsy to 474 having transperineal biopsy. The transperineal approach required more (local) anaesthesia [158].

Table 5.2.6.1: Percentage of complications per TRUS biopsy session, irrespective of the number of cores

Complications	Percentage of patients affected
Haematospermia	37.4
Haematuria > 1 day	14.5
Rectal bleeding < 2 days	2.2
Prostatitis	1.0
Fever > 38.5°C	0.8
Epididymitis	0.7
Rectal bleeding > 2 days +/- surgical intervention	0.7
Urinary retention	0.2
Other complications requiring hospitalisation	0.3

5.2.6.5 Seminal vesicle biopsy

Indications for seminal vesicle (staging) biopsies are poorly defined. At a PSA of > 15 ng/mL, the odds of tumour involvement are 20-25% [224]. A seminal vesicle staging biopsy is only useful if it has a decisive impact on treatment, such as ruling out radical tumour resection or for potential subsequent radiotherapy (RT). Its added value compared with mpMRI is questionable.

5.2.6.6 Transition zone biopsy

Transition zone sampling during baseline biopsies has a low detection rate and should be limited to repeat biopsies [225].

5.2.6.7 Fine-needle aspiration biopsy

Fine-needle aspiration biopsy is no longer recommended.

5.2.7 Pathology of prostate needle biopsies

5.2.7.1 Processing

Prostate core biopsies from different sites are processed separately. Before processing, the number and length of the cores are recorded. The length of biopsy tissue significantly correlates with the PCa detection rate [226]. To achieve optimal flattening and alignment, a maximum of three cores should be embedded per tissue cassette, and sponges or paper used to keep the cores stretched and flat [227, 228]. To optimise detection of small lesions, paraffin blocks should be cut at three levels and intervening unstained sections kept for immunohistochemistry [225].

5.2.7.2 Microscopy and reporting

Diagnosis of PCa is based on histology. The diagnostic criteria include features pathognomonic of cancer, major and minor features favouring cancer and features against cancer. Ancillary staining and additional (deeper) sections should be considered if a suspect lesion is identified [229-231]. Diagnostic uncertainty is resolved by intradepartmental or external consultation [229]. Table 5.2.7.1 lists the recommended terminology for reporting prostate biopsies [227].

Table 5.2.7.1: Recommended terminology for reporting prostate biopsies [227]

Recommended terminology	LE	Strength rating
Benign/negative for malignancy; if appropriate, include a description	3	Strong
Active inflammation		
Granulomatous inflammation		
High-grade prostatic intraepithelial neoplasia (PIN)		
High-grade PIN with atypical glands, suspicious for adenocarcinoma (PINATYP)		
Focus of atypical glands/lesion suspicious for adenocarcinoma/atypical small acinar proliferation, suspicious for cancer		
Adenocarcinoma		
Intraductal carcinoma		

Each biopsy site should be reported individually, including its location (in accordance with the sampling site) and histopathological findings, which include the histological type and the ISUP 2014 grade [75]. A global ISUP grade comprising all biopsies is also reported (see Section 4.2). The global ISUP grade takes into account all biopsies positive for carcinoma, by estimating the total extent of each Gleason grade present. For instance, if three biopsy sites are entirely composed of Gleason grade 3 and one biopsy site of Gleason grade 4 only, the global ISUP grade would be 2 (i.e. Gleason score 7[3+4]) or 3 (i.e. Gleason score 7[4+3]), dependent on whether the extent of Gleason grade 3 exceeds that of Gleason grade 4, whereas the worse grade would be ISUP grade 4 (i.e. Gleason score 8[4+4]). Recent publications demonstrated that global ISUP grade is somewhat superior in predicting prostatectomy ISUP grade [232] and BCR [233].

Intraductal carcinoma, lymphovascular invasion (LVI) and extraprostatic extension (EPE) must each be reported, if identified. More recently, expansile cribriform pattern of PCa as well as intraductal carcinoma in biopsies were identified as independent prognosticators of metastatic disease [234] and PCa-specific survival [235].

The proportion of carcinoma-positive cores as well as the extent of tumour involvement per biopsy core correlate with the ISUP grade, tumour volume, surgical margins and pathologic stage in RP specimens and predict BCR, post-prostatectomy progression and RT failure. These parameters are included in nomograms created to predict pathologic stage and seminal vesicle invasion after RP and RT failure [236-238]. A pathology report should therefore provide both the proportion of carcinoma-positive cores and the extent of cancer involvement for each core. The length in mm and percentage of carcinoma in the biopsy have equal prognostic impact [239]. An extent of > 50% of adenocarcinoma in a single core is used in some AS protocols as a cut off [240] triggering immediate treatment vs. AS in patients with ISUP grade 1.

A prostate biopsy that does not contain glandular tissue should be reported as diagnostically inadequate. Mandatory elements to be reported for a carcinoma-positive prostate biopsy are:

- type of carcinoma;
- primary and secondary/worst Gleason grade (per biopsy site and global);
- percentage high-grade carcinoma (global);

- extent of carcinoma (in mm or percentage) (at least per biopsy site);
- if present: EPE, seminal vesicle invasion, LVI, intraductal carcinoma/cribiform pattern, peri-neural invasion;
- ISUP grade (global).

5.2.7.3 *Tissue-based prognostic biomarker testing*

The Prolaris test (Myriad Genetics) measures the expression of 31 cell-cycle associated genes in biopsy-derived PCa tissue and may be of clinical use to determine whether a patient needs curative treatment or may have his treatment deferred [241]. A SR on the topic concluded that cell-cycle-associated gene expression can be helpful in predicting BCR risk after local treatment and may alter clinical decision-making but the economic impact on healthcare systems remains to be determined [242].

Similarly, Oncotype Dx® is a RNA-based test based on twelve carcinoma-associated genes and five reference genes which can be applied to carcinoma tissue in prostate biopsies to determine the aggressiveness of the carcinoma. Both tests were shown in prospective studies to provide prognostic information in men with clinically localised PCa, additional to conventional clinico-pathological parameters, including ISUP grade and PSA level. The results of prospective multicentre studies are awaited before a recommendation can be made regarding their routine application.

5.2.7.4 *Histopathology of radical prostatectomy specimens*

5.2.7.4.1 *Processing of radical prostatectomy specimens*

Histopathological examination of RP specimens describes the pathological stage, histopathological type, grade and surgical margins of PCa. It is recommended that RP specimens are totally embedded, to enable assessment of cancer location, multifocality and heterogeneity. For cost-effectiveness, partial embedding may also be considered, particularly for prostates > 60 g. The most widely accepted method includes complete embedding of the posterior prostate, and a single mid-anterior left and right section. Compared with total embedding, partial embedding detected 98% of PCa with an ISUP grade ≥ 2 with accurate staging in 96% of cases [243].

Ink the entire RP specimen upon receipt in the laboratory, to demonstrate the surgical margins. Specimens are fixed by immersion in buffered formalin for at least 24 hours, preferably before slicing. Fixation can be enhanced by injecting formalin, which provides more homogeneous fixation and sectioning after 24 hours [244]. After fixation, the apex and the base (bladder neck) are removed and cut into (para)sagittal or radial sections; the shave method is not recommended [74]. The remainder of the specimen is cut in transverse, 3-4 mm sections, perpendicular to the long axis of the urethra. The resultant tissue slices can be embedded and processed as whole-mounts or after quadrant sectioning. Whole-mounts provide better topographic visualisation, faster histopathological examination and better correlation with pre-operative imaging, although they are more time-consuming and require specialist handling. For routine sectioning, the advantages of whole mounts do not outweigh their disadvantages.

5.2.7.4.1.1 *Guidelines for processing prostatectomy specimens*

Recommendations	LE	Strength rating
Ensure total embedding, by conventional (quadrant) or whole-mount sectioning.	3	Strong
Ink the entire surface before cutting, to evaluate the surgical margin.	3	Strong
Examine the apex and base separately, using the cone method with sagittal or radial sectioning.	3	Strong

5.2.7.4.2 *Radical prostatectomy specimen report*

The pathology report provides essential information on the prognostic characteristics relevant for clinical decision-making (Table 5.2.7.1). As a result of the complex information to be provided for each RP specimen, the use of synoptic(-like) or checklist reporting is recommended (Table 5.2.7.2). Synoptic reporting results in more transparent and complete pathology reporting [245].

Table 5.2.7.1: Mandatory elements provided by the pathology report

Histopathological type: > 95% of PCa represents conventional (acinar) adenocarcinoma.
Grading according to ISUP grade (or not applicable if therapy-related changes).
Tumour (sub)staging and surgical margin status: location and extent of EPE, presence of bladder neck invasion, laterality of EPE or seminal vesicle invasion, location and extent of positive surgical margins.
Additional information may be provided on multifocality, and diameter/volume and zonal location of the dominant tumour.

Table 5.2.7.2: Example checklist: reporting of prostatectomy specimens

Histopathological type
Type of carcinoma, e.g. conventional acinar, or ductal
Histological grade
Primary (predominant) Gleason grade
Secondary Gleason grade
Tertiary Gleason grade (if applicable)
Global ISUP grade
Approximate percentage of Gleason grade 4 or 5
Tumour quantitation (optional)
Percentage of prostate involved
Size/volume of dominant tumour nodule
Pathological staging (pTNM)
<i>If extraprostatic extension is present:</i> indicate whether it is focal or extensive; specify sites; indicate whether there is seminal vesicle invasion.
<i>If applicable, regional lymph nodes:</i> location; number of nodes retrieved; number of nodes involved.
Surgical margins
<i>If carcinoma is present at the margin:</i> specify sites.
Other
Presence of lymphovascular/angio-invasion
Location of dominant tumour
Presence of intraductal carcinoma/cribriform architecture

5.2.7.4.3 ISUP grade in prostatectomy specimens

Grading of conventional prostatic adenocarcinoma using the (ISUP 2014 modified) Gleason system is the strongest prognostic factor for clinical behaviour and treatment response [75]. The ISUP grade is incorporated in nomograms that predict disease-specific survival (DSS) after prostatectomy [246].

The ISUP grade is based on the sum of the most and second-most dominant (in terms of volume) Gleason grade. ISUP grade 1 is any Gleason score ≤ 6 (including $< 5\%$ Gleason grade 4). ISUP grades 2 and 3 represent carcinomas constituted of Gleason grade 3 and 4 components, with ISUP grade 2 when 50% of the carcinoma, or more, is Gleason grade 3 and ISUP grade 3 when the grade 4 component represents more than 50% of the carcinoma. ISUP grade 4 is largely composed of Gleason grade 4 and ISUP grade 5 of a combination of Gleason grade 4 and 5 or only Gleason grade 5. A global ISUP grade is given for multiple tumours, but a separate tumour focus with a higher ISUP grade should also be mentioned. Tertiary Gleason grade 5, particularly if $> 5\%$ of the PCa volume, is an unfavourable prognostic indicator for BCR. The tertiary Gleason grade and its approximate proportion of the cancer volume should also be reported in addition to the global ISUP grade (see Section 4.2) [247].

5.2.7.4.4 Definition of extraprostatic extension

Extraprostatic extension is defined as carcinoma mixed with periprostatic adipose tissue, or tissue that extends beyond the prostate gland boundaries (e.g., neurovascular bundle, anterior prostate). Microscopic bladder

neck invasion is considered EPE. It is useful to report the location and extent of EPE because the latter is related to recurrence risk [248].

There are no internationally accepted definitions of focal or microscopic, vs. non-focal or extensive EPE. Some describe focal as a few glands [249] or extension as < 1 per high-power field (HPF) [250], whereas others measure the depth of extent in millimetres [251].

At the apex of the prostate, tumour mixed with skeletal muscle does not constitute EPE. In the bladder neck, microscopic invasion of smooth muscle fibres is not equated to bladder wall invasion, i.e. not as pT4, because it does not carry independent prognostic significance for PCa recurrence [252, 253] and should be recorded as EPE (pT3a). A positive margin at the bladder neck should be reported as EPE (pT3a) with positive margin, and not as pT4. Stage pT4 is only assigned when the tumour invades the bladder muscle wall as determined macroscopically [254].

5.2.7.4.5 PCa volume

The independent prognostic value of PCa volume in RP specimens has not been established [250, 255-258]. Nevertheless, a cut-off of 0.5 mL is traditionally used to distinguish insignificant from clinically relevant cancer [255]. Improvement in prostatic radio-imaging allows more accurate pre-operative measurement of cancer volume. It is recommended that at least the diameter/volume of the dominant tumour nodule should be assessed, or a rough estimate of the percentage of cancer tissue provided [259].

5.2.7.4.6 Surgical margin status

Surgical margin is an independent risk factor for BCR. Margin status is positive if tumour cells are in contact with the ink on the specimen surface. Margin status is negative if tumour cells are close to the inked surface [256] or at the surface of the tissue lacking ink. In tissues that have severe crush artefacts, it may not be possible to determine margin status [260].

Surgical margin is separate from pathological stage, and a positive margin is not evidence of EPE [261]. There is insufficient evidence to prove a relationship between margin extent and recurrence risk [250]. However, some indication must be given of the multifocality extent of margin positivity, such as the linear extent in mm of involvement: focal, ≤ 1 mm vs. extensive, > 1 mm [262], or number of blocks with positive margin involvement. Gleason score at the positive margin was found to correlate with outcome, and should be reported [263].

5.2.8 Guidelines for the clinical diagnosis of prostate cancer

Recommendations	LE	Strength rating
In symptomatic men, base the initial decision to perform a biopsy on prostate-specific antigen testing and digital rectal examination.	2b	Strong
Perform transrectal prostate needle biopsies under antibiotic protection.	1b	Strong
Use a local anaesthetic by periprostatic infiltration for transrectal prostate needle biopsies.	1a	Strong
Do not offer transition zone sampling at initial biopsies due to low detection rates.	2b	Weak
Ensure that prostate core biopsies from different sites are submitted separately for processing and pathology reporting.	3	Strong
Use the International Society of Urological Pathology (ISUP) 2014 system for grading of PCa.	2a	Strong
Do not use transurethral resection of the prostate as a tool for cancer detection.	2a	Strong

5.3 Diagnosis – Clinical Staging

The extent of PCa is evaluated by DRE and PSA, and may be supplemented with mpMRI, bone scanning and computed tomography (CT).

5.3.1 T-staging

The cT category used in the risk table only refers to the DRE finding. The imaging parameters and biopsy results for local staging are, so far, not part of the risk category stratification.

5.3.1.1 TRUS

Transrectal ultrasound is no more accurate at predicting organ-confined disease than DRE [264]. Transrectal US-derived techniques (e.g. 3D-TRUS, colour Doppler) cannot differentiate between T2 and T3 tumours with sufficient accuracy to be recommended for staging [197, 265, 266].

5.3.1.2 *mpMRI*

T2-weighted imaging remains the most useful method for local staging on mpMRI. At 1.5 Tesla, mpMRI has good specificity but low sensitivity for detecting T3 stages. Pooled data from a meta-analysis for EPE, SVI, and overall stage T3, showed a sensitivity and specificity of 0.57 (95% CI: 0.49-0.64) and 0.91 (95% CI: 0.88-0.93), 0.58 (95% CI: 0.47-0.68) and 0.96 (95% CI: 0.95-0.97), and 0.61 (95% CI: 0.54-0.67) and 0.88 (95% CI: 0.85-0.91), respectively [267]. Multiparametric MRI cannot detect microscopic EPE. Its sensitivity increases with the radius of extension within periprostatic fat. In one study, the EPE detection rate increased from 14 to 100% when the radius of extension increased from < 1 mm to > 3 mm [268]. In another study, mpMRI sensitivity, specificity and accuracy for detecting pT3 stage were 40%, 95% and 76%, respectively, for focal (i.e. microscopic) EPE, and 62%, 95% and 88% for extensive EPE [269].

The use of high field strength (3 Tesla) or functional imaging in addition to T2-weighted imaging improves sensitivity for EPE or SVI detection [267], but the experience of the reader remains of paramount importance [270] and the inter-reader agreement remains moderate with kappa values ranging from 0.41 to 0.68 [271]. Multiparametric MRI, although not perfect for local staging, may improve the prediction of the pathological stage when combined with clinical data [272, 273]. Other MRI-derived parameters such as the tumour volume or the contact length of the tumour with the capsule [274-276], or the ISUP grade obtained through MRI-TBx [277] could further improve the local staging.

Given its low sensitivity for focal (microscopic) EPE, mpMRI is not recommended for local staging in low-risk patients [272, 278, 279]. However, mpMRI can still be useful for treatment planning.

5.3.2 ***N-staging***

5.3.2.1 *Computed tomography (CT) and magnetic resonance imaging*

Abdominal CT and T1-T2-weighted MRI indirectly assess nodal invasion by using LN diameter and morphology. However, the size of non-metastatic LNs varies widely and may overlap the size of LN metastases. Usually, LNs with a short axis > 8 mm in the pelvis and > 10 mm outside the pelvis are considered malignant. Decreasing these thresholds improves sensitivity but decreases specificity. As a result, the ideal size threshold remains unclear [280, 281]. Computed tomography and MRI sensitivity is less than 40% [282, 283]. Among 4,264 patients, 654 (15.3%) of whom had positive LNs at LND, CT was positive in only 105 patients (2.5%) [280]. In a multicentre database of 1,091 patients who underwent pelvic LN dissection, CT sensitivity and specificity were 8.8% and 98%, respectively [284]. Detection of microscopic LN invasion by CT is < 1% in patients with ISUP grade < 4 cancer, PSA < 20 ng/mL, or localised disease [285-287].

Diffusion-weighted MRI may detect metastases in normal-sized nodes, but a negative diffusion-weighted MRI cannot rule out the presence of LN metastases [281, 288].

5.3.2.2 *Choline PET/CT*

In a meta-analysis of 609 patients, pooled sensitivity and specificity of choline PET/CT for pelvic LN metastases were 62% (95% CI: 51-66%) and 92% (95% CI: 89-94%), respectively [289]. In a prospective trial of 75 patients at intermediate risk of nodal involvement (10-35%), the sensitivity was only 8.2% at region-based analysis and 18.9% at patient-based analysis, which is too low to be of clinical value [290]. The sensitivity of choline PET/CT increases to 50% in patients at high risk and to 71% in patients at very high risk, in both cases outperforming contrast-enhanced CT [291]. However, comparisons between choline PET/CT and diffusion-weighted MRI yielded contradictory results, with PET/CT sensitivity found to be superior [292], similar [293, 294] or inferior [290] than that of diffusion-weighted MRI.

Due of its low sensitivity, choline PET/CT does not reach clinically acceptable diagnostic accuracy for detection of LN metastases, or to rule out a nodal dissection based on risk factors or nomograms (see Section 6.1.2.1.1).

5.3.2.3 *Prostate-specific membrane antigen-based PET/CT*

⁶⁸Ga- or ¹⁸F-labelled prostate-specific membrane antigen PET/CT (PSMA PET/CT) is increasingly used, because it provides excellent contrast-to-noise ratio, thereby improving the detectability of lesions. Prostate-specific membrane antigen is also an attractive target because of its specificity for prostate tissue, even if non-prostatic expression of PSMA in other malignancies, sarcoidosis or benign bone diseases may cause incidental false-positive findings [295-298].

Preliminary assessment of PSMA PET/CT showed promising sensitivity for LN involvement. A meta-analysis of five retrospective studies using histological correlation as reference standard and performed in an initial staging and/or recurrence setting reported combined sensitivities and specificities of 86% (95% CI: 37-98%) and 86% (95% CI: 3-100%) at patient level, and 80% (95% CI: 66-89%) and 97% (95% CI: 92-99%) at lesion level, [299] using LND as reference. A multicentre prospective study has recently compared PSMA PET/CT and LN dissection findings in 51 high-risk patients with negative ^{99m}Tc bone scan. At patient level, PSMA PET/CT sensitivity and specificity were 53% and 86%, respectively. The mean maximal length of metastases within LNs detected and missed by PSMA PET/CT was 13.1 ± 7.7 mm and 3.9 ± 2.7 mm

respectively [300]. Another prospective single-centre study also found that metastatic LNs missed by PSMA PET/CT were on average < 5 mm [301]. The tracer uptake is also influenced by the ISUP grade and the PSA level. In a series of 90 patients with primary PCa, tumours with a ISUP grade between 1 and 3 showed significantly lower tracer uptake than tumours with a ISUP grade \geq 4. Similarly, patients with PSA levels \geq 10 ng/mL showed significantly higher uptake than those with PSA levels < 10 ng/mL [302].

Comparison between PSMA PET/CT and mpMRI yielded similar results in a group of 42 consecutive patients with intermediate- to high-risk PCa [303]. Another prospective trial reported superior sensitivity of PSMA PET/CT as compared to mpMRI for nodal staging of 36 high-risk PCas [304]. Therefore, PSMA PET/CT has higher sensitivity for LN metastases as compared to abdominal contrast-enhanced CT or choline PET/CT; however, small LN metastases may still be missed.

5.3.3 M-staging

5.3.3.1 Bone scan

^{99m}Tc-Bone scan has been the most widely used method for evaluating bone metastases of PCa. A recent meta-analysis showed combined sensitivity and specificity of 79% (95% CI: 73-83%) and 82% (95% CI: 78-85%) at patient level and 59% (95% CI: 55-63%) and 75% (95% CI: 71-79%) at lesion level [305]. Bone scan diagnostic yield is significantly influenced by the PSA level, the clinical stage and the tumour ISUP grade and these three factors were the only independent predictors of bone scan positivity in a study of 853 patients [306]. The mean bone scan positivity rate in 23 different series was 2.3% in patients with PSA levels < 10 ng/mL, 5.3% in patients with PSA levels between 10.1 and 19.9 ng/mL and 16.2% in patients with PSA levels of 20.0-49.9 ng/mL. It was 6.4% in men with organ-confined cancer and 49.5% in men with locally advanced cancers. Detection rates were 5.6% and 29.9% for ISUP grade 2 and \geq 3, respectively [280]. In two studies, a major Gleason pattern of 4 was found to be a significant predictor of positive bone scan [307, 308].

Bone scanning should be performed in symptomatic patients, independent of PSA level, ISUP grade or clinical stage [280].

5.3.3.2 Fluoride PET and PET/CT, choline PET/CT and MRI

¹⁸F-sodium fluoride (¹⁸F-NaF) PET or PET/CT shows similar specificity and superior sensitivity to bone scan [309, 310]. However, unlike choline PET/CT, ¹⁸F-NaF PET does not detect LN metastases, and is less cost-effective compared to bone scan [309].

It remains unclear whether choline PET/CT is more sensitive than bone scan, but it has higher specificity, with fewer indeterminate bone lesions [289, 311, 312].

Diffusion-weighted whole-body and axial MRI are more sensitive than bone scan and targeted conventional radiography in detecting bone metastases in high-risk PCa [313, 314]. Whole-body MRI is also more sensitive and specific than combined bone scan, targeted radiography and abdominopelvic CT [315]. A meta-analysis found that MRI is more sensitive than choline PET/CT and bone scan for detecting bone metastases on a per-patient basis, although choline PET/CT had the highest specificity [305].

It is of note that choline PET/CT and diffusion-weighted MRI can also detect visceral metastases. Bone scan and ¹⁸F-NaF PET/CT only assess the presence of bone metastases.

5.3.3.3 Prostate-specific membrane antigen-based PET/CT

There is growing evidence on the performance of ⁶⁸Ga-PSMA PET/CT in initial staging. A recent SR including twelve studies and comprising a total of 322 patients reported high variation in sensitivity (range 33-99% median sensitivity on per-lesion analysis 33-92%, and on per-patient analysis 66-91%), with good specificity (per-lesion 82-100%, and per-patient 67-99%), with most studies demonstrating increased detection rates with respect to conventional imaging modalities (bone scan and CT) [316]. Table 5.3.1 reports the data of the five studies including histopathologic correlation.

Table 5.3.1: PSMA PET/CT results in primary staging alone [316]

Study	Sensitivity (per lesion)	Specificity (per lesion)	PPV (per lesion)	NPV (per lesion)
Budaus	33%	100%	100%	69%
Herlemann	84%	82%	84%	82%
Van Leeuwen	58%	100%	94%	98%
Maurer	74%	99%	95%	94%
Rahbar	92%	92%	96%	85%

NPV = negative predictive value; PPV = positive predictive value.

One prospective multicentre study evaluated changes in planned management before and after PSMA PET/CT in 108 intermediate- and high-risk patients referred for primary staging. As compared to conventional staging, additional LNs and bone/visceral metastases were detected in 25% and 6% of patients, respectively [317]; management changes occurred in 21% of patients.

5.3.4 **Summary of evidence and practical considerations on initial N/M staging**

The field of non-invasive nodal and metastatic staging of PCa is evolving very rapidly. Evidence shows that choline PET/CT, PSMA PET/CT and MRI provide a more sensitive detection of LN and bone metastases than the classical work-up associating bone scan and abdominopelvic CT. It could be tempting to conclude that bone scan and abdominopelvic CT must be replaced by more sensitive tests in all patients undergoing initial PCa staging. Yet, the clinical benefit of detecting metastases at an earlier time-point remains unclear [318].

The prognosis and ideal management of patients diagnosed as metastatic by these more sensitive tests is unknown. In particular, it is unclear whether patients with metastases, detectable only with PET/CT or MRI, should be managed using systemic therapies, or whether they should be submitted to aggressive local and metastases-directed therapies [319].

Results from RCTs evaluating the management and outcome of patients with (and without) metastases detected by choline PET/CT, PSMA PET/CT and MRI are awaited, before a decision can be made to treat patients based on the results of these tests [320].

5.3.5 **Guidelines for staging of prostate cancer**

Any risk group staging	LE	Strength rating
Do not use computed tomography and transrectal ultrasound for local staging.	2a	Strong
Use pre-biopsy mpMRI for staging information.	2a	Weak
Low-risk localised disease		
Do not use additional imaging for staging purposes.	2a	Strong
Intermediate-risk disease		
In ISUP grade ≥ 3 , include at least a cross-sectional abdominopelvic imaging and bone-scan for metastatic screening.	2a	Weak
High-risk localised disease/locally advanced disease		
Perform metastatic screening including at least cross-sectional abdominopelvic imaging and a bone-scan.	2a	Strong

5.4 **Evaluating life expectancy and health status**

5.4.1 **Introduction**

Evaluation of life expectancy and health status is important in clinical decision-making on screening, diagnosis, and treatment of PCa. Prostate cancer is common in older men (median age 68) and diagnoses in men > 65 will result in a 70% increase in annual diagnosis by 2030 in Europe and the USA [321, 322].


Active treatment mostly benefits patients with intermediate- or high-risk PCa and longest expected survival. In localised disease, over ten years life expectancy is considered mandatory for any benefit from local treatment and an improvement in CSS may take longer to become apparent. Older age and worse baseline health status have been associated with a smaller benefit in PCa-specific mortality (PCSM) and life expectancy of surgery vs. AS [323]. Although in a RCT the benefit of surgery with respect to death from PCa was largest in men < 65 years of age (RR: 0.45), RP was associated with a reduced risk of metastases and use of androgen deprivation therapy (ADT) among older men (RR: 0.68 and 0.60, respectively) [324]. External beam radiotherapy shows similar cancer control regardless of age, assuming a dose of > 72 Gy when using intensity-modulated or image-guided RT [325].

Older men with a high incidence of PCa may be under-treated despite the high overall mortality rates [326, 327]. Of all PCa-related deaths 71% occur in men aged ≥ 75 years [328], probably due to the higher incidence of advanced disease and death from PCa despite higher death rates from competing causes [329-331]. In the USA, only 41% of patients aged > 75 years with intermediate- and high-risk disease receive curative treatment compared to 88% aged 65-74 [332].

5.4.2 **Life expectancy**

Life expectancy tables for European men are available at: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_mlexpec&lang=en. Individual survival may be very variable and therefore must be individualised. Gait speed is a good single predictive measure (from a standing start, at usual pace, generally over six meters). For men at age 75, ten-year survival ranged from 19% < 0.4 m/s to 87%, for ≥ 1.4 m/s [333].

Figure 5.4.1: Predicted Median Life Expectancy by Age and Gait Speed for males* [333].



*Figure reproduced with permission of the publisher, from Studenski S, et al. JAMA 2011 305(1)50.

5.4.3 Health status screening

The International SIOG PCa Working Group recommends that treatment for senior adults should be based on a systematic evaluation of health status using the G8 (Geriatric 8) screening tool (Table 5.4.1) [334]. Healthy patients with a G8 score > 14 or frail patients with reversible impairment after resolution of their geriatric problems should receive the same treatment as younger patients. Disabled patients with irreversible impairment should receive adapted treatment. Patients who are too ill should receive only palliative treatment (Figure 1) [334]. Patients with a G8 score ≤ 14 should undergo a full geriatric evaluation as this score is associated with three-year mortality, assessing comorbidity, nutritional status, and cognitive and physical functions, to determine if the impairment is reversible [335].

5.4.3.1 Comorbidity

Comorbidity is a major predictor of non-cancer-specific death in localised PCa treated with RP and is more important than age [336, 337]. Ten years after not receiving active treatment for PCa, most men with a high comorbidity score had died from competing causes, irrespective of age or tumour aggressiveness [336]. Measures for comorbidity include: Cumulative Illness Score Rating-Geriatrics (CISR-G) [338, 339] (Table 5.4.2) and Charlson Comorbidity Index (CCI) [340].

5.4.3.2 Nutritional status

Malnutrition can be estimated from body weight during the previous three months (good nutritional status < 5% weight loss; risk of malnutrition: 5-10% weight loss; severe malnutrition: > 10% weight loss) [341].

5.4.3.3 Cognitive function

Cognitive impairment can be measured using mini-COG (<https://mini-cog.com/>), which assesses the patient's ability to make an informed decision which is an increasingly important factor in health status assessment [342-344].

5.4.3.4 Physical function

Measures for overall physical functioning include: Karnofsky score and ECOG scores [345]. Measures for dependence in daily activities include: Activities of Daily Living (ADL; basic activities) and Instrumental Activities of Daily Living (IADL; activities requiring higher cognition and judgement) [346-348].


5.4.4 Conclusion

Individual life expectancy, health status, and comorbidity, not only age, should be central in clinical decisions on screening, diagnostics, and treatment for PCa. A life expectancy of ten years is most commonly used as a threshold for benefit of local treatment. Older men may be undertreated. Resolution of impairments in frail men allows a similar urological approach as in fit patients.

Table 5.4.1: G8 screening tool (adapted from [349])

	Items	Possible responses (score)
A	Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing, or swallowing difficulties?	0 = severe decrease in food intake
		1 = moderate decrease in food intake
		2 = no decrease in food intake
B	Weight loss during the last 3 months?	0 = weight loss > 3 kg
		1 = does not know
		2 = weight loss between 1 and 3 kg
		3 = no weight loss
C	Mobility?	0 = bed or chair bound
		1 = able to get out of bed/chair but does not go out
		2 = goes out
D	Neuropsychological problems?	0 = severe dementia or depression
		1 = mild dementia
		2 = no psychological problems
E	BMI? (weight in kg)/(height in m ²)	0 = BMI < 19
		1 = BMI 19 to < 21
		2 = BMI 21 to < 23
		3 = BMI ≥ 23
F	Takes more than three prescription drugs per day?	0 = yes
		1 = no
G	In comparison with other people of the same age, how does the patient consider his/her health status?	0.0 = not as good
		0.5 = does not know
		1.0 = as good
		2.0 = better
	Age	0: > 85
	1: 80-85	
	2: < 80	
	Total score	0-17

Figure 5.4.1: Decision tree for health status screening (men > 70 years)* [334]



*Reproduced with permission of Elsevier, from Droz J-P, et al. *Eur Urol* 2017;72(4): 521 [334].
 Mini-COG™ = cognitive test; ADL = activities of daily living; CISR-G = cumulative illness rating score-geriatrics; CGA = comprehensive geriatric assessment.

Table 5.4.2: Cumulative Illness Score Rating-Geriatrics (CISR-G)

1	Cardiac (heart only)
2	Hypertension (rating is based on severity; affected systems are rated separately)
3	Vascular (blood, blood vessels and cells, marrow, spleen, lymphatics)
4	Respiratory (lungs, bronchi, trachea below the larynx)
5	ENT (eye, ear, nose, throat, larynx)
6	Upper GI (esophagus, stomach, duodenum. Biliar and parcreatic trees; do not include diabetes)
7	Lower GI (intestines, hernias)
8	Hepatic (liver only)
9	Renal (kidneys only)
10	Other GU (ureters, bladder, urethra, prostate, genitals)
11	Musculo-Skeletal-Integumentary (muscles, bone, skin)
12	Neurological (brain, spinal cord, nerves; do not include dementia)
13	Endocrine-Metabolic (includes diabetes, diffuse infections, infections, toxicity)
14	Psychiatric/Behavioural (includes dementia, depression, anxiety, agitation, psychosis)
All body systems are scores on a 0 - 4 scale. - 0: No problem affecting that system. - 1: Current mild problem or past significant problem. - 2: Moderate disability or morbidity and/or requires first line therapy. - 3: Severe problem and/or constant and significant disability and/or hard to control chronic problems. - 4: Extremely severe problem and/or immediate treatment required and/or organ failure and/or severe functional impairment.	
Total score 0-52	

5.4.5 Guidelines for evaluating health status and life expectancy

Recommendations	Strength rating
Use individual life expectancy, health status, and comorbidity in PCa management.	Strong
Systematically screen the health status of older men (> 70 years) diagnosed with PCa.	Strong
Use the Geriatric-8 and mini-COG tools for health status screening.	Strong
Perform a full specialist geriatric evaluation in patients with a G8 score \leq 14.	Strong
Consider standard treatment in frail patients with reversible impairments (after resolution of geriatric problems) similar to fit patients, if life expectancy is > 10 years.	Weak
Offer adapted treatment to patients with irreversible impairment.	Weak
Offer palliation to patients with poor health status.	Weak

6. TREATMENT

This chapter reviews the available treatment modalities, followed by separate sections addressing treatment for the various disease stages.

6.1 Treatment modalities

6.1.1 Deferred treatment (active surveillance/watchful waiting)

In localised disease a life expectancy of at least ten years is considered mandatory for any benefit from local treatment. Remember that comorbidity is more important than age in predicting life expectancy in men with PCa. Increasing comorbidity greatly increases the risk of dying from non-PCa-related causes and for those men with a short life expectancy, watchful waiting (WW) with symptom-guided treatment is appropriate in order to maintain QoL [350]. In addition, many men with low-risk screening-detected localised PCa will not benefit from curative treatment [351]. Mortality from untreated screen-detected PCa in patients with ISUP grade 1-2 might be as low as 7% at fifteen years follow-up [351]. Consequently, approximately 45% of men with PSA-detected PCa are suitable for close follow-up through a robust surveillance programme.

There are two distinct strategies for conservative management that aim to reduce over-treatment: AS and WW (Table 6.1.1).

6.1.1.1 Definitions

Active surveillance aims to avoid unnecessary treatment in men with clinically localised PCa who do not require immediate treatment, but at the same time achieve the correct timing for curative treatment in those who eventually do [352]. Patients remain under close surveillance through structured surveillance programmes with regular follow-up, and curative treatment is prompted by predefined thresholds indicative of potentially life-threatening disease which is still potentially curable, while considering individual life expectancy.

Watchful waiting refers to conservative management for patients deemed unsuitable for curative treatment right from the outset, and patients are 'watched' for the development of local or systemic progression with (imminent) disease-related complaints, at which stage they are then treated palliatively according to their symptoms, in order to maintain QoL.

Table 6.1.1: Definitions of active surveillance and watchful waiting [351]

	Active surveillance	Watchful waiting
Treatment intent	Curative	Palliative
Follow-up	Predefined schedule	Patient-specific
Assessment/markers used	DRE, PSA, re-biopsy, mpMRI	Not predefined
Life expectancy	> 10 years	< 10 years
Aim	Minimise treatment-related toxicity without compromising survival	Minimise treatment-related toxicity
Comments	Low-risk patients	Can apply to patients with all stages

DRE = digital rectal examination; PSA = prostate-specific antigen; mpMRI = multiparametric magnetic resonance imaging.

6.1.1.2 Active surveillance

No formal RCT is available comparing this modality to standard treatment. The Prostate Testing for Cancer and Treatment (ProtecT) trial is discussed later as it is not a formal AS strategy but rather Active Monitoring (AM), which would represent a 'very light' AS strategy with less stringent surveillance criteria in terms of clinical follow-up, imaging and repeat biopsies [353].

Several cohorts have investigated AS in organ-confined disease, the findings of which were summarised in a SR [354]. More recently, the largest prospective series of men with low-risk PCa managed by AS was published [355]. Table 6.1.2 summarises the results of selective AS cohorts. It is clear that the long-term OS and CSS for patients on AS are extremely good. However, more than one-third of patients are 're-classified' during follow-up, most of whom require curative treatment due to disease upgrading, increase in disease extent, disease stage, progression or patient preference. There is considerable variation and heterogeneity between studies regarding patient selection and eligibility, follow-up policies (including frequency and type of imaging such as mpMRI scan, type and frequency of repeat prostate biopsies, such as MRI-targeted biopsies or transperineal template biopsies, use of PSA kinetics and density, and frequency of clinical follow-up), when active treatment should be instigated (i.e. reclassification criteria), and which outcome measures should be prioritised [352]. These will be discussed further in section 6.2.1.

Table 6.1.2: Active surveillance in screening-detected prostate cancer

Studies	n	Median FU (mo)	pT3 in RP patients	10-year OS (%)	10-year CSS (%)
Van As, <i>et al.</i> 2008 [356]	326	22	8/18 (44%)	98	100
Carter, <i>et al.</i> 2007 [350]	407	41	10/49 (20%)	98	100
Adamy, <i>et al.</i> 2011 [357]	533-1,000	48	4/24 (17%)	90	99
Soloway, <i>et al.</i> 2010 [358]	99	45	0/2	100	100
Roemeling, <i>et al.</i> 2007 [359]	278	41	-	89	100
Khatami, <i>et al.</i> 2007 [360]	270	63	-	n.r.	100
Klotz, <i>et al.</i> 2015 [361]	993	77	-	85	98.1
Tosoian, <i>et al.</i> 2015 [355]	1,298	60	-	93	99.9
Total	4,204-4,671	46.5	-	93	100

* Patients receiving active therapy following initial active surveillance.

CSS = cancer-specific survival; FU = follow-up; mo = months; n = number of patients; n.r. = not reported; OS = overall survival; RP = radical prostatectomy.

6.1.1.3 Watchful Waiting

6.1.1.3.1 Introduction

Studies on WW have included patients with up to 25 years of follow-up, with endpoints of OS and CSS. Several series have shown a consistent CSS rate of 82-87% at ten years [362-367], and 80-95% for T1/T2 and ISUP grade ≤ 2 [368]. In three studies with data beyond fifteen years, the DSS was 80%, 79% and 58% [364, 366, 367], and two reported twenty-year CSS rates of 57% and 32%, respectively [364, 366]. Many patients classified as ISUP grade 1 would now be classified as ISUP grade 2-3 based on the 2005 Gleason classification, suggesting that the above-mentioned results should be considered as minimal. Patients with well-, moderately- and poorly-differentiated tumours had ten-year CSS rates of 91%, 90% and 74%, respectively, correlating with data from the pooled analysis [368]. Observation was most effective in men aged 65-75 years with low-risk PCa [369].

In an analysis at ten years follow up in 19,639 patients aged > 65 years who were not given curative treatment, most men with a CCI score ≥ 2 died from competing causes at ten years whatever their initial age. Tumour aggressiveness had little impact on OS suggesting that patients could have been spared biopsy and diagnosis of cancer. Men with a CCI score ≤ 1 had a low risk of death at ten years, especially for well- or moderately-differentiated lesions [336]. This highlights the importance of checking the CCI before considering a biopsy.

6.1.1.3.2 Outcome of watchful waiting compared with active treatment

The SPCG-4 study randomised patients to either WW or RP (Table 6.1.3) [324] before the PSA era and found RP to provide superior CSS, OS and progression-free survival (PFS) compared to WW at a median follow-up of 13.4 years (range 3 weeks - 23.2 years). The PIVOT trial made a similar comparison in 731 randomised men (50% with non-palpable disease) [370] but in contrast to SPCG-4, it found no benefit of RP within a median follow-up period of 12.7 years (interquartile range, 7.3 to 15.5 years). Only patients with serum PSA > 10 ng/mL or high-risk PCa had a significant OS benefit from RP, with a RR reduction in mortality of 33% and

31%, respectively. Patients who underwent RP also had a significant reduction in bone metastases (4.7% vs. 10.6%). Overall, no adverse effects on HRQoL and psychological well-being was apparent in the first years [371]. However, one of the criticisms of the PIVOT trial is the relatively high-observed overall mortality rate in the WW group (almost 50% at a median of ten years), compared with more contemporary series.

Table 6.1.3: Outcome of SPCG-4 at fifteen years follow-up [324]

	RP (n = 348) (%)	Watchful waiting (n = 348) (%)	Relative risk (95% CI)	p-value
Disease-specific mortality	14.6	20.7	0.62	0.010
Overall mortality	46.1	57.2	0.75 (0.61-0.92)	0.007
Metastatic progression	21.7	33.4	0.59 (0.45-0.79)	< 0.001
Local progression	21.5	49.3	0.34 (0.26-0.45)	n.r.

CI = confidence interval; n.r. = not reported; RP = radical prostatectomy.

6.1.1.4 The ProtecT study

The ProtecT trial randomised 1,643 patients, three-ways, between active treatment (RP or EBRT) and AM [353]. In this AM schedule, patients with a PSA rise of more than 50% in twelve months underwent a repeat biopsy, but none had systematic repeat biopsies. Fifty-six percent of patients had low-risk disease, with 90% having a PSA < 10 ng/mL, 77% ISUP grade 1 (20% ISUP grade 2-3), and 76% T1c, while the other were mainly intermediate risk. After ten years of follow up, the CSS was the same between those actively treated and those on AM (99% and 98.8%, respectively), as was the OS. Only metastatic progression differed (6% in the AM group as compared to 2.6% in the treated group).

The key finding is that AM is as effective as active treatment at ten years, at a cost of increased progression and double the metastatic risk. Metastases remained quite rare (6%), but more frequent than seen with AS protocols probably driven by differences in intensity of monitoring and patient selection. It is important to note that the AM arm in ProtecT represents an intermediate approach between contemporary AS protocols and WW in terms of a monitoring strategy based almost entirely on PSA measurements alone; there was no use of mpMRI scan either at recruitment nor during the monitoring period, nor was there any protocol-mandated repeat prostate biopsies at regular intervals. In addition, approximately 40% of randomised patients had intermediate-risk disease.

Nevertheless, in spite of these caveats, the ProtecT study has reinforced the role of deferred active treatment (i.e. either AS or some form of initial AM) as a feasible alternative to active curative interventions for patients with low-grade and low-stage disease. Beyond ten years, no data is available as yet, and AS is possibly safer, especially in younger men, based on initial patient selection and more stringent criteria regarding follow-up, imaging, repeat biopsy and reclassification. Individual life expectancy must be evaluated before considering any active treatment in low-risk situations, and for those with up to ten years individual life expectancy, AM or WW are probably very good options.

6.1.2 Radical prostatectomy

The goal of RP by any approach is the eradication of cancer, while whenever possible, preserving continence and potency [372]. The procedure involves removing the entire prostate with its capsule intact and seminal vesicles, followed by undertaking vesico-urethral anastomosis. Since its description in 1905, the technique has evolved. An estimation of life expectancy is paramount in counselling a patient about surgery [362] (see Section 5.4 – Evaluating health status and life expectancy). The main results from multicentre RCTs involving RP are summarised in Table 6.1.4.

Table 6.1.4: Oncological results of radical prostatectomy in organ-confined disease in RCTs

Study	Acronym	Population	Year of treatment	Median FU (mo)	Risk category	CSS (%)
Bill-Axelsson, <i>et al.</i> 2018 [373]	SPCG-4	Pre-PSA era	1989-1999	283	Low risk and Intermediate risk	80.4 (at 23 yr.)
Wilt, <i>et al.</i> 2017 [370]	PIVOT	Early years of PSA testing	1994-2002	152	Low risk Intermediate risk	95.9 91.5 (at 19.5 yr.)
Hamdy, <i>et al.</i> 2016 [353]	ProtecT	Screened population	1999-2009	120	Mainly low- and intermediate risk	99 (at 10 yr.)

CSS = cancer-specific survival; FU = follow-up; mo = months; PSA = prostate-specific antigen; yr. = year.

6.1.2.1 Surgical techniques

Prostatectomy can be performed by open, laparoscopic or robot-assisted (RARP) approaches. In a randomised phase III trial, RARP was shown to have reduced admission times and blood loss but not early (twelve weeks) functional or oncological outcomes [374]. An updated analysis with follow-up at 24 months did not reveal any significant differences in functional outcomes between the approaches [375]. Increased surgical experience has lowered the complication rates of RP and improved cancer cure [366-369]. Lower rates of positive surgical margins for high-volume surgeons suggest that experience and careful attention to surgical details, can improve cancer control with RP [376-378]. There is a lack of studies comparing the different surgical modalities for these longer-term outcomes [365, 370, 371, 379]. A first SR and meta-analysis of non-RCTs demonstrated that RARP had lower perioperative morbidity and a reduced risk of positive surgical margins compared with laparoscopic prostatectomy (LRP), although there was considerable methodological uncertainty [380]. There was no evidence of differences in urinary incontinence at twelve months and there was insufficient evidence to draw conclusions on differences in cancer-related, patient-driven or erectile dysfunction (ED) outcomes. Another SR and meta-analysis included two small RCTs comparing RARP vs. LRP [381]. The results suggested higher rates of return of erectile function (RR: 1.51; 95% CI: 1.19-1.92) and return to continence function (RR: 1.14; 95% CI: 1.04-1.24) in the RARP group. However, a recent Cochrane review comparing either RARP or LRP vs. open RP included two RCTs and found no significant differences between the comparisons for oncological, urinary function and sexual function outcomes, although RARP and LRP both resulted in statistically significant improvements in duration of hospital stay and blood transfusion rates over open RP [382]. Therefore, no surgical approach can be recommended over another.

6.1.2.1.1 Pelvic lymph node dissection

A recent SR demonstrated that performing pelvic lymph node dissection (PLND) during RP failed to improve oncological outcomes, including survival [383]. However, it is generally accepted that extended pelvic LN dissection (eLND) provides important information for staging and prognosis which cannot be matched by any other currently available procedure [383]. The individual risk of finding positive LNs can be estimated using pre-operative tools. A recent SR and meta-analysis found similar diagnostic accuracy in predicting LN invasion between the Briganti, Partin and Memorial Sloan Kettering Cancer Center (MSKCC) nomograms [384]. However, only a few of these tools are based on eLND templates. A risk of nodal metastases over 5% (Briganti nomogram [385, 386] or Roach formula [387] which has been shown to be almost as good as the nomogram) is an indication to perform nodal sampling by an extended nodal dissection [388-390]. Extended LND includes removal of the nodes overlying the external iliac artery and vein, the nodes within the obturator fossa located cranially and caudally to the obturator nerve, and the nodes medial and lateral to the internal iliac artery. With this template, 94% of patients are correctly staged [391]. However, there is currently no consensus on the recommended minimum number of LNs which should be retrieved, due to the lack of standardisation of techniques in tissue harvesting and processing.

6.1.2.1.2 Sentinel node biopsy analysis

The rationale for a sentinel node biopsy (SNB) is based on the concept that a sentinel node is the first to be involved by migrating tumour cells. Therefore, when this node is negative, it is possible to avoid an ePLND. There is heterogeneity and variation in techniques in relation to SNB (e.g. the optimal tracer), but a multi-disciplinary collaborative endeavour attempted to standardise definitions, thresholds and strategies in relation to techniques of SNB using consensus methods [392]. Indeed SNB has been shown to have a sensitivity of 95.2% and NPV of 98.0% for detecting men with metastases at eLND in a SR [393]. However, there is still insufficient quality evidence supporting oncological effectiveness of SNB for nodal staging. Sentinel node biopsy is therefore still considered as an experimental nodal staging procedure.

6.1.2.1.3 Nerve-sparing surgery

Nerve-sparing RP can be performed safely in most men with localised PCa [394, 395]. Relative contraindications are patients in whom there is a high risk of extracapsular disease, such as any cT2c or cT3 PCa or any ISUP grade > 3 on biopsy. An externally validated nomogram predicting side-specific extracapsular extension can help guide decision making [396, 397]. If any doubt remains regarding residual tumour, the surgeon should remove the neurovascular bundle (NVB). Alternatively, the use of intra-operative frozen-section analysis or imaging with pre-operative mpMRI can help guide these decisions [398, 399].

6.1.2.1.4 Neoadjuvant androgen deprivation therapy

Several RCTs have analysed the impact of neoadjuvant ADT before RP, most of them using a 3 month period. The main findings were summarised in a Cochrane review [400]. It is associated with a decreased rate of pT3 (downstaging), decreased positive margins, and a lower incidence of positive LNs. These benefits are greater with increased treatment duration (up to eight months). However, since neither the PSA relapse-free survival nor CSS were shown to improve, neoadjuvant ADT should not be considered as standard clinical practice.

6.1.2.1.5 Lymph-node-positive patients during radical prostatectomy

Although no RCTs are available, data from prospective cohort studies comparing survival of pN+ patients (as defined following pathological examination after RP) support that RP may have a survival benefit over abandonment of RP in node-positive cases [401]. As a consequence there is no role for performing frozen section of suspicious LNs.

6.1.2.2 Comparing effectiveness of radical prostatectomy vs. other interventions for localised disease

6.1.2.2.1 Radical prostatectomy vs. deferred treatment

Currently, three large prospective RCTs have compared RP over deferred treatment (see Section 6.1.2). In summary, there was conflicting evidence regarding the benefit of RP over deferred treatment. The only study to find a benefit of RP over WW (SPCG-4) was conducted in the pre-PSA era [324]. When comparing RP against WW [370] or against AM [353], no statistically significant benefit in OS at ten years' of follow-up was observed. These findings indicate the good prognosis for the majority of patients with low-risk localised PCa, and highlight the need to carefully risk stratify patients to ensure that patients are appropriately managed and treated.

6.1.2.2.2 Radical prostatectomy vs. radiotherapy

ProtecT compared RP vs. AM vs. EBRT (combined with six months of ADT) [353]. At a median follow-up of ten years, there were no differences between surgery vs. EBRT in all oncological outcomes.

6.1.2.3 Acute complications of surgery

Post-operative incontinence and ED are common problems following surgery for PCa. A key consideration is whether these problems are reduced by using newer techniques such as robotic-assisted laparoscopic prostatectomy (RALP). Recent SRs have documented complication rates after RALP [380, 402-405], and can be compared with contemporaneous reports after radical retropubic prostatectomy (RRP) [406]. From these reports, the mean continence rates at twelve months were 89-100% for patients treated with RALP and 80-97% for patients treated with RRP. There is, as yet, no evidence from retrospective studies on differences in urinary incontinence at twelve months and there was insufficient evidence to draw conclusions on differences in cancer-related, patient-driven or ED outcomes. The major limitations of the included studies were the retrospective study design and the use of different assessment tools preventing comparison between techniques and series. Recently, a prospective, controlled, non-RCT of patients undergoing RP in fourteen centres using RALP or RRP was published. At twelve months after RALP, 21.3% were incontinent, as were 20.2% after RRP. The adjusted OR was 1.08 (95% CI: 0.87-1.34). Erectile dysfunction was observed in 70.4% after RALP and 74.7% after RRP. The adjusted OR was 0.81 (95% CI: 0.66-0.98) [407]. A RCT comparing RALP and RRP reported outcomes at twelve weeks in 326 patients and functional outcomes at two years [374]. The intra- and peri-operative complications of retropubic RP and RALP are listed in Table 6.1.5. The early use of phosphodiesterase-5 (PDE5) inhibitors in penile rehabilitation remains controversial resulting in a lack of clear recommendations (see Section 8.3.2).

Table 6.1.5: Intra- and peri-operative complications of retropubic RP and RALP (Adapted from [380])

Predicted probability of event	RALP (%)	Laparoscopic RP (%)	RRP (%)
Bladder neck contracture	1.0	2.1	4.9
Anastomotic leak	1.0	4.4	3.3
Infection	0.8	1.1	4.8
Organ injury	0.4	2.9	0.8
Ileus	1.1	2.4	0.3
Deep-vein thrombosis	0.6	0.2	1.4
Predicted rates of event	RALP (%)	Laparoscopic RP (%)	RRP (%)
Clavien I	2.1	4.1	4.2
Clavien II	3.9	7.2	17.5
Clavien IIIa	0.5	2.3	1.8
Clavien IIIb	0.9	3.6	2.5
Clavien IVa	0.6	0.8	2.1
Clavien V	< 0.1	0.2	0.2

RALP = robot-assisted laparoscopic prostatectomy; RP = radical prostatectomy; RRP = radical retropubic prostatectomy.

6.1.2.3.1 Early complications of extended lymph node dissection

Pelvic eLND increases morbidity in the treatment of PCa [383]. Overall complication rates of 19.8% vs. 8.2% were noted for eLND vs. limited LND, respectively, with lymphoceles (10.3% vs. 4.6%) being the most common adverse event. Other authors have reported more acceptable complication rates [408]. Similar rates of lymphoceles have been observed in RALP series; however, in one subgroup analysis lymphoceles were more common with the extraperitoneal approach (19%) vs. the transperitoneal approach (0%) [409, 410]. Briganti *et al.* [411] also showed more complications after extended compared to limited LND. Twenty percent of men suffer a complication of some sort after eLND. Thromboembolic events occur in less than 1% of cases.

6.1.3 **Radiotherapy**

Intensity-modulated radiotherapy (IMRT), with or without image-guided radiotherapy (IGRT), is the gold standard for EBRT.

6.1.3.1 *External Beam Radiation Therapy:*

6.1.3.1.1 Technical aspects: intensity-modulated external-beam radiotherapy (IMRT) and volumetric arc external-beam radiotherapy (VMAT)

Intensity-modulated external-beam radiotherapy and VMAT employ dynamic multileaf collimators, which automatically and continuously adapt to the contours of the target volume seen by each beam. The advantage of VMAT over IMRT is shorter treatment times, generally two to three minutes. Both techniques allow for a more complex distribution of the dose to be delivered within the treatment field and provide concave isodose curves, which are particularly useful as a means of sparing the rectum. Radiotherapy treatment planning for IMRT and VMAT differs from that used in conventional EBRT, requiring a computer system capable of 'inverse planning', and the appropriate physics expertise. Treatment plans must conform to pre-specified dose constraints to critical organs at risk of normal tissue damage, and a formal quality assurance process should be routine.

With dose escalation using IMRT, organ movement becomes a critical issue, in terms of both tumour control and treatment toxicity. Evolving techniques will therefore combine IMRT with some form of image-guided radiotherapy (IGRT), in which organ movement can be visualised and corrected for in real time, although the optimum means of achieving this is still unclear [412]. Tomotherapy is another technique for the delivery of IMRT, using a linear accelerator mounted on a ring gantry that rotates as the patient is delivered through the centre of the ring, analogous to spiral CT scanning.

6.1.3.1.2 Dose escalation

Several RCTs have shown that dose escalation (range 74-80 Gy) has a significant impact on five-year biochemical relapse [413-419]. These trials have generally included patients from several risk groups, and the use of neoadjuvant/adjuvant hormone therapy (HT) has varied (see Table 6.1.6). The best evidence of an OS benefit for patients with intermediate- or high-risk PCa, but not with low-risk PCa, comes from a non-randomised but well conducted propensity matched retrospective analysis of the U.S. National Cancer Database covering a total of 42,481 patients [420]. In everyday practice, a minimum dose of ≥ 74 Gy is recommended for EBRT plus hormonal therapy (HT), with no different recommendations according to the patient's risk group. If IMRT and IGRT are used for dose escalation, rates of severe late side-effects (\geq grade 3) for the rectum are 2-3% and for the GU tract 2-5% [416, 419, 421-434].

Table 6.1.6: Randomised trials of dose escalation in localised PCa

Trial	n	PCa condition	Radiotherapy Dose	Follow-up (median)	Outcome	Results
MD Anderson study 2011 [414]	301	T1-T3, N0, M0, PSA 10 ng/mL vs. PSA > 10 ng/mL	70 vs. 78 Gy	9 yr.	DSM vs. other cause of death	High risk/PSA > 10 16% DSM at 70 Gy 4% DSM at 78 Gy (p = 0.05) Higher risk 15% DSM at 70 Gy 2% DSM at 78 Gy (p = 0.03)
PROG 95-09 2010 [415]	393	T1b-T2b PSA 15 ng/mL 75%	70.2 vs. 79.2 Gy including proton boost 19.8 vs. 28.8 Gy	8.9 yr.	10-year ASTRO BCF	All patients: 32% BF at 70.2 Gy 17% BF at 79.2 Gy (p < 0.0001) Low-risk patients: 28% BF at 70.2 Gy 7% BF at 79.2 Gy (p < 0.0001)
MRC RT01 2014 [435]	843	T1b-T3a, N0, M0 PSA < 50 ng/mL neoadjuvant HT	64 vs. 74 Gy	10 yr.	BFS; OS	43% BFS at 64 Gy 55% BFS at 74 Gy (p = 0.0003) 71% OS both groups (p = 0.96)
Dutch randomised phase III trial 2014 [419]	664	T1b-T4 143 pts. with (neo) adjuvant HT	68 vs. 78 Gy	110 mo.	Freedom biochemical (Phoenix) and/or clinical failure at 10 yr.	43% FFF at 68 Gy 49% FFF at 78 Gy (p = 0.045)
GETUG 06 2011 [418]	306	T1b-T3a, N0, M0 PSA < 50 ng/mL	70 vs. 80 Gy	61 mo.	BCF (ASTRO)	39% BF at 70 Gy 28% BF at 80 Gy
RTOG 0126 2018 [413]	1,532	T1b-T2b ISUP grade 1 + PSA 10-20 ng/mL or ISUP grade 2/3 + PSA < 15 ng/mL	70.2 vs. 79.2 Gy	100 mo.	OS DM BCF (ASTRO)	75% OS at 70.2 Gy 76% OS at 79.2 Gy 6% DM at 70.2 Gy 4% DM at 79.2 Gy (p = 0.05) 47% BCF at 70.2 Gy 31% BCF at 79.2 Gy (p < 0.001; Phoenix, p < 0.001)

(B)CF = biochemical failure; BFS = biochemical progression-free survival; DM = distant metastases; DSM = disease specific mortality; FFF = freedom from biochemical or clinical failure; HT = hormone therapy; mo = months; n = number of patients; OS = overall survival; PSA = prostate-specific antigen; yr = year.

6.1.3.1.3 Hypofractionation (HFX)

Fractionated RT utilises differences in the DNA repair capacity of normal and tumour tissue, and slowly proliferating cells are very sensitive to an increased dose per fraction [436]. A meta-analysis of 25 studies including > 14,000 patients concluded that because PCa has a slow proliferation rate, hypofractionated RT could be more effective than conventional fractions of 1.8-2 Gy [437]. Hypofractionation (HFX) has the added advantage of being more convenient for the patient and cheaper for the health care system.

Several studies report on HFX applied in various techniques and, in part, also including HT [438-446]. An SR concludes that studies on moderate HFX (2.5-4 Gy/fx) delivered with conventional three-dimensional conformal radiotherapy (3D-CRT)/IMRT have sufficient follow-up to support the safety of this therapy, but long-term efficacy data are still lacking [447]. Moderate HFX should only be done by experienced teams using high quality EBRT using IGRT and IMRT in carefully selected patients and adhere to published phase III protocols (see Table 6.1.7 below).

Table 6.1.7: Major phase III randomised trials of moderate hypofractionation for primary treatment

Study/ Author	n	Risk, ISUP grade, or NCCN	ADT	RT Regimen	BED, Gy	Median FU, mo	Outcome
Lee, <i>et al.</i> 2016 [442]	550 542	low risk	None	70 Gy/28 fx 73.8 Gy/41 fx	80 69.6	70	5 yr. DFS 86.3% (n.s.) 5 yr. DFS 85.3%
Dearnaley, <i>et al.</i> CHHiP 2012 [438] and 2016 [443]	1077/19 fx 1074/20 fx 1065/37 fx	15% low 73% intermediate 12% high	3-6 mo. before and during EBRT	57 Gy/19 fx 60 Gy/20 fx 74 Gy/37 fx	73.3 77.1 74	62	5 yr. BCDF 85.9% (19 fx) 90.6% (20 fx) 88.3% (37 fx)
Aluwini, <i>et al.</i> 2015 [441], 2016 [444, 445]	403 392	30% ISUP grade 1 45% ISUP grade 2-3, 25% ISUP grade 4-5	None	64.6 Gy/19 fx 78 Gy/39 fx	90.4 78	60	5 yr. RFS 80.5% (n.s.) 5 yr. RFS 77.1%
Catton, <i>et al.</i> 2017 [446]	608	intermediate risk 53% T1c 46% T2a-c	None	60 Gy/20 fx	77.1	72	5 yr. BCDF both arms 85% HR: 0.96 (n.s)
	598	9% ISUP grade 1 63% ISUP grade 2 28% ISUP grade 3		78 Gy/39 fx 78			

ADT = androgen deprivation therapy; BCDF = biochemical or clinical disease failure; BED = biologically equivalent dose, calculated to be equivalent in 2 Gy fractions using an α/β of 1.5 Gy; DFS = disease-free survival; EBRT = external beam radiotherapy; FU = follow-up; fx = fractions; HR = hazard ratio; n = number of patients; NCCN = National Comprehensive Cancer Network; n.s. = not significant; y = year.

Extreme HFX has been defined as radiotherapy with > 3.4 Gy per fraction [448]. It requires IGRT and stereotactic body radiotherapy (SBRT). Table 6.1.8 gives an overview of selected studies. Short-term biochemical control is comparable to conventional fractionation. However, there are concerns about high-grade GU and rectal toxicity, and long-term side-effects may not all be known yet [447, 449, 450]. Therefore it seems prudent to restrict extreme HFX to prospective clinical trials and to inform patients on the uncertainties of the long-term outcome.

Table 6.1.8: Selected trials on extreme hypofractionation for intact localised PCa

Reference	n	med FU (mo)	Risk-Group	Regimen (TD/fx)	Outcome
Freeman, <i>et al.</i> 2014 [451]	1,743	-	41% low 42% intermediate 10% high 7% data missing	35-40 Gy/4-5 fx (8% SBRT-boost 19.5-21.8 Gy/3 fx after 45-50 Gy EBRT)	FFBF 92% at 2 yr. 99% low risk 97-85% intermediate 87% high risk
Katz, <i>et al.</i> 2014 [452]	515	72	63% low 30% intermediate 7% high	35-36.25 Gy/5 fx	FFBF at 7 yr. 96% low risk 89% intermediate 69% high risk

EBRT = external beam radiotherapy in standard fractionation; FFBF = freedom from biochemical failure; FU = follow-up; fx = number fractions; mo = months; n = number of patients; TD = total dose; SBRT = stereotactic body radiotherapy; y = year.

6.1.3.1.4 Neoadjuvant or adjuvant hormone therapy plus radiotherapy

The combination of RT with luteinising-hormone-releasing hormone (LHRH) ADT has definitively proven its superiority compared with RT alone followed by deferred ADT on relapse, as shown by phase III RCTs [453-457] (Table 6.1.9). The main message is that for intermediate risk a short duration of around 6 months is optimal, while a longer one, around three years, is needed for high-risk patients.

Table 6.1.9: Selected studies of use and duration of ADT in combination with RT for PCa

Trial	TNM stage	n	Trial	ADT	RT	Effect on OS
RTOG 85-31 2005 [454]	T3 or N1 M0	977	EBRT ± ADT	Orchiectomy or LHRH agonist 15% RP	65-70 Gy RT	Significant benefit for combined treatment (p = 0.002) seems to be mostly caused by patients with ISUP grade 2-5
RTOG 94-13 2007 [458]	T1c-4 N0-1 M0	1292	ADT timing comparison	2 mo. neoadjuvant plus concomitant vs. 4 mo. adjuvant suppression	Whole pelvic RT vs. prostate only; 70.2 Gy	No significant difference between neoadjuvant plus concomitant vs. adjuvant androgen suppression therapy groups (interaction suspected)
RTOG 86-10 2008 [455]	T2-4 N0-1	456	EBRT ± ADT	Goserelin plus flutamide 2 mo. before, plus concomitant therapy	65-70 Gy RT	No significant difference at 10 yr.
D'Amico AV, <i>et al.</i> 2008 [456]	T2 N0 M0 (localised unfavourable risk)	206	EBRT ± ADT	LHRH agonist plus flutamide for 6 mo.	70 Gy 3D-CRT	Significant benefit (HR: 0.55, 95% CI: 0.34-0.90, p = 0.01) that may pertain only to men with no or minimal comorbidity
RTOG 92-02 2008 [459]	T2c-4 N0-1 M0	1554	Short vs. prolonged ADT	LHRH agonist given for 2 yr. as adjuvant after 4 mo. as neoadjuvant	65-70 Gy RT	p = 0.73, p = 0.36 overall; significant benefit (p = 0.044) (p = 0.0061) in subset with ISUP grade 4-5
EORTC 22961 2009 [460]	T1c-2ab N1 M0, T2c-4 N0-1 M0	970	Short vs. prolonged ADT	LHRH agonist for 6 mo. vs. 3 yr.	70 Gy 3D-CRT	Better result with 3 yr. treatment than with 6 mo. (3.8% improvement in survival at 5 yr.)
EORTC 22863 2010 [453]	T1-2 poorly differentiated and M0, or T3-4 N0-1 M0	415	EBRT ± ADT	LHRH agonist for 3 yr. (adjuvant)	70 Gy RT	Significant benefit at 10 yr. for combined treatment (HR: 0.60, 95% CI: 0.45-0.80, p = 0.0004).
TROG 96-01 2011 [457]	T2b-4 N0 M0	802	Neoadjuvant ADT duration	Goserelin plus flutamide 3 or 6 mo. before, plus concomitant suppression	66 Gy 3D-CRT	No significant difference in OS reported; benefit in PCa-specific survival (HR: 0.56, 95% CI: 0.32-0.98, p = 0.04) (10 yr.: HR: 0.84, 0.65-1.08, p = 0.18)

RTOG 99-10 2015 [461]	intermediate risk (94% T1-T2, 6% T3-4)	1579	Short vs. prolonged ADT	LHRH agonist 8 + 8 vs. 8 + 28 wk.	70.2 Gy 2D/3D	67 vs. 68%, p = 0.62, confirms 8 + 8 wk. LHRH as a standard
--------------------------	---	------	-------------------------------	---	------------------	---

ADT = androgen deprivation therapy; CI = confidence interval; EBRT = external beam radiotherapy in standard fractionation; HR = hazard ratio; LHRH = luteinising hormone-releasing hormone; mo = months; n = number of patients; OS = overall survival; RP = radical prostatectomy; RT = radiotherapy; wk = week; yr. = year.

The question of the added value of EBRT combined with ADT has been clarified with 3 RCTs. All showed a clear benefit of adding EBRT to long-term ADT (see Table 6.1.10).

Table 6.1.10: Selected studies of ADT in combination with- or without RT for PCa

Trial	Year	TNM stage	n	Trial	ADT	RT	Effect on OS
SPCG-7/ SFUO-3 2016 [462]	2016	T1b-2 WHO Grade 1-3, T3 N0 M0	875	ADT ± EBRT	LHRH agonist for 3 mo. plus continuous flutamide	70 Gy 3D-CRT vs. no RT	34% (95% CI: 29-39%) vs. 17% (95% CI: 13-22% CSM at 12 (15) yr. favouring combined treatment (p < 0.0001 for 15-yr. results) NCIC CTG PR.3/MRC
PRO7/NCIC 2011 [464] and 2015 [465]	2015	T3-4 (88%), PSA > 20 ng/ mL (64%), ISUP grade 4-5 (36%) N0 M0	1,205	ADT ± EBRT	Continuous LHRH agonist	65-70 Gy 3D-CRT vs. no RT	10-yr. OS = 49% vs. 55% favouring combined treatment HR: 0.7, p < 0.001)
Mottet N, et al. 2012 [466]	2012	T3-4 N0 M0	273 264	ADT ± EBRT	LHRH agonist for 3 yr.	70 Gy 3D-CRT vs. no RT	Significant reduction of clinical progression; 5-yr. OS 71.4% vs. 71.5%

ADT = androgen deprivation therapy; CSM = cancer-specific mortality; EBRT = external beam radiotherapy; HR = hazard ratio; LHRH = luteinising hormone-releasing hormone; mo = months; n = number of patients; OS = overall survival; RT = radiotherapy; 3D-CRT = three-dimensional conformal radiotherapy.

6.1.3.1.5 Combined dose-escalated radiotherapy and androgen-deprivation therapy

Zelevsky *et al.* reported a retrospective analysis comprising 571 patients with low-risk PCa, 1,074 with intermediate-risk PCa, and 906 with high-risk PCa. 3D-conformal RT or IMRT were administered [467]. The prostate dose ranged from 64.8 to 86.4 Gy; doses beyond 81 Gy were delivered during the last ten years of the study using image-guided IMRT. Complete androgen blockade was administered at the discretion of the treating physician to 623 high-risk PCa (69%), 456 intermediate-risk PCa (42%) and 170 low-risk PCa (30%) patients. The duration of ADT was three months for low-risk patients and six months for intermediate-risk and high-risk patients, starting at three months before RT. The ten-year biochemical disease-free rate was significantly improved by dose escalation: above 75.6 Gy in low risk, and above 81 Gy for the intermediate- and high-risk groups. It was also improved by adding six months of ADT in intermediate- and high-risk patients. In the multivariate analysis, neither the dose > 81 Gy, nor adding ADT influenced OS. Three RCTs have shown that the benefits of ADT are independent of dose escalation, and that the use of ADT would not compensate for a lower radiotherapy dose:

1. The GICOR study which shows a better biochemical DFS for high-risk patients for 3D-CRT radiation dose > 72 Gy when combined with long-term ADT [426].
2. DART01/05 GICOR which shows that two years of adjuvant ADT combined with high-dose RT improved biochemical control and OS in high-risk patients [468].
3. EORTC trial 22991 which shows that six months ADT improves biochemical and clinical DFS whatever the dose (70, 74, 78 Gy) in intermediate-risk and low-volume high-risk localised PCa [469].

6.1.3.2 Proton beam therapy

In theory, proton beams are an attractive alternative to photon-beam RT for PCa, as they deposit almost all their radiation dose at the end of the particle's path in tissue (the Bragg peak), in contrast to photons, which deposit radiation along their path. There is also a very sharp fall-off for proton beams beyond their deposition depth, meaning that critical normal tissues beyond this depth could be effectively spared. In contrast, photon beams continue to deposit energy until they leave the body, including an exit dose.

One RCT on dose escalation (70.2 vs. 79.2 Gy) has incorporated protons for the boost doses of either 19.8 or 28.8 Gy. This trial shows improved outcome with the higher dose, but it cannot be used as evidence for the superiority of proton therapy per se [415]. Thus, unequivocal information that shows an advantage of protons over IMRT photon therapy is still not available. Studies from the SEER database and from Harvard describing toxicity and patient-reported outcomes do not point to an inherent superiority for protons [470, 471]. In terms of longer-term gastrointestinal (GI) toxicity, proton therapy might even be inferior to IMRT [471].

A RCT comparing equivalent doses of proton-beam therapy with IMRT is underway. Meanwhile, proton therapy must be regarded as a promising, but experimental, alternative to photon-beam therapy.

6.1.3.3 Brachytherapy

6.1.3.3.1 Low-dose rate (LDR) brachytherapy

Low-dose rate brachytherapy uses radioactive seeds permanently implanted into the prostate. There is a consensus on the following eligibility criteria for LDR monotherapy [472]: Stage cT1b-T2a N0, M0; ISUP grade 1 with $\leq 50\%$ of biopsy cores involved with cancer or ISUP grade 2 with $\leq 33\%$ of biopsy cores involved with cancer; an initial PSA level of ≤ 10 ng/mL; a prostate volume of < 50 cm³; an International Prostatic Symptom Score (IPSS) ≤ 12 and maximal flow rate > 15 mL/min on urinary flow tests [473].

The only available RCT comparing RP and brachytherapy as monotherapy was closed due to poor accrual [474]. Outcome data are available from a number of large population cohorts with mature follow-up [475-482]. The biochemical disease-free survival for ISUP grade 1 patients after five and ten years has been reported to range from 71% to 93% and 65% to 85%, respectively [475-482]. A significant correlation has been shown between the implanted dose and biochemical control [483]. A D90 (dose covering 90% of the prostate volume) of > 140 Gy leads to a significantly higher biochemical control rate (PSA < 1.0 ng/mL) after four years (92 vs. 68%). There is no benefit in adding neoadjuvant or adjuvant ADT to LDR monotherapy [475].

Low-dose rate brachytherapy can be combined with EBRT in intermediate-/high-risk patients (see Section 6.2.3.2.3)

6.1.3.3.2 High-dose rate brachytherapy

High-dose-rate (HDR) brachytherapy uses a radioactive source temporarily introduced into the prostate to deliver radiation. The technical differences are outlined in Table 6.1.11. The use of published guidelines is strongly recommended [484]. High-dose rate brachytherapy can be delivered in single or multiple fractions and is often combined with EBRT of at least 45 Gy [485]. A single RCT of EBRT (55 Gy in 20 fractions) vs. EBRT (35.75 Gy in 13 fractions), followed by HDR brachytherapy (17 Gy in two fractions over 24 hours) has been reported [486]. In 218 patients with organ-confined PCa the combination of EBRT and HDR brachytherapy showed a significant improvement in the biochemical disease-free rate ($p = 0.04$) at five and ten year (75% and 46% compared to 61% and 39%). However, a very high, uncommon, rate of early recurrences was observed in the EBRT arm alone, even after two years, possibly due to a dose lower than the current standard used [486]. A SR of non-RCTs has suggested outcomes with EBRT plus HDR brachytherapy are superior to brachytherapy alone, but this needs confirmation in a prospective RCT [487].

Fractionated HDR brachytherapy as monotherapy can be offered to patients with low- and intermediate-risk PCa, who should be informed that results are only available from limited series in very experienced centres [488, 489]. Five-year PSA control rates over 90% are reported, with late grade 3+ GU toxicity rates $< 5\%$ and no or very minimal grade 3+ GI toxicity rates [488, 489].

Table 6.1.11: Difference between LDR and HDR brachytherapy

	Differences in prostate brachytherapy techniques
Low dose rate (LDR)	<ul style="list-style-type: none"> • Permanent seeds implanted • Uses Iodine-125 (I-125) (most common), Palladium-103 (Pd-103) or Cesium-131 isotopes • Radiation dose delivered over weeks and months • Acute side-effects resolve over months • Radiation protection issues for patient and carers
High dose rate (HDR)	<ul style="list-style-type: none"> • Temporary implantation • Iridium-192 (Ir-192) isotope introduced through implanted needles or catheters • Radiation dose delivered in minutes • Acute side-effects resolve over weeks • No radiation protection issues for patient or carers

6.1.3.4 Acute side-effects of external beam radiotherapy and brachytherapy

Gastrointestinal and urinary side-effects are common during and after EBRT. In the EORTC 22991 trial, approximately 50% of patients reported acute GU toxicity of grade 1, 20% of grade 2, and 2% grade 3. In the same trial, approximately 30% of patients reported acute grade 1 GI toxicity, 10% grade 2, and less than 1% grade 3. Common toxicities included dysuria, urinary frequency, urinary retention, haematuria, diarrhoea, rectal bleeding and proctitis [425]. In addition, general side-effects such as fatigue are common. It should be noted that the incidence of acute side-effects is greater than that of late effects (see Section 8.2.2.1), implying that most acute effects resolve. In a RCT of conventional dose EBRT vs. EBRT and LDR brachytherapy the incidence of acute proctitis was reduced in the brachytherapy arm, but other acute toxicities were equivalent [490]. Acute toxicity of HDR brachytherapy has not been documented in a RCT, but retrospective reports confirm lower rates of GI toxicity compared with EBRT alone and grade 3 GU toxicity in 10%, or fewer, patients, but a higher incidence of urinary retention [491]. Similar findings are reported using HFX; in a pooled analysis of 864 patients treated using extreme HFX and stereotactic radiotherapy, declines in urinary and bowel domains were noted at three months, which returned to baseline, or better, by six months [492].

6.1.4 Hormonal therapy

6.1.4.1 Introduction

6.1.4.1.1 Different types of hormonal therapy

Androgen deprivation can be achieved by either suppressing the secretion of testicular androgens or inhibiting the action of circulating androgens at the level of their receptor. These two methods can be combined to achieve what is known as complete (or maximal or total) androgen blockade (CAB) [493].

6.1.4.1.1.1 Testosterone-lowering therapy (castration)

6.1.4.1.1.1.1 Castration level

Surgical castration is still considered the primary treatment modality for ADT. It leads to a considerable decline in testosterone levels: the 'castration level'.

The castration level is < 50 ng/dL (1.7 nmol/L), which was defined more than 40 years ago when testosterone testing was limited. Current methods have shown that the mean value after surgical castration is 15 ng/dL [494]. Therefore, a more appropriate level is defined as < 20 ng/dL (1 nmol/L). This new definition is important as better results are repeatedly observed with lower testosterone levels compared to 50 ng/dL [495-497]. However, the castrate level considered by the regulatory authorities and in clinical trials addressing castration in PCa is still < 50 ng/dL (1.7 mmol/L).

6.1.4.1.1.1.2 Bilateral orchiectomy

Bilateral orchiectomy, or subcapsular pulpectomy, is a simple, cheap and virtually complication-free surgical procedure. It is easily performed under local anaesthesia and it is the quickest way to achieve a castration level, which is usually reached within less than twelve hours. It is irreversible and therefore does not allow for intermittent treatment [498].

6.1.4.1.1.2 Oestrogens

Treatment with oestrogens results in testosterone suppression and is not associated with bone loss [499]. Early studies tested oral diethylstilboestrol (DES) at several doses. Due to severe side-effects, especially thromboembolic complications, even at lower doses these drugs are not considered as standard first-line treatment [500-502].

6.1.4.1.1.3 Luteinising-hormone-releasing hormone agonists

Long-acting LHRH agonists are currently the main forms of ADT. These synthetic analogues of LHRH, are delivered as depot injections on a 1-, 2-, 3-, 6-monthly, or yearly, basis. The first injection induces a transient rise in luteinising hormone (LH) and follicle-stimulating hormone (FSH) leading to the 'testosterone surge' or 'flare-up' phenomenon, which starts two to three days after administration and lasts for about one week. This may lead to detrimental clinical effects (the clinical flare) such as increased bone pain, acute bladder outlet obstruction, obstructive renal failure, spinal cord compression, and cardiovascular death due to hypercoagulation status [503]. Patients at risk are usually those with high-volume, symptomatic, bony disease. Concomitant therapy with an anti-androgen decreases the incidence of clinical flare, but does not completely remove the risk.

Anti-androgen therapy is usually continued for four weeks but neither the timing nor the duration of anti-androgen therapy are based on strong evidence. In addition, the long-term impact of preventing 'flare-up' is unknown [504].

Chronic exposure to LHRH agonists results in the down-regulation of LHRH-receptors, suppressing LH and FSH secretion and therefore testosterone production. A castration level is usually obtained within two to four weeks [505]. Although there is no formal direct comparison between the various compounds, they are considered to be equally effective [506] and at least comparable to orchiectomy [507].

The different products have practical differences that need to be considered in everyday practice, including the storage temperature, whether a drug is ready for immediate use or requires reconstitution, and whether a drug is given by subcutaneous or intramuscular injection.

6.1.4.1.1.4 Luteinising-hormone-releasing hormone antagonists

Luteinising-hormone releasing hormone antagonists immediately bind to LHRH receptors, leading to a rapid decrease in LH, FSH and testosterone levels without any flare. The practical shortcoming of these compounds is the lack of a long-acting depot formulation with, so far, only monthly formulations being available.

Degarelix is a LHRH antagonist. The standard dosage is 240 mg in the first month, followed by monthly injections of 80 mg. Most patients achieve a castrate level at day three [508]. An extended follow-up has been published, suggesting a better PSA PFS compared to monthly leuprorelin [509]. A SR did not show major difference between agonists and degarelix and highlighted the paucity of on-treatment data beyond twelve months as well as the lack of survival data [510]. Its definitive superiority over the LHRH analogues remains to be proven.

6.1.4.1.1.5 Anti-androgens

These oral compounds are classified according to their chemical structure as:

- steroidal, e.g. cyproterone acetate (CPA), megestrol acetate and medroxyprogesterone acetate;
- non-steroidal or pure, e.g. nilutamide, flutamide and bicalutamide.

Both classes compete with androgens at the receptor level. This leads to an unchanged or slightly elevated testosterone level. Conversely, steroidal anti-androgens have progestational properties leading to central inhibition by crossing the blood-brain barrier.

6.1.4.1.1.5.1 Steroidal anti-androgens

These compounds are synthetic derivatives of hydroxyprogesterone. Their main pharmacological side-effects are secondary to castration (gynaecomastia is quite rare) whilst the non-pharmacological side-effects are cardiovascular toxicity (4-40% for CPA) and hepatotoxicity.

6.1.4.1.1.5.1.1 Cyproterone acetate

Cyproterone acetate was the first licensed anti-androgen, but the least studied. Its most effective dose as monotherapy is still unknown. Although CPA has a relatively long half-life (31-41 hours), it is usually administered in two or three fractionated doses of 100 mg each. In one RCT, CPA showed a poorer OS when compared with LHRH analogues [511]. An underpowered RCT comparing CPA monotherapy with flutamide in M1b PCa did not show any difference in disease-specific and OS at a median follow-up of 8.6 years [512]. Other CPA monotherapy studies suffer from methodological limitations preventing firm conclusions.

6.1.4.1.1.5.2 Non-steroidal anti-androgens

Non-steroidal anti-androgen monotherapy does not suppress testosterone secretion and it is claimed that libido, overall physical performance and bone mineral density (BMD) are frequently preserved [513]. Non-androgen-related pharmacological side-effects differ between agents. Bicalutamide shows a more favourable safety and tolerability profile than flutamide and nilutamide [514]. All three agents share the potential for liver toxicity (occasionally fatal), requiring regular monitoring of patients' liver enzymes.

6.1.4.1.1.5.2.1 Nilutamide

Nilutamide monotherapy has not been compared to castration and is not licensed for monotherapy. Direct drug-related side-effects are visual disturbances (i.e. delayed adaptation to darkness), alcohol intolerance, nausea, and of note, severe interstitial pneumonitis (potentially life-threatening). As a consequence it is rarely used.

6.1.4.1.1.5.2.2 Flutamide

Flutamide has been studied as monotherapy. Flutamide is a pro-drug, and the half-life of the active metabolite is five to six hours, requiring a three times daily dose. The recommended total daily dose is 750 mg. The non-androgen-related pharmacological side-effect of flutamide is diarrhoea.

6.1.4.1.1.5.2.3 Bicalutamide

The dosage licensed for use in CAB is 50 mg/day, and 150 mg for monotherapy. The androgen pharmacological side-effects are mainly gynaecomastia (70%) and breast pain (68%). However, bicalutamide monotherapy offers clear bone protection compared with LHRH analogues and probably LHRH antagonists [513, 515].

6.1.4.1.1.6 New compounds

Once on castration, the development of castration-resistance (CRPC) is only a matter of time. It is considered to be mediated through two main overlapping mechanisms: androgen-receptor (AR)-independent and AR-dependent mechanisms (see Section 6.5 - Castrate-resistant PCa). In CRPC, the intracellular androgen level is increased compared to androgen sensitive cells, and an over-expression of the AR has been observed, suggesting an adaptive mechanism [516]. This has led to the development of several new compounds targeting the androgen axis. Abiraterone acetate and enzalutamide are both approved for mCRPC. Abiraterone acetate has also been approved for hormone-sensitive PCa, combined with ADT. Apalutamide has been approved by the EMA for M0 CRPC at high risk of further metastases [517].

6.1.4.1.1.6.1 Abiraterone acetate

Abiraterone acetate is a CYP17 inhibitor (a combination of 17 α -hydroxylase and 17,20-lyase inhibition). By blocking CYP17, Abiraterone acetate significantly decreases the intracellular testosterone level by suppressing its synthesis at the adrenal level and inside the cancer cells (intracrine mechanism). This compound must be used together with prednisone/prednisolone to prevent drug-induced hyperaldosteronism.

6.1.4.1.1.6.2 Enzalutamide

Enzalutamide is a novel anti-androgen with a higher affinity for the AR receptor than bicalutamide. While non-steroidal anti-androgens still allow transfer of ARs to the nucleus, enzalutamide also blocks AR transfer and therefore suppresses any possible agonist-like activity.

6.1.4.1.1.6.3 Apalutamide

Apalutamide is a novel anti-androgen closely related to enzalutamide with an identical mechanism of action although it but does not cross the blood-brain barrier.

6.1.5 **Investigational therapies**

6.1.5.1 *Background*

Besides RP, EBRT and brachytherapy, other modalities have emerged as potential therapeutic options in patients with clinically localised PCa [518-521]. In this section, both whole gland and focal treatment will be considered, looking particularly at high-intensity focused US (HIFU), cryotherapeutic ablation of the prostate (cryotherapy) and focal photodynamic therapy, as sufficient data are available to form the basis of some initial judgements. Other options, such as radiofrequency ablation and electroporation, among others, are considered to be in the early phases of evaluation [522]. In addition, a relatively newer development is focal ablative therapy [522, 523], whereby lesion-targeted ablation is undertaken in a precise, organ-sparing manner. All these modalities have been developed as minimally invasive procedures with the aim of providing equivalent oncological safety, reduced toxicity and improved functional outcomes.

6.1.5.2 *Cryotherapy*

Cryotherapy uses freezing techniques to induce cell death by dehydration resulting in protein denaturation, direct rupture of cellular membranes by ice crystals and vascular stasis and microthrombi, resulting in stagnation of the microcirculation with consecutive ischaemic apoptosis [518-521]. Freezing of the prostate is ensured by the placement of 17 gauge cryo-needles under TRUS guidance, placement of thermosensors at the level of the external sphincter and rectal wall, and insertion of a urethral warmer. Two freeze-thaw cycles

are used under TRUS guidance, resulting in a temperature of -40°C in the mid-gland and at the neurovascular bundle. Currently, third and fourth generation cryotherapy devices are mainly used. Since its inception, cryotherapy has been used for whole-gland treatment in PCa either as a primary or salvage treatment option. The main adverse effects of cryosurgery are ED (18%), urinary incontinence (2-20%), urethral sloughing (0-38%), rectal pain and bleeding (3%) and recto-urethral fistula formation (0-6%) [524]. There is a lack of prospective comparative data regarding oncological outcomes of whole-gland cryosurgery as a curative treatment option for men with localised PCa, with most studies being non-comparative single-arm case series with short follow-up periods [524].

6.1.5.3 High-intensity focused ultrasound

High-intensity focused ultrasound (HIFU) consists of focused US waves, emitted from a transducer, that cause tissue damage by mechanical and thermal effects as well as by cavitation [525]. The goal of HIFU is to heat malignant tissues above 65°C so that it is destroyed by coagulative necrosis. High-intensity focused US is performed under general or spinal anaesthesia, with the patient lying in the lateral or supine position. High-intensity focused US has previously been widely used for whole-gland therapy. The major adverse effects of HIFU include acute urinary retention (10%), ED (23%), urethral stricture (8%), rectal pain or bleeding (11%), recto-urethral fistula (0-5%) and urinary incontinence (10%) [524]. Disadvantages of HIFU include difficulty in achieving complete ablation of the prostate, especially in glands larger than 40 mL, and in targeting cancers in the anterior zone of the prostate. Similar to cryosurgery, the lack of any long-term prospective comparative data on oncological outcomes prevents whole-gland HIFU from being considered as a reasonable alternative to the established curative treatment options [524].

6.1.5.4 Focal therapy

During the past two decades, there has been a trend towards earlier diagnosis of PCa as a result of greater public and professional awareness, leading to the adoption of both formal and informal screening strategies. The effect of this has been to identify men at an earlier stage with smaller tumours that occupy only 5-10% of the prostate volume, with a greater propensity for unifocal or unilateral disease [526-528]. Most focal therapies to date have been achieved with ablative technologies: cryotherapy, HIFU, photodynamic therapy, electroporation, and focal RT by brachytherapy or CyberKnife® Robotic Radiosurgery System technology (Accuray Inc., Sunnyvale, CA, USA). The main purpose of focal therapy is to ablate tumours selectively whilst limiting toxicity by sparing the neurovascular bundles, sphincter and urethra [529-531].

A previous SR and network meta-analysis [524] on ablative therapy in men with localised PCa performed a sub-group analysis of focal therapy vs. RP and EBRT. Nine case series reporting on focal therapy were identified (five studies reporting on focal cryosurgical ablation of the prostate (CSAP), three studies on focal HIFU, and one study reported on both). For focal CSAP vs. RP or EBRT, no statistically significant differences were found for BCR at three years. For focal HIFU vs. RP or EBRT, there were neither comparable data on oncological, continence nor potency outcomes at one year, or more. More recently, Valerio *et al.* [523] performed a SR to summarise the evidence regarding the effectiveness of focal therapy in localised PCa. Data from 3,230 patients across 37 studies were included, covering different energy sources including HIFU, CSAP, photodynamic therapy, laser interstitial thermotherapy, focal brachytherapy, irreversible electroporation and radiofrequency ablation. The overall quality of the evidence was low, due to the majority of studies being single-centre, non-comparative and retrospective in design, heterogeneity of definitions, approaches, follow-up strategies, outcomes, and duration of follow-up. Although the review suggests that focal therapy has a favourable toxicity profile in the short to medium-term, its oncological effectiveness remains unproven due to lack of reliable comparative data against standard interventions such as RP and EBRT.

An RCT compared focal therapy using padeliporfin-based vascular-targeted photodynamic therapy (PDT) vs. AS in men with very low-risk PCa [532]. The study found at a median follow-up of 24 months, less patients progressed in the PDT arm compared with the AS arm (adjusted HR: 0.34, 95% CI: 0.24-0.46). In addition, more men in the PDT arm had a negative prostate biopsy at two years than men in the AS arm (adjusted RR: 3.67, 95% CI: 2.53-5.33). Nevertheless, limitations of the study include inappropriately comparing an intervention designed to destroy cancer tissue in men with low-risk PCa against an intervention primarily aimed at avoiding unnecessary treatment in men with low-risk PCa, and an unusually high observed rate of disease progression in the AS arm (58% in two years). Another prospective but uncontrolled, single-arm case series on focal therapy using HIFU on patients with localised intermediate-risk disease was recently published [533]. Overall, given the lack of robust comparative data on medium to long-term oncological outcomes for focal therapy against curative interventions (i.e. RP or EBRT), focal therapy should remain investigational for the time being; robust prospective trials reporting standardised outcomes [534] are needed before recommendations in support of focal therapy for routine clinical practice can be made [522, 533, 534].

6.1.6 General guidelines for active treatment

Recommendations	Strength rating
Inform patients that no active treatment modality has shown superiority over any other active management options in terms of survival.	Strong
Inform patients that all active treatments have side effects.	Strong
Surgical treatment	
Inform patients that no surgical approach (open, laparoscopic- or robotic radical prostatectomy) has clearly shown superiority in terms of functional or oncological results.	Strong
Perform an extended lymph node dissection (LND), when a LND is deemed necessary.	Strong
Do not perform nerve-sparing surgery when there is a risk of extracapsular extension (based on cT stage, ISUP grade, nomogram, multiparametric magnetic resonance imaging).	Strong
Do not offer neoadjuvant androgen deprivation therapy before surgery.	Strong
Radiotherapeutic treatment	
Offer intensity-modulated radiation therapy (IMRT) or volumetric arc external-beam radiotherapy (VMAT) for definitive treatment of PCa by external-beam radiation therapy.	Strong
Offer moderate hypofractionation (HFX) with IMRT/VMAT, including image-guided radiation therapy to the prostate, to carefully selected patients with localised disease.	Strong
Ensure that moderate HFX adheres to radiotherapy protocols from trials with equivalent outcome and toxicity, i.e. 60 Gy/20 fractions in four weeks or 70 Gy/28 fractions in six weeks.	Strong
Active therapeutic options outside surgery and radiotherapy	
Only offer cryotherapy and high-intensity focused ultrasound within a clinical trial setting.	Strong
Only offer focal therapy within a clinical trial setting.	Strong

6.1.7 Discussing treatment options

Management decisions should be made after all treatments have been discussed in a multidisciplinary team (including urologists, radiation oncologists, medical oncologists and radiologists), and after the balance of benefits and side-effects of appropriate therapy modalities has been considered together with the patient. The following paragraphs will only address active modalities where the aim is to try to be “curative” in patients where that is appropriate.

6.2 Treatment by disease stages

6.2.1 Treatment of low-risk disease

6.2.1.1 Active surveillance

The main risk for men with low-risk disease is over-treatment (see Sections 6.1.1.2 and 6.1.1.4) and therefore AS should be considered for all such patients.

6.2.1.1.1 Selection criteria for active surveillance based on clinical and pathological variables

Selection criteria for AS are limited by a lack of prospective RCTs, or findings from a formal consensus meeting. The criteria most often published include: ISUP grade 1, when specified < 2-3 positive cores with < 50% cancer involvement in every positive core, a clinical T1c or T2a, a PSA < 10 ng/mL and a PSA density < 0.15 ng/mL/cc [354, 535]. The latter threshold remains controversial [535, 536]. A pathology consensus group suggested excluding men from AS when any of the following features were present: predominant ductal carcinoma (including pure intraductal carcinoma), sarcomatoid carcinoma, small cell carcinoma, EPE or LVI in needle biopsy [537] and perineal invasion [538]. A Canadian consensus group considered AS as the treatment of choice for low-risk disease, without stratifying for biopsy results, although they clearly recommended that men < 55 years should be closely scrutinised for high-volume ISUP 1 cancer [539]. This position has been endorsed by the ASCO [540]. In this setting, re-biopsy within six to twelve months to exclude sampling error is mandatory [535, 539] even if this could be modified in the future [541]. A SR and meta-analysis found three clinico-pathological variables which were significantly associated with reclassification, which were; PSA-density, ≥ 2 positive cores, and African-American race [542]. In summary, there is significant heterogeneity regarding selection and eligibility criteria into AS programmes [8].

6.2.1.1.2 Biological markers

Biological markers, including urine PCA3, transmembrane protease, serine 2-*TMPRSS2-ERG* fusion, or PSA isoforms appear promising, as does genomics on the tissue sample itself [543-545]. However, further data will be needed before such markers can be used in standard clinical practice [153].

6.2.1.1.3 Imaging for treatment selection

6.2.1.1.3.1 mpMRI in men eligible for active surveillance based on systematic biopsy findings only

A recent meta-analysis evaluated the proportion of men eligible for AS based on systematic TRUS-guided biopsy in whom the cancer was upgraded by MRI-TBx and systematic biopsy at confirmatory biopsy [546]. The cancer was upgraded in 27% of men using a combination of biopsy techniques. The MRI-TBx upgraded the tumour in 17% (95% CI: 10-26%) of patients and TRUS-guided systematic biopsies in 20% (95% CI: 16-25%) of patients. Just 10% of patients were upgraded by both biopsy methods, meaning MRI-TBx identified an additional 7% (95% CI: 5-10%) of men who were upgraded, whilst systematic biopsy identified an additional 10% (95% CI: 8-14%) of men who were upgraded. Even if the analysed series used different definitions for csPCa (and thus for cancer upgrading), MRI-TBx and systematic biopsy appear to be complementary to each other, both missing a significant proportion of cancer upgrading or reclassification. Thus, combining the two biopsy techniques seems the best way to select patients for AS at confirmatory biopsy.

A recently published multicentre RCT on men on AS and scheduled for confirmatory biopsy surprisingly did not show the benefit of additional use of MRI-TBx (ASIST trial) [547]. Men were randomised to either twelve-core systematic biopsy or to MRI with targeted biopsy (when indicated) combined with systematic biopsy, up to twelve cores in total, avoiding oversampling in the MRI arm. Overall, ISUP grade ≥ 2 cancer upgrading was 23% (31/136) for systematic biopsy vs. 21% (29/137) for MRI-TBx and systematic biopsy. However, the centre responsible for inclusion of 55% of the patients in the trial and most experience with mpMRI and targeted biopsy showed an ISUP grade ≥ 2 cancer upgrading rate of 20% (14/71) for systematic biopsy vs. 33% (24/71) for MRI-TBx and systematic biopsy ($p = 0.09$). At the two sites with less experience, the upgrading rate for systematic biopsies alone (29% and 26%) was unexpectedly much higher than for MRI-TBx and systematic biopsy (10% and 8%). This underscores that both experience in mpMRI and in targeting biopsy is mandatory in this clinical setting.

6.2.1.1.3.1.1 Reduction of systematic biopsies in MRI-negative men on active surveillance.

Surveillance management should not only focus on upgrading cancer but also on limiting the number of biopsies in AS since avoiding further biopsy when the MRI is negative is attractive. In the SR mentioned above [546], 30% of men eligible for AS had a negative mpMRI, which may show the potential reduction of biopsy procedures. However, 12% of men with a negative mpMRI showed cancer upgrading from low-risk to intermediate/high-risk disease, identified by systematic biopsies. In another review, a negative mpMRI was associated with upgrading in 27% of men when referenced to RPs, suggesting that this imaging modality alone cannot be used to monitor men on AS [548]. However, caution must be exercised when extrapolating surgical data to all men on surveillance, as those getting surgery are more likely to harbour higher volumes of cancer, compared to the average men on AS.

For some men with a negative MRI, omitting TRUS-guided biopsies would be acceptable considering the harms and benefits; for other men this would be unacceptable. This would promote a multivariate risk-based approach objectively weighing all relevant factors [549, 550].

6.2.1.1.3.1.2 Multivariate risk prediction at confirmatory biopsy

Cancer upgrading was identified almost three-times more often in men with a positive mpMRI in contrast to a negative mpMRI (RR: 2.77, 95% CI: 1.76-4.38) [546]. For this reason, a positive mpMRI should be marked as a positive predictor for upgrading in men on AS at confirmatory biopsies. However, still 11% of men with a positive mpMRI showed cancer upgrading by systematic biopsies only, most likely due to tumour heterogeneity. Furthermore, a MRI suspicion score ≥ 4 of overall PI-RADS and an index lesion size > 10 mm are strongly associated with patient withdrawal from AS [551]. This further supports a multivariate risk-based approach weighing all relevant factors, not compromising the identification of all high-grade PCas [549, 550, 552]. A negative MRI, in combination with other stable negative predictors (low PSA kinetics, low PSA density) may support the decision to omit additional systematic TRUS-guided biopsies at routine repeat biopsies, at least on an individual basis with adequate counselling.

Men on AS with a PI-RADS 3 lesion upgrade at confirmatory biopsy in an estimated proportion of 17% (range 9-31%), which is still a surprisingly large fraction [553]. The PFS in negative mpMRI, including PI-RADS 1-3, was 99, 90 and 86% at 1, 2 and 3 years respectively [554], suggesting that also PI-RADS 3 lesions should be targeted at MRI-TBx.

6.2.1.1.3.2 Follow-up mpMRI in men eligible for active surveillance based on mpMRI and systematic and targeted-biopsy findings

Several authors have reported data on sequential mpMRI evaluation, considering an increase in mpMRI suspicion score or lesion diameter on mpMRI as a sign of disease progression. In these surveillance cohorts, summarised in a review [550], the overall upgrading from ISUP grade 1 to ISUP grade ≥ 2 PCa was 30% (81/269), following combined targeted and standard biopsies. Upgrading occurred in 39% of patients with MRI showing progression and in 21% of patients with MRI showing stable findings or regression.

Data on the combination of serial mpMRI and PSA as a trigger for re-biopsy are even more limited. Using mpMRI and PSA changes as the sole triggers for re-biopsy would have detected only 14/20 (70%) of progressions and resulted in fifteen additional biopsy procedures which failed to show pathological progression [555]. Protocol based re-biopsy, without mpMRI or PSA changes, however, still detected pathological progressions in 6 out of 87 (6.9%) men. When specific suspicious sites on mpMRI were resampled in men undergoing AS for PCa, upgrading was detected more often than by systematic biopsy [556].

Very limited data are available on unchanged negative mpMRI. In a small study on 75 men included within PRIAS, with a mpMRI at baseline, 46 (61%) had a negative mpMRI (suspicion score 1-2). Of these 46 patients, twelve (26%) were reclassified at twelve months by systematic biopsies [557]. However, of the 29 patients (39%) from the same series with a positive initial mpMRI, 21 (72%) were reclassified at twelve months.

Even though mpMRI is useful for the initial categorisation of men as candidates for AS, it is not yet sufficient as a primary test during surveillance [558].

6.2.1.1.3.3 Guidelines for imaging in men on active surveillance

Recommendations in men on active surveillance	LE	Strength rating
Perform mpMRI before confirmatory prostate biopsy if not done before the first biopsy.	1a	Strong
Perform the combination of targeted biopsy (of any PI-RADS \geq 3 lesion) and systematic biopsy at confirmatory biopsy.	2a	Weak

6.2.1.1.4 Follow up

The follow up strategy is based on serial DRE (at least once yearly), PSA (at least once, every six months) and repeated biopsy (at a minimum interval of three to five years). Based on two small single centre studies [559, 560], not all patients with progression/reclassification at biopsy had radiological progression and vice versa. Therefore, mpMRI cannot be used as a stand-alone tool to trigger follow-up biopsies, but efforts are being made to define and standardise radiological progression during AS [558].

Risk prediction in men on AS is under investigation to further reduce unnecessary biopsies and misclassification [539]. In an AS cohort of 259 men with ISUP grade 1 and 2 cancers detected by MRI-targeted and systematic biopsies, independent predictors of upgrading at 3 years were ISUP grade 2, PSA density \geq 0.15 ng/mL/cm³ and a score 5 lesion on MRI [561]. Therefore, the role of mpMRI in risk prediction should be further investigated.

6.2.1.1.5 Switching to active treatment

The decision to start active treatment should be based on a change in the biopsy results (ISUP grade, number of positive cores, core length involvement), or T-stage progression. These criteria are recognised in all published cohorts but are limited by the heterogeneity of inclusion criteria for AS. A PSA change (especially a PSA-DT < three years) is a less powerful indicator to change management based on its weak link with grade progression [562, 563]. Active treatment may also be instigated upon a patient's request. This occurs in around 10% of patients on AS [564]. A recent SR on AS protocols showed a lack of consensus regarding what criteria should trigger reclassification.

Given the significant heterogeneity and uncertainty regarding the criteria and thresholds for patient selection, imaging, repeat biopsies, frequency and timing of clinical follow-up, reclassification and primary outcome measures of AS protocols, there is a need to achieve formal consensus regarding the major domains of AS, in order to standardise practice for prospective AS programmes, and trials involving AS vs. other treatments. Efforts are underway to address this important knowledge gap [565].

6.2.1.2 Active treatment

Patients not meeting criteria listed for AS or showing progression during surveillance or who are unwilling to proceed with AS should be discussed for active treatment.

6.2.1.2.1 Radical prostatectomy

At ten years' follow-up in the ProtecT study, where 60% had a low risk disease, a benefit for metastases-free and PFS, but neither cancer-specific nor OS, for RP compared to AM and RT was observed [353]. In the SPCG-4 study [363], death from any cause and distant metastases were significantly reduced in low-risk PCa at eighteen years for RP compared with WW. However, death from PCa was not reduced. In the PIVOT trial, a pre-planned subgroup analysis of men with low-risk PCa showed that RP did not significantly reduce all-cause mortality or death from PCa at ten years compared with WW [370].

The decision to offer RP in cases of low-risk cancer should be based upon the probabilities of clinical progression, side-effects and potential benefit to survival [566]. Individual patient preferences should always be considered in shared decision-making. If RP is performed in low-risk PCa, pelvic LN dissection is not necessary (pN+ risk \leq 5%) [567].

6.2.1.2.2 Radiation therapy treatment policy

The ProtecT study also confirmed that RT combined with six months of ADT failed to improve cancer-specific or OS in this PSA-screened population, but did improve PFS, as per RP [353]. As with RP, the decision to offer treatment should be based upon the probabilities of clinical progression, side-effects and potential benefit to survival [566]. Individual patient preferences should always be considered in shared decision-making. If RT is performed in this group, intensity-modulated RT with escalated dose (74-80 Gy) and without ADT, or moderate HFX (see Section 6.1.3.1.3) should be used. Low-dose rate brachytherapy is a valid alternative provided the patient fulfils the criteria (see Section 6.1.3.3.1).

6.2.1.3 Other treatments

All other treatment modalities should be considered as investigational. Neither whole gland treatment nor focal treatment can be considered as standard (see 6.1.5). Ideally, they should only be performed in a clinical trial setting.

6.2.1.4 Guidelines for the treatment of low-risk disease

Recommendations	Strength rating
Watchful waiting (WW)	
Offer a WW policy to asymptomatic patients with a life expectancy < ten years (based on comorbidities).	Strong
Active surveillance (AS)	
Offer AS to patients suitable for curative treatment but with low-risk PCa.	Strong
Perform multiparametric magnetic resonance imaging before a confirmatory biopsy.	Strong
During confirmatory biopsy include systematic and targeted biopsies.	Strong
Base follow up on digital rectal examination, prostate-specific antigen and repeated biopsies.	Strong
Counsel patients about the possibility of needing further treatment in the future.	Strong
Active treatment	
Offer surgery and radiotherapy as alternatives to AS to patients suitable for such treatments and who accept a trade-off between toxicity and prevention of disease progression.	Weak
Pelvic lymph node dissection (PLND)	
Do not perform a PLND (estimated risk for pN+ < 5%).	Strong
Radiotherapeutic treatment	
Offer low-dose rate brachytherapy to patients with low-risk PCa, without a previous transurethral resection of the prostate and with a good International Prostatic Symptom Score and a prostate volume < 50 mL.	Strong
Use intensity-modulated radiation therapy with a total dose of 74-80 Gy or moderate hypofractionation (60 Gy/20 fx in four weeks or 70 Gy/28 fx in six weeks), without androgen deprivation therapy.	Strong
Other therapeutic options	
Only offer whole gland treatment (such as cryotherapy, high-intensity focused ultrasound, etc.) or focal treatment within a clinical trial setting.	Strong

6.2.2 Treatment of Intermediate-risk disease

When managed with non-curative intent, intermediate-risk PCa is associated with ten-year and fifteen-year PCSM rates of 13.0% and 19.6%, respectively [568].

6.2.2.1 Active Surveillance

In the ProtecT trial, up to 22% of the randomised patients in the AM arm had ISUP grade > 1 and 10% a PSA > 10 ng/mL [353]. A Canadian consensus group proposes that low volume ISUP grade 2 (< 10% Gleason pattern 4) may also be considered for AS. These recommendations have been endorsed by the American Society of Clinical Oncology ASCO [540]. However, recent findings suggest that any grade 4 pattern is associated with a three-fold increased risk of metastases compared to ISUP grade 1, while a PSA up to

20 ng/mL might be an acceptable threshold [539, 569, 570]. Including mpMRI and a systematic re-biopsy (eventually targeted) might improve the accuracy of staging. However clear evidence to support AS in the intermediate-risk group is not available and therefore care must be taken if advocating this treatment strategy especially in patients with the longest life expectancy.

6.2.2.2 *Surgery*

Patients with intermediate-risk PCa should be informed about the results of two RCTs (SPCG-4 and PIVOT) comparing RRP vs. WW in localised PCa. In the SPCG-4 study, death from any cause (RR: 0.71; 95% CI: 0.53-0.95), death from PCa (RR: 0.38; 95% CI: 0.23-0.62) and distant metastases (RR: 0.49; 95% CI: 0.32-0.74) were significantly reduced in intermediate-risk PCa at eighteen years. In the PIVOT trial, according to a pre-planned subgroup analysis among men with intermediate-risk tumours, RP significantly reduced all-cause mortality (HR: 0.69 [95% CI: 0.49-0.98]), but not death from PCa (0.50; 95% CI: 0.21-1.21) at ten years.

The risk of having positive LNs in intermediate-risk PCa is between 3.7-20.1% [567]. An eLND should be performed in intermediate-risk PCa if the estimated risk for pN+ exceeds 5% [567]. In all other cases eLND can be omitted, which means accepting a low risk of missing positive nodes.

6.2.2.3 *Radiation therapy*

6.2.2.3.1 Recommended external beam radiation therapy for intermediate-risk PCa

Patients suitable for ADT can be given combined IMRT with short-term ADT (4-6 months) [571-573]. For patients unsuitable for ADT (e.g. due to comorbidities) or unwilling to accept ADT (e.g. to preserve their sexual health), the recommended treatment is IMRT or VMAT at an escalated dose (76-80 Gy) or a combination of IMRT or VMAT and brachytherapy (see Section 6.2.3.2.3).

6.2.2.3.2 Brachytherapy monotherapy

Low-dose rate brachytherapy can be offered to highly selected patients (ISUP grade 2 with \leq 33% of biopsy cores involved with cancer), provided they fulfil all the other criteria. Fractionated HDR brachytherapy as monotherapy can be offered to selected patients with intermediate-risk PCa although they should be informed that results are only available from small series in very experienced centres. Five-year PSA control rates over 90% are reported, with late grade 3+ GU toxicity rates $<$ 5% and no, or very minimal, grade 3+ GI toxicity rates [488, 574]. There are no direct data to inform on the use of ADT in this setting.

6.2.2.4 *Other options for the primary treatment of intermediate-risk PCa (experimental therapies)*

All other treatment modalities should be considered as investigational. A prospective study on focal therapy using HIFU on patients with localised intermediate-risk disease was recently published [533], but the data was derived from an uncontrolled, single-arm case series. Consequently, neither whole gland treatment nor focal treatment can be considered as standard (see Section 6.1.5), and ideally should only be offered in clinical trials [575].

6.2.2.5 Guidelines for the treatment of intermediate-risk disease

Recommendations	Strength rating
Active surveillance (AS)	
Offer AS to highly selected patients (< 10% pattern 4) accepting the potential increased risk of further metastases.	Weak
Radical prostatectomy (RP)	
Offer RP to patients with intermediate-risk disease and a life expectancy of > ten years.	Strong
Offer nerve-sparing surgery to patients with a low risk of extracapsular disease.	Strong
Pelvic lymph node dissection (ePLND)	
Perform an ePLND in intermediate-risk disease if the estimated risk for positive lymph nodes exceeds 5%.	Strong
Radiotherapeutic treatment	
Offer low-dose rate brachytherapy to selected patients (see Section 6.2.3.2.3); patients without a previous transurethral resection of the prostate and with a good International Prostatic Symptom Score and a prostate volume < 50 mL.	Strong
For external-beam radiation therapy (EBRT), use a total dose of 76-78 Gy or moderate hypofractionation (60 Gy/20 fx in four weeks or 70 Gy/28 fx in six weeks), in combination with short-term neoadjuvant plus concomitant androgen deprivation therapy (ADT) (four to six months).	Strong
In patients not willing to undergo ADT, use an escalated dose of EBRT (76-80 Gy) or a combination with brachytherapy.	Weak
Other therapeutic options	
Only offer whole gland treatment (such as cryotherapy, high-intensity focused ultrasound, etc.) or focal treatment within a clinical trial setting.	Strong
Do not offer ADT monotherapy to intermediate-risk asymptomatic men not able to receive any local treatment.	Strong

6.2.3 Treatment of high-risk localised disease

Patients with high-risk PCa are at an increased risk of PSA failure, need for secondary therapy, metastatic progression and death from PCa. Nevertheless, not all high-risk PCa patients have a uniformly poor prognosis after RP [576]. When managed with non-curative intent, high-risk PCa is associated with ten-year and fifteen-year PCSM rates of 28.8 and 35.5%, respectively [568]. There is no consensus regarding the optimal treatment of men with high-risk PCa.

6.2.3.1 Radical prostatectomy

Provided that the tumour is not fixed to the pelvic wall, or there is no invasion of the urethral sphincter, RP is a reasonable option in selected patients with a low tumour volume. Extended PLND should be performed in all high-risk PCa cases undergoing RP as the estimated risk for positive LNs is 15-40% [567]. Patients should be aware pre-operatively that surgery may be part of multimodality treatment.

6.2.3.1.1 ISUP grade 4-5

The incidence of organ-confined disease is 26-31% in men with an ISUP grade ≥ 4 on systematic biopsy. A high rate of downgrading exists between the biopsy ISUP grade and the ISUP grade of the resected specimen [577]. Several retrospective case series have demonstrated CSS rates over 60% at fifteen years after RP in the context of a multimodal approach (adjuvant or salvage ADT and/or RT) for patients with a biopsy ISUP grade 5 [324, 374, 578, 579].

6.2.3.1.2 Prostate-specific antigen > 20 ng/mL

Reports in patients with a PSA > 20 ng/mL who underwent surgery as initial therapy within a multimodal approach demonstrated a CSS at fifteen years of over 70% [324, 374, 381, 580-582].

6.2.3.1.3 Radical prostatectomy in cN0 patients who are found to have pathologically confirmed lymph node invasion (pN1)

cN0 patients who undergo RP but who were found to have pN1 were reported to have an overall CSS and OS of 45% and 42%, respectively, at fifteen years [583-589]. However, this is a very heterogeneous patient group and further treatment must be individualised based on risk factors (see Section 6.2.4.5).

6.2.3.2 External beam radiation therapy

6.2.3.2.1 Recommended external beam radiation therapy treatment policy for high-risk localised PCa

For high-risk localised PCa, use a combined modality approach, consisting of dose-escalated IMRT or VMAT, plus long-term ADT. The duration of ADT has to take into account PS, comorbidities and the number of poor prognostic factors. It is important to recognise that in several studies, EBRT plus short-term ADT did not improve OS in high-risk localised PCa [455, 456, 458], and long-term ADT (at least two to three years) is currently recommended for these patients.

6.2.3.2.2 Lymph node irradiation in cNO

There is no level 1 evidence for prophylactic whole-pelvic irradiation, since RCTs have failed to show that patients benefit from prophylactic irradiation (46-50 Gy) of the pelvic LNs in high-risk cases [590-592]. In the RTOG 94-13 study [458], there were no PFS differences between patients treated with whole-pelvic or prostate-only RT, but interactions between whole-pelvic RT and the duration of ADT were reported following the subgroup analysis. Furthermore, in most trials dealing with high-risk PCa, a whole pelvis field was considered standard of care. The benefits of pelvic nodal irradiation using IMRT or VMAT merit further investigation in RCTs as conducted by the RTOG or the UK NCRI group. Performing an ePLND in order to decide whether or not pelvic RT is required (in addition to combined prostate EBRT plus long-term ADT) remains purely experimental in the absence of level 1 evidence.

6.2.3.2.3 Low-dose rate brachytherapy boost

In men with intermediate- or high-risk PCa, LDR brachytherapy boost with supplemental EBRT and hormonal treatment [593] may be considered. Dose-escalated EBRT (total dose of 78 Gy) has been compared with EBRT (total dose 46 Gy) followed by LDR brachytherapy boost (prescribed dose 115 Gy) in intermediate-risk and high-risk patients in a randomised trial with twelve months of ADT in both arms [594]. The LDR boost resulted in five- and seven-year PSA PFS increase (89% and 86%, respectively, compared to 84% and 75%). This improvement came with an increase in late grade 3+ urinary toxicity (18% compared to 8%) [595]. Toxicity was mainly due to urethral strictures and incontinence and great care should be taken during treatment planning.

6.2.3.3 Options other than surgery and radiotherapy for the primary treatment of localised prostate cancer.

Currently there is a lack of evidence supporting any other treatment option or focal therapy in localised high-risk PCa.

6.2.3.4 Guidelines for radical treatment of high-risk localised disease

Recommendation	Strength rating
Radical Prostatectomy (RP)	
Offer RP to patients with high-risk localised PCa and a life expectancy of > ten years only as part of multi-modal therapy.	Strong
Extended pelvic lymph node dissection (ePLND)	
Perform an ePLND in high-risk disease.	Strong
Do not perform a frozen section of nodes during RP to decide whether to proceed with, or abandon, the procedure.	Strong
Radiotherapeutic treatment	
In patients with high-risk localised disease, use external-beam radiation therapy (EBRT) with 76-78 Gy in combination with long-term androgen deprivation therapy (ADT) (two to three years).	Strong
In patients with high-risk localised disease, use EBRT with brachytherapy boost (either high-dose rate or low-dose rate), in combination with long-term ADT (two to three years).	Weak
Therapeutic options outside surgery and radiotherapy	
Do not offer either whole gland or focal therapy to high-risk patients.	Strong
Do not use ADT monotherapy in asymptomatic patients.	Strong

6.2.4 Treatment of locally advanced prostate cancer

No standard treatment can be defined in the absence of level 1 evidence. But a local treatment combined with a systemic one provides the best outcome, provided the patient is ready and fit enough to receive both. The optimal local treatment is still a matter of debate. Randomised controlled trials are only available for EBRT.

6.2.4.1 Surgery

Surgery for locally advanced disease as part of a multimodal therapy has been reported [577, 596, 597]. However, the comparative oncological effectiveness of RP as part of a multimodality treatment strategy vs. upfront EBRT with ADT for locally advanced PCa remains unknown, although a prospective phase III RCT (SPCG-15) comparing RP (with or without adjuvant or salvage EBRT) against primary EBRT and ADT among patients with locally advanced (T3) disease is currently recruiting [598]. Data from retrospective case series demonstrated over 60% CSS at fifteen years and over 75% OS at ten years [574, 577, 596, 597, 599-602]. For cT3b-T4 disease, PCa cohort studies showed ten year CSS of over 87% and OS of 65% [603-605]. The indication for RP in all previously described stages assumes the absence of clinically detectable nodal involvement (cN0). In case of suspected positive LNs during RP (initially considered cN0), the procedure should not be abandoned since RP may have a survival benefit in these patients. Intra-operative frozen section analysis is not justified in this case [401]. Only limited evidence exists supporting RP for cN+ patients. Moschini *et al.* compared the outcomes of 50 patients with cN+ with those of 252 patients with pN1, but cN0 at pre-operative staging. cN+ was not a significant predictor of CSS [606]. An ePLND is considered standard if a RP is planned.

6.2.4.2 Radiotherapy for locally advanced PCa

In locally advanced disease, RCTs have clearly established that the additional use of long-term ADT combined with RT produces better OS than ADT or RT alone (see Section 6.1.3.1.4 and Tables 6.1.9 and 6.1.10). In clinical or pathological node-positive disease, RT monotherapy is associated with poor outcomes [460], and these patients should receive RT plus long-term ADT. A subgroup analysis from the RTOG 85-31 with a median follow-up period of 6.5 years, showed that 95 of the 173 pN1 patients who received pelvic RT with immediate HT had better five-year (54%) and nine-year (10%) PFS rates vs. 33% and 4%, respectively, for radiation alone ($p < 0.0001$). Multivariate analysis showed that this combination had a statistically significant impact on the OS [454]. These findings are also confirmed from the control arm of the STAMPEDE trial (HR: 0.48 [95% CI: 0.29-0.79]) in a non-randomised comparison [607].

6.2.4.3 Options other than surgery and radiotherapy for primary treatment

Currently cryotherapy, HIFU or focal therapies have no place in the management of locally advanced PCa.

The deferred use of ADT as single treatment modality has been answered by the EORTC 30891 trial [567]. Nine hundred and eighty-five patients with T0-4 N0-2 M0 PCa received ADT alone, either immediately or after symptomatic progression or occurrence of serious complications. After a median follow-up of 12.8 years, the OS favoured immediate treatment (HR: 1.21 [95% CI: 1.05-1.39]). Surprisingly, no different disease-free or symptom-free survival were observed, raising the question of survival benefit. In locally advanced T3-T4 M0 disease unsuitable for surgery or RT, immediate ADT may only benefit patients with a PSA > 50 ng/mL and a PSA-DT < 12 months [567, 608], or those that are symptomatic. The median time to start deferred treatment was seven years. In the deferred treatment arm, 25.6% died without needing treatment.

6.2.4.4 Guidelines for radical treatment of locally-advanced disease

Recommendations	Strength rating
Radical Prostatectomy (RP)	
Offer RP to highly selected patients with (cT3b-T4 N0 or any T N1) only as part of multimodal therapy.	Strong
Extended pelvic lymph node dissection (ePLND)	
Perform an ePLND in high-risk PCa.	Strong
Do not perform a frozen section of nodes during RP to decide whether to proceed with, or abandon, the procedure.	Strong
Radiotherapeutic treatments	
In patients with locally advanced cN0 disease, offer radiotherapy in combination with long-term androgen deprivation therapy (ADT).	Strong
Offer long-term ADT for two to three years.	Weak
Therapeutic options outside surgery and radiotherapy	
Do not offer whole gland treatment or focal treatment to high-risk patients.	Strong
Only offer ADT monotherapy to those patients unwilling or unable to receive any form of local treatment and who are either symptomatic or asymptomatic, but with a prostate-specific antigen (PSA)-doubling time < 12 months or a PSA > 50 ng/mL, or a poorly-differentiated tumour.	Strong

6.2.5 Adjuvant treatment after radical prostatectomy

6.2.5.1 Introduction

Adjuvant treatment is by definition additional to the primary or initial therapy with the aim of decreasing the risk of relapse. Clearly a post-operative detectable PSA is an indication of persistent PCa cells (see Section 6.2.6). All information listed below, refers to patients with a post-operative undetectable PSA.

6.2.5.2 Risk factors for relapse

ISUP score ≥ 2 or patients classified as pT3 pN0 after RP due to positive margins (highest impact), capsule rupture and/or invasion of the seminal vesicles are at high risk of relapse which can be as high as 50% after five years [609]. Irrespective of the pT stage, the number of removed nodes [394, 610-616], tumour volume within the LNs and capsular perforation of the nodal metastases are predictors of early recurrence after RP for pN1 disease [395]. A LN density (defined as the percentage of positive LNs in relation to the total number of analysed/removed LNs) over 20% was found to be associated with poor prognosis [617]. Finally the number of involved nodes seems to be a major factor for predicting relapse [611, 612, 618], the threshold being considered to be less than three positive nodes from an ePLND [383, 611, 618]. However, prospective data are needed before defining a definitive threshold value.

6.2.5.3 Immediate (adjuvant) post-operative external irradiation after RP (cN0 or pN0)

Three prospective RCTs have assessed the role of immediate post-operative RT (adjuvant RT [ART]) (Table 6.2.5.1). It must be emphasised that PSA was undetectable at inclusion only in the ARO 96-02 trial, representing a major limitation in interpretation, as patients with a detectable PSA would now be considered for salvage therapy rather than adjuvant radiotherapy [619]. Thus, for patients at increased risk of local relapse, who present with a PSA level of < 0.1 ng/mL, two options can be offered in the framework of informed consent. These are:

- Immediate ART to the surgical bed after recovery of urinary function, during the first six months post-surgery [619-621];
or
- Clinical and biological monitoring followed by salvage radiotherapy (SRT) before the PSA exceeds 0.5 ng/mL [622, 623] (see Section 6.3.5.1 on Salvage EBRT).

Table 6.2.5.1: Overview of all three randomised trials for adjuvant surgical bed radiation therapy after RP*

Reference	n	Inclusion criteria	Randomisation	Definition of BCR PSA (ng/mL)	Median FU (mo)	Biochemical progression-free survival	Overall survival
SWOG 8794 2009 [619]	431	pT3 cN0 \pm involved SM	60-64 Gy vs. observation	> 0.4	152	10 yr.: 53% vs. 30% (p < 0.05)	10 yr.: 74% vs. 66% Median time: 15.2 vs. 13.3 yr., p = 0.023
EORTC 22911 2012 [620]	1,005	pT3 \pm involved SM pN0 pT2 involved SM pN0	60 Gy vs. observation	> 0.2	127	10 yr.: 60.6% vs. 41% (p < 0.001)	81% vs. 77% n.s.
ARO 96-02 2014 [621]	388	pT3 (\pm involved SM) pN0 PSA post-RP undetectable	60 Gy vs. observation	> 0.05 + confirmation	112	10 yr.: 56% vs. 35% (p = 0.0001)	10 yr.: 82% vs. 86% n.s.

*See Section 6.3.5 for delayed (salvage) post-radical prostatectomy external irradiation.

BCR = biochemical recurrence; FU = follow-up; mo = months; n = number of patients; n.s. = not significant; PSA = prostate-specific antigen; RP = radical prostatectomy; SM = surgical margin.

6.2.5.4 Adjuvant androgen ablation

6.2.5.4.1 Adjuvant androgen ablation in men with N0 disease

Adjuvant androgen ablation with bicalutamide 150 mg daily did not improve PFS in localised disease while it

did for locally advanced disease after RT. However this never translated to an OS benefit [624]. A SR showed a possible benefit for PFS, but not OS for adjuvant androgen ablation [400].

6.2.5.4.2 Adjuvant androgen ablation in men with pN1 disease

The combination of RP and early adjuvant HT in pN+ PCa has been shown to achieve a ten-year CSS rate of 80% and has been shown to significantly improve CSS and OS in a prospective RCT [625, 626]. However, this trial included mostly patients with high-volume nodal disease and multiple adverse tumour characteristics and the findings may not apply to men with less extensive nodal metastases.

6.2.5.5 Adjuvant radiotherapy combined with ADT in men with pN1 disease

In a retrospective multicentre cohort study, maximal local control with RT to the prostatic fossa appeared to be beneficial in PCa patients with pN1 after RP, treated “adjuvantly” (within 6 months after surgery irrespective of PSA) with continuous ADT. The beneficial impact of adjuvant RT on survival in patients with pN1 PCa was highly influenced by tumour characteristics. Men with low-volume nodal disease (< 3 LNs), ISUP grade 2-5 and pT3-4 or R1, as well as men with three to four positive nodes were more likely to benefit from RT after surgery, while the other subgroups were not [627].

In a series of 2,596 pN1 patients receiving ADT (n = 1,663) or ADT plus RT (n = 906), combined treatment was associated with improved OS, with a HR of 1.5 for sole ADT [628]. In a SEER retrospective population-based analysis, adding RT to RP showed a non-significant trend to improved OS but not PCa-specific survival, but data on the extent of additional RT is lacking in this study [629]. No recommendations can be made on the extent of adjuvant RT in pN1 disease (prostatic fossa only or whole pelvis) although whole pelvis RT was given in more than 70% of men in a large retrospective series that found a benefit for adding RT to androgen ablation in pN1 patients [627]. No data is available regarding adjuvant EBRT without ADT.

6.2.5.6 Adjuvant chemotherapy

The TAX3501 trial comparing the role of leuprolide (eighteen months) with and without docetaxel (six cycles) ended prematurely due to poor accrual. A recent phase III RCT comparing adjuvant docetaxel against surveillance after RP for locally advanced PCa showed that adjuvant docetaxel did not confer any oncological benefit [630]. Consequently, adjuvant chemotherapy after RP should only be considered in a clinical trial [631].

6.2.5.7 Guidelines for adjuvant treatment options after radical prostatectomy

Recommendations	Strength rating
Only discuss adjuvant treatment in men with a post-operative prostate-specific antigen (PSA) < 0.1 ng/mL.	Strong
Do not prescribe adjuvant androgen deprivation therapy (ADT) in pN0 patients.	Strong
Offer adjuvant external-beam radiation therapy to the surgical field to patients at increased risk of local relapse: pT3 pN0 with positive margins (highest impact), and/or invasion of the seminal vesicles.	Strong
Discuss three management options with patients with pN+ disease after an extended lymph node dissection, based on nodal involvement characteristics: 1. Offer adjuvant ADT for node-positive (pN+). 2. Offer adjuvant ADT with additional radiotherapy. 3. Offer observation (expectant management) to a patient after eLND and ≤ 2 nodes with microscopic involvement, and a PSA < 0.1 ng/mL and absence of extranodal extension.	Weak

6.2.5.8 Guidelines for non-curative or palliative treatments in prostate cancer

Recommendations	LE	Strength rating
Watchful waiting (WW) for localised prostate cancer		
Offer WW to asymptomatic patients not eligible for local curative treatment and those with a short life expectancy.	1b	Strong
While on WW, base the decision to start non-curative treatment on symptoms and disease progression.		Strong
Watchful waiting for locally advanced prostate cancer		
Offer a deferred treatment policy using androgen deprivation (ADT) monotherapy to M0 asymptomatic patients with a prostate-specific antigen (PSA) doubling time > twelve months, a PSA < 50 ng/mL and well differentiated tumour, who are unwilling or unable to receive any form of local treatment.	1b	Strong

6.2.6 **Persistent PSA after radical prostatectomy**

6.2.6.1 Introduction

Between 5 and 20% of men continue to have detectable or persistent PSA after RP (when defined in the majority of studies as detectable post-RP PSA of ≥ 0.1 ng/mL within four to eight weeks of surgery) [632, 633]. It may result from persistent local disease, pre-existing metastases or residual benign prostate tissue.

6.2.6.2 Natural history of persistently elevated PSA after RP

Several studies (See table 6.3.1) have shown that persistent PSA after RP is associated with more advanced disease (such as positive surgical margins (PSM), pathologic stage $\geq T3a$, positive nodal status and/or pathologic ISUP grade ≥ 3) and poor prognosis. Initially defined as ≥ 0.1 ng/mL, improvements in the sensitivity of PSA assays now allow for the detection of PSA at much lower levels.

Moreira *et al.* demonstrated that failure to achieve a PSA of less than 0.03 ng/mL within 6 months of surgery was associated with an increased risk of BCR and overall mortality [634, 635]. However, since the majority of the published literature is based on the ≥ 0.1 ng/mL PSA cut-off, there is significantly more long-term data for this definition.

Predictors of PSA persistence were higher BMI, higher pre-operative PSA and ISUP grade ≥ 3 [635]. In patients with PSA persistence, one and five-year BCR-free survival were 68% and 36%, compared to 95% and 72%, respectively, in men without PSA persistence [634]. Ten-year OS in patients with and without PSA persistence was 63% and 80%, respectively. In line with these data, Ploussard *et al.* reported that approximately 74% of patients with persistent PSA develop BCR [632]. Spratt *et al.* confirmed that a persistently detectable PSA after RP represents one of the worst prognostic factors associated with oncological outcome [636]. Of 150 patients with a persistent PSA, 95% received RT before detectable metastasis. In a multivariable analysis, the presence of a persistently detectable PSA post-RP was associated with a four-fold increase in the risk of developing metastasis. This was confirmed by recent data from Preisser *et al.* who showed that persistent PSA is prognostic of an increased risk of metastasis and death [637]. At fifteen years after RP, metastasis-free survival rates, OS and CSS rates were 53.0 vs. 93.2% ($p < 0.001$), 64.7 vs. 81.2% ($p < 0.001$) and 75.5 vs. 96.2% ($p < 0.001$) for persistent vs. undetectable PSA, respectively. The median follow-up was 61.8 months for patients with undetectable PSA vs. 46.4 months for patients with persistent PSA. In multivariable Cox regression models, persistent PSA represented an independent predictor for metastasis (HR: 3.59, $p < 0.001$), death (HR: 1.86, $p < 0.001$) and cancer-specific death (HR: 3.15, $p < 0.001$).

However, not all patients with persistent PSA after RP experience disease recurrence. Xiang *et al.* showed that five-year BCR-free survival for men who had a persistent PSA level > 0.1 but ≤ 0.2 ng/mL at 6-8 weeks after RP and were monitored was 50% [638].

Rogers *et al.* assessed the clinical outcome of 160 men with a persistently detectable PSA level after RP [639]. No patient received adjuvant therapy before documented metastasis. In their study, 38% of patients had no evidence of metastases for \geq seven years while 32% of the patients were reported to develop metastases within three years. Noteworthy is that a significant proportion of patients had low-risk disease. In multivariable analysis, the PSA slope after RP (as calculated using PSA levels three to twelve months after surgery) and pathological ISUP grade were significantly associated with the development of distant metastases.

Table 6.2.6.1: Studies on the natural history of patients with persistent PSA after RP

Authors	Study population	n	Definition PSA persistence	Treatment	Outcome	Other details/comments
Ploussard <i>et al.</i> , J Urol 2013 [632]	496 men pN0 with persistent PSA 14 centres 1998 - 2011		PSA \geq 0.1 ng/mL at 6 wk.		74.4% with BCR 5% with metastasis	
Moreira <i>et al.</i> , BJUI 2009 [635]	901 men Shared Equal Access Regional Cancer Hospital (SEARCH) database. 2001-2008	230 (8 pN1)	PSA persistence definition of a PSA nadir \geq 0.03 ng/mL,	No RT info	Increased risk for BCR after surgery	Relative to men with undetectable PSA levels, those with a PSA nadir of 0.03 (HR: 3.88, $p < 0.001$), 0.04 (HR: 4.87, $p < 0.001$), 0.05-0.09 (HR: 12.69, $p < 0.001$), 0.1-0.19 (HR: 13.17, $p < 0.001$), and 0.2 ng/mL (HR: 13.23, $p < 0.001$) were at increased risk of BCR while men with a nadir of 0.01 (HR: 1.36, $p = 0.400$) and 0.02 (HR: 1.64, $p = 0.180$) were not.
Moreira <i>et al.</i> , J Urol 2009 [634]	1,156 men Shared Equal Access Regional Cancer Hospital (SEARCH) database. After 1997	291 (10 pN1)	PSA $>$ 0.03 ng/mL within 6 mo.	No RT info	Increased BCR and overall mortality	Median FU 48 mo. In patients with persistent PSA 1 and 5-yr. BFS was 68% and 36%, significantly lower than 95% and 72%, respectively, in men without persistent PSA. Ten-year OS in patients with vs. without persistent PSA was 63% vs. 80%. In men with persistent PSA independent predictors of BCR were higher PSA nadir (HR: 2.19, $p < 0.001$), positive surgical margins (HR: 1.75, $p = 0.022$) and high pathological ISUP grade (4-5 vs. 1, HR: 2.40, $p = 0.026$). Independent predictors of overall mortality were a higher PSA nadir (HR: 1.46, $p = 0.013$) and seminal vesicle invasion (HR: 3.15, $p = 0.047$)
Rogers <i>et al.</i> , Cancer 2004 [639]	224 men Single centre (Johns Hopkins) 1989 - 2002	160 men (58 pN1)	PSA \geq 0.1 ng/mL at 3 mo.	No treatment before onset of metastasis	Metastasis-free survival at 3, 5 and 10 yr. was 68%, 49%, and 22%, respectively.	Mean FU 5.3 yr. Seventy-five men (47%) developed distant metastases after RP (median time to metastases 5.0 yr.; range, 0.5-13 yr.). The slope of PSA changes approximately 3-12 mo. after RP at a cut-off value \geq 0.05 ng/mL was found to be predictive of distant metastasis-free survival (HR: 2.9, $p < 0.01$).

BCR = biochemical recurrence; FU = follow-up; HR = hazard ratio; mo = months; n = number of patients; PSA = prostate-specific antigen; RT = radiotherapy.

6.2.6.3 Imaging in patients with persistently elevated PSA after RP

Standard imaging with bone scan and MRI has a low pick-up rate for men with a PSA below 2 ng/mL. However, PSMA PET/CT has been shown to identify residual cancer in 15-58%, 25-73%, 69-100% and 71-100% of men with post-RP PSA ranges of 0.2-0.5 ng/mL, 0.5-1 ng/mL, 1-2 ng/mL and > 2 ng/mL, respectively [318, 640-644] which can guide salvage radiation therapy (SRT) planning [645]. Using this, Schmidt-Hegemann *et al.* studied 129 patients who had either persistent PSA (52%) or BCR (48%) after RP [646]. Interestingly, men with a persistent PSA had significantly more pelvic nodal involvement on PSMA PET/CT than those developing a detectable PSA. At present there is uncertainty regarding the best treatment if PSMA PET/CT shows metastatic disease.

6.2.6.4 Impact of post-operative RT and/or ADT in patients with persistent PSA

The benefit of SRT in patients with persistent PSA remains unclear due to a lack of RCTs, however, it would appear that men with a persistent PSA do less well than men with BCR undergoing RT.

Wiegel *et al.* [633] showed that following salvage RT to the prostate bed, patients with a detectable PSA after RP had significantly worse oncological outcomes when compared with those who achieved an undetectable PSA. Ten-year metastasis-free survival was 67% vs. 83% and OS was 68% vs. 84%, respectively. Recent data from Preisser *et al.* [637] also compared oncological outcomes of patients with persistent PSA who received SRT vs. those who did not. In the subgroup of patients with persistent PSA, after 1:1 propensity score matching between patients with salvage RT vs. no RT, OS rates at ten years after RP were 86.6 vs. 72.6% in the entire cohort ($p < 0.01$), 86.3 vs. 60.0% in patients with positive surgical margin ($p = 0.02$), 77.8 vs. 49.0% in pT3b disease ($p < 0.001$), 79.3 vs. 55.8% in ISUP grade 1 disease ($p < 0.01$) and 87.4 vs. 50.5% in pN1 disease ($p < 0.01$), for salvage RT and no RT respectively. Moreover, CSS rates at ten years after RP were 93.7 vs. 81.6% in the entire cohort ($p < 0.01$), 90.8 vs. 69.7% in patients with positive surgical margin ($p = 0.04$), 82.7 vs. 55.3% in pT3b disease ($p < 0.01$), 85.4 vs. 69.7% in ISUP grade 1 disease ($p < 0.01$) and 96.2 vs. 55.8% in pN1 disease ($p < 0.01$), for salvage RT and no RT respectively. In multivariable models, after 1:1 propensity score matching, salvage RT was associated with lower risk for death (HR: 0.42, $p = 0.02$) and lower cancer-specific death (HR: 0.29, $p = 0.03$). These survival outcomes for patients with persistent PSA who underwent SRT suggest they benefit although outcomes are worse than for men experiencing BCR.

It is clear from a number of studies [633, 647-651] that poor outcomes are driven by the level of pre-RT PSA, the presence of ISUP grade ≥ 4 in the RP histology and pT3b disease. Fossati *et al.* suggested that only men with a persistent PSA after RP and ISUP grade ≤ 3 benefited significantly [652], although this is not supported by Preisser *et al.* [637]. The current data does not allow making any clear treatment decisions.

Addition of ADT may improve PFS [647]. Choo *et al.* studied the addition of two-year ADT to immediate RT to the prostate bed for patients with pathologic T3 disease (pT3) and/or positive surgical margins after RP [647]. Twenty-nine of 78 included patients had persistently detectable post-operative PSA. The relapse-free rate was 85% at five years and 68% at seven years, which was superior to the five-year progression-free estimates of 74% and 61% in the post-operative RT arms of the EORTC and the SWOG studies, respectively, which included patients with undetectable PSA after RP [619, 620]. Patients with persistently detectable post-operative PSA comprised approximately 50% and 12% of the study cohorts in the EORTC and the SWOG studies, respectively.

In the ARO 96-02, a prospective RCT, 74 patients with PSA persistence (20%) received immediate SRT only with 66 Gy per protocol (arm C). The ten-year clinical relapse-free survival was 63% [633]. The GETUG-22 trial comparing RT with RT plus short-term ADT for post-RP PSA persistence (0.2-2.0 ng/mL) reported good tolerability of the combined treatment. The oncological end-points are yet to be published [653].

6.2.6.5 Conclusion

The available data, suggests that patients with PSA persistence after RP may benefit from early aggressive multi-modality treatment, however, the lack of prospective RCTs makes firm recommendations difficult.

6.2.6.6 Recommendations for the management of persistent PSA after radical prostatectomy

Recommendations	Strength rating
Offer a prostate-specific membrane antigen positron emission tomography (PSMA PET) scan to men with a persistent PSA > 0.2 ng/mL to exclude metastatic disease.	Weak
Treat men with no evidence of metastatic disease with salvage radiotherapy and additional hormonal therapy.	Weak

6.3 Management of PSA-only recurrence after treatment with curative intent

The follow up policy is described in chapter 7 and will not be discussed here.

6.3.1 Background

Between 27% and 53% of all patients undergoing RP or RT develop a rising, PSA (PSA recurrence). Whilst a rising PSA level universally precedes metastatic progression, physicians must inform the patient that the natural history of PSA-only recurrence may be prolonged and that a measurable PSA may not necessarily lead to clinically apparent metastatic disease. Physicians treating patients with PSA-only recurrence face a difficult set of decisions in attempting to delay the onset of metastatic disease and death while avoiding over-treating patients whose disease may never affect their OS or QoL. It should be emphasised that the treatment recommendations for these patients should be given after discussion in a multidisciplinary team.

6.3.2 Definitions of clinically relevant PSA relapse

The PSA level that defines treatment failure depends on the primary treatment. Patients with rising PSA after RP or primary RT have different risks of subsequent symptomatic metastatic disease based on various parameters, including the PSA level. Therefore, physicians should carefully interpret BCR end-points when comparing treatments.

After RP, the threshold that best predicts further metastases is a PSA > 0.4 ng/mL and rising [654-656]. However, with access to ultra-sensitive PSA testing, a rising PSA much below this level will be a cause for concern for patients. After primary RT, with or without short-term hormonal manipulation, the RTOG-ASTRO Phoenix Consensus Conference definition of PSA failure (with an accuracy of > 80% for clinical failure) is any PSA increase ≥ 2 ng/mL higher than the PSA nadir value, regardless of the serum concentration of the nadir [657].

After HIFU or cryotherapy no end-points have been validated against clinical progression or survival; therefore, it is not possible to give a firm recommendation of an acceptable PSA threshold after these alternative local treatments [2].

6.3.3 Natural history of biochemical recurrence

Once a PSA relapse has been diagnosed, it is important to determine, whether the recurrence has developed at local or distant sites. A recent SR and meta-analysis investigated the impact of BCR on hard end-points and concluded that patients experiencing BCR are at an increased risk of developing distant metastases, PCa-specific and overall mortality [2]. However, the effect size of BCR as a risk factor for mortality is highly variable. After primary RP, its impact ranges from HR 1.03 (95% CI: 1.004-1.06) to HR: 2.32 (95% CI: 1.45-3.71) [658, 659]. After primary RT, OS rates are approximately 20% lower at eight to ten years follow-up, even in men with minimal comorbidity [660, 661]. Still, the variability in reported effect sizes of BCR remains high and suggests that only certain patient subgroups with BCR might be at an increased risk of mortality.

The risk of subsequent metastases, PCa-specific - and overall mortality may be predicted by the initial clinical and pathologic factors (e.g. T-category, PSA, ISUP grade) and PSA kinetics (PSA-DT and interval to PSA failure), which was further investigated by this SR [2].

For patients with BCR after RP, the following outcomes were found to be associated with significant prognostic factors:

- distant metastatic recurrence: positive surgical margins, high RP specimen pathological ISUP grade, high pT category, short PSA-DT, high pre-sRT PSA;
- prostate-cancer-specific mortality: high RP specimen pathological ISUP grade, short interval to biochemical failure as defined by investigators, short PSA-DT;
- overall mortality: high RP specimen pathological ISUP grade, short interval to biochemical failure, high PSA-DT.

For patients with biochemical recurrence after RT, the corresponding outcomes are:

- distant metastatic recurrence: high biopsy ISUP grade, high cT category, short interval to biochemical failure;
- prostate-cancer-specific mortality: short interval to biochemical failure;
- overall mortality: high age, high biopsy ISUP grade, short interval to biochemical failure, high initial (pretreatment) PSA.

Based on the meta-analysis, proposal is to stratify patients into EAU Low-Risk BCR (PSA-DT > 1 year AND pathological ISUP grade < 4 for RP; interval to biochemical failure > eighteen months AND biopsy ISUP grade < 4 for RT) or EAU High-Risk BCR (PSA-DT \leq 1 year OR pathological ISUP grade 4-5 for RP, interval to

biochemical failure \leq 18 months OR biopsy ISUP grade 4-5 for RT), since not all patients with BCR will have similar outcomes. The stratification into “EAU Low-Risk” or “EAU High-Risk” BCR has recently been validated in a European cohort [662].

6.3.4 **The role of imaging in PSA-only recurrence**

Patients (and physicians) are acutely aware that any sustained rise in PSA heralds the presence of PCa cells. Understandably, this drives the question whether imaging would reveal the site(s) of recurrence. However, imaging is only of value if it leads to a treatment change and therefore to a better outcome. In practice, limited data are available regarding the outcome based on imaging at relapse.

6.3.4.1 *Assessment of metastases*

6.3.4.1.1 Bone scan and abdominopelvic CT

Because BCR after RP or RT precedes clinical metastases by seven to eight years on average [613, 663], the diagnostic yield of common imaging techniques (bone scan and abdominopelvic CT) is low in asymptomatic patients [664]. In men with PSA-only relapse after RP, the probability of a positive bone scan is $<$ 5%, when the PSA level is $<$ 7 ng/mL [665, 666].

Only 11-14% of patients with BCR after RP have a positive CT [665]. In a series of 132 men with BCR after RP, the mean PSA level and PSA velocity associated with a positive CT were 27.4 ng/mL and 1.8 ng/mL/month, respectively [667].

6.3.4.1.2 Choline PET/CT

In two different meta-analyses, the combined sensitivities and specificities of choline PET/CT for all sites of recurrence in patients with BCR were 86-89% and 89-93%, respectively [668, 669].

Choline PET/CT may detect multiple bone metastases in patients showing a single metastasis on bone scan [670] and may be positive for bone metastases in up to 15% of patients with BCR after RP and negative bone scan [671]. The specificity of choline PET/CT is also higher than bone scan with fewer false-positive and indeterminate findings [305]. Detection of LN metastases using choline PET/CT remains limited by the relatively poor sensitivity of the technique (see Section 5.3.2.2). Choline PET/CT sensitivity is strongly dependent on the PSA level and kinetics [311, 672, 673]. In patients with BCR after RP, PET/CT detection rates are only 5-24% when the PSA level is $<$ 1 ng/mL, but rises to 67-100% when the PSA level is $>$ 5 ng/mL. Despite its limitations, choline PET/CT may change medical management in 18-48% of patients with BCR after primary treatment [674-676].

Choline PET/CT should only be recommended in patients fit enough for curative loco-regional salvage treatment. The sensitivity of choline PET is well known to be strongly influenced by PSA level and kinetics [673] and drops to sub-optimal values in patients with a low PSA [673]; after RP a possible PSA cut-off level for choline PET/CT analysis seems to be between 1 and 2 ng/mL [673].

6.3.4.1.3 Fluoride PET and PET/CT

^{18}F -NaF PET/CT has a higher sensitivity than bone scan in detecting bone metastases [677]. However, ^{18}F -NaF PET is limited by a relative lack of specificity and by the fact that it does not assess soft-tissue metastases [678].

6.3.4.1.4 Fluciclovine PET/CT

^{18}F -Fluciclovine PET/CT have a slightly higher sensitivity than choline PET/CT in detecting the site of relapse in BCR [679]. In a recent multicentre trial evaluating 596 patients with BCR in a mixed population (33.3% after RP, 59.5% after RT \pm RP, 7.1% other), fluciclovine PET/CT showed an overall detection rate of 67.7%, with a sensitivity of 62.7% (95% CI: 56-69%); lesions could be visualised either at local level (38.7%) or in lymph nodes and bones (9%) [680]. As for Choline PET/CT, fluciclovine PET/CT sensitivity is dependent on the PSA level, with a sensitivity likely inferior to 50% at PSA $<$ 1 ng/mL.

It is noteworthy that ^{18}F -fluciclovine has been approved in the US and Europe, and therefore is currently the only PCa-specific radiotracer widely commercially available.

6.3.4.1.5 Prostate-specific membrane antigen positron emission tomography computed tomography

Prostate-specific membrane antigen PET/CT has shown good potential in patients with BCR, although most studies are limited by their retrospective design. Detection rates of 15-58%, 25-73% and 69-100%, 71-100% have been reported for PSA ranges of 0.2-0.5 ng/mL, 0.5-1 ng/mL, 1-2 ng/mL and $>$ 2 ng/mL, respectively [318, 640-644]. Prostate-specific membrane antigen PET/CT seems substantially more sensitive than choline PET/CT, especially for PSA levels $<$ 1 ng/mL [641, 681]. Prostate-specific membrane antigen PET/CT identified the site of recurrence in 59 of 88 patients (67%) in a recent prospective trial [682]. A higher PSA velocity seems associated with higher PSMA PET/CT-positivity rates [299, 318, 640].

In a prospective multicentre study of 323 patients with BCR, PSMA PET/CT changed the management intent in 62% of patients as compared to conventional staging. This was due to a significant reduction in the number of men in whom the site of disease recurrence was unknown (77% vs. 19%, $p < 0.001$) and a significant increase in the number of men with metastatic disease (11% vs. 57%) [317]. A recent prospective study in a subgroup of 119 BCR patients with low PSA (< 0.5 ng/mL) reported a change in the intended treatment in 30.2% of patients [683]; however, no data exist on the impact on final outcome.

A single-centre study retrospectively assessed 164 men from a prospectively-acquired database who underwent imaging with PSMA PET/CT for a rising PSA after RP with PSA levels < 0.5 ng/mL. In men with a negative PSMA PET/CT who received salvage RT, 85% (23 out of 27) demonstrated a treatment response, compared to further PSA increase in 65% of those not treated (22 out of 34). In the 36/99 men with disease confined to the prostate fossa on PSMA, 83% (29 out of 36) responded to salvage RT [684]. Thus, PSMA PET/CT might stratify men into a group with high response (negative findings or recurrence confined to the prostate) and poor response (positive nodes or distant disease) to salvage RT.

It is worth noting that the term “PSMA PET” refers to several different radiopharmaceuticals; the majority of published studies used ^{68}Ga -PSMA-11 [640-643, 681, 684-686] but other authors are reporting data with ^{18}F -labelled PSMA [644]. At present there are no conclusive data about comparison of such tracers [687].

6.3.4.1.6 Whole-body and axial MRI

Little is known regarding the accuracy of whole-body or axial MRI in patients with BCR after RP or RT [688]. Therefore, the role of these techniques in detecting occult bone or LN metastases in the case of BCR remains to be assessed.

6.3.4.2 Assessment of local recurrences

6.3.4.2.1 Local recurrence after radical prostatectomy

Because the sensitivity of anastomotic biopsies is low, especially for PSA levels < 1 ng/mL [664], salvage RT is usually decided on the basis of BCR without histological proof of local recurrence, preferably when the PSA level is below 0.5 ng/mL. The dose delivered to the prostatic fossa tends to be uniform since it has not been demonstrated that a focal dose escalation at the site of recurrence improves the outcome. Therefore, most patients undergo salvage RT without local imaging.

Multiparametric magnetic resonance imaging can detect local recurrences in the prostatic bed, but its sensitivity in patients with a PSA level < 0.5 ng/mL remains controversial [689, 690]. Choline PET/CT is less sensitive than mpMRI when the PSA level is < 1 ng/mL [691]. Prostate-specific membrane antigen PET/CT is positive in 15-58% of patients with BCR and PSA levels < 0.5 ng/mL, but published series are difficult to interpret since they usually mix patients with a history of RP and RT [641, 642, 644]. Recent data support the potential role of PSMA PET/CT especially for the identification of distant metastases, even at PSA levels < 0.5 ng/mL [683].

Precise detection and location of local recurrences after RP will be needed but not until it has been proven that stereotaxic boost to the recurrence site during salvage RT improves the patient outcome which, so far, remains investigational.

6.3.4.2.2 Local recurrence after radiation therapy

In patients with BCR after RT, biopsy status is a major predictor of outcome, provided the biopsies are obtained 18-24 months after treatment. Given the morbidity of local salvage options it is necessary to obtain histological proof of the local recurrence before treating the patient [664].

Transrectal US is not reliable in identifying local recurrence after RT. In contrast, mpMRI has yielded excellent results and can be used for biopsy targeting and guiding local salvage treatment [664, 692-694]. Detection of recurrent cancer is also feasible with choline PET/CT [695], but choline PET/CT has not been compared to mpMRI yet. Prostate-specific membrane antigen PET/CT can play a role in the detection of local recurrences after RT [299], but data are still limited by a lack of robust results from well-designed trials.

6.3.4.3 Summary of evidence on imaging in case of biochemical recurrence

In patients with BCR, imaging has the potential to play a role in detecting distant metastases and detecting and localising local recurrence.

Early detection of metastases in a BCR setting is clinically highly relevant, either after RT or after RP. Salvage therapies for local recurrences after RT induce substantial morbidity and it is necessary to detect metastatic patients with the highest possible sensitivity to avoid the morbidity of useless salvage therapies in these patients. Many recent studies suggest that PSMA PET/CT is substantially more sensitive than abdominopelvic CT, bone scan and choline PET/CT in the detection of distant metastases in patients with BCR. Although most studies are retrospective and/or monocentric, they all come to the same conclusion, as

confirmed by a recent SR comparing all imaging methods [696]. After RP, compared to choline PET/CT, PSMA PET/CT showed high positivity rates, even for PSA levels < 1 ng/mL.

The role of imaging (MRI or PET/CT) in the detection and localisation of local recurrence after RP to guide further salvage treatment is questionable since there is no data to support that a subsequent salvage stereotaxic boost to the recurrence site will improve outcome.

However, local recurrence after RT prior to salvage treatment is confirmed by biopsy and, so far, mpMRI is the best technique to evaluate local recurrence and guide targeted biopsies.

6.3.4.4 Guidelines for imaging in patients with biochemical recurrence

Prostate-specific antigen (PSA) recurrence after radical prostatectomy	LE	Strength rating
Perform prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography (CT) if the PSA level is > 0.2 ng/mL and if the results will influence subsequent treatment decisions.	2b	Weak
In case PSMA PET/CT is not available, and the PSA level is \geq 1 ng/mL, perform fluciclovine PET/CT or choline PET/CT imaging if the results will influence subsequent treatment decisions.		Weak
PSA recurrence after radiotherapy		
Perform prostate multiparametric magnetic resonance imaging to localise abnormal areas and guide biopsies in patients fit for local salvage therapy.	3	Strong
Perform PSMA PET/CT (if available) or fluciclovine PET/CT or choline PET/CT in patients fit for curative salvage treatment.	2b	Strong

6.3.5 Treatment of PSA-only recurrences

The timing and treatment modality for PSA-only recurrences after RP or RT remain a matter of controversy based on the limited evidence.

6.3.5.1 Salvage radiotherapy [SRT] for PSA-only recurrence after radical prostatectomy

Early SRT provides the possibility of cure for patients with an increasing PSA after RP. Boorjian *et al.* reported a 75% reduced risk of systemic progression with SRT, when comparing 856 SRT patients with 1,801 non-SRT patients. The PSA level at BCR was shown to be prognostic [697]. More than 60% of patients who are treated before the PSA level rises to > 0.5 ng/mL will achieve an undetectable PSA level [698-701], corresponding to a ~80% chance of being progression-free five years later [623]. A retrospective analysis of 635 patients who were followed after RP and experienced BCR and/or local recurrence and either received no salvage treatment (n = 397) or salvage RT alone (n = 160) within two years of BCR showed that salvage RT was associated with a three-fold increase in PCa-specific survival relative to those who received no salvage treatment ($p < 0.001$). Salvage RT has been shown to be effective mainly in patients with a short PSA-DT [702]. Despite the indication for salvage RT, a “wait and see” strategy remains an option in patients with a PSA-DT of more than twelve months and other favourable factors such a time to BCR > three year, \leq pT3a, ISUP grade \leq 2/3 [2, 703]. For an overview see Table 6.3.1.

Table 6.3.1: Selected studies of post-prostatectomy salvage radiotherapy, stratified by pre-salvage radiotherapy (SRT) PSA level*

Reference	Year	n	Median FU (mo)	pre-SRT PSA (ng/mL) median	RT dose ADT	bNED/PFS (year)	5-yr. results
Bartkowiak, <i>et al.</i> [704]	2017	464	71	0.31	66.6 Gy	54% (5.9)	73% vs. 56%; PSA < 0.2 vs. ≥ 0.2 ng/mL p < 0.0001
Soto, <i>et al.</i> [705]	2012	441	36	< 1 (58%)	68 Gy 24% ADT	63/55% (3) ADT/no ADT	44/40% ADT/no ADT p < 0.16
Stish, <i>et al.</i> [698]	2016	1,106	107	0.6	68 Gy 16% ADT	50% (5) 36% (10)	44% vs. 58%; PSA ≤ 0.5 vs. > 0.5 ng/mL p < 0.001
Tendulkar, <i>et al.</i> [706]	2016	2,460	60	0.5	66 Gy 16% ADT	56% (5)	SRT; PSA < 0.2 ng/mL 71% 0.21-0.5 ng/mL 63% 0.51-1.0 ng/mL 54% 1.01-2.0 ng/mL 43% > 2 ng/mL 37% p < 0.001

* Androgen deprivation therapy can influence the outcome 'biochemically no evidence of disease (bNED)' or 'progression-free survival'. To facilitate comparisons, 5-year bNED/PFS read-outs from Kaplan-Meier plots are included.

ADT = androgen deprivation therapy; bNED = biochemically no evidence of disease; FU = follow up; mo = months; n = number of patients; PFS = progression-free survival; PSA = prostate-specific antigen; SRT = salvage radiotherapy; yr. = year.

Although biochemical progression is now widely accepted as a surrogate marker of PCa recurrence; metastatic disease, disease specific- and OS are more meaningful end-points to support clinical decision making. A SR and meta-analysis on the impact of BCR after RP reports SRT to be favourable for OS and PCa-specific mortality. In particular SRT should be initiated in patients with rapid PSA kinetics after RP and with a PSA cut-off of 0.4 ng/mL [2]. A recent, international, multi-institutional analysis of pooled data from RCTs has suggested that metastasis-free survival is the most valid surrogate end-point with respect to impact on OS [707, 708]. Table 6.3.2 summarises results of recent studies on clinical end-points after SRT.

Table 6.3.2: Recent studies reporting clinical end-points after SRT

Reference	Year	n	Median FU (mo)	Regimen	Outcome
Bartkowiak, <i>et al.</i> [704]	2017	464	71	66.6 (59.4-72) Gy no ADT	5.9 yr. OS post-SRT PSA < 0.1 ng/mL 98% post-SRT PSA ≥ 0.1 ng/mL 92% p = 0.005
Jackson, <i>et al.</i> [709]	2014	448	64	68.4 Gy no ADT	5 yr. DM post-SRT PSA < 0.1 ng/mL 5% post-SRT PSA ≥ 0.1 ng/mL 29% p < 0.0001 5 yr. DSM post-SRT PSA < 0.1 ng/mL 2% post-SRT PSA ≥ 0.1 ng/mL 7% p < 0.0001 OS post-SRT PSA < 0.1 ng/mL 97% post-SRT PSA ≥ 0.1 ng/mL 90% p < 0.0001

Stish, <i>et al.</i> [698]	2016	1,106	107	68 (64.8-70.2) Gy 39% 2D treatment planning incl. 16% ADT	5 and 8.9 yr. DM SRT: PSA ≤ 0.5 ng/mL 7% and 12% SRT: PSA > 0.5 ng/mL 14% and 23% p < 0.001 5 and 8.9 yr. DSM SRT: PSA ≤ 0.5 ng/mL < 1% and 6% SRT: PSA > 0.5 ng/mL 5% and 10% p = 0.02 5 and 8.9 yr. OS SRT: PSA ≤ 0.5 ng/mL 94% and 86% SRT: PSA > 0.5 ng/mL 91% and 78% p = 0.14
Tendulkar, <i>et al.</i> [706]	2016	2,460	60	66 (64.8-68.4) Gy incl. 16% ADT	10 yr. DM SRT: PSA 0.01-0.2 ng/mL 9% SRT: PSA 0.21-0.50 ng/mL 15% SRT: PSA 0.51-1.0 ng/mL 19% SRT: PSA 1.01-2.0 ng/mL 20% SRT: PSA > 2 ng/mL 37%, p < 0.001

ADT = androgen deprivation therapy; DM = distant metastasis; DSM = disease specific mortality; FU = follow up; mo = months; n = number of patients; OS = overall survival; PSA = prostate specific antigen; SRT = salvage radiotherapy.

Data from RTOG 9601 [710] suggest both CSS and OS benefit when adding two years of bicalutamide to SRT. According to GETUG-AFU 16, also six months treatment with a LHRH-analogue can significantly improve five-year biochemical PFS, but CSS and OS data will require a longer follow-up [711]. When interpreting these data, it has to be kept in mind that RTOG 9601 used outdated radiation dosages (< 66 Gy) and technique. Table 6.3.3 provides an overview of these two RCTs. A recent review addressing benefit from hormone therapy with SRT suggested risk stratification of patients, based on the pre-SRT PSA (> 0.7 ng/mL), margin status (positive), and high ISUP grade, as a framework to individualise treatment. [712]. These findings were confirmed by a retrospective multicentre-study including 525 patients which showed that only in patients with more aggressive disease characteristics (pT3b/4 and ISUP grade > 4 or pT3b/4 and PSA at early SRT > 0.4 ng/mL) the administration of concomitant ADT was associated with a reduction in distant metastasis [713].

Table 6.3.3: RCTs comparing salvage radiotherapy combined with androgen deprivation therapy vs. salvage radiotherapy alone

Reference	Year	n	Risk groups	Median FU (mo)	Regimen	Outcome
GETUG-AFU 16 Carrie, <i>et al.</i> [711]	2016	369 RT + ADT 374 RT	ISUP grade ≤ 2/3 89%, ISUP grade ≥ 4 11% cN0	63	66 Gy + GnRH analogue 6 mo. 66 Gy	5 yr. PFS 80% p < 0.0001 5 yr. PFS 62%
RTOG 9601 Shipley, <i>et al.</i> [710]	2017	384 RT + ADT 376 RT	pT2 R1, pT3 cN0	156	64.8 Gy + bicalutamide 24 mo. 64.8 Gy + placebo	12 yr. DM 14% p = 0.005 12 yr. DM 23% 12 yr. OS 76% p = 0.04 12 yr. OS 71% 12 yr. DSM 5.8% p < 0.001 12 yr. DSM 13.4%

ADT = androgen deprivation therapy; DM = distant metastasis; DSM = disease specific mortality; PFS = progression free survival; FU = follow-up; GnRH = gonadotropin-releasing hormone; OS = overall survival; PFS = progression-free survival; mo = months; n = number of patients; RT = radiotherapy; yr. = years.

6.3.5.1.1 Target volume, dose, toxicity

There have been various attempts to define common outlines for “clinical target volumes” of PCa [714-717] and for organs at risk of normal tissue complications [718]. However, given the variations of techniques and

dose-constraints, a satisfactory consensus has not yet been achieved. A benefit in biochemical PFS but not metastasis-free survival (MFS) has been reported in patients receiving whole pelvis SRT (\pm ADT) but the advantages must be weighed against possible side effects [719].

The optimal SRT dose has not been well defined. It should be at least 66 Gy to the prostatic fossa (plus/minus the base of the seminal vesicles, depending on the pathological stage after RP) [699, 720]. In a SR, the pre-SRT PSA level and SRT dose both correlated with BCR, showing that relapse-free survival decreased by 2.4% per 0.1 ng/mL PSA and improved by 2.6% per Gy, suggesting that a treatment dose above 70 Gy should be administered at the lowest possible PSA level [721]. The combination of pT stage, margin status and ISUP grade and the PSA at SRT seems to define the risk of biochemical progression, metastasis and overall mortality [722-724]. In a study on 894 node-negative PCa patients, doses ranging from 64 to \geq 74 Gy were assigned to twelve risk groups, defined by their pre-SRT PSA classes $<$ 0.1, 0.1-0.2, 0.2-0.4, and $>$ 0.4 ng/mL and ISUP grade, \leq 1 vs. 2/3 vs. \geq 4 [725]. The updated Stephenson nomograms incorporate the SRT and ADT doses as predictive factors for biochemical failure and distant metastasis [706].

Salvage RT is also associated with toxicity. In one report on 464 SRT patients receiving median 66.6 (max. 72) Gy, acute grade 2 toxicity was recorded in 4.7% for both the GI and GU tract. Two men had late grade 3 reactions of the GI tract. Severe GU tract toxicity was not observed. Late grade 2 complications occurred in 4.7% (GI tract) and 4.1% (GU tract), respectively, and 4.5% of the patients developed moderate urethral stricture [704].

In a RCT on dose escalation for SRT involving 350 patients, acute grade 2 and 3 GU toxicity was observed in 13.0% and 0.6%, respectively, with 64 Gy and in 16.6% and 1.7%, respectively, with 70 Gy. Gastrointestinal tract toxicity of grades 2 and 3 occurred in 16.0% and 0.6%, respectively, with 64 Gy, and in 15.4% and 2.3%, respectively, with 70 Gy. Late effects have yet to be reported [726, 727].

With dose escalation over 72 Gy and/or up to a median of 76 Gy, the rate of severe side-effects, especially genitourinary symptoms, clearly increases, even with newer planning and treatment techniques [728, 729]. In particular, when compared with 3D-CRT, IMRT was associated with a reduction in grade 2 GI toxicity from 10.2 to 1.9% ($p = 0.02$), but had no differential effect on the relatively high level of GU toxicity (five-year, 3D-CRT 15.8% vs. IMRT 16.8%) [728]. After a median salvage IMRT dose of 76 Gy, the five-year risk of grade 2-3 toxicity rose to 22% for genitourinary and 8% for gastrointestinal symptoms, respectively [729]. Doses of at least 66 Gy, and up to 72 Gy can be recommended [704, 726].

6.3.5.1.2 Comparison of adjuvant radiotherapy (ART) and salvage radiotherapy

The largest retrospective risk-matched study evaluating ART vs. early SRT comprised 510 pT3N0 R0/R1 patients (ADT was excluded). With a median follow-up of 94 months, 243 patients who had ART and 267 patients who had SRT at a PSA $<$ 0.5 ng/mL, did not differ significantly in MFS (92% vs. 91%, $p = 0.9$) or OS (89% vs. 92%, $p = 0.9$). Conclusion was that early salvage RT does not impair PCa control but clearly helps reducing over-treatment, which is a major issue in both ART and in SRT [723]. Similarly, Buscarillo *et al.* reported no difference in MFS or OS among two groups of 149 propensity-matched PCa patients with adverse pathologic features [730]. However, these retrospective studies are underpowered for high-risk cases such as pT3b/R1/ ISUP grade 4-5. In contrast to these studies, a propensity score-matched retrospective analysis of two cohorts of 366 pT3 and/or R1 patients found that compared to SRT at a PSA between 0.1 and 0.5 ng/mL, ART given at an undetectable PSA ($<$ 0.1 ng/mL) improved all three end-points, biochemically no evidence of disease, MFS, and OS [731].

Both approaches (ART and SRT) together with the efficacy of adjuvant ADT are currently being compared in three prospective RCTs: the Medical Research Council (MRC) Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) in the United Kingdom, the Trans-Tasman Oncology Group (TROG) Radiotherapy Adjuvant Versus Early Salvage (RAVES), and Groupe d'Etude des Tumeurs Uro-Génitales (GETUG 17).

It remains difficult to decide whether to proceed with adjuvant RT, for high-risk PCa, pT3-4 pN0 M0 with undetectable PSA after RP, or to postpone RT as an early salvage procedure in the event of biochemical relapse. In everyday practice, before RP, the urologist should explain to the patient that adjuvant RT may be needed in the presence of negative prognostic risk factors.

6.3.5.1.3 Management of PSA failures after radiation therapy

Therapeutic options in these patients are ADT or local procedures such as salvage RP (SRP), cryotherapy,

interstitial brachytherapy and HIFU [732-741]. As the available evidence for these treatment options is of low quality, strong recommendations regarding the choice of any of these techniques cannot be made as. The following is an overview of the most important findings for each of these techniques with a proposal for their indications.

6.3.5.2 Salvage radical prostatectomy

Salvage RP after RT has the best likelihood of achieving local control relative to other salvage treatments. However, this must be weighed against the possible adverse events, which are increased compared to primary surgery because of the risk of fibrosis and poor wound healing due to radiation.

6.3.5.2.1 Oncological outcomes

In a SR of the literature, Chade, *et al.* showed that SRP provided five- and ten-year BCR-free survival estimates ranging from 47-82% and from 28-53%, respectively. The ten-year CSS and OS rates ranged from 70-83% and from 54-89%, respectively. The pre-SRP PSA value and prostate biopsy ISUP grade were the strongest predictors of the presence of organ-confined disease, progression, and CSS [742].

In most contemporary series, organ-confined disease, negative surgical margins, and the absence of seminal vesicle and/or LN metastases were favourable prognostic indicators associated with a better DFS of approximately 70-80%, in comparison with 40-60% in patients with locally advanced PCa [741].

Table 6.3.4: Oncological results of selected salvage radical prostatectomy case series, including at least 30 patients

Reference	n	Median FU (mo)	Pathologic Organ-confined (%)	PSM (%)	Lymph-node involvement (%)	BCR-free probability (%)	CSS (%)	Time probability (yr.)
Sanderson, <i>et al.</i> 2006 [743]	51	-	25	36	28	47	-	5
Leonardo, <i>et al.</i> 2009 [744]	32	35	53	34	0	75	-	3
Heidenreich, <i>et al.</i> 2010 [740]	55	23 (2-56)	73	11	20	87	-	2
Chade, <i>et al.</i> 2011 [745]	404	55	55	25	16	37	83	10
Mandel, <i>et al.</i> 2016 [746]	55	36	50	27	22	49	89	5

BCR = biochemical recurrence; CSS = cancer-specific survival; FU = follow-up; mo = months; n = number of patients; PSM = positive surgical margin.

6.3.5.2.2 Morbidity

Compared to primary open RP, SRP is associated with a higher risk of later anastomotic stricture (47 vs. 5.8%), urinary retention (25.3% vs. 3.5%), urinary fistula (4.1% vs. 0.06%), abscess (3.2% vs. 0.7%) and rectal injury (9.2 vs. 0.6%) [747]. In more recent series, these complications appear to be less common [739, 742]. Functional outcomes are also worse compared to primary surgery, with urinary incontinence ranging from 21% to 90% and ED in nearly all patients [742].

Table 6.3.5: Peri-operative morbidity in selected salvage radical prostatectomy case series, including at least 30 patients

Reference	n	Rectal injury (%)	Anastomotic stricture (%)	Clavien 3-5 (%)	Blood loss, mL, mean, range
Stephenson, <i>et al.</i> 2004 [739]	100	15 vs. 2*	30	33 vs. 13*	-
Ward, <i>et al.</i> 2005 [748]	138	5	22	-	-
Sanderson, <i>et al.</i> 2006 [743]	51	2	41	6	-
Gotto, <i>et al.</i> 2010 [747]	98	9	41	25	-
Heidenreich, <i>et al.</i> 2010 [740]	55	2	11	3.6	360 (150-1450)

* SRP performed before vs. after 1993.

n = number of patients.

6.3.5.2.3 Summary of salvage radical prostatectomy

In general, SRP should be considered only for patients with low comorbidity, a life expectancy of at least ten years, a pre-SRP PSA < 10 ng/mL and biopsy ISUP grade ≤ 2/3, no LN involvement or evidence of distant metastatic disease pre-SRP, and those whose initial clinical staging was T1 or T2 [742]. A meta-regression analysis suggested that SRP may be associated with worse continence outcomes than non-surgical approaches [749].

6.3.5.3 Salvage cryoablation of the prostate

6.3.5.3.1 Oncological outcomes

Salvage cryoablation of the prostate (SCAP) has been proposed as an alternative to SRP, as it has a potentially lower risk of morbidity and equal efficacy. However, the very few studies available have shown disappointing results. In a review of the use of SCAP for recurrent cancer after RT, the five-year biochemical disease-free survival estimates ranged from 50-70%. A durable response can be achieved in ~50% of patients with a pre-SCAP PSA < 10 ng/mL [750]. In a multicentre study reporting the current outcome of SCAP in 279 patients, the five-year BCR-free survival estimate according to the Phoenix criteria was 54.5 ± 4.9%. Positive biopsies were observed in 15/46 patients (32.6%) who underwent prostate biopsy after SCAP [751].

A case-matched control study comparing SRP and SCAP was performed in men with recurrent PCa after RT. The authors compared the oncological outcomes of the two salvage treatment options after mean follow-up periods of 7.8 (SRP group) and 5.5 years (SCAP group). The five-year OS was significantly higher in the SRP group (95% vs. 85%) [752].

Table 6.3.6: Oncological results of selected salvage cryoablation of the prostate case series, including at least 50 patients

Reference	n	Median FU (mo)	BCR-free probability (%)	Time probability (yr.)	Definition of failure
Pisters, <i>et al.</i> 1997 [752]	150	17	44	-	Nadir + 0.2
Bahn, <i>et al.</i> 2003 [753]	59	82	59	7	PSA > 0.5
Ismail, <i>et al.</i> 2007 [750]	100	33	73 (low risk)	5	ASTRO
Pisters, <i>et al.</i> 2008 [751]	279	22	58	5	ASTRO and Phoenix
Williams, <i>et al.</i> 2011 [754]	187	7.46 yr.	39	10	Nadir +2
Spiess, <i>et al.</i> 2010 [755]	450	40.8	34	-	PSA > 0.5

ASTRO = American Society for Therapeutic Radiology and Oncology; BCR = biochemical recurrence; FU = follow-up; mo = months; n = number of patients; PSA = prostate-specific antigen; yr. = year.

6.3.5.3.2 Morbidity

According to Cespedes, *et al.* [756], the risks of urinary incontinence and ED at at least twelve months after SCAP were as high as 28% and 90%, respectively. In addition, 8-40% of patients reported persistent rectal pain, and an additional 4% of patients underwent surgical procedures for the management of treatment-associated complications. In an on-line registry by Pisters, *et al.*, urinary incontinence rates were 4.4%. The rectal fistulae rate was 1.2% and 3.2% of patients requiring a TURP for removal of sloughed tissue [751]. With the use of third-generation technology, complications such as urinary incontinence and obstruction/retention have significantly decreased during the last decade (see Table 6.3.5) [757].

Table 6.3.7: Peri-operative morbidity, erectile function and urinary incontinence in selected salvage cryoablation of the prostate case series, including at least 50 patients

Reference	n	Incontinence (%)	Obstruction/ Retention (%)	Rectourethral fistula (%)	ED (%)
Pisters, <i>et al.</i> 1997 [758]	150	73	67	1	72
Bahn, <i>et al.</i> 2003 [753]	59	8	-	3.4	-
Ismail, <i>et al.</i> 2007 [750]	100	13	4	1	-
Pisters, <i>et al.</i> 2008 [751]	279	4.4	3.2	1.2	-
Ahmad, <i>et al.</i> 2013 [759]	283	12	7	1.8	83

ED = erectile dysfunction; n = number of patients.

6.3.5.3.3 Summary of salvage cryoablation of the prostate

In general, SCAP should be considered only for patients with low comorbidity, a life expectancy of at least

ten years, an initial organ-confined PCa cT1c to cT2, initial ISUP grade $\leq 2/3$, a pre-salvage PSA-DT \geq sixteen months and a pre-salvage PSA < 10 ng/mL.

6.3.5.4 Salvage brachytherapy for radiotherapy failure

Although there is no role for salvage EBRT following local recurrence after previous definitive RT, in carefully selected patients with a good PS, primary localised PCa and histologically proven local recurrence (based on Phoenix criteria [657]), HDR- or LDR brachytherapy remain effective treatment options with an acceptable toxicity profile [760-762]. However, the published series are relatively small and consequently this treatment should be offered in experienced centres only. Fifty-two patients were treated at the Scripps Clinic with HDR brachytherapy over a period of nine years [760]. With a median follow-up of 60 months the five-year biochemical control was 51% and only 2% grade 3 genitourinary toxicities were reported (Phoenix criteria). Comparable with these data, 42 patients were treated in a phase II trial at MSKCC in New York [763]. Of note, the median pre-treatment dose was 81 Gy given with IMRT and the prescription HDR-dose of 32 Gy was delivered in four fractions over 30 hours. The biochemical relapse-free survival after five years was 69% (median follow-up 36 months). Grade 2 late side-effects were seen in 15% and one patient developed grade 3 incontinence. However, older data with higher rates of side-effects have been reported [764].

Using LDR brachytherapy with 103 palladium, long-term outcome was reported in 37 patients with a median follow-up of 86 months [761]. The biochemical control rate after ten years was 54%. However, the crude rate of \geq grade 2 toxicity was 46% and \geq grade 3 toxicity was 11%. These side-effects were comparable with a series of 31 patients treated with salvage I-125 brachytherapy in the Netherlands. Therefore, in these small series, late side-effects seem to be lower with HDR brachytherapy [765]. In conclusion, freedom from BCR after salvage HDR- and LDR brachytherapy is promising and the rate of severe side-effects in experienced centres seem to be acceptable. Salvage brachytherapy remains a treatment option for selected patients with histologically proven local recurrence after RT.

6.3.5.5 Salvage high-intensity focused ultrasound

6.3.5.5.1 Oncological outcomes

Salvage HIFU has more recently emerged as an alternative thermal ablation option for radiation-recurrent PCa. Most of the data were generated by one high-volume centre. Median follow-up was very short, and outcome measures were non-standardised.

Table 6.3.8: Oncological results of selected salvage high-intensity focused ultrasound case series, including at least 20 patients

Reference	n	Median FU (mo)	BCR-free probability (%) ASTRO and Phoenix criteria	Negative biopsy rate
Colombel, <i>et al.</i> 2006 [766]	224	15-18	-	80
Gelet, <i>et al.</i> 2000 [767]	-	-	-	-
Gelet, <i>et al.</i> 2004 [768]	-	-	-	-
Uchida, <i>et al.</i> 2011 [769]	22	24	59 (Phoenix) (24 mo.)	92 (only 12 biopsied)
Berge, <i>et al.</i> 2011 [770]	46	9	60.9 (9 mo)	-
Crouzet, <i>et al.</i> 2017 [771]	418	42	49% (5 yr.); 82% CSS (7 yr.)	-

BCR = biochemical recurrence; CSS = cancer-specific survival; FU = follow-up; mo = months; n = number of patients; yr. = year.

6.3.5.5.2 Morbidity

Most of the data were generated by one high-volume HIFU centre. Important complication rates were mentioned and are at least comparable to other salvage treatment options.

6.3.5.5.3 Summary of salvage high-intensity focused ultrasound

There is a lack of quality data which prohibits any recommendation regarding the indications for salvage HIFU.

6.3.6 Salvage lymph node dissection

Novel imaging modalities improve the early detection of nodal metastases [772]. The surgical management of (recurrent) nodal metastases in the pelvis has been the topic of several retrospective analyses [772-774]. The majority of treated patients showed BCR but clinical recurrence-free and CSS ten-year survival over 70% has been reported [773, 775]. Neither the template nor the real value of nodal salvage dissection is available. It must, however, be remembered that the imaging modalities under-evaluate the real nodal involvement. Biochemical recurrence rates were found to be dependent on PSA at surgery and location and number of

positive nodes [776]. Addition of RT to the lymphatic template after salvage LND may improve the BCR rate [777]. The real efficacy of this salvage procedure remains unproven, as is its impact on survival [778].

6.3.7 **Hormonal therapy**

The Guidelines Panel conducted a SR including studies published from 2000 onwards [779]. Conflicting results were found on the clinical effectiveness of HT after previous curative therapy of the primary tumour. Some studies reported a favourable effect of HT, including the only RCT addressing the research question of this review (86% vs. 79% advantage in OS in the early HT group) [780]. Other studies did not find any differences between early vs. delayed, or no, HT. One study found an unfavourable effect of HT [781]. This may be the result of selecting clinically unfavourable cases for (early) HT and more intensive diagnostic work-up and follow-up in these patients.

The studied population is highly heterogeneous regarding their tumour biology and therefore clinical course. Predictive factors for poor outcomes were; CRPC, distant metastases, CSS, OS, short PSA-DT, high ISUP grade, high PSA, increased age and comorbidities. In some studies, such as the Boorjian, *et al.* study [703], high-risk patients, mainly defined by a high ISUP grade and a short PSA-DT (most often less than six months), seem to benefit most from (early) HT, especially in men with a long life expectancy.

No data were found on the effectiveness of different types of HT, although it is unlikely that this will have a significant impact on survival outcomes in this setting. Non-steroidal anti-androgens have been claimed to be inferior compared to castration, but this difference was not seen in M0 patients [702]. One of the included RCTs suggested that intermittent HT is not inferior to continuous HT in terms of OS and CSS [782]. A small advantage was found in some QoL domains but not overall QoL outcomes. An important limitation of this RCT is the lack of any stratifying criteria such as PSA-DT or initial risk factors.

Based on the lack of definitive efficacy and the undoubtedly associated significant side-effects, patients with recurrence after primary curative therapy should not receive standard HT. Only a minority of them will progress to metastases or PCa-related death. The objective of HT should be to improve OS, postpone distant metastases, and improve QoL. Biochemical response to only HT holds no clinical benefit for a patient. For older patients and those with comorbidities, the side-effects of HT may even decrease life expectancy; in particular, cardiovascular risk factors need to be considered [783, 784]. Early HT should be reserved for those at highest risk of disease progression, defined mainly by a short PSA-DT at relapse (> 6-12 months) or a high initial ISUP grade (> 2/3), and a long life expectancy.

6.3.8 **Observation**

For patients with EAU low-risk BCR features (see Section 6.3.3), unfit patients with a life expectancy of less than ten years or patients unwilling to undergo salvage treatment, active follow-up may represent a viable option. In unselected relapsing patients, the median actuarial time to the development of metastasis will be eight years and the median time from metastasis to death will be a further five years [613].

6.3.9 **Guidelines for second-line therapy after treatment with curative intent**

Local salvage treatment	Strength rating
Recommendations for biochemical recurrence after radical prostatectomy	
Offer active surveillance and possibly delayed salvage radiotherapy (SRT) to patients with biochemical recurrence and classified as EAU low-risk group at relapse who may not benefit from intervention.	Strong
Treat patients with a PSA rise from the undetectable range with SRT. Once the decision for SRT has been made, SRT (at least 66 Gy) should be given as soon as possible.	Strong
Offer pN0 patients undergoing SRT hormonal therapy (with bicalutamide 150 mg for two years, or LHRH agonists for up to two years).	Weak
Do not offer hormonal therapy to every pN0 patient treated with SRT.	Strong
Recommendations for biochemical recurrence after radiotherapy	
Treat highly selected patients with localised PCa and a histologically proven local recurrence with salvage radical prostatectomy.	Weak
Salvage RP should only be performed in experienced centres.	Strong
Do not offer high intensity focused ultrasound, cryosurgical ablation and salvage brachytherapy to patients with proven local recurrence since it is still experimental.	Strong
Recommendations for systemic salvage treatment	
Do not offer androgen deprivation therapy to M0 patients with a PSA-DT > twelve months.	Strong

6.4 Treatment: Metastatic prostate cancer

6.4.1 Introduction

All prospective data available rely on the definition of M1 disease based on CT scan and bone scan. The influence on treatment and outcome of newer, more sensitive imaging has not been assessed yet.

6.4.2 Prognostic factors

Median survival of patients with newly diagnosed metastases is approximately 42 months [785]. However, the M1 population is heterogeneous. Several prognostic factors for survival have been suggested including the number and location of bone metastases, presence of visceral metastases, ISUP grade, PS status and initial PSA alkaline phosphatase but only few have been validated [786-789].

“Volume” of disease as a potential predictor was introduced by CHAARTED (Chemo-hormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) [789-791] and has been shown to be predictive in a powered subgroup analysis for benefit of addition of prostate radiotherapy ADT [792].

Based on a large SWOG 9346 cohort, the PSA level after seven months of ADT was used to create three prognostic groups (see Table 6.4.2) [793]. PSA \leq 0.2 ng/mL at seven months has been confirmed as a prognostic marker for men receiving ADT for metastatic disease in the CHAARTED study independent of the addition of docetaxel [794].

Table 6.4.1 Definition of high- and low volume and risk in CHAARTED [789-791] and LATITUDE [795]

	High	Low
CHAARTED (volume)	\geq 4 Bone metastasis including \geq 1 outside vertebral column or spine OR Visceral metastasis	Not high
LATITUDE (risk)	\geq 2 high risk features of <ul style="list-style-type: none"> • \geq 3 Bone metastasis • Visceral metastasis • \geq ISUP grade 4 	Not high

Table 6.4.2: Prognostic factors based on the SWOG 9346 study [793]

PSA after 7 months of castration	Median survival
< 0.2 ng/mL	75 months
0.2 < 4 ng/mL	44 month
> 4 ng/mL	13 months

6.4.3 First-line hormonal treatment

Primary ADT has been the standard of care for over 50 years [493]. There is no level 1 evidence in favour of a specific type of ADT, neither for orchiectomy nor for an LHRH analogue or antagonist. Exception is patients with impending spinal cord compression for whom either a bilateral orchidectomy or LHRH antagonists are the preferred options.

6.4.3.1 Non-steroidal anti-androgen monotherapy

Based on a Cochrane SR comparing non-steroidal anti-androgen (NSAA) monotherapy to castration (either medical or surgical), NSAA was considered to be less effective in terms of OS, clinical progression, treatment failure and treatment discontinuation due to adverse events [796]. The evidence quality of the studies included in this review was rated as moderate.

6.4.3.2 Intermittent versus continuous androgen deprivation therapy

Three independent reviews [797-799] and two meta-analyses [800, 801], looked at the clinical efficacy of intermittent androgen deprivation (IAD) therapy. All of these reviews included eight RCTs of which only three were conducted in patients with exclusively M1 disease. The five remaining trials included different patient groups, mainly locally advanced and metastatic patients relapsing.

So far, the SWOG 9346 is the largest trial addressing IAD in M1b patients [802]. Out of 3,040 screened patients, only 1,535 patients finally met the inclusion criteria. This highlights that, at best, only 50% of M1b patients can be expected to be candidates for IAD, i.e. the best PSA responders. This was a non-inferiority trial leading to

inconclusive results: the actual upper limit was above the pre-specified 90% upper limit of 1.2 (HR: 1.1; CI: 0.99-1.23), the pre-specified non-inferiority limit was not achieved, and the results did not show a significant inferiority for any treatment arm. However, based on this study inferior survival with IAD cannot be completely ruled out.

Other trials did not show any survival difference with an overall HR for OS of 1.02 (0.94-1.11) [797]. These reviews and the meta-analyses came to the conclusion that a difference in OS or CSS between IAD and continuous ADT is unlikely. A recent review of the available phase III trials highlighted the limitations of most trials and suggested a cautious interpretation of the non-inferiority results [803]. None of the trials that addressed IAD vs. continuous ADT in M1 patients showed a survival benefit, but there was a trend towards improved OS and PFS with continuous ADT. Most of these trials, however, were non-inferiority trials. In some cohorts the negative impact on sexual function was less pronounced with IAD. There is a trend favouring IAD in terms of QoL, especially regarding treatment-related side-effects, such as hot flushes [804, 805].

Other possible long-term benefits of IAD from non-RCTs include a protective effect against bone loss, metabolic syndrome and cardiovascular problems [806]. This possible protective effect was recently challenged by the results from a detailed analysis of the SWOG 9346 trial [807]. These results showed an increased risk for thrombotic and ischaemic events, while there was no benefit concerning endocrine, psychiatric, sexual and neurological side-effects with IAD. Testosterone recovery was observed in most studies [808] leading to only intermittent castration. These outcomes, as well as the lack of any survival benefit in M1 patients, suggest that this treatment modality should only be considered as an option in a well-informed patient bothered by significant side-effects.

The PSA threshold at which ADT must be stopped or resumed for IAD still needs to be defined in prospective studies [798, 808]. Nevertheless, there is consensus amongst many authors on the following statements:

- Intermittent androgen deprivation is based on intermittent castration; therefore, only drugs leading to castration are suitable.
- Luteinising-hormone releasing hormone antagonist might be a valid alternative to an agonist.
- The induction cycle should not be longer than nine months, otherwise testosterone recovery is unlikely.
- Androgen deprivation therapy should be stopped only if all of the following criteria have been met:
 - well-informed and compliant patient;
 - no clinical progression;
 - a clear PSA response, empirically defined as a PSA < 4 ng/mL in metastatic disease.
- Strict follow-up is mandatory which should include a clinical examination every three to six months. The more advanced the disease, the closer the follow-up should be.
- PSA should always be measured by the same laboratory.
- Treatment is resumed when the patient progresses clinically, or has a PSA rising above a pre-determined (empirically set) threshold: usually 10-20 ng/mL in metastatic patients.
- The same treatment is used for at least three to six months.
- Subsequent cycles of treatment are based on the same principles until the first sign of castration resistance becomes apparent.
- The group of patients who will benefit most from IAD still has to be defined but the most important factor seems to be the patient's response to the first cycle of IAD, e.g. the PSA level response [798].

6.4.3.3 *Immediate versus deferred androgen deprivation therapy*

In symptomatic patients immediate treatment is mandatory. However, controversy still exists for asymptomatic metastatic patients due to the lack of quality studies. A Cochrane review extracted four RCTs: the VACURG I and II trials, the MRC trial, and the ECOG 7887 study [794, 796]. All of these studies were conducted in the pre-PSA era and included patients with advanced PCa either metastatic or non metastatic, who received immediate vs. deferred ADT [809]. No improvement in PCa CSS was observed, although immediate ADT significantly reduced disease progression.

6.4.4 **Combination therapies**

6.4.4.1 *Complete androgen blockade*

The largest RCT in 1,286 M1b patients found no difference between surgical castration with or without flutamide [810]. However, results with other anti-androgens or castration modalities have differed and SRs have shown that CAB using a NSAA appears to provide a small survival advantage (< 5%) vs. monotherapy (surgical castration or LHRH agonists) [811, 812] beyond five years of survival [813] but this minimal advantage in a small subset of patients must be balanced against the increased side-effects associated with long-term use of NSAAs.

6.4.4.2 Androgen deprivation combined with other agents

6.4.4.2.1 Combination with abiraterone acetate

In two large RCTs (STAMPEDE, LATITUDE) the addition of abiraterone acetate (1000 mg daily) plus prednisone (5 mg daily) to ADT in men with hormone-sensitive PCa (mHSPC) was studied [33, 795]. The primary objective of both trials was an improvement in OS. Both trials showed a significant OS benefit but in LATITUDE with a HR of 0.62 (0.51-0.76) [795] in high-risk metastatic patients only. The HR in STAMPEDE was very similar with 0.63 (0.52-0.76) in the total patient population (metastatic and non metastatic) and a HR of 0.61 in the subgroup of metastatic patients [33]. The inclusion criteria in the two trials differed, but both trials were positive for OS.

All secondary objectives such as PFS, time to radiographic progression, time to pain, or time to chemotherapy were positive and in favour of the combination. The key findings are summarised in Table 6.4.3. No difference in treatment-related deaths was observed with the combination of ADT plus abiraterone acetate and prednisone compared to ADT monotherapy [HR: 1.37 (0.82-2.29)]. However, twice as many patients discontinued treatment due to toxicity in the combination arms in STAMPEDE (20%) compared to LATITUDE (12%). Based on these data, upfront abiraterone acetate plus prednisone combined with ADT should be considered as a standard in men presenting with metastases at first presentation, provided they are fit enough to receive the drug [814].

Table 6.4.3: Results from the STAMPEDE arm G and LATITUDE studies

	STAMPEDE [James] [33]		LATITUDE [Fizazi] [795]	
	ADT	ADT + AA + P	ADT + placebo	ADT + AA + P
n	957	960	597	602
Newly diagnosed N+	20%	19%	0	0
Newly diagnosed M+	50%	48%	100%	100%
Key inclusion criteria	Patients scheduled for long-term ADT - newly diagnosed M1 or N+ situations - locally advanced (at least two of cT3 cT4, ISUP grade ≥ 4, PSA ≥ 40 ng/mL) - relapsing locally treated disease with a PSA > 4 ng/mL and a PSA-DT < 6 mo. OR PSA > 20 ng/mL, OR nodal OR metastatic relapse		Newly diagnosed M1 disease and 2 out of the 3 risk factors: ISUP grade ≥ 4, ≥ 3 bone lesions, measurable visceral metastasis	
Primary objective	OS		OS Radiographic PFS	
Median follow up (mo)	40		30.4	
3 year OS	83% (ADT + AA + P) 76% (ADT)		66% (ADT + AA + P) 49% (ADT + placebo)	
HR (95% CI)	0.63 (0.52 - 0.76)		0.62 (0.51-0.76)	
M1 only				
n	1,002		1,199	
3 year OS	NA		66% (ADT + AA + P) 49% (ADT + placebo)	
HR (95% CI)	0.61 (0.49-0.75)		0.62 (0.51-0.76)	
HR	Failure-free survival (biological, radiological, clinical or death): 0.29 (0.25-0.34)		Radiographic PFS: 0.49 (0.39-0.53)	

AA = abiraterone acetate; ADT = androgen deprivation therapy; CI = confidence interval;

HR = hazard ratio; mo = month; n = number of patients; NA = not available; OS = overall survival;

P = prednisone; PFS = progression-free survival; PSA = prostate-specific antigen.

6.4.4.2.2 Androgen deprivation therapy combined with chemotherapy

Three large RCTs were conducted [571, 789, 815]. All trials compared ADT alone as the standard of care with ADT combined with immediate docetaxel (75 mg/sqm, every three weeks) (within three months of ADT initiation). The primary objective in all three studies was OS. The key findings are summarised in Table 6.4.4.

Table 6.4.4: Key findings - Hormonal treatment combined with chemotherapy

	STAMPEDE James [571]		GETUG Gravis [815]		CHAARTED Sweeney [789]	
	ADT	ADT + Docetaxel + P	ADT	ADT + Docetaxel	ADT	ADT + Docetaxel
n	1,184	592	193	192	393	397
Newly diagnosed M+	58%	59%	75%	67%	73%	73%
Key inclusion criteria	Patients scheduled for long-term ADT - newly diagnosed M1 or N+ situations - locally advanced (at least two of cT3 cT4, ISUP grade ≥ 4, PSA ≥ 40 ng/mL) - relapsing locally treated disease with a PSA > 4 ng/mL and a PSA-DT < 6 mo. OR PSA > 20 ng/mL, OR nodal OR metastatic relapse		Metastatic disease Karnofsky score ≥ 70%		Metastatic disease ECOG PS 0, 1 or 2	
Primary objective	OS		OS		OS	
Median follow up (mo)	43		50		29	
HR (95% CI)	0.78 (0.66-0.93)		1.01 (0.75-1.36)		0.61 (0.47-0.80)	
M1 only						
n	1,086					
HR (95% CI)	0.76 (0.62-0.92)					

ADT = androgen deprivation therapy; FU = follow-up; HR = hazard ratio; n = number of patients; OS = overall survival; P = prednisone; PSA-DT = prostate-specific antigen – doubling time.

In the GETUG 15 trial, all patients had newly diagnosed M1 PCa, either *de novo* or after a primary treatment [815]. They were stratified based on previous treatment, and Glass risk factors [786]. In the CHAARTED trial, the same inclusion criteria applied and patients were stratified according to disease volume; high volume being defined as either presence of visceral metastases or four, or more, bone metastases, with at least one outside the spine and pelvis [789].

STAMPEDE is a multi-arm multi-stage trial in which the reference arm (ADT monotherapy) included 1,184 patients. One of the experimental arms was docetaxel combined with ADT (n = 593), another was docetaxel combined with zoledronic acid (n = 593). Patients were included with either M1, or N1, or having two of the following three criteria: T3/4, PSA ≥ 40 ng/mL or ISUP grade 4-5. Also relapsed patients after local treatment were included if they met one of the following criteria: PSA ≥ 4 ng/mL with a PSA-DT < 6 months or a PSA ≥ 20 ng/mL, N1 or M1. No stratification was used regarding metastatic disease volume (high/low volume) [571].

In all three trials toxicity was mainly haematological with around 12-15% grade 3-4 neutropenia, and 6-12% grade 3-4 febrile neutropenia. The use of granulocyte colony-stimulating factor receptor (GCSF) was shown to be beneficial in reducing febrile neutropenia. Primary or secondary prophylaxis with GCSF should be based on available guidelines [814, 816].

Based on these data, upfront docetaxel combined with ADT should be considered as a standard in men presenting with metastases at first presentation, provided they are fit enough to receive the drug [814]. Docetaxel is used at the standard dose of 75 mg/sqm combined with steroids as premedication. Continuous oral corticosteroid therapy is not mandatory.

In subgroup analyses from GETUG-AFU 15 and CHAARTED the beneficial effect of the addition of docetaxel to ADT is most evident in men with *de novo* metastatic high-volume disease [790, 791].

6.4.5 Treatment selection and patient selection

There are no head-to-head data comparing six cycles of docetaxel and the long-term use of abiraterone acetate plus prednisone in newly diagnosed mHSPC. However, for a period, patients in STAMPEDE were contemporaneously randomised to either the addition of abiraterone or docetaxel to standard of care. Data from the two experimental arms has been extracted although this was not pre-specified in the protocol and the data were therefore not powered for this comparison. The survival advantage for both drugs appeared

similar [817]. There was also no significant OS benefit for either drug found in a recent meta-analysis [818]. In the STOPCAP SR and meta-analysis, abiraterone acetate plus prednisone was found to have the highest probability of being the most effective treatment [819]. Both modalities have different and agent-specific side-effects and require strict monitoring of side-effects during treatment. Therefore, the choice will most likely be driven by patient preference, the specific side-effects, availability and cost.

6.4.6 *Deferred treatment for metastatic PCa (stage M1)*

The only candidates with metastasised disease who may possibly be considered for deferred treatment are asymptomatic patients with a strong wish to avoid treatment-related side-effects. However, since the median survival is 42 months only, the time without treatment (before symptoms) is short in most cases. The risk of developing symptoms, and even death from PCa, without receiving any benefit from hormone treatment has been highlighted [568, 576]. Patients with deferred treatment for advanced PCa must be amenable to close follow-up.

6.4.7 *Treatment of the primary tumour in newly diagnosed metastatic disease*

The first reported trial evaluating prostate RT in men with metastatic castration-sensitive disease was the HORRAD trial. 432 patients were randomised to ADT alone or ADT plus EBRT to the prostate. Overall survival was not significantly different (HR: 0.9 (0.7-1.14)), Median time to PSA progression was significantly improved in the RT arm (HR: 0.78 (0.63-0.97) [820]. The STAMPEDE trial evaluated 2,061 men with mCSPC who were randomised to ADT alone vs. ADT plus radiotherapy to the prostate. This trial confirmed radiotherapy to the primary tumour did not improve OS in unselected patients. However, following the results from CHARTED and prior to analysing the data, the original screening investigations were retrieved and patients categorised as low- or high volume. In the low-volume subgroup (n = 819) (high-volume, n = 1,120) there was a significant OS benefit by the addition of prostate RT. Therefore RT to the prostate in patients with low-volume metastatic disease should be considered. Of note, only 18% of these patients had additional docetaxel, and no patients had additional abiraterone acetate plus prednisone so no clear recommendation can be made about triple combinations. In addition, it is not clear if these data can be extrapolated to RP as local treatment, awaiting results of ongoing trials.

6.4.8 *Metastasis-directed therapy*

In patients relapsing after a local treatment, a metastases-targeting therapy has been proposed, with the aim to delay systemic treatment. There is one randomised Phase II trial testing metastasis-directed therapy (MDT) vs. surveillance in men with oligo-recurrent PCa. Oligo-recurrence was defined as ≤ 3 lesions. The sample size was small with 62 patients; about half of them had nodal disease only. Androgen deprivation therapy-free survival was the primary end-point which was longer with MDT than with surveillance [821]. Currently there is no data to suggest an improvement in OS. A SR highlighted that at this time this approach must, as yet, be considered as experimental [776].

6.4.9 Guidelines for the first-line treatment of metastatic disease

Recommendations	Strength rating
Offer immediate systemic treatment to palliate symptoms and reduce the risk for potentially serious sequelae of advanced disease (spinal cord compression, pathological fractures, ureteral obstruction) to M1 symptomatic patients.	Strong
Offer luteinising hormone-releasing hormone (LHRH) antagonists, especially to patients with an impending spinal cord compression or bladder outlet obstruction.	Weak
Offer surgery and/or local radiotherapy to any patient with M1 disease and evidence of impending complications such as spinal cord compression or pathological fracture.	Strong
Offer immediate systemic treatment to improve survival, defer progression to a symptomatic stage and prevent serious disease progression-related complications to M1 patients asymptomatic from their tumour.	Strong
Discuss deferred castration with well-informed M1 patients asymptomatic from their tumour since it lowers the treatment side-effects, provided the patient is closely monitored.	Weak
Offer initial short-term administration of antiandrogens to M1 patients treated with a LHRH agonist to reduce the risk of the 'flare-up' phenomenon.	Weak
Do not offer anti-androgen monotherapy to patients with M1 disease.	Strong
Offer castration combined with chemotherapy (docetaxel) to all patients whose first presentation is M1 disease and who are fit enough for docetaxel.	Strong
Offer castration combined with abiraterone acetate plus prednisone to all patients whose first presentation is M1 disease and who are fit enough for the regimen.	Strong
Offer castration combined with prostate radiotherapy to patients whose first presentation is M1 disease and who have low volume of disease by CHAARTED criteria.	Weak
Do not offer castration combined with any local treatment (radiotherapy/surgery) to patients with high volume M1 disease outside of clinical trials (except for symptom control).	Strong
Offer castration alone, with or without an anti-androgen, to patients unfit for, or unwilling to consider, castration combined with docetaxel or abiraterone acetate plus prednisone or prostate radiotherapy.	Strong
Intermittent treatment	
Only offer intermittent treatment to highly motivated asymptomatic M1 patients who have a major PSA response after the induction period.	Strong

6.5 Treatment: Castration-resistant PCa (CRPC)

6.5.1 Definition of Castration-resistant PCa

Castrate serum testosterone < 50 ng/dL or 1.7 nmol/L plus either;

- Biochemical progression: Three consecutive rises in PSA one week apart resulting in two 50% increases over the nadir, and a PSA > 2 ng/mL or,
- Radiological progression: The appearance of new lesions: either two or more new bone lesions on bone scan or a soft tissue lesion using RECIST (Response Evaluation Criteria in Solid Tumours) [822]. Symptomatic progression alone must be questioned and subject to further investigation. It is not sufficient to diagnose CRPC.

6.5.2 Non-metastatic castration-resistant PCa

Frequent PSA testing for men on treatment with ADT has resulted in earlier detection of biochemical progression. Of these men approximately one-third will develop bone metastases detectable on bone scan within two years [823].

In men with CRPC and no detectable clinical metastases using bone scan and CT-scan, baseline PSA level, PSA velocity and PSA-DT have been associated with time to first bone metastasis, bone metastasis-free and OS [823, 824]. These factors may be used when deciding which patients should be evaluated for metastatic disease. A consensus statement by the PCa Radiographic Assessments for Detection of Advanced Recurrence (RADAR) group [825] suggested a bone scan and a CT scan when the PSA reached 2 ng/mL and if this was negative it should be repeated when the PSA reached 5 ng/mL, and again after every doubling of the PSA based on PSA testing every three months for asymptomatic men. Symptomatic patients should undergo relevant investigation regardless of PSA level. With more sensitive imaging techniques like PSMA PET CT or wbMRI, more patient are expected to be diagnosed with early mCRPC.

Two large randomised controlled phase III trials, PROSPER [826] and SPARTAN [827], evaluated MFS as the primary end-point in patients with non-metastatic castration-resistant PCa (M0 CRPC) treated with

enzalutamide (PROSPER) vs. placebo or apalutamide (SPARTAN) vs. placebo, respectively. The M0 status was established by CT and bone scans. Only patients at high risk for the development of metastasis with a short PSA-DT of ten months or less were included. Patient characteristics in both trials revealed that about two thirds of participants had a PSA-DT of less than six months. Both trials showed a significant MFS benefit (PROSPER: median MFS was 36.6 months in the enzalutamide group vs. 14.7 months in the placebo group [HR for metastasis or death, 0.29; 95% CI: 0.24-0.35, $p < 0.001$]; SPARTAN: median MFS was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group [HR for metastasis or death, 0.28, 95% CI: 0.23-0.35, $p < 0.001$]). Time to symptomatic progression was significantly prolonged with apalutamide vs. placebo (HR 0.45; 95% CI: 0.32-0.63, $p < 0.001$). Overall survival data were still immature at the time of the first analysis and the median was not yet reached in both arms. In view of the long-term treatment with these AR targeted agents in asymptomatic patients, potential adverse events need to be taken into consideration and the patient informed accordingly. Overall, severe toxicity was low in both trials.

6.5.3 Metastatic castration-resistant PCa

The remainder of this section focuses on the management of men with proven metastatic CRPC (mCRPC).

6.5.3.1 Conventional androgen deprivation in castration-resistant PCa

Eventually men with PCa will show evidence of disease progression despite castration. Two trials have shown only a marginal survival benefit for patients remaining on LHRH analogues during second- and third-line therapies [828, 829]. However, in the absence of prospective data, the modest potential benefits of a continuing castration outweigh the minimal risk of treatment. In addition, all subsequent treatments have been studied in men with ongoing androgen suppression and therefore it should be continued in these patients.

Table 6.5.1: Randomised phase III controlled trials - first-line treatment of mCRPC

Author	Intervention	Comparison	Selection criteria	Main outcomes
DOCETAXEL				
SWOG 99-16 Petrylak, DP, <i>et al.</i> 2004 [830]	docetaxel/EMP, every 3 weeks, 60 mg/m ² , EMP 3 x 280 mg/day	mitoxantrone, every 3 weeks, 12 mg/m ² prednisone 5 mg BID		OS: 17.52 vs. 15.6 mo. ($p = 0.02$, HR: 0.80; 95% CI: 0.67-0.97) PFS: 6.3 vs. 3.2 mo. ($p < 0.001$)
TAX 327 2008 [831, 832]	docetaxel, every 3 weeks, 75 mg/m ² prednisone 5 mg BID Or docetaxel, weekly, 30 mg/m ² prednisone 5 mg BID	mitoxantrone, every 3 weeks, 12 mg/m ² , Prednisone 5 mg BID		OS: 19.2 for 3 weekly vs. 17.8 mo. 4-weekly and 16.3 in the control group. ($p = 0.004$, HR: 0.79 95% CI: 0.67-0.93)
ABIRATERONE				
COU-AA-302 Ryan CJ, <i>et al.</i> 2013 [833-835]	abiraterone + prednisone	placebo + prednisone	- No previous docetaxel. - ECOG 0-1. - PSA or radiographic progression. - No or mild symptoms. - No visceral metastases.	OS: 34.7 vs. 30.3 mo. (HR: 0.81, $p = 0.0033$). FU: 49.2 mo. rPFS: 16.5 vs. 8.3 mo. ($p < 0.0001$)
ENZALUTAMIDE				
PREVAIL Beer TM, <i>et al.</i> 2014 [836]	enzalutamide	placebo	- No previous docetaxel. - ECOG 0-1. - PSA or radiographic progression. - No or mild symptoms. - 10% had visceral mets.	OS: 32.4 vs. 30.2 mo. ($p < 0.001$). FU: 22 mo. ($p < 0.001$ HR: 0.71, 95% CI: 0.60-0.84) rPFS: 20.0 mo. vs. 5.4 mo. HR: 0.186 (95% CI: 0.15-0.23) $p < 0.0001$)

SIPULEUCEL-T Kantoff PW, <i>et al.</i> 2010 [837]	sipuleucel-T [838]	placebo [838]	- Some with previous docetaxel. - ECOG 0-1. - Asymptomatic or minimally symptomatic.	OS: 25.8 vs. 21.7 mo. (p = 0.03 HR: 0.78, 95% CI: 0.61-0.98). FU: 34.1 mo. PFS: 3.7 vs. 3.6 mo. (no difference)
Small EJ, <i>et al.</i> 2006 [839]	sipuleucel-T [839]	placebo [839]	- ECOG 0-1. - No visceral metastases. - No - No corticosteroids.	OS: 25.9 vs. 21.4 mo. (p = 0.1). FU: 36 mo. PFS: 11.7 vs. 10.0 wk.

BID = twice a day; *CI* = confidence interval; *ECOG* = Eastern Cooperative Oncology Group;
EMP = estramustine; *FU* = follow-up; *HR* = hazard ratio; *mo* = month; *PFS* = progression-free survival;
rPFS = radiographic progression-free survival; *OS* = overall survival.

6.5.4 First-line treatment of metastatic castration-resistant PCa

In general, anti-tumour monotherapies should not be used for CRPC outside clinical trials. Any combinations should be avoided both for first line and beyond until evidence proves them to be safe and more effective than sequential monotherapies (see also chapter 6.5.5.4).

6.5.4.1 Abiraterone

Abiraterone was evaluated in 1,088 chemo-naïve, asymptomatic or mildly symptomatic mCRPC patients in the phase III trial COU-AA-302. Patients were randomised to abiraterone acetate or placebo, both combined with prednisone [833]. Patients with visceral metastases were excluded. The main stratification factors were Eastern Cooperative Oncology Group (ECOG) PS 0 or 1 and asymptomatic or mildly symptomatic disease. Overall survival and radiographic PFS (rPFS) were the co-primary end-points. After a median follow-up of 22.2 months, there was significant improvement of rPFS (median 16.5 vs. 8.2 months, HR: 0.52, p < 0.001) and the trial was unblinded. At the final analysis with a median follow-up of 49.2 months, the OS end-point was significantly positive (34.7 vs. 30.3 months, HR: 0.81, 95% CI: 0.70-0.93, p = 0.0033) [835]. Adverse events (AEs) related to mineralocorticoid excess and liver function abnormalities were more frequent with abiraterone, but mostly grade 1-2. Sub-set analysis of this trial showed the drug to be equally effective in an elderly population (> 75 years) [840].

6.5.4.2 Enzalutamide

A randomised phase III trial (PREVAIL) [836] included a similar patient population and compared enzalutamide and placebo. Men with visceral metastases were eligible but the numbers included were small. Corticosteroids were allowed but not mandatory. PREVAIL was conducted in a chemo-naïve mCRPC population of 1,717 men and showed a significant improvement in both co-primary end-points, rPFS (HR: 0.186; CI: 0.15-0.23, p < 0.0001), and OS (HR: 0.706; CI: 0.6-0.84, p < 0.001). A ≥ 50% decrease in PSA was seen in 78% of patients. The most common clinically relevant AEs were fatigue and hypertension. Enzalutamide was equally effective and well tolerated in men > 75 years [841] as well as in those with or without visceral metastases [842]. However, for men with liver metastases, there seems to be no discernible benefit [842, 843].

Enzalutamide has also been compared with 50 mg per day bicalutamide in a randomised double blind phase II study (TERRAIN) [844] revealing a significant improvement in PFS (15.7 months vs. 5.8 months, HR: 0.44, p < 0.0001) in favour of enzalutamide. With extended follow-up and final analysis the benefit in OS and rPFS were confirmed [845].

6.5.4.3 Docetaxel

A significant improvement in median survival of 2-2.9 months occurred with docetaxel-based chemotherapy compared to mitoxantrone plus prednisone therapy [832, 846]. The standard first-line chemotherapy is docetaxel 75 mg/m² three-weekly doses combined with prednisone 5 mg twice a day (BID), up to ten cycles. Prednisone can be omitted if there are contraindications or no major symptoms. The following independent prognostic factors: visceral metastases, pain, anaemia (Hb < 13 g/dL), bone scan progression, and prior estramustine may help to stratify response to docetaxel. Patients can be categorised into three risk groups: low risk (0 or 1 factor), intermediate (2 factors) and high risk (3 or 4 factors), and show three significantly different median OS estimates of 25.7, 18.7 and 12.8 months, respectively [847].

Age by itself is not a contraindication to docetaxel [848], but attention must be paid to careful monitoring and comorbidities as discussed in Section 5.4 [849]. In men with mCRPC who are thought to be unable to tolerate the standard dose and schedule, docetaxel 50 mg/m² every two weeks seems to be well tolerated with less grade 3-4 AEs and a prolonged time to treatment failure [850].

6.5.4.4 Sipuleucel-T

In 2010, a phase III trial of sipuleucel-T showed a survival benefit in 512 asymptomatic or minimally symptomatic mCRPC patients [824]. After a median follow-up of 34 months, the median survival was 25.8 months in the sipuleucel-T group compared to 21.7 months in the placebo group, with a HR of 0.78 ($p = 0.03$). No PSA decline was observed and PFS was similar in both arms. The overall tolerance was very good, with more cytokine-related AEs grade 1-2 in the sipuleucel-T group, but the same grade 3-4 AEs in both arms. Sipuleucel-T is not available in Europe (and had its licence withdrawn).

Table 6.5.2: Randomised controlled phase III - second-line trials in mCRPC

Author	Intervention	Comparison	Selection criteria	Main outcomes
ABIRATERONE				
Fizazi, <i>et al.</i> 2012 [851]	abiraterone + prednisone HR	placebo + prednisone	Previous docetaxel. ECOG 0-2. PSA or radiographic progression.	OS: 15.8 vs. 11.2 mo ($p < 0.0001$). FU: 20.2 mo. Radiologic PFS: no change
de Bono, <i>et al.</i> 2011 [852]				OS: 14.8 vs. 10.9 mo. ($p < 0.001$ HR: 0.65; 95% CI: 0.54-0.77). FU: 12.8 mo. Radiologic PFS: 5.6 vs. 3.6 mo.
Radium-223				
Parker, <i>et al.</i> 2013 [853]	radium-223	placebo	Previous or no previous docetaxel. ECOG 0-2. Two or more symptomatic bone metastases. No visceral metastases.	OS: 14.9 vs. 11.3 mo. ($p = 0.002$, HR: 0.61; 95% CI: 0.46-0.81). All secondary end-points show a benefit over best standard of care.
CABAZITAXEL				
Bahl, <i>et al.</i> 2013 [854]	cabazitaxel + prednisone	mitoxantrone + prednisone	Previous docetaxel. ECOG 0-2.	OS: 318/378 vs. 346/377 events (odds ratio 2.11; 95% CI: 1.33-3.33). FU: 25.5 months OS \geq 2y 27% vs. 16% PFS: -
deBono, <i>et al.</i> 2010 [855]				OS: 15.1 vs. 12.7 mo. ($p < 0.0001$, HR: 0.70; 95% CI: 0.59-0.83). FU: 12.8 mo. PFS: 2.8 vs. 1.4 mo. ($p < 0.0001$, HR: 0.74; 95% CI: 0.64-0.86)
ENZALUTAMIDE				
Scher, <i>et al.</i> 2012 [856]	enzalutamide	placebo	Previous docetaxel. ECOG 0-2.	OS: 18.4 vs. 13.6 mo. ($p < 0.001$ HR: 0.63; 95% CI: 0.53-0.75). FU: 14.4 mo. Radiologic PFS: 8.3 vs. 2.9 mo. (HR: 0.40; 95% CI: 0.35-0.47 $p < 0.0001$)

*Only studies reporting survival outcomes as primary end-points have been included.

CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; FU = follow-up; HR = hazard ratio; mo = months OS = overall survival; PFS = progression-free survival.

6.5.5 Second-line treatment for mCRPC

All patients who receive treatment for mCRPC will eventually progress. All treatment options in this setting are presented in Table 6.5.2. High level evidence exists only for second-line treatments after first-line treatment with docetaxel.

6.5.5.1 Cabazitaxel

Cabazitaxel is a novel taxane with activity in docetaxel-resistant cancers. It was studied in a large prospective, randomised, phase III trial (TROPIC trial) comparing cabazitaxel plus prednisone vs. mitoxantrone plus prednisone in 755 patients with mCRPC, who had progressed after or during docetaxel-based chemotherapy [855]. Patients received a maximum of ten cycles of cabazitaxel (25 mg/m²) or mitoxantrone (12 mg/m²) plus

prednisone (10 mg/day), respectively. Overall survival was the primary end-point, which was significantly longer with cabazitaxel (median: 15.1 vs. 12.7 months $p < 0.0001$). There was also a significant improvement in PFS (median: 2.8 vs. 1.4 months, $p < 0.0001$), objective RECIST response (14.4% vs. 4.4%, $p < 0.005$), and PSA response rate (39.2% vs. 17.8%, $p < 0.0002$). Treatment-associated WHO grade 3-4 AEs developed significantly more often in the cabazitaxel arm, particularly haematological (68.2% vs. 47.3%, $p < 0.0002$) but also non-haematological (57.4 vs. 39.8%, $p < 0.0002$) toxicity [857]. In two post-marketing randomised phase III trials, cabazitaxel was shown not to be superior to docetaxel in the first-line setting; in the second-line setting in terms of OS, 20 mg/m² cabazitaxel was not inferior to 25 mg/m², but less toxic. Therefore, the lower dose should be preferred [858, 859]. Cabazitaxel should preferably be given with prophylactic granulocyte colony-stimulating factor and should be administered by physicians with expertise in handling neutropenia and sepsis [860].

6.5.5.2 *Abiraterone acetate after prior docetaxel*

Positive results of the large phase III COU-AA-301 trial were reported after a median follow-up of 12.8 months [852] and confirmed by the final analysis [851]. A total of 1,195 patients with mCRPC were randomised 2:1 to abiraterone acetate plus prednisone or placebo plus prednisone. All patients had progressive disease based on the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria after docetaxel therapy (with a maximum of two previous chemotherapeutic regimens). The primary end-point was OS, with a planned HR of 0.8 in favour of abiraterone. After a median follow-up of 20.2 months, the median survival in the abiraterone group was 15.8 months compared to 11.2 months in the placebo arm (HR: 0.74, $p < 0.0001$). The benefit was observed in all subgroups and all the secondary objectives were in favour of abiraterone (PSA, radiologic tissue response, time to PSA or objective progression). The incidence of the most common grade 3-4 AEs did not differ significantly between arms, but mineralocorticoid-related side-effects were more frequent in the abiraterone group, mainly grade 1-2 (fluid retention, oedema and hypokalaemia).

6.5.5.3 *Enzalutamide after docetaxel*

The planned interim analysis of the AFFIRM study was published in 2012 [856]. This trial randomised 1,199 patients with mCRPC in a 2:1 fashion to enzalutamide or placebo. The patients had progressed after docetaxel treatment, according to the PCWG2 criteria. Corticosteroids were not mandatory, but could be prescribed, and were received by about 30% of the patients. The primary end-point was OS, with an expected HR benefit of 0.76 in favour of enzalutamide. After a median follow-up of 14.4 months, the median survival in the enzalutamide group was 18.4 months compared to 13.6 months in the placebo arm (HR: 0.63, $p < 0.001$). This led to the recommendation to halt and unblind the study. The benefit was observed irrespective of age, baseline pain intensity, and type of progression. In the final analysis with longer follow-up the OS results were confirmed despite crossover and extensive post progression therapies [845]. Enzalutamide was active also in patients with visceral metastases.

All the secondary objectives were in favour of enzalutamide (PSA, soft tissue response, QoL, time to PSA or objective progression). No difference in terms of side-effects was observed in the two groups, with a lower incidence of grade 3-4 AEs in the enzalutamide arm. There was a 0.6% incidence of seizures in the enzalutamide group compared to none in the placebo arm.

6.5.5.4 *Radium-223*

The only bone-specific drug that is associated with a survival benefit is the α -emitter radium-223. In a large phase III trial (ALSYMPCA), 921 patients with symptomatic mCRPC, who failed or were unfit for docetaxel, were randomised to six injections of 50 kBq/kg radium-223 or placebo, plus standard of care. The primary end-point was OS. Radium-223 significantly improved median OS by 3.6 months (HR: 0.70, $p < 0.001$) [853]. It was also associated with prolonged time to first skeletal event, improvement in pain scores and improvement in QoL. The associated toxicity was mild and, apart from slightly more haematologic toxicity and diarrhoea with radium-223, it did not differ significantly from that in the placebo arm [853]. Radium-223 was effective and safe no matter if the patients were docetaxel pre-treated, or not [861]. Due to safety concerns, the label of radium-223 was recently restricted to the use after docetaxel and at least one androgen receptor targeted agent [862]. The early use of radium-223 plus abiraterone acetate plus prednisolone showed significant safety risks in particular fractures and more deaths. This was particularly striking in patients without the concurrent use of antiresorptive agents [863].

6.5.6 **Treatment after docetaxel and one line of hormonal treatment for mCRPC**

The choice of further treatment after docetaxel and one line of hormonal treatment for mCRPC is open [864]. Either radium-223 or second-line chemotherapy (cabazitaxel) are reasonable options. In general, subsequent treatments in unselected patients are expected to have less benefit than with earlier use [865, 866] and there is evidence of cross-resistance between enzalutamide and abiraterone [867, 868]. Poly(ADP-ribose) polymerase

(PARP) inhibitors have shown high rates of response in men with somatic homologous recombination deficiency (HRD) in initial studies. Men previously treated with both docetaxel and at least one novel hormonal agent and whose tumours demonstrated homozygous deletions or deleterious mutations in DNA-repair genes showed an 88% response rate [869]. Patients without HRD did not show a clear benefit from olaparib. Interestingly in a randomised phase II trial which assigned 142 patients to receive olaparib and abiraterone (n = 71) or placebo and abiraterone (n = 71) patients received clinical benefit regardless of HRD status. Combination treatment is toxic with serious side effects reported in 34% of the olaparib/abiraterone group vs. 18% in the placebo/abiraterone group [870]. Nevertheless, although not yet available, PARP inhibitors offer an exciting new opportunity to tailor therapy based on the mutation profile contained within a tumour [871]. For patients with mismatch repair deficiency, the PD-1 inhibitor pembrolizumab was approved by the FDA irrespective of the tumour origin, this also includes PCa.

6.5.7 Monitoring of treatment

Baseline examinations should include history and clinical examination as well as baseline bloods (PSA, FBC, renal function, LFTs, ALP), bone scan and CT of chest abdomen and pelvis [872]. The use of Choline or PSMA PET CT scans for progressing CRPC is unclear and most likely not as beneficial as for patients with BCR or hormone naïve disease. Flares, PSMA upregulation and discordant results compared with PSA response or progression on androgen receptor targeting therapies have been described [873]. Prostate-specific antigen alone is not reliable enough [874] for monitoring disease activity in advanced CRPC, since visceral metastases may develop in men without rising PSA [875]. Instead, the PCWG2 recommends a combination of bone scintigraphy and CT scans, PSA measurements and clinical benefit in assessing men with CRPC [846]. A majority of experts at a recent consensus meeting suggested regular review and repeat blood profile every two to three months with bone scintigraphy and CT scans at least every six months, even in the absence of a clinical indication [872]. This reflects that the agents with a proven OS survival benefit all have potential toxicity and considerable cost, and patients with no objective benefit should have treatment modified. The Panel stress that such treatments should not be stopped for PSA progression alone. Instead, at least two of the three criteria (PSA progression, radiographic progression and clinical deterioration) should be fulfilled to stop treatment. For trial purposes, the updated PCWG3 put more weight on the importance of documenting progression in existing lesions and introduced the concept of “no longer clinically benefiting” to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment [876]. These recommendations also seem valid for clinical practice outside trials.

6.5.8 When to change treatment

The timing of mCRPC treatment change remains a matter of debate in mCRPC although it is clearly advisable to start or change treatment immediately in men with symptomatic progressing metastatic disease. Although, the number of effective treatments is increasing, head-to-head comparisons are still lacking, as are data assessing the sequencing of available agents. Therefore it is not clear how to choose the appropriate “second-line” treatment. In the absence of other data, the inclusion criteria from licensing trials have been used to prioritise treatment sequencing.

The ECOG PS has been used to stratify patients. Generally men with a PS of 0-1 are likely to tolerate treatments and those with PS of 2 or more are less likely to benefit. However, it is important that treatment decisions are individualised. This applies particularly where symptoms related to disease progression are determining PS. In such cases it may be appropriate to trial active life-prolonging agents to establish if treatment would improve PS. Sequencing is discussed in a summery paper published following the St. Gallen Advanced Prostate Cancer Consensus Conference 2017 [872, 877].

6.5.9 Symptomatic management in metastatic castration-resistant PCa

Castration-resistant PCa is usually a debilitating disease, often affecting the elderly male. A multidisciplinary approach is required with input from urologists, medical oncologists, radiation oncologists, nurses, psychologists and social workers [878]. Critical issues of palliation must be addressed when considering additional systemic treatment, including management of pain, constipation, anorexia, nausea, fatigue and depression.

6.5.9.1 Common complications due to bone metastases

Most patients with CRPC have painful bone metastases. External beam radiotherapy is highly effective [879], even as a single fraction [880]. A single infusion of a third generation bisphosphonate could be considered when RT is not available [881]. Common complications due to bone metastases include vertebral collapse or deformity, pathological fractures and spinal cord compression. Cementation can be an effective treatment for painful spinal fracture, whatever its origin, clearly improving both pain and QoL [882]. However, it is still important to offer standard palliative surgery, which can be effective for managing osteoblastic metastases

[883, 884]. Impending spinal cord compression is an emergency. It must be recognised early and patients should be educated to recognise the warning signs. Once suspected, high-dose corticosteroids must be given and MRI performed as soon as possible. A systematic neurosurgery or orthopaedic surgeon consultation should be planned to discuss a possible decompression, followed by EBRT [885]. Otherwise, EBRT with, or without, systemic therapy, is the treatment of choice.

6.5.10 Preventing skeletal-related events

6.5.10.1 Bisphosphonates

Zoledronic acid has been evaluated in mCRPC to reduce skeletal-related events (SRE). This study was conducted when no active anticancer treatments but docetaxel were available. Six hundred and forty three patients who had CRPC [886] with bone metastases were randomised to receive zoledronic acid, 4 or 8 mg every three weeks for fifteen consecutive months, or placebo. The 8 mg dose was poorly tolerated and reduced to 4 mg but did not show a significant benefit. However, at fifteen and 24 months of follow-up, patients treated with 4 mg zoledronic acid had fewer SREs compared to the placebo group (44 vs. 33%, $p = 0.021$) and in particular fewer pathological fractures (13.1 vs. 22.1%, $p = 0.015$). Furthermore, the time to first SRE was longer in the zoledronic acid group. No survival benefit has been seen in any prospective trial with bisphosphonates.

6.5.10.2 RANK ligand inhibitors

Denosumab is a fully human monoclonal antibody directed against RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast formation, function, and survival. In M0 CRPC, denosumab has been associated with increased bone-metastasis-free survival compared to placebo (median benefit: 4.2 months, HR: 0.85, $p = 0.028$) [885]. This benefit did not translate into a survival difference (43.9 compared to 44.8 months, respectively) and neither the FDA or the EMA have approved denosumab for this indication [887].

The efficacy and safety of denosumab ($n = 950$) compared with zoledronic acid ($n = 951$) in patients with metastatic CRPC was assessed in a phase III trial. Denosumab was superior to zoledronic acid in delaying or preventing SREs, as shown by time to first on-study SRE (pathological fracture, radiation or surgery to bone, or spinal cord compression) of 20.7 vs. 17.1 months, respectively (HR: 0.82, $p = 0.008$). Both urinary N-telopeptide and bone-specific alkaline phosphatase were significantly suppressed in the denosumab arm compared with the zoledronic acid arm ($p < 0.0001$ for both). However, these findings were not associated with any survival benefit and in a recent post-hoc re-evaluation of end-points, denosumab showed identical results when comparing SREs and symptomatic skeletal events [888].

The potential toxicity (e.g., osteonecrosis of the jaw) of these drugs must always be kept in mind (5-8.2% in M0 CRPC and mCRPC, respectively) [879, 885, 888, 889]. Patients should have a dental examination before starting therapy as the risk of jaw necrosis is increased by several risk factors including a history of trauma, dental surgery or dental infection [890]. Also, the risk for osteonecrosis of the jaw increased numerically with the duration of use [891] in the pivotal trial (one year vs. two years with denosumab), but this was not statistically significant when compared to zoledronic acid [887].

6.5.11 Summary of evidence and guidelines for life-prolonging treatments of castrate-resistant disease

Summary of evidence	LE
First-line treatment for mCRPC will be influenced by which treatments were used when metastatic cancer was first discovered.	4
No clear-cut recommendation can be made for the most effective drug for first-line CRPC treatment (i.e. hormone therapy, chemotherapy or radium-223) as no validated predictive factors exist.	3

Recommendations	Strength rating
Ensure that testosterone levels are confirmed to be < 50 ng/dL, before diagnosing castration-resistant PCa (CRPC).	Strong
Counsel, manage and treat patients with metastatic CRPC in a multidisciplinary team.	Strong
Treat patients with mCRPC with life-prolonging agents. Base the choice of first-line treatment on the performance status, symptoms, comorbidities, location and extent of disease, patient preference, and on the previous treatment for hormone-sensitive metastatic PCa (HSPC) (alphabetical order: abiraterone, docetaxel, enzalutamide, radium-223, sipuleucel-T).	Strong

6.5.12 Guidelines for cytotoxic treatment of castrate-resistant disease

Recommendations	Strength rating
Counsel, manage and treat patients with mCRPC in a multidisciplinary team.	Strong
Offer patients with mCRPC who are candidates for cytotoxic therapy docetaxel with 75 mg/m ² every three weeks.	Strong
Offer patients with mCRPC and progression following docetaxel chemotherapy further life-prolonging treatment options, which include abiraterone, cabazitaxel, enzalutamide and radium-223.	Strong
Base second-line treatment decisions of mCRPC on pre-treatment performance status, symptoms, patient preference, comorbidities and extent of disease.	Strong

6.5.13 Guidelines for supportive care of castrate-resistant disease

These recommendations are in addition to appropriate systemic therapy.

Recommendations	Strength rating
Offer bone protective agents to patients with mCRPC and skeletal metastases to prevent osseous complications.	Strong
Offer calcium and vitamin D supplementation when prescribing either denosumab or bisphosphonates.	Strong
Treat painful bone metastases early on with palliative measures such as external beam radiotherapy, and adequate use of analgesics.	Strong
In patients with spinal cord compression start immediate high-dose corticosteroids and assess for spinal surgery followed by irradiation. Offer radiation therapy alone if surgery is not appropriate.	Strong

6.5.14 Guidelines for non-metastatic castrate-resistant disease

Recommendation	Strength rating
Offer apalutamide or enzalutamide to patients with M0 CRPC and a high risk of developing metastasis (PSA-DT ≤ 10 months) to prolong time to metastases.	Strong

6.6 Summary of guidelines for the treatment of prostate cancer

Table 6.6.1: EAU risk groups for biochemical recurrence of localised and locally advanced prostate cancer

Definition			
Low-risk	Intermediate-risk	High-risk	
PSA < 10 ng/mL and GS < 7 (ISUP grade 1) and cT1-2a	PSA 10-20 ng/mL or GS 7 (ISUP grade 2/3) or cT2b	PSA > 20 ng/mL or GS > 7 (ISUP grade 4/5) or cT2c	any PSA any GS (any ISUP grade) cT3-4 or cN+
Localised			Locally advanced

GS = Gleason score; ISUP = International Society for Urological Pathology; PSA = prostate-specific antigen.

6.6.1 General guidelines recommendations for active treatment

Recommendations	Strength rating
Inform patients that no active treatment modality has shown superiority over any other active management options in terms of survival.	Strong
Inform patients that all active treatments have side-effects.	Strong
Surgical treatment	
Inform patients that no surgical approach (open, laparoscopic- or robotic radical prostatectomy) has clearly shown superiority in terms of functional or oncological results.	Strong
Perform an extended pelvic lymph node dissection (ePLND), when a LND is deemed necessary.	Strong
Do not perform nerve-sparing surgery when there is a risk of extracapsular extension (based on cT stage, ISUP, nomogram, multiparametric magnetic resonance imaging).	Strong
Do not offer neoadjuvant androgen deprivation therapy before surgery.	Strong
Radiotherapeutic treatment	
Offer intensity-modulated radiation therapy (IMRT) or volumetric arc external-beam radiotherapy (VMAT) for definitive treatment of PCa by external-beam radiation therapy.	Strong
Only offer moderate hypofractionation (HFX) with IMRT/VMAT, including image-guided radiation therapy (IGRT) to the prostate, to carefully selected patients with localised disease.	Strong
Ensure that moderate HFX adheres to radiotherapy protocols from trials with equivalent outcome and toxicity, i.e. 60 Gy/20 fractions in four weeks or 70 Gy/28 fractions in six weeks.	Strong
Active therapeutic options outside surgery and radiotherapy	
Only offer cryotherapy and high-intensity focused ultrasound within a clinical trial setting.	Strong
Only offer focal therapy within a clinical trial setting.	Strong

6.6.2 Guidelines recommendations for the various disease stages

Recommendations	Strength rating	
Low-risk disease		
Watchful waiting (WW)	Offer a WW policy to asymptomatic patients with a life expectancy < 10 years (based on comorbidities).	Strong
Active surveillance (AS)	Offer AS to patients suitable for curative treatment but with low-risk PCa.	Strong
	Perform multiparametric magnetic resonance imaging (mpMRI) before a confirmatory biopsy.	Strong
	During confirmatory biopsy include systematic and targeted biopsies.	Strong
	Base follow up on digital rectal examination, prostate-specific antigen (PSA) and repeat biopsies.	Strong
	Counsel patients about the possibility of needing further treatment in the future.	Strong
Active treatment	Offer surgery and radiotherapy (RT) as alternatives to AS to patients suitable for such treatments and who accept a trade-off between toxicity and prevention of disease progression.	Weak
Pelvic lymph node dissection (PLND)	Do not perform a PLND (estimated risk for pN+ < 5%).	Strong
Radiotherapeutic treatment	Offer low-dose rate (LDR) brachytherapy to patients with low-risk PCa, without a previous transurethral resection of the prostate (TURP) and with a good International Prostatic Symptom Score (IPSS) and a prostate volume < 50 mL.	Strong
	Use intensity-modulated radiation therapy (IMRT) with a total dose of 74-80 Gy or moderate hypofractionation (60 Gy/20 fx in four weeks, or 70 Gy/28 fx in six weeks), without androgen deprivation therapy (ADT).	Strong
Other options	Only offer whole gland treatment (such as cryotherapy, high-intensity focused ultrasound [HIFU], etc.) or focal treatment within a clinical trial setting.	Strong

Intermediate-risk disease		
Active surveillance	Offer AS to highly selected patients (< 10% Gleason pattern 4) accepting the potential increased risk of further metastases.	Weak
Radical prostatectomy (RP)	Offer RP to patients with intermediate-risk disease and a life expectancy > 10 years.	Strong
	Offer nerve-sparing surgery to patients with a low risk of extracapsular disease.	Strong
Extended pelvic lymph node dissection (ePLND)	Perform an ePLND in intermediate-risk disease if the estimated risk for positive lymph nodes exceeds 5%.	Strong
Radiotherapeutic treatment	Offer LDR brachytherapy to selected patients; patients without a previous TURP and with a good IPSS and a prostate volume < 50 mL.	Strong
	For external-beam radiation therapy (EBRT), use a total dose of 76-78 Gy or moderate hypofractionation (60 Gy/20 fx in four weeks or 70 Gy/28 fx in six week), in combination with short-term neoadjuvant plus concomitant ADT (four to six months).	Strong
	In patients not willing to undergo ADT, use an escalated dose of EBRT (76-80 Gy) or a combination with brachytherapy.	Weak
Other therapeutic options	Only offer whole gland treatment (such as cryotherapy, HIFU, etc.) or focal treatment within a clinical trial setting.	Strong
	Do not offer ADT monotherapy to intermediate-risk asymptomatic men not able to receive any local treatment.	Strong
High-risk localised disease		
Radical prostatectomy	Offer RP to patients with high-risk localised PCa and a life expectancy of > ten years only as part of multi-modal therapy.	Strong
Extended pelvic lymph node dissection	Perform an ePLND in high-risk disease.	Strong
	Do not perform a frozen section of nodes during RP to decide whether to proceed with, or abandon, the procedure.	Strong
Radiotherapeutic treatments	In patients with high-risk localised disease, use ERBT with 76-78 Gy in combination with long-term ADT (two to three years).	Strong
	In patients with high-risk localised disease, use EBRT with brachytherapy boost (either HDR or LDR), in combination with long-term ADT (two to three years).	Weak
Therapeutic options outside surgery and radiotherapy	Do not offer either whole gland or focal therapy to high-risk patients.	Strong
	Do not use ADT monotherapy in asymptomatic patients.	Strong
Locally-advanced disease		
Radical prostatectomy	Offer RP to highly selected patients with (cT3b-T4 N0 or any T N1) only as part of multi-modal therapy.	Strong
Extended pelvic lymph node dissection	Perform an ePLND in high-risk PCa.	Strong
	Do not perform a frozen section of nodes during RP to decide whether to proceed with, or abandon, the procedure.	Strong
Radiotherapeutic treatments	In patients with locally advanced cN0 disease, offer RT in combination with long-term ADT.	Strong
	Offer long-term ADT for two to three years.	Weak
Therapeutic options outside surgery and radiotherapy	Do not offer whole gland treatment or focal treatment to high-risk patients.	Strong
	Only offer ADT monotherapy to those patients unwilling or unable to receive any form of local treatment and who are either symptomatic or asymptomatic, but with a PSA-doubling time (DT) < twelve months or a PSA > 50 ng/mL, or a poorly differentiated tumour.	Strong

Adjuvant treatment after radical prostatectomy		
	Only discuss adjuvant treatment in men with a post-operative PSA < 0.1 ng/mL.	Strong
	Do not prescribe adjuvant ADT in pN0 patients.	Strong
	Offer adjuvant EBRT to the surgical field to patients at increased risk of local relapse: pT3 pN0 with positive margins (highest impact), and/or invasion of the seminal vesicles.	Strong
	Discuss three management options with patients with pN+ disease after an ePLND, based on nodal involvement characteristics: <ol style="list-style-type: none"> 1. Offer adjuvant ADT for node-positive (pN+). 2. Offer adjuvant ADT with additional RT. 3. Offer observation (expectant management) to a patient after eLND and ≤ 2 nodes with microscopic involvement, and a PSA < 0.1 ng/mL and absence of extranodal extension. 	Weak
Non-curative or palliative treatments in a first-line setting		
Localised disease		
Watchful waiting	Offer WW to asymptomatic patients not eligible for local curative treatment and those with a short life expectancy.	Strong
	While on WW, base the decision to start non-curative treatment on symptoms and disease progression.	Strong
Locally-advanced disease		
Watchful waiting	Offer a deferred treatment policy using ADT monotherapy to M0 asymptomatic patients with a PSA-DT > twelve months, a PSA < 50 ng/mL and well differentiated tumour, who are unwilling or unable to receive any form of local treatment.	Strong
Persistent PSA after radical prostatectomy		
	Offer a prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) scan to men with a persistent PSA > 0.2 ng/mL to exclude metastatic disease.	Weak
	Treat men with no evidence of metastatic disease with salvage RT with additional hormonal therapy.	Weak

6.6.3 Guidelines for metastatic disease, second-line and palliative treatments

Recommendations	Strength rating
Metastatic disease in a first-line setting	
Symptomatic M1 patients	Offer immediate systemic treatment to palliate symptoms and reduce the risk for potentially serious sequelae of advanced disease (spinal cord compression, pathological fractures, ureteral obstruction) to M1 symptomatic patients.
Asymptomatic M1 patients	Offer immediate systemic treatment to improve survival, defer progression to a symptomatic stage and prevent serious disease progression-related complications to M1 patients asymptomatic from their tumour.
	In well-informed M1 patients, asymptomatic from their tumour, discuss deferred castration since it lowers the treatment side effects, provided the patient is closely monitored.

All M1 patients	Offer luteinising hormone-releasing hormone (LHRH) antagonists, especially to patients with an impending spinal cord compression or bladder outlet obstruction.	Weak
	Offer surgery and/or local RT to any patient with M1 disease and evidence of impending complications such as spinal cord compression or pathological fracture.	Strong
	Offer initial short-term administration of antiandrogens to M1 patients treated with a LHRH agonist to reduce the risk of the 'flare-up' phenomenon.	Weak
	Do not offer anti-androgen monotherapy for M1 disease.	Strong
	Offer castration combined with chemotherapy (docetaxel) to all patients whose first presentation is M1 disease and who are fit enough for docetaxel.	Strong
	Offer castration combined with abiraterone acetate plus prednisone to all patients whose first presentation is M1 disease and who are fit enough for the regimen.	Strong
	Offer castration combined with prostate RT to patients whose first presentation is M1 disease and who have low volume of disease by CHAARTED criteria.	Weak
	Do not offer castration combined with any local treatment (RT/surgery) to patients with high volume M1 disease outside of clinical trials (except for symptom control).	Strong
	Offer castration alone, with or without an anti-androgen, to patients unfit for, or unwilling to consider, castration combined with docetaxel or abiraterone acetate plus prednisone or prostate RT.	Strong
M1 patients receiving Intermittent treatment	Only offer intermittent treatment to highly motivated asymptomatic M1 patients who have a major PSA response after the induction period.	Strong
Biochemical recurrence after treatment with curative intent		
Biochemical recurrence after radical prostatectomy (RP)	Offer AS and possibly delayed salvage RT (SRT) to patients with biochemical recurrence and classified as EAU low-risk group at relapse who may not benefit from intervention.	Strong
	Treat patients with a PSA rise from the undetectable range with SRT. Once the decision for SRT has been made, SRT (at least 66 Gy) should be given as soon as possible.	Strong
	Offer pN0 patients undergoing SRT hormonal therapy (with bicalutamide 150 mg for two years, or LHRH agonists for up to two years).	Weak
	Do not offer hormonal therapy to every pN0 patient treated with SRT.	Strong
Biochemical recurrence after RT	Treat highly selected patients with localised PCa and a histologically proven local recurrence with SRP.	Weak
	Salvage RP should only be performed in experienced centres.	Strong
	Do not offer HIFU, cryosurgical ablation and salvage brachytherapy to patients with proven local recurrence since it is still experimental.	Strong
Systemic salvage treatment	Do not offer ADT to M0 patients with a PSA-DT > twelve months.	Strong
Life-prolonging treatments of castration-resistant disease		
Ensure that testosterone levels are confirmed to be < 50 ng/dL, before diagnosing castration-resistant PCa (CRPC).		Strong
Counsel, manage and treat patients with metastatic CRPC (mCRPC) in a multidisciplinary team.		Strong
Treat patients with mCRPC with life-prolonging agents. Base the choice of first-line treatment on the performance status (PS), symptoms, comorbidities, location and extent of disease, patient preference, and on the previous treatment for hormone-sensitive PCa (alphabetical order: abiraterone, docetaxel, enzalutamide, radium-223, sipuleucel-T).		Strong

Cytotoxic treatments of castration-resistant disease	
Counsel, manage and treat patients with mCRPC in a multidisciplinary team.	Strong
Offer patients with mCRPC who are candidates for cytotoxic therapy docetaxel with 75 mg/m ² every three weeks.	Strong
Offer patients with mCRPC and progression following docetaxel chemotherapy further life-prolonging treatment options, which include abiraterone, cabazitaxel, enzalutamide and radium-223.	Strong
Base second-line treatment decisions of mCRPC on pre-treatment PS, symptoms, patient preference, comorbidities and extent of disease.	Strong
Supportive care of castration-resistant disease	
Offer bone protective agents to patients with mCRPC and skeletal metastases to prevent osseous complications.	Strong
Offer calcium and vitamin D supplementation when prescribing either denosumab or bisphosphonates.	Strong
Treat painful bone metastases early on with palliative measures such as EBRT, and adequate use of analgesics.	Strong
In patients with spinal cord compression start immediate high-dose corticosteroids and assess for spinal surgery followed by irradiation. Offer radiation therapy alone if surgery is not appropriate.	Strong
Non-metastatic castrate-resistant disease	
Offer apalutamide or enzalutamide to patients with M0 CRPC and a high risk of developing metastasis (PSA-DT ≤ 10 months) to prolong time to metastases.	Strong

7. FOLLOW-UP

The rationale for following up patients is to assess immediate- and long-term oncological results, ensure treatment compliance and allow initiation of further therapy, when appropriate. In addition follow-up allows monitoring of side-effects or complications of therapy, functional outcomes and an opportunity to provide psychological support to PCa survivors, all of which is covered in Chapter 8.

7.1 Follow-up: After local treatment

7.1.1 Definition

Local treatment is defined as RP or RT, either by EBRT or LDR- or HDR-brachytherapy, or any combination of these. Unestablished alternative treatments such as HIFU, cryosurgery and focal therapy options do not have a well-defined, validated PSA cut-off to define BCR, but follow the general principles as presented in this section. In general, a rising PSA is considered a sign of disease recurrence.

7.1.2 Why follow-up?

The first post-treatment clinic visit focuses on detecting treatment-related complications and assist patients in coping with their new situation apart from providing information on the pathological analysis. Men with PCa are at increased risk of depression and attention for mental health status is required [892, 893]. Tumour or patient characteristics may prompt changing the follow-up schedule.

7.1.3 How to follow-up?

The procedures indicated at follow-up visits vary according to the clinical situation. The examinations discussed below are routinely used to detect PCa progression or residual disease. Prostate specific antigen level and DRE are the only tests that should be performed routinely. A disease-specific history is mandatory at every follow-up visit and includes psychological aspects, signs of disease progression, and treatment-related complications. Evaluation of treatment-related complications must be individualised, which is beyond the scope of these Guidelines. The examinations used for cancer-related follow-up after curative surgery or RT are discussed below.

7.1.3.1 Prostate-specific antigen monitoring

Measurement of PSA is a cornerstone in follow-up after local treatment. Normal PSA values differ after RP and RT, but PSA recurrence almost always precedes clinical recurrence [656, 894]. No recent consensus exists regarding the best definition of PSA relapse after local treatment. Main aim is to establish when a PSA rise is clinically significant since not all PSA increases have the same clinical value (see Section 6.3) [2].

7.1.3.2 Prostate-specific antigen monitoring after radical prostatectomy

Prostate-specific antigen is expected to be undetectable within six weeks after successful RP [895]. Persistently measurable PSA in patients treated with RP is thought to be due to residual cancer, either micrometastases or residual disease in the prostatic fossa (see chapter on persistent PSA). Ultrasensitive PSA assays remain controversial for routine follow-up after RP. Men with an ultrasensitive PSA nadir < 0.01 ng/mL have a 4% likelihood of biochemical relapse within 2 years [896]. Detectable post-operative ultrasensitive PSA does not predict BCR in all cases, although it adds prognostic value. In men with ultrasensitive PSA > 0.05 ng/mL, 67% remained free of biochemical disease at five years [897]. If survival is improved by early additional treatment after RP (before the PSA level reaches > 0.2 ng/mL), lower PSA nadir levels, as well as a lower PSA-DT calculated based on the first detectable PSA level up to 0.2 ng/mL, may help identify suitable candidates [898]. Post-prostatectomy ultrasensitive PSA levels > 0.01 ng/mL in combination with clinical characteristics such as ISUP grade and surgical margin status may predict PSA progression and can be useful to establish follow-up intervals [899].

7.1.3.3 Prostate-specific antigen monitoring after radiotherapy

Following RT, PSA drops more slowly as compared to RP. A nadir < 0.5 ng/mL is associated with a favourable outcome after RT, although the optimal cut-off value remains controversial [900]. The interval before reaching the nadir can be up to three years or more. At the 2006 RTOG-ASTRO Consensus Conference, the Phoenix definition of radiation failure was proposed to establish a better correlation between definition and clinical outcome, namely, an increase of 2 ng/mL above the post-treatment PSA nadir [657]. This definition also applies to patients who received HT [657]. After RT, PSA-DT correlates with the site of recurrence; patients with local recurrence have a PSA-DT of thirteen months compared to three months for those with distant failure [901].

7.1.3.4 Digital rectal examination

Local recurrence after curative treatment is possible without a concomitant rise in PSA level [902]. However, this has only been proven in patients with unfavourable pathology, namely, undifferentiated tumours. Prostate-specific antigen measurement and DRE comprise the most useful combination for first-line examination in follow-up after RT but the role of DRE was questioned since it failed to detect any local recurrence in the absence of a rising PSA in a series of 899 patients [903]. In a series of 1,118 prostatectomy patients no local histologically proven recurrence was found by DRE alone and PSA measurement may be the only test needed after RP [904, 905].

7.1.3.5 Transrectal ultrasound, bone scintigraphy, computed tomography, magnetic resonance imaging, and positron emission tomography computed tomography

Imaging techniques have no place in routine follow-up of localised PCa as long as the PSA is not rising. Imaging is only justified in patients for whom the findings will affect treatment decisions, either in case of BCR or in patients with symptoms. (See Section 6.3.4.2.1 for a more detailed discussion).

7.1.3.5.1 Transrectal ultrasonography/magnetic resonance imaging guided biopsy.

Biopsy of the prostate bed and urethrovesical anastomosis of the remaining prostate after radiotherapy are only indicated if detection of a local recurrence affects treatment decisions (See Section 6.2.6.3 on imaging).

7.1.4 How long to follow-up?

Most patients who fail treatment for PCa do so within seven years after local therapy [370]. Patients should be followed up more closely during the initial post-treatment period when risk of failure is highest. Prostate-specific antigen measurement, disease-specific history and DRE (if considered) are recommended at three, six and twelve months post-operatively, every six months thereafter until three years, and then annually. Whether follow-up should be stopped in case PSA remains undetectable (after RP) or stable (after RT) remains an unanswered question.

7.1.5 Summary of evidence and guidelines for follow-up after treatment with curative intent

Summary of evidence	LE
After radical prostatectomy rising serum prostate-specific antigen (PSA) level is considered a biochemical recurrence (BCR).	3
After radiotherapy, an increase in PSA > 2 ng/mL above the nadir, rather than a specific threshold value, is considered as clinically meaningful BCR.	3
Palpable nodules and increasing serum PSA are signs of local recurrence.	2a

Recommendations	Strength rating
Routinely follow up asymptomatic patients by obtaining at least a disease-specific history and serum prostate-specific antigen (PSA) measurement. These should be performed at three, six and twelve months after treatment, then every six months until three years, and then annually.	Strong
At recurrence, only perform imaging to detect local recurrence if the outcome will affect treatment planning.	Strong
Do not routinely offer bone scans and other imaging modalities to asymptomatic patients if there are no signs of biochemical relapse. In case patients have bone pain or other symptoms of possible progression, restaging should be considered irrespective of serum PSA level.	Strong

7.2 Follow-up: During first line hormonal treatment (androgen sensitive period)

7.2.1 Introduction

Follow up must be individualised as a rising PSA might be associated with rapid symptomatic progression or evolve without progression on imaging or symptoms over time. Follow-up for mCRPC is addressed in treatment Section 6.3.4.1, as first-line management of mCRPC and follow-up are closely linked.

7.2.2 Purpose of follow-up

The main objectives of follow-up in these patients are to ensure treatment compliance, to monitor treatment response and side-effects, and to guide treatment at the time of CRPC.

Complementary investigations must be restricted to those that are clinically helpful to avoid unnecessary examinations and costs.

7.2.3 Methods of follow-up

7.2.3.1 Clinical follow-up

Clinical follow-up is mandatory on a regular basis, and it cannot be replaced, neither by laboratory tests nor by imaging modalities. Of utmost importance in metastatic situations is to advise patients about early signs of spinal cord compression, check for occult cord compression, urinary tract complications (ureteral obstruction, bladder outlet obstruction) or bone lesions that are at an increased fracture risk.

7.2.3.1.1 Prostate-specific antigen monitoring

Prostate-specific antigen is a key marker for following the course of androgen-sensitive PCa. Treatment response may be assessed using the change in serum PSA level as a surrogate end-point for survival in patients with newly diagnosed metastatic PCa receiving ADT [793], or ADT combined with docetaxel [794].

A rise in PSA level usually precedes the onset of clinical symptoms by several months. Clinical progression has been reported without a rising PSA in up to 25% of patients [908]. However, due to a lack of follow-up data a recommendation cannot be provided.

Other serum markers may be considered for prognostication [909-911] but the effects of their use on patient outcome are, as yet, unknown.

7.2.3.1.2 Creatinine, haemoglobin and liver function monitoring

Estimated glomerular filtration rate monitoring is good clinical practice as an increase may be linked to bilateral ureteral obstruction or bladder retention. Liver function tests may suggest treatment toxicity (especially NSAA), but rarely disease progression. A decline in Hb after three months of ADT is independently associated with shorter progression-free and OS rates and might explain significant fatigue [912]. Alkaline phosphatase may increase secondary to bone metastases and androgen-induced osteoporosis [913]. Therefore, it may be helpful to determine bone-specific isoenzymes as none are directly influenced by HT.

7.2.3.1.3 Imaging

Asymptomatic patients with a stable PSA level should not undergo imaging [914]. New symptomatic bone lesions require a bone scan, as well as a PSA progression suggesting CRPC status if a treatment modification is considered. The PCWG has clarified the definition of bone scan progression as the appearance of at least two new lesions, later confirmed [846].

Suspicion of disease progression indicates the need for additional imaging modalities, most often initially a CT-scan but further imaging will be guided by symptoms or possible subsequent treatments. In CRPC, imaging must be individualised with the aim of maintaining the patient's QoL.

7.2.3.1.4 Testosterone monitoring

This should be considered part of clinical practice for men on LHRH therapy. Many men receiving medical

castration will achieve a castrate testosterone level (< 20 ng/dL), and most a testosterone level < 50 ng/dL. However, approximately 13-38% of patients fail to achieve this goal and up to 24% of men may experience temporary testosterone surges (testosterone > 50 ng/dL) during long-term treatment [495], known as the 'acute on-chronic effect' or 'breakthrough response'.

The timing of measurements is not clearly defined. A three to six-month testosterone level assessment has been suggested to ensure castration is achieved and maintained. If not, switching to another agonist or antagonist, or to an orchiectomy, should be considered. In patients with a rising PSA and/or clinical progression, serum testosterone must be evaluated in all cases to confirm a castrate-resistant state.

7.2.3.1.5 Monitoring of metabolic complications

The most severe complications of androgen suppression are metabolic syndrome, cardiovascular morbidity, mental health problems, and bone resorption (see Section 8.2.4.5).

All patients should be screened for diabetes by checking fasting glucose and HbA1c (at baseline and regularly), in addition to checking blood lipid levels. Men with impaired glucose tolerance and/or diabetes should be referred for an endocrine consultation. A cardiology consultation should be considered in men with a history of cardiovascular disease and men older than 65 years prior to starting ADT. Men on enzalutamide or abiraterone acetate are at increased risk of cardiovascular problems and hypertension and regular checks are required [915]. Monitoring serum levels of vitamin D and calcium is important. It is suggested that routine bone monitoring should be performed every two years during castration [916], or yearly if there are other risk factors [917, 918]. However, there is no evidence that this favourably impacts on bone complications due to ADT. The FRAX score can help identify men at risk of osteoporotic complications but validation of the score in the ADT settings is required [919, 920].

Men on anti-androgen therapy should have their transaminase levels checked at least twice/year in view of liver toxicity..

Patients on ADT should be given advice on modifying their lifestyle (e.g. diet, exercise, smoking cessation, etc.) and should be treated for existing conditions, such as diabetes, hyperlipidaemia, and/or hypertension [912, 913]. Androgen deprivation therapy may affect mental health and men with ADT are three times more likely to report depression [921]. Attention for mental health should therefore be part of the follow-up scheme. Furthermore, the risk-to-benefit ratio of ADT must be considered in patients with a higher risk of cardiovascular complications, especially if it is possible to delay starting ADT.

7.2.4 **When to follow-up**

After the initiation of ADT, it is recommended that patients are followed at three to six month intervals. This must be individualised and each patient should be advised to contact his physician in the event of troublesome symptoms.

7.2.4.1 *Stage M0 - M1 patients*

In case there is a favourable treatment response, i.e. PSA response (< 4 ng/mL), symptomatic improvement, good psychological coping and good treatment compliance, follow-up visits may be scheduled every three to six months.

7.2.5 **Imaging as a marker of response in metastatic prostate cancer**

Treatment response in soft-tissue metastases can be assessed by morphological imaging methods using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria. However, these criteria cannot be used in bone where response assessment is difficult [922, 923].

Quantitative estimation of tracer uptake at BS can be obtained through automated methods such as the Bone Scan Index [924]. Nonetheless, BS is limited by the so-called 'flare' phenomenon which is defined by the development of new images induced by treatment on a first follow-up scan which, after longer observation, actually represent a favourable response. Flare is observed within eight to twelve weeks of treatment initiation and can lead to false-positive diagnosis of disease progression. As a result, the PCWG suggested that all patients with at least two new lesions on the first follow-up BS require a confirmatory BS at least six weeks later while the treatment is continued [846]. This means that management change for primary therapy resistance cannot occur until after at least fourteen weeks of treatment. Computed tomography cannot be used to monitor sclerotic bone lesions because bone sclerosis can occur under effective treatment and reflects bone healing. The ability of PET/CT to assess response has been evaluated in a few studies but, until further data are available, PET/CT has no role in this setting. Magnetic resonance imaging can directly assess the bone marrow and demonstrate progression based on morphologic criteria or changes in apparent diffusion coefficient. A standardisation for reporting is available [925].

In practice, imaging to assess progression leading to treatment change must be limited to a clear progression: RECIST criteria for non-bone lesions; for bone lesions, only BS progression (occurrence of two new hot spots, later confirmed) should be considered. The practical impact of mpMRI in assessing bone progression remains unclear.

7.2.6 Guidelines for follow-up during hormonal treatment

Recommendations	Strength rating
Evaluate patients at three to six months after the initiation of treatment.	Strong
The follow-up strategy must be individualised based on stage of disease, prior symptoms, prognostic factors and the treatment given.	Strong
In patients with stage M0 disease, schedule follow-up every six months. As a minimum requirement, include a disease-specific history and serum PSA determination in the diagnostic work-up.	Strong
In patients with stage M1 disease, schedule follow-up every three to six months. As a minimum requirement, include a disease-specific history, DRE, serum PSA, haemoglobin, serum creatinine and alkaline phosphatase measurements in the diagnostic work-up. The testosterone level should be checked, especially during the first year.	Strong
Counsel patients (especially with M1b status) about the clinical signs suggestive of spinal cord compression.	Strong
When disease progression is suspected, adapt/individualise follow-up.	Strong
In patients with suspected progression, assess the testosterone level. By definition, castration resistant PCa (CRPC) requires a testosterone level < 50 ng/dL (< 1 mL/L).	Strong
Do not offer routine imaging to otherwise stable asymptomatic patients.	Weak

8. QUALITY OF LIFE OUTCOMES IN PROSTATE CANCER

This chapter is presented in two parts. The first (8.2) will summarise long-term consequences (≥ 12 months) of therapies for PCa. Based on two SRs, the second (8.3) will make evidence-based recommendations for supporting patients when selecting primary treatment options for localised disease and also supportive interventions aimed at improving disease-specific QoL across all stages of disease.

8.1 Introduction

Quality of life and personalised care go hand in hand. Treating PCa can affect an individual both physically and mentally, as well as his close relations and his work or vocation. These multifaceted issues all have a bearing on his perception of QoL [926]. Approaching care from a holistic point of view requires the intervention of a multi-disciplinary team including urologists, medical oncologists, radiation oncologists, oncology nurses, behavioural practitioners and many others. Attention to the psychosocial concerns of men with PCa is integral to quality clinical care, and this can include the needs of carers and partners [860]. Prostate cancer care should not be reduced to focusing on the organ in isolation: side-effects or late adverse effects of treatment can manifest systemically and have a major influence on the patient's QoL. Taking QoL into consideration relies on understanding the patient's values and preferences so that optimal treatment proposals can be formulated and discussed.

8.2 Adverse effects of prostate cancer therapies

8.2.1 Surgery

The absence of standardisation in reporting surgical complications for RP and the introduction of different techniques has resulted in a wide variation in the types of complications reported, as well as variation in the overall incidence of complications [927-930]. The most common post-operative issue is ED but other related issues to consider include dry ejaculation, which occurs with removal of the prostate, change in the quality of orgasm and occasional pain on orgasm. Men also complain of loss of penile length (3.73%, 19/510 men) [931]. The second most commonly occurring complication is long-term incontinence [927-930] but voiding difficulties may also occur associated with bladder neck contracture (e.g. 1.1% after RALP) [932].

For those men undergoing minimally invasive procedures port site hernia has been reported in 0.66% after inserting 12 mm bladeless trocar [933] and can occur more rarely with 8 mm and 5 mm trocars

[933]. A key consideration for men is whether long-term consequences of surgery are reduced by using newer techniques such as RALP. Systematic reviews have documented complication rates after RALP [380, 402-405], and can be compared with contemporaneous reports after RRP [406]. From these reports, the mean continence rates at twelve months were 89-100% for patients treated with RALP and 80-97% for patients treated with RRP. A prospective, controlled, non-randomised trial of patients undergoing RP in fourteen centres using RALP or RRP demonstrates that at twelve months after RALP, 21.3% were incontinent, as were 20.2% after RRP. The unadjusted OR was 1.08 (95% CI: 0.87-1.34). Erectile dysfunction was observed in 70.4% after RALP and 74.7% after RRP. The unadjusted OR was 0.81 (95% CI: 0.66-0.98) [407, 934]. Further follow-up demonstrates similar functional outcomes with both techniques at 24 months [934, 935]. A single centre randomised phase III study comparing RALP and RRP (n = 326) also demonstrates similar functional outcomes with both techniques at 24 months [375].

8.2.2 **Radiotherapy**

8.2.2.1 *Side-effects of external beam radiotherapy*

Analysis of the toxicity outcomes of the Prostate Testing for Cancer and Treatment (ProtecT) trial [936] shows that men treated with EBRT and six months of ADT report bowel toxicity including persistent diarrhoea, bowel urgency and/or incontinence and rectal bleeding (described in detail in section 8.3.1.1 below). Participants in the ProtecT study were treated with 3D CRT and more recent studies using IMRT demonstrate less bowel toxicity than noted previously with 3D CRT [937].

A SR and meta-analysis of observational studies comparing patients exposed or unexposed to radiotherapy in the course of treatment for PCa demonstrate an increased risk of developing second cancers for bladder (OR: 1.39), colorectal (OR: 1.68) and rectum (OR: 1.62) with similar risks over lag times of five and ten years. Absolute excess risks over ten years are small (1-4%) but should be discussed with younger men in particular [938].

8.2.2.2 *Side-effects from brachytherapy*

Some patients experience significant urinary complications following implantation, such as urinary retention (1.5-22%), with post-implantation TURP reported as being required in up to 8.7% of cases, and incontinence (0-19%) [939]. Chronic urinary morbidity can occur in up to 20% of patients, depending on the severity of the symptoms before brachytherapy. Previous TURP for BPH increases the risk of post-implantation incontinence and urinary morbidity. Prevention of morbidity depends on careful patient selection, and expert assessment of IPSS score, backed up by urodynamic studies.

8.2.3 **Local primary whole-gland treatments other than surgery or radiotherapy**

8.2.3.1 *Cryosurgery*

In Ramsay *et al.*'s SR and meta-analysis there was evidence that the rate of urinary incontinence at one year was lower for cryotherapy than for RP, but the size of the difference decreased with longer follow-up [524]. There was no significant difference between cryotherapy vs. EBRT in terms of urinary incontinence at one year (< 1%); cryotherapy had a similar ED rate (range 0-40%) to RP at one year. There was insufficient data to compare cryotherapy vs. EBRT in terms of ED.

8.2.3.2 *High-intensity focused ultrasound*

In terms of toxicity, there are insufficient data on urinary incontinence, ED or bowel dysfunction to draw any conclusions, although at one year HIFU had lower incontinence rates than RP (OR: 0.06, 95% CI: 0.01-0.48) [524].

8.2.4 **Hormonal therapy**

A summary of impacts on psychological factors due to the use of ADT such as sexual function, mood, depression, cognitive function and impact on men's partners can be found in two clinical reviews [940, 941]. A small RCT evaluated the QoL at one-year follow-up in patients with non-localised PCa, between various ADT regimens, or no treatment. ADT patients reported a significant decline in spatial reasoning, spatial abilities and working memory as well as increased depression, tension, anxiety, fatigue and irritability during treatment [942]. Conversely, a prospective observational study with follow-up to three years failed to demonstrate an association with cognitive decline in men on ADT when compared to men with PCa not treated with ADT and healthy controls [943]. A prospective observational study of non-metastatic PCa, found that immediate ADT was associated with a lower overall QoL compared to deferred treatment [944]. Another retrospective, non-randomised study suggested that men receiving LHRH agonists reported more worry and physical discomfort and poorer overall health, and were less likely to believe themselves free of cancer than orchiectomised patients. The stage at diagnosis had no effect on health outcomes [945].

Using a specific non-validated questionnaire, bicalutamide monotherapy showed a significant

advantage over castration in the domains of physical capacity and sexual interest (not sexual function) at twelve months [946]. A *post-hoc* analysis, including only patients with sexual interest suggested that bicalutamide was associated with better sexual preservation, including maintained sexual interest, feeling sexually attractive [947], preserved libido and erectile function [948]. Intermittent androgen deprivation has been discussed elsewhere (see Section 6.4.4.3).

8.2.4.1 Sexual function

Cessation of sexual activity is very common in men undergoing ADT, affecting up to 93% of men [949]. ADT reduces both libido and the ability to gain and maintain erections. The management of acquired ED is mostly non-specific [950].

8.2.4.2 Hot flushes

Hot flushes are a common side-effect of ADT (prevalence estimated between 44-80% of men on ADT) [949]. They appear three months after starting ADT, usually persist long-term and have a significant impact on QoL. Oestrogen-receptor modulators or low-dose oestrogen therapies, e.g. DES, 0.5-1 mg/day, reduce the frequency and severity of hot flushes. Both treatments carry a risk of cardiovascular complications [951].

Serotonin re-uptake inhibitors (e.g. venlafaxine or sertraline) also appear to be effective in men, but less than hormone therapies based on a prospective RCT comparing venlafaxine, 75 mg daily, with medroxyprogesterone, 20 mg daily, or cyproterone acetate, 100 mg daily [952]. After six months of LHRH (n = 919), 311 men had significant hot flushes and were randomised to one of the treatments. Based on median daily hot-flush score, Venlafaxine was inferior -47.2% (IQR -74.3 to -2.5) compared to -94.5% (-100.0 to -74.5) in the cyproterone group, and -83.7% (-98.9 to -64.3) in the medroxyprogesterone group. With a placebo effect influencing up to 30% of patients [953], the efficacy of clonidine, veralipride, gabapentine [954] and acupuncture [955] need to be compared in prospective RCTs.

8.2.4.3 Non-metastatic bone fractures

Due to increased bone turnover and decreased bone mineral density (BMD) in a time-dependent manner, ADT use is linked to an increased risk of fracture (up to 45% RR with long-term ADT) [956]. Hip fractures in men are associated with a significant risk of death [957]. A precise evaluation of BMD should be performed by dual emission X-ray absorptiometry (DEXA) before starting long-term ADT. An initial low BMD (T-score < -2.5 or < -1, with other risk factors) indicates a high risk of subsequent non-metastatic fracture. The WHO FRAX tool (<http://www.shef.ac.uk/FRAX>) should be used to evaluate individual risk. Obesity (increase in body fat mass by up to 10%) and sarcopenia (decrease in lean tissue mass by up to 3%) as well as weight loss are common and occur during the first year of ADT [958]. These changes increase the fracture risk [959].

8.2.4.3.1 Hormonal treatment modalities

Bicalutamide monotherapy may have less impact on BMD [960, 961], but is limited by its suboptimal efficacy (see Section 6.1.4.1.1.5.2.3 - Metastatic PCa - Hormonal Therapy). The intermittent LHRH-agonist modality might be associated with less bone impact [962].

8.2.4.4 Metabolic effects

Lipid alterations are common and may occur as early as the first three months of treatment [958]. ADT also decreases insulin sensitivity and increases fasting plasma insulin levels, which is a marker of insulin resistance. In diabetic patients, metformin appears to be an attractive option for protection against metabolic effects based on retrospective analysis [963], but there is insufficient data to recommend its use in non-diabetic patients.

Metabolic syndrome is an association of independent cardiovascular disease risk factors, often associated with insulin resistance. The definition requires at least three of the following criteria [964]:

- waist circumference > 102 cm;
- serum triglyceride > 1.7 mmol/L;
- blood pressure > 130/80 mmHg or use of medication for hypertension;
- high-density lipoprotein (HDL) cholesterol < 1 mmol/L;
- glycaemia > 5.6 mmol/L or the use of medication for hyperglycaemia.

The prevalence of a metabolic-like syndrome is higher during ADT compared with men not receiving ADT [965].

Skeletal muscle mass heavily influences basal metabolic rate and is in turn heavily influenced by endocrine pathways [966]. Androgen deprivation therapy-induced hypogonadism results in negative effects on skeletal

muscle health. A prospective longitudinal study involving 252 men on ADT for a median of 20.4 months reported lean body mass decreases progressively over three years; 1.0% at one year, 2.1% at two years, and 2.4% at three years which appears more pronounced in men at ≥ 70 years of age [967].

8.2.4.5 Cardiovascular morbidity

Cardiovascular mortality is a common cause of death in PCa patients [784, 968, 969]. Several studies showed that ADT, after only six months, was associated with an increased risk of diabetes mellitus, cardiovascular disease, and myocardial infarction [970]. The RTOG 92-02 [971] and 94-08 [972] trials confirmed an increased cardiovascular risk, unrelated to the duration of ADT and not accompanied by an overall increased cardiovascular mortality. No increase in cardiovascular mortality has been reported in a systematic meta-analysis of trials RTOG 8531, 8610, 9202, EORTC 30891 or EORTC 22863 [973]. However, serious concerns about the conclusions of this meta-analysis have been raised due to poor consideration of bias in the included studies [974, 975]. Meta-analysis of observational data reports consistent links between ADT and the risk of cardiovascular disease in men treated for PCa e.g. the associations between GnRH agonists and nonfatal or fatal myocardial infarction or stroke RR: 1.57 (95% CI: 1.26-1.94) and RR: 1.51 (95% CI: 1.24-1.84), respectively [976]. An increase in cardiovascular mortality has been reported in patients suffering from previous congestive heart failure or myocardial infarction in a retrospective database analysis [977] or presenting with a metabolic syndrome [978]. It has been suggested that LHRH antagonists might be associated with less cardiovascular morbidity compared to agonists [979]. However, the methodology used in these studies does not provide convincing evidence to show a clear superiority of these compounds.

These concerns resulted in an FDA warning and consensus paper from the American Heart, Cancer Society and Urological Associations [783]. Preventive advice includes non-specific measures such as loss of weight, increased exercise, improved nutrition and smoking cessation [980].

8.2.4.6 Fatigue

Fatigue often develops as a side-effect of ADT. Regular exercise appears to be the best protective measure. Anaemia may be a cause of fatigue [949, 981]. Anaemia requires an etiological diagnosis (medullar invasion, renal insufficiency, iron deficiency, chronic bleeding) and individualised treatment. Iron supplementation (using injectable formulations only) must be systematic if deficiency is observed. Regular blood transfusions are required if severe anaemia is present. Erythropoiesis-stimulating agents might be considered in dedicated cases, taking into account the possible increased risk of thrombovascular events [982].

8.2.4.7 Neurological side-effects

Castration seems also to be associated with an increased risk of stroke [983], and is suspect to be associated with an increased risk for depression and cognitive decline such as Alzheimer disease [984].

8.3 Overall quality of life in men with prostate cancer

Living longer with PCa, does not necessarily equate to living well [860, 926]. There is clear evidence of unmet needs and ongoing support requirements for some men after diagnosis and treatment for PCa [985]. Cancer impacts on the wider family and cognitive behavioural therapy can help reduce depression, anxiety and stress in caregivers [986]. Radical treatment for PCa can negatively impact long-term QoL (e.g. sexual, urinary and bowel dysfunction), as can ADT used in short or long-term treatment e.g. sexual problems, fatigue, psychological morbidity, adverse metabolic sequelae increased cardiovascular and bone fracture risk [940, 987]. Direct symptoms from advanced or metastatic cancer e.g. pain, hypercalcaemia, spinal cord compression, pathological fractures, also adversely affect health [988, 989]. Men's QoL including domains such as sexual function, urinary function and bowel function is worse after treatment for PCa compared to non-cancer controls [990, 991].

The concept of 'quality of life' is subjective and can mean different things to different men, but there are some generally common features across virtually all patients. Drawing from these common features, specific tools or 'patient-reported outcome measures' (PROMs) have been developed and validated for men with PCa. These questionnaires assess common issues that affect men after PCa diagnosis and treatment and generate scores which reflect the impact on perceptions of HRQoL. During the process of undertaking two dedicated SRs around cancer-specific QoL outcomes in men with PCa as the foundation for our guideline recommendations, the following validated PROMs were found in our searches (see Table 8.3.1).

Table 8.3.1: PROMs assessing cancer specific quality of life

Questionnaire	Domains / items
Functional Assessment of Cancer Therapy-General (FACT-G) [992]	Physical well-being, Social/family well-being, Emotional well-being, and Functional well-being
Functional Assessment of Cancer Therapy-Prostate (FACT-P) [993]	12 cancer site specific items to assess for prostate related symptoms. Can be combined with FACT-G or reported separately.
European Organisation for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) [994]	Five functional scales (physical, role, cognitive, emotional, and social); Three symptom scales (fatigue, pain, and nausea and vomiting); Global health status/QoL scale; and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease.
European Organisation for Research and Treatment of Cancer QLQ-PR 25 (EORTC QLQ-PR 25) [995]	Urinary, bowel and treatment-related symptoms, as well as sexual activity and sexual function.
Expanded prostate cancer index composite (EPIC) [996]	Urinary, bowel, sexual, and hormonal symptoms.
Expanded prostate cancer index composite short form 26 (EPIC 26) [997]	Urinary, sexual, bowel, and hormonal domains.
UCLA Prostate Cancer Index (UCLA PCI) [998]	Urinary, bowel, and sexual domains.
Prostate Cancer Quality of Life Instrument (PCQoL) [999]	Urinary, sexual, and bowel domains, supplemented by a scale assessing anxiety.
Prostate Cancer Outcome Study Instrument [1000]	Urinary, bowel, and sexual domains.

8.3.1 Long-term (> 12 months) quality of life outcomes in men with localised disease

8.3.1.1 Men undergoing local treatments

The results of the Prostate Testing for Cancer and Treatment (ProtecT) trial (n = 1,643 men) reported no difference in EORTC QLQ-C30 assessed global QoL, up to five years of follow-up in men aged 50-69 years with T1-T2 disease randomised for treatment with AM, RP or RT with six months of ADT [936]. However, EPIC urinary summary scores (at six years) were worse in men treated with RP compared to AM or RT (88.7 vs. 89.0 vs. 91.4, respectively) as were urinary incontinence (80.9 vs. 85.8 vs. 89.4, respectively) and sexual summary, function and bother scores (32.3 vs. 40.6 vs. 41.3 for sexual summary, 23.7 vs. 32.5 vs. 32.7 for sexual function and 51.4 vs. 57.9 vs. 60.1 for sexual bother, respectively) at six years of follow-up. Minimal clinically important differences for the 50 item EPIC questionnaire are not available. For men receiving RT with six months of ADT, EPIC bowel scores were poorer compared to AM and RP in all domains: function (90.8 vs. 92.3 vs. 92.3, respectively), bother (91.7 vs. 94.2 vs. 93.7, respectively) and summary (91.2 vs. 93.2 vs. 93.0, respectively) at six years of follow-up in the ProtecT trial.

The findings regarding RP and RT are supported by other observational studies, the most important being The Prostate Cancer Outcomes Study (PCOS) [930] that studied a cohort of 1,655 men, of whom 1,164 had undergone RP and 491 RT. The study reported that at five years of follow-up, men who underwent RP had a higher prevalence of urinary incontinence and ED, while men treated with RT had a higher prevalence of bowel dysfunction. However, despite these differences detected at five years, there were no significant differences in the adjusted odds of urinary incontinence, bowel dysfunction or ED between RP and RT at fifteen years. More recently, investigators reported that although EBRT was associated with a negative effect in bowel function, the difference in bowel domain score was below the threshold for clinical significance twelve months after treatment [937]. As 81% of patients in the EBRT arm of the study received IMRT, these data suggest that the risk of side-effects in contemporary treatments may be slightly less.

With respect to brachytherapy cancer-specific QoL outcomes, one small RCT (n = 200) evaluated bilateral nerve-sparing RP and brachytherapy in men with localised disease (up to T2a), which reported worsening of physical functioning as well as irritative urinary symptomatology in 20% of brachytherapy patients at one year of follow-up. However, there were no significant differences in EORTC QLQ-C30/PR-25 scores at five years of follow-up when comparing to pre-treatment values [1001]. It should be noted of this trial within group tests only were reported. In a subsequent study by the same group comparing bilateral nerve-sparing RARP and brachytherapy (n = 165), improved continence was noted with brachytherapy in the first six months but lower potency rates up to two years [1002]. These data and a synthesis of eighteen randomised and non-randomised studies in a SR involving 13,604 patients, are the foundation of the following recommendations [1003].

8.3.1.2 Guidelines for quality of life in men undergoing local treatments

Recommendations	Strength rating
Advise eligible patients for active surveillance, that global quality of life is equivalent for up to five years compared to radical prostatectomy or external beam radiotherapy.	Strong
Discuss the negative impact of surgery on urinary and sexual function, as well as the negative impact of radiotherapy on bowel function with patients.	Strong
Advise patients treated with brachytherapy of the negative impact on irritative urinary symptomatology at one year but not after five years.	Weak

8.3.2 Improving quality of life in men who have been diagnosed with prostate cancer

Men undergoing local treatments

In men with localised disease, nurse led multi-disciplinary rehabilitation (addressing sexual functioning, cancer worry, relationship issues depression, managing bowel and urinary function problems) provided positive short-term effects (four months) on sexual function (effect size 0.45) and long-term (twelve months) positive effects on sexual limitation (effect size 0.5) and cancer worry (effect size 0.51) [1004].

In men with post-surgical urinary incontinence, conservative management options include pelvic floor muscle training with or without biofeedback, electrical stimulation, extra-corporeal magnetic innervation (ExMI), compression devices (penile clamps), lifestyle changes, or a combination of methods. Uncertainty around the effectiveness and value of these conservative interventions remains [1005]. Surgical interventions including sling and artificial urinary sphincter significantly decrease the number of pads used per day and increase the QoL compared with before intervention. The overall cure rate is around 60% and results in improvement in incontinence by about 25% [1006].

The use of PDE5 inhibitors in penile rehabilitation has been subject to some debate. A single centre, double blind RCT of 100 men undergoing nerve-sparing surgery reported no benefit of nightly sildenafil (50 mg) compared to on-demand use [1007]. However, a multicentre double blind RCT (n = 423) in men aged < 68 years, with normal pre-treatment erectile function undergoing either open, conventional or robot-assisted laparoscopic nerve-sparing RP, Tadalafil (5 mg) once per day improved participants EPIC sexual domain-scores (least squares mean difference +9.6: 95% CI: 3.1-16.0) when compared to 20 mg 'on demand' or placebo at nine months of follow-up [435]. Therefore, based on discordant results, no clear recommendation is possible, even if a trend exists for early use of PDE5 inhibitors after RP for penile rehabilitation [1008]. A detailed discussion can be found in the EAU Male Sexual Dysfunction Guidelines [1009].

Men undergoing systemic treatments

Similar to men treated with a radical approach (see above), in men with T1-T3 disease undergoing RT and ADT, a combined nurse led psychological support and physiotherapist led multi-disciplinary rehabilitation has reported improvements in QoL. Specifically this intervention involved action planning around patients' needs related to lifestyle changes, weight control, toilet habits, sexuality, and psychological problems. This was complemented with pelvic floor muscle therapy. Improvements in urinary (adjusted mean 4.5: 95% CI: 0.6-8.4), irritative (adjusted mean 5.8: 95% CI: 1.4-10.3) and hormonal (adjusted mean 4.8: 95% CI: 0.8-8.8) EPIC domains were found up to 22 weeks of follow-up [1010].

Providing supervised aerobic and resistance exercise training of a moderate intensity improves EORTC QLQ-C30 role (adjusted mean 15.8: 95% CI: 6.6-24.9) and cognitive domain outcomes (adjusted mean 11.4: 95% CI: 3.3-19.6) as well as symptom scales for fatigue (adjusted mean 11.0: 95% CI: 20.2-1.7), nausea (adjusted mean 4.0: 95% CI: 7.4-0.25), and dyspnoea (adjusted mean 12.4: 95% CI: 22.5-2.3) up to three months in men treated with ADT [1011]. Such interventions have also reported clinically relevant improvements in FACT-P (mean difference 8.9: 95% CI: 3.7-14.2) in men on long-term ADT [1012, 1013]. These findings are supported by a SR which reported improvements up to twelve weeks in cancer-specific QoL in a meta-analysis of high quality trials (SMD 0.33: 95% CI: 0.08-0.58) [981].

Bisphosphonates increase BMD in the hip and spine by up to 7% in one year. The optimal regimen for zoledronic acid remains unclear: quarterly [1014] or yearly [1015] injections. The question is relevant as the risk of jaw necrosis is both dose- and time-related [1016]. A quarterly regimen could be considered for a BMD ≤ 2.5 as a yearly injection is unlikely to provide sufficient protection [1017].

In M0 patients, denosumab has been shown to increase the lumbar BMD by 5.6% compared to a 1% decrease in the placebo arm after two years, using a 60 mg subcutaneous regimen every six months [1018]. This was associated with a significant decrease in vertebral fracture risk (1.5% vs. 3.9%, p = 0.006). The benefits were similar whatever the age (< or > 70 years), the duration or type of ADT, the initial BMD, the patient's weight or the initial BMI. This benefit was not associated with any significant toxicity, e.g. jaw osteonecrosis or delayed

healing in vertebral fractures. In M0 patients, with the use of a higher dosage (120 mg every four weeks), a delay in bone metastases of 4.2 months has been shown [888] without any impact on OS, but with an increase in side-effects. Therefore, this later regimen cannot be recommended.

8.3.2.1 Guidelines for quality of life in men undergoing systemic treatments

Recommendations	Strength rating
Offer men on androgen deprivation therapy, twelve weeks of supervised (by trained exercise specialists) combined aerobic and resistance exercise.	Strong
Advise men on androgen deprivation therapy to maintain a healthy weight and diet, to stop smoking and have yearly screening for diabetes and hypercholesterolemia. Supplementation with vitamin D and calcium is advised.	Strong
Offer men with T1-T3 disease specialist nurse led, multi-disciplinary rehabilitation based on the patients' personal goals addressing incontinence, sexuality, depression and fear of recurrence, social support and positive lifestyle changes after any radical treatment.	Strong

9. REFERENCES

1. Drost, F.J.H., *et al.* Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews, 2019. In press.
2. Van den Broeck, T., *et al.* Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. *Eur Urol*, 2018. S0302: 30752.
<https://www.ncbi.nlm.nih.gov/pubmed/30342843>
3. Guyatt, G.H., *et al.* What is "quality of evidence" and why is it important to clinicians? *BMJ*, 2008. 336: 995.
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>
4. Guyatt, G.H., *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. 336: 924.
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>
5. Phillips, B., *et al.* Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.
<https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
6. Guyatt, G.H., *et al.* Going from evidence to recommendations. *BMJ*, 2008. 336: 1049.
<https://www.ncbi.nlm.nih.gov/pubmed/18467413>
7. Van den Broeck T., *et al.* A systematic review of oncological effectiveness and harms of primary local interventions for high-risk localized and locally advanced prostate cancer. PROSPERO International prospective register of systematic reviews, 2017. CRD42017078862
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=78862
8. Willemse, P.M., *et al.* Systematic review of deferred treatment with curative intent for localised prostate cancer to explore heterogeneity of definitions, thresholds and criteria and clinical effectiveness. PROSPERO International prospective register of systematic reviews, 2018. CRD42018071780.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=71780
9. Ferlay, J., *et al.* Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 2015. 136: E359.
<https://www.ncbi.nlm.nih.gov/pubmed/25220842>
10. Haas, G.P., *et al.* The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. *Can J Urol*, 2008. 15: 3866.
<https://www.ncbi.nlm.nih.gov/pubmed/18304396>
11. Bell, K.J., *et al.* Prevalence of incidental prostate cancer: A systematic review of autopsy studies. *Int J Cancer*, 2015. 137: 1749.
<https://www.ncbi.nlm.nih.gov/pubmed/25821151>
12. Jansson, K.F., *et al.* Concordance of tumor differentiation among brothers with prostate cancer. *Eur Urol*, 2012. 62: 656.
<https://www.ncbi.nlm.nih.gov/pubmed/22386193>

13. Hemminki, K. Familial risk and familial survival in prostate cancer. *World J Urol*, 2012. 30: 143.
<https://www.ncbi.nlm.nih.gov/pubmed/22116601>
14. Bratt, O., *et al.* Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. *J Natl Cancer Inst*, 2016. 108.
<https://www.ncbi.nlm.nih.gov/pubmed/27400876>
15. Stewart, R.W., *et al.* Screening for prostate cancer. *Semin Oncol*, 2017. 44: 47.
<https://www.ncbi.nlm.nih.gov/pubmed/28395763>
16. Randazzo, M., *et al.* A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). *BJU Int*, 2016. 117: 576.
<https://www.ncbi.nlm.nih.gov/pubmed/26332304>
17. Tan, D.S., *et al.* Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. *J Clin Oncol*, 2016. 34: 91.
<https://www.ncbi.nlm.nih.gov/pubmed/26578615>
18. Conti, D.V., *et al.* Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. *J Natl Cancer Inst*, 2017. 109.
<https://www.ncbi.nlm.nih.gov/pubmed/29117387>
19. Eeles, R.A., *et al.* Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nat Genet*, 2013. 45: 385.
<https://www.ncbi.nlm.nih.gov/pubmed/23535732>
20. Amin Al Olama, A., *et al.* Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. *Hum Mol Genet*, 2015. 24: 5589.
<https://www.ncbi.nlm.nih.gov/pubmed/26025378>
21. Schumacher, F.R., *et al.* Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet*, 2018. 50: 928.
<https://www.ncbi.nlm.nih.gov/pubmed/29892016>
22. Pritchard, C.C., *et al.* Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *N Engl J Med*, 2016. 375: 443.
<https://www.ncbi.nlm.nih.gov/pubmed/27433846>
23. Lynch, H.T., *et al.* Screening for familial and hereditary prostate cancer. *Int J Cancer*, 2016. 138: 2579.
<https://www.ncbi.nlm.nih.gov/pubmed/26638190>
24. Ewing, C.M., *et al.* Germline mutations in HOXB13 and prostate-cancer risk. *N Engl J Med*, 2012. 366: 141.
<https://www.ncbi.nlm.nih.gov/pubmed/22236224>
25. Bancroft, E.K., *et al.* Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. *Eur Urol*, 2014. 66: 489.
<https://www.ncbi.nlm.nih.gov/pubmed/24484606>
26. Castro, E., *et al.* Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. *Eur Urol*, 2015. 68: 186.
<https://www.ncbi.nlm.nih.gov/pubmed/25454609>
27. Leitzmann, M.F., *et al.* Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. *Clin Epidemiol*, 2012. 4: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/22291478>
28. Breslow, N., *et al.* Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. *Int J Cancer*, 1977. 20: 680.
<https://www.ncbi.nlm.nih.gov/pubmed/924691>
29. Esposito, K., *et al.* Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. *J Endocrinol Invest*, 2013. 36: 132.
<https://www.ncbi.nlm.nih.gov/pubmed/23481613>
30. Blanc-Lapierre, A., *et al.* Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. *BMC Public Health*, 2015. 15: 913.
<https://www.ncbi.nlm.nih.gov/pubmed/26385727>
31. Preston, M.A., *et al.* Metformin use and prostate cancer risk. *Eur Urol*, 2014. 66: 1012.
<https://www.ncbi.nlm.nih.gov/pubmed/24857538>
32. Freedland, S.J., *et al.* Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. *Prostate Cancer Prostatic Dis*, 2013. 16: 254.
<https://www.ncbi.nlm.nih.gov/pubmed/23567655>
33. James, N.D., *et al.* Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *N Engl J Med*, 2017. 377: 338.
<https://www.ncbi.nlm.nih.gov/pubmed/28578639>

34. YuPeng, L., *et al.* Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of 14 Prospective Studies. *Cancer Epidemiol Biomarkers Prev*, 2015. 24: 1086.
<https://www.ncbi.nlm.nih.gov/pubmed/25953767>
35. Vidal, A.C., *et al.* Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. *Cancer Epidemiol Biomarkers Prev*, 2014. 23: 2936.
<https://www.ncbi.nlm.nih.gov/pubmed/25261967>
36. Davies, N.M., *et al.* The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. *Cancer Causes Control*, 2015. 26: 1603.
<https://www.ncbi.nlm.nih.gov/pubmed/26387087>
37. Dickerman, B.A., *et al.* Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. *Cancer Causes Control*, 2016. 27: 1049.
<https://www.ncbi.nlm.nih.gov/pubmed/27351919>
38. Zhao, J., *et al.* Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. *BMC Cancer*, 2016. 16: 845.
<https://www.ncbi.nlm.nih.gov/pubmed/27842506>
39. Key, T.J. Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. *Recent Results Cancer Res*, 2014. 202: 39.
<https://www.ncbi.nlm.nih.gov/pubmed/24531775>
40. Alexander, D.D., *et al.* Meta-Analysis of Long-Chain Omega-3 Polyunsaturated Fatty Acids (LCOmega-3PUFA) and Prostate Cancer. *Nutr Cancer*, 2015. 67: 543.
<https://www.ncbi.nlm.nih.gov/pubmed/25826711>
41. Lippi, G., *et al.* Fried food and prostate cancer risk: systematic review and meta-analysis. *Int J Food Sci Nutr*, 2015. 66: 587.
<https://www.ncbi.nlm.nih.gov/pubmed/26114920>
42. Chen, P., *et al.* Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. *Medicine (Baltimore)*, 2015. 94: e1260.
<https://www.ncbi.nlm.nih.gov/pubmed/26287411>
43. Rowles, J.L., 3rd, *et al.* Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis. *Prostate Cancer Prostatic Dis*, 2018. 21: 319.
<https://www.ncbi.nlm.nih.gov/pubmed/29317772>
44. Ilic, D., *et al.* Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. *Maturitas*, 2012. 72: 269.
<https://www.ncbi.nlm.nih.gov/pubmed/22633187>
45. Bylsma, L.C., *et al.* A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. *Nutr J*, 2015. 14: 125.
<https://www.ncbi.nlm.nih.gov/pubmed/26689289>
46. Zhang, M., *et al.* Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic review of epidemiological studies based on 17,546 cases. *Andrology*, 2016. 4: 745.
<https://www.ncbi.nlm.nih.gov/pubmed/27260185>
47. Applegate, C.C., *et al.* Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis. *Nutrients*, 2018. 10.
<https://www.ncbi.nlm.nih.gov/pubmed/29300347>
48. Reger, M.K., *et al.* Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Int J Cancer*, 2018. 142: 719.
<https://www.ncbi.nlm.nih.gov/pubmed/29114854>
49. Kristal, A.R., *et al.* Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. *Cancer Epidemiol Biomarkers Prev*, 2014. 23: 1494.
<https://www.ncbi.nlm.nih.gov/pubmed/24732629>
50. Nyame, Y.A., *et al.* Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. *J Clin Oncol*, 2016. 34: 1345.
<https://www.ncbi.nlm.nih.gov/pubmed/26903577>
51. Cui, Z., *et al.* Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis. *Medicine (Baltimore)*, 2017. 96: e5944.
<https://www.ncbi.nlm.nih.gov/pubmed/28151881>
52. Allen, N.E., *et al.* Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies. *J Natl Cancer Inst*, 2016. 108.
<https://www.ncbi.nlm.nih.gov/pubmed/27385803>

53. Lippman, S.M., *et al.* Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA*, 2009. 301: 39.
<https://www.ncbi.nlm.nih.gov/pubmed/19066370>
54. Kramer, B.S., *et al.* Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. *J Clin Oncol*, 2009. 27: 1502.
<https://www.ncbi.nlm.nih.gov/pubmed/19252137>
55. Andriole, G.L., *et al.* Effect of dutasteride on the risk of prostate cancer. *N Engl J Med*, 2010. 362: 1192.
<https://www.ncbi.nlm.nih.gov/pubmed/20357281>
56. Thompson, I.M., *et al.* The influence of finasteride on the development of prostate cancer. *N Engl J Med*, 2003. 349: 215.
<https://www.ncbi.nlm.nih.gov/pubmed/12824459>
57. Haider, A., *et al.* Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. *J Urol*, 2015. 193: 80.
<https://www.ncbi.nlm.nih.gov/pubmed/24980615>
58. Watts, E.L., *et al.* Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. *Eur Urol*, 2018. 74: 585.
<https://www.ncbi.nlm.nih.gov/pubmed/30077399>
59. Zhou, C.K., *et al.* Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. *Am J Epidemiol*, 2016. 183: 210.
<https://www.ncbi.nlm.nih.gov/pubmed/26764224>
60. Lian, W.Q., *et al.* Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies. *Med Sci Monit*, 2015. 21: 1902.
<https://www.ncbi.nlm.nih.gov/pubmed/26126881>
61. Rao, D., *et al.* Does night-shift work increase the risk of prostate cancer? a systematic review and meta-analysis. *Onco Targets Ther*, 2015. 8: 2817.
<https://www.ncbi.nlm.nih.gov/pubmed/26491356>
62. Islami, F., *et al.* A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. *Eur Urol*, 2014. 66: 1054.
<https://www.ncbi.nlm.nih.gov/pubmed/25946735>
63. Ju-Kun, S., *et al.* Association Between Cd Exposure and Risk of Prostate Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis. *Medicine (Baltimore)*, 2016. 95: e2708.
<https://www.ncbi.nlm.nih.gov/pubmed/26871808>
64. Russo, G.I., *et al.* Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. *Aging Male*, 2018: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/29571270>
65. Bhindi, B., *et al.* The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis. *JAMA Intern Med*, 2017. 177: 1273.
<https://www.ncbi.nlm.nih.gov/pubmed/28715534>
66. Cremers, R.G., *et al.* Self-reported acne is not associated with prostate cancer. *Urol Oncol*, 2014. 32: 941.
<https://www.ncbi.nlm.nih.gov/pubmed/25011577>
67. Huang, T.B., *et al.* Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. *Int Urol Nephrol*, 2014. 46: 1715.
<https://www.ncbi.nlm.nih.gov/pubmed/24687637>
68. Bhindi, B., *et al.* The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. *Urology*, 2014. 84: 1073.
<https://www.ncbi.nlm.nih.gov/pubmed/25443907>
69. Lin, S.W., *et al.* Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. *Int J Cancer*, 2012. 131: E1015.
<https://www.ncbi.nlm.nih.gov/pubmed/22539073>
70. Pabalan, N., *et al.* Association of male circumcision with risk of prostate cancer: a meta-analysis. *Prostate Cancer Prostatic Dis*, 2015. 18: 352.
<https://www.ncbi.nlm.nih.gov/pubmed/26215783>
71. Rider, J.R., *et al.* Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. *Eur Urol*, 2016. 70: 974.
<https://www.ncbi.nlm.nih.gov/pubmed/27033442>

72. Brierley, J.D., *et al.*, TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017.
<https://www.uicc.org/resources/tnm/publications-resources>
73. Cooperberg, M.R., *et al.* The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. *J Urol*, 2005. 173: 1938.
<https://www.ncbi.nlm.nih.gov/pubmed/15879786>
74. Epstein, J.I., *et al.* The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol*, 2005. 29: 1228.
<https://www.ncbi.nlm.nih.gov/pubmed/16096414>
75. Epstein, J.I., *et al.* The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. *Am J Surg Pathol*, 2016. 40: 244.
<https://www.ncbi.nlm.nih.gov/pubmed/26492179>
76. Epstein, J.I., *et al.* A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. *Eur Urol*, 2016. 69: 428.
<https://www.ncbi.nlm.nih.gov/pubmed/26166626>
77. Kane, C.J., *et al.* Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. *Eur Urol Focus*, 2017. 3: 487.
<https://www.ncbi.nlm.nih.gov/pubmed/28753804>
78. Gulati, R., *et al.* Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. *Cancer Epidemiol Biomarkers Prev*, 2017. 26: 222.
<https://www.ncbi.nlm.nih.gov/pubmed/27742670>
79. IARC. IARC France All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. 2014.
<http://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-29.pdf>
80. Etzioni, R., *et al.* Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. *Med Care*, 2013. 51: 295.
<https://www.ncbi.nlm.nih.gov/pubmed/23269114>
81. Loeb, S. Guideline of guidelines: prostate cancer screening. *BJU Int*, 2014. 114: 323.
<https://www.ncbi.nlm.nih.gov/pubmed/24981126>
82. Andriole, G.L., *et al.* Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med*, 2009. 360: 1310.
<https://www.ncbi.nlm.nih.gov/pubmed/19297565>
83. Schroder, F.H., *et al.* Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med*, 2009. 360: 1320.
<https://www.ncbi.nlm.nih.gov/pubmed/19297566>
84. Hugosson, J., *et al.* Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol*, 2010. 11: 725.
<https://www.ncbi.nlm.nih.gov/pubmed/20598634>
85. Carter, H.B., *et al.* Early detection of prostate cancer: AUA Guideline. *J Urol*, 2013. 190: 419.
<https://www.ncbi.nlm.nih.gov/pubmed/23659877>
86. Chou, R., *et al.* Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2011. 155: 762.
<https://www.ncbi.nlm.nih.gov/pubmed/21984740>
87. Tsodikov, A., *et al.* Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. *Ann Intern Med*, 2017. 167: 449.
<https://www.ncbi.nlm.nih.gov/pubmed/28869989>
88. Bibbins-Domingo, K., *et al.* The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. *JAMA*, 2017. 317: 1949.
<https://www.ncbi.nlm.nih.gov/pubmed/28397958>
89. Auffenberg, G.B., *et al.* Application of the 2013 American Urological Association early detection of prostate cancer guideline: who will we miss? *World J Urol*, 2014. 32: 959.
<https://www.ncbi.nlm.nih.gov/pubmed/24946729>
90. Banerji, J.S., *et al.* Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening. *J Urol*, 2016. 195: 66.
<https://www.ncbi.nlm.nih.gov/pubmed/26254722>

91. Grossman, D.C., *et al.* Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. *Jama*, 2018. 319: 1901.
<https://www.ncbi.nlm.nih.gov/pubmed/2680553>
92. U.S. Preventive Services, Task Force. Prostate Cancer Screening Draft Recommendations. 2017.
<https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prostate-cancer-screening1>
93. Arnsrud Godtman, R., *et al.* Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. *Eur Urol*, 2015. 68: 354.
<https://www.ncbi.nlm.nih.gov/pubmed/25556937>
94. Ilic, D., *et al.* Screening for prostate cancer. *Cochrane Database Syst Rev*, 2013. 1: CD004720.
<https://www.ncbi.nlm.nih.gov/pubmed/23440794>
95. Hayes, J.H., *et al.* Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. *JAMA*, 2014. 311: 1143.
<https://www.ncbi.nlm.nih.gov/pubmed/24643604>
96. Booth, N., *et al.* Health-related quality of life in the Finnish trial of screening for prostate cancer. *Eur Urol*, 2014. 65: 39.
<https://www.ncbi.nlm.nih.gov/pubmed/23265387>
97. Vasarainen, H., *et al.* Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC). *Acta Oncol*, 2013. 52: 1615.
<https://www.ncbi.nlm.nih.gov/pubmed/23786174>
98. Heijnsdijk, E.A., *et al.* Quality-of-life effects of prostate-specific antigen screening. *N Engl J Med*, 2012. 367: 595.
<https://www.ncbi.nlm.nih.gov/pubmed/22894572>
99. Schroder, F.H., *et al.* Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet*, 2014. 384: 2027.
<https://www.ncbi.nlm.nih.gov/pubmed/25108889>
100. The benefits and harms of breast cancer screening: an independent review. *Lancet*, 2012. 380: 1778.
<https://www.ncbi.nlm.nih.gov/pubmed/23117178>
101. Carlsson, S., *et al.* Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. *Eur Urol*, 2017. 71: 46.
<https://www.ncbi.nlm.nih.gov/pubmed/27084245>
102. Albright, F., *et al.* Prostate cancer risk prediction based on complete prostate cancer family history. *Prostate*, 2015. 75: 390.
<https://www.ncbi.nlm.nih.gov/pubmed/25408531>
103. Kamangar, F., *et al.* Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol*, 2006. 24: 2137.
<https://www.ncbi.nlm.nih.gov/pubmed/16682732>
104. Vickers, A.J., *et al.* Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. *BMJ*, 2013. 346: f2023.
<https://www.ncbi.nlm.nih.gov/pubmed/23596126>
105. Carlsson, S., *et al.* Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. *Bmj*, 2014. 348: g2296.
<https://www.ncbi.nlm.nih.gov/pubmed/24682399>
106. Naji, L., *et al.* Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. *Ann Fam Med*, 2018. 16: 149.
<https://www.ncbi.nlm.nih.gov/pubmed/29531107>
107. Loeb, S., *et al.* Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. *J Urol*, 2006. 175: 902.
<https://www.ncbi.nlm.nih.gov/pubmed/16469576>
108. Martin, R.M., *et al.* Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. *Jama*, 2018. 319: 883.
<https://www.ncbi.nlm.nih.gov/pubmed/29509864>
109. Gelfond, J., *et al.* Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. *J Urol*, 2015. 194: 46.
<https://www.ncbi.nlm.nih.gov/pubmed/25686543>

110. Droz, J.P., *et al.* Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. *Lancet Oncol*, 2014. 15: e404.
<https://www.ncbi.nlm.nih.gov/pubmed/25079103>
111. Vedder, M.M., *et al.* The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. *Eur Urol*, 2014. 66: 1109.
<https://www.ncbi.nlm.nih.gov/pubmed/25168616>
112. Leyten, G.H., *et al.* Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. *Eur Urol*, 2014. 65: 534.
<https://www.ncbi.nlm.nih.gov/pubmed/23201468>
113. Boegemann, M., *et al.* The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged \leq 65 years. *BJU Int*, 2016. 117: 72.
<https://www.ncbi.nlm.nih.gov/pubmed/25818705>
114. Bryant, R.J., *et al.* Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. *J Natl Cancer Inst*, 2015. 107.
<https://www.ncbi.nlm.nih.gov/pubmed/25863334>
115. Roobol, M.J., *et al.* Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. *Eur Urol*, 2017. 72: 45.
<https://www.ncbi.nlm.nih.gov/pubmed/28162815>
116. Louie, K.S., *et al.* Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. *Ann Oncol*, 2015. 26: 848.
<https://www.ncbi.nlm.nih.gov/pubmed/25403590>
117. Richie, J.P., *et al.* Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. *Urology*, 1993. 42: 365.
<https://www.ncbi.nlm.nih.gov/pubmed/7692657>
118. Carvalho, G.F., *et al.* Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. *J Urol*, 1999. 161: 835.
<https://www.ncbi.nlm.nih.gov/pubmed/10022696>
119. Okotie, O.T., *et al.* Characteristics of prostate cancer detected by digital rectal examination only. *Urology*, 2007. 70: 1117.
<https://www.ncbi.nlm.nih.gov/pubmed/18158030>
120. Gosselaar, C., *et al.* The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. *Eur Urol*, 2008. 54: 581.
<https://www.ncbi.nlm.nih.gov/pubmed/18423977>
121. Stamey, T.A., *et al.* Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *N Engl J Med*, 1987. 317: 909.
<https://www.ncbi.nlm.nih.gov/pubmed/2442609>
122. Catalona, W.J., *et al.* Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. *J Urol*, 1994. 151: 1283.
<https://www.ncbi.nlm.nih.gov/pubmed/7512659>
123. Semjonow, A., *et al.* Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. *Prostate Suppl*, 1996. 7: 3.
<https://www.ncbi.nlm.nih.gov/pubmed/8950358>
124. Thompson, I.M., *et al.* Prevalence of prostate cancer among men with a prostate-specific antigen level $<$ or $=$ 4.0 ng per milliliter. *N Engl J Med*, 2004. 350: 2239.
<https://www.ncbi.nlm.nih.gov/pubmed/15163773>
125. Dong, F., *et al.* Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. *J Urol*, 2008. 180: 150.
<https://www.ncbi.nlm.nih.gov/pubmed/18485398>
126. Carter, H.B., *et al.* Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. *JAMA*, 1992. 267: 2215.
<https://www.ncbi.nlm.nih.gov/pubmed/1372942>
127. Schmid, H.P., *et al.* Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. *Cancer*, 1993. 71: 2031.
<https://www.ncbi.nlm.nih.gov/pubmed/7680277>

128. Arlen, P.M., *et al.* Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. *J Urol*, 2008. 179: 2181.
<https://www.ncbi.nlm.nih.gov/pubmed/18423743>
129. Heidenreich, A. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity. *Eur Urol*, 2008. 54: 976.
<https://www.ncbi.nlm.nih.gov/pubmed/18640768>
130. Ramirez, M.L., *et al.* Current applications for prostate-specific antigen doubling time. *Eur Urol*, 2008. 54: 291.
<https://www.ncbi.nlm.nih.gov/pubmed/18439749>
131. O'Brien, M.F., *et al.* Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. *J Clin Oncol*, 2009. 27: 3591.
<https://www.ncbi.nlm.nih.gov/pubmed/19506163>
132. Vickers, A.J., *et al.* Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. *J Clin Oncol*, 2009. 27: 398.
<https://www.ncbi.nlm.nih.gov/pubmed/19064972>
133. Stephan, C., *et al.* The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. *Cancer*, 1997. 79: 104.
<https://www.ncbi.nlm.nih.gov/pubmed/8988733>
134. Catalona, W.J., *et al.* Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. *JAMA*, 1998. 279: 1542.
<https://www.ncbi.nlm.nih.gov/pubmed/9605898>
135. Huang, Y., *et al.* Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis. *Medicine (Baltimore)*, 2018. 97: e0249.
<https://www.ncbi.nlm.nih.gov/pubmed/29595681>
136. Loeb, S., *et al.* The Prostate Health Index: a new test for the detection of prostate cancer. *Ther Adv Urol*, 2014. 6: 74.
<https://www.ncbi.nlm.nih.gov/pubmed/24688603>
137. de la Calle, C., *et al.* Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men. *J Urol*, 2015. 194: 65.
<https://www.ncbi.nlm.nih.gov/pubmed/25636659>
138. Catalona, W.J., *et al.* A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol*, 2011. 185: 1650.
<https://www.ncbi.nlm.nih.gov/pubmed/21419439>
139. Nordstrom, T., *et al.* Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. *Eur Urol*, 2015. 68: 139.
<https://www.ncbi.nlm.nih.gov/pubmed/25151013>
140. Deras, I.L., *et al.* PCA3: a molecular urine assay for predicting prostate biopsy outcome. *J Urol*, 2008. 179: 1587.
<https://www.ncbi.nlm.nih.gov/pubmed/18295257>
141. Hessels, D., *et al.* DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. *Eur Urol*, 2003. 44: 8.
<https://www.ncbi.nlm.nih.gov/pubmed/12814669>
142. Nakanishi, H., *et al.* PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. *J Urol*, 2008. 179: 1804.
<https://www.ncbi.nlm.nih.gov/pubmed/18353398>
143. Hessels, D., *et al.* Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. *Prostate*, 2010. 70: 10.
<https://www.ncbi.nlm.nih.gov/pubmed/19708043>
144. Auprich, M., *et al.* Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. *Eur Urol*, 2011. 60: 1045.
<https://www.ncbi.nlm.nih.gov/pubmed/21871709>
145. Nicholson, A., *et al.* The clinical effectiveness and cost-effectiveness of the PROGENSA(R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*, 2015. 19: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/26507078>

146. Wei, J.T., *et al.* Can urinary PCA3 supplement PSA in the early detection of prostate cancer? *J Clin Oncol*, 2014. 32: 4066.
<https://www.ncbi.nlm.nih.gov/pubmed/25385735>
147. Van Neste, L., *et al.* Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. *Eur Urol*, 2016. 70: 740.
<https://www.ncbi.nlm.nih.gov/pubmed/27108162>
148. Tomlins, S.A., *et al.* Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science*, 2005. 310: 644.
<https://www.ncbi.nlm.nih.gov/pubmed/16254181>
149. Tomlins, S.A., *et al.* Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. *Eur Urol*, 2016. 70: 45.
<https://www.ncbi.nlm.nih.gov/pubmed/25985884>
150. Donovan, M.J., *et al.* A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. *Prostate Cancer Prostatic Dis*, 2015. 18: 370.
<https://www.ncbi.nlm.nih.gov/pubmed/26345389>
151. McKiernan, J., *et al.* A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. *JAMA Oncol*, 2016. 2: 882.
<https://www.ncbi.nlm.nih.gov/pubmed/27032035>
152. Seisen, T., *et al.* Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. *Prostate*, 2015. 75: 103.
<https://www.ncbi.nlm.nih.gov/pubmed/25327361>
153. Lamy, P.J., *et al.* Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. *Eur Urol Focus*, 2017.
<https://www.ncbi.nlm.nih.gov/pubmed/28753865>
154. Roobol, M.J., *et al.* A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. *Eur Urol*, 2010. 57: 79.
<https://www.ncbi.nlm.nih.gov/pubmed/19733959>
155. Eastham, J.A., *et al.* Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. *JAMA*, 2003. 289: 2695.
<https://www.ncbi.nlm.nih.gov/pubmed/12771116>
156. Stephan, C., *et al.* Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. *Clin Chem*, 2006. 52: 59.
<https://www.ncbi.nlm.nih.gov/pubmed/16391327>
157. Eggener, S.E., *et al.* Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. *BJU Int*, 2013. 112: 925.
<https://www.ncbi.nlm.nih.gov/pubmed/23890317>
158. Xue, J., *et al.* Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. *Oncotarget*, 2017. 8: 23322.
<https://www.ncbi.nlm.nih.gov/pubmed/28177897>
159. Roberts, M.J., *et al.* Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. *Urology*, 2017. 104: 11.
<https://www.ncbi.nlm.nih.gov/pubmed/28007492>
160. Zigeuner, R., *et al.* Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. *Urology*, 2003. 62: 883.
<https://www.ncbi.nlm.nih.gov/pubmed/14624913>
161. Smeenge, M., *et al.* Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. *BJU Int*, 2012. 110: 942.
<https://www.ncbi.nlm.nih.gov/pubmed/22462566>
162. Bratan, F., *et al.* Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. *Eur Radiol*, 2013. 23: 2019.
<https://www.ncbi.nlm.nih.gov/pubmed/23494494>
163. Le, J.D., *et al.* Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. *Eur Urol*, 2015. 67: 569.
<https://www.ncbi.nlm.nih.gov/pubmed/25257029>
164. Borofsky, S., *et al.* What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. *Radiology*, 2018. 286: 186.
<https://www.ncbi.nlm.nih.gov/pubmed/29053402>
165. van Hove, A., *et al.* Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. *World J Urol*, 2014. 32: 847.
<https://www.ncbi.nlm.nih.gov/pubmed/24919965>

166. Schoots, I.G., *et al.* Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. *Eur Urol*, 2015. 68: 438.
<https://www.ncbi.nlm.nih.gov/pubmed/25480312>
167. Kasivisvanathan, V., *et al.* MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med*, 2018. 378: 1767.
<https://www.nejm.org/doi/full/10.1056/NEJMoa1801993>
168. Rouvière O, *et al.* Added value of prostate systematic and targeted biopsy based on multiparametric MRI in biopsy-naïve patients (MRI-FIRST): a prospective multicentre paired diagnostic study. *Lancet Oncol* 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/30470502>
169. van der Leest, M., *et al.* Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. *Eur Urol*, 2018. S0302: 30880.
<https://www.ncbi.nlm.nih.gov/pubmed/30477981>
170. Weinreb, J.C., *et al.* PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *Eur Urol*, 2016. 69: 16.
<https://www.ncbi.nlm.nih.gov/pubmed/26427566>
171. Rosenkrantz, A.B., *et al.* Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. *Radiology*, 2016. 280: 793.
<https://www.ncbi.nlm.nih.gov/pubmed/27035179>
172. Muller, B.G., *et al.* Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. *Radiology*, 2015. 277: 741.
<https://www.ncbi.nlm.nih.gov/pubmed/26098458>
173. Zhao, C., *et al.* The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer. *Clin Imaging*, 2016. 40: 885.
<https://www.ncbi.nlm.nih.gov/pubmed/27179959>
174. Kasel-Seibert, M., *et al.* Assessment of PI-RADS v2 for the Detection of Prostate Cancer. *Eur J Radiol*, 2016. 85: 726.
<https://www.ncbi.nlm.nih.gov/pubmed/26971415>
175. Farrell, C., *et al.* Prostate Multiparametric Magnetic Resonance Imaging Program Implementation and Impact: Initial Clinical Experience in a Community Based Health System. *Urology Practice*, 2018. 5: 165.
[https://www.jurology.com/article/S2352-0779\(17\)30072-9/abstract](https://www.jurology.com/article/S2352-0779(17)30072-9/abstract)
176. Niaf, E., *et al.* Prostate focal peripheral zone lesions: characterization at multiparametric MR imaging--influence of a computer-aided diagnosis system. *Radiology*, 2014. 271: 761.
<https://www.ncbi.nlm.nih.gov/pubmed/24592959>
177. Litjens, G.J., *et al.* Clinical evaluation of a computer-aided diagnosis system for determining cancer aggressiveness in prostate MRI. *Eur Radiol*, 2015. 25: 3187.
<https://www.ncbi.nlm.nih.gov/pubmed/26060063>
178. Hoang Dinh, A., *et al.* Quantitative Analysis of Prostate Multiparametric MR Images for Detection of Aggressive Prostate Cancer in the Peripheral Zone: A Multiple Imager Study. *Radiology*, 2016. 280: 117.
<https://www.ncbi.nlm.nih.gov/pubmed/26859255>
179. Wegelin, O., *et al.* Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? *Eur Urol*, 2017. 71: 517.
<https://www.ncbi.nlm.nih.gov/pubmed/27568655>
180. Puech, P., *et al.* Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. *Radiology*, 2013. 268: 461.
<https://www.ncbi.nlm.nih.gov/pubmed/23579051>
181. Wysock, J.S., *et al.* A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. *Eur Urol*, 2014. 66: 343.
<https://www.ncbi.nlm.nih.gov/pubmed/24262102>

182. Arsov, C., *et al.* Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. *Eur Urol*, 2015. 68: 713.
<https://www.ncbi.nlm.nih.gov/pubmed/26116294>
183. Cornud, F., *et al.* Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. *Radiology*, 2018. 287: 534.
<https://www.ncbi.nlm.nih.gov/pubmed/29361246>
184. Moldovan, P., *et al.* Accuracy of Elastic Fusion of Prostate Magnetic Resonance and Transrectal Ultrasound Images under Routine Conditions: A Prospective Multi-Operator Study. *PLoS One*, 2016. 11: e0169120.
<https://www.ncbi.nlm.nih.gov/pubmed/28033423>
185. Bryk, D.J., *et al.* The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. *Urology*, 2017. 102: 178.
<https://www.ncbi.nlm.nih.gov/pubmed/27871829>
186. Moldovan, P.C., *et al.* What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. *Eur Urol*, 2017. 72: 250.
<https://www.ncbi.nlm.nih.gov/pubmed/28336078>
187. Hansen, N.L., *et al.* The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. *BJU Int*, 2017. 119: 724.
<https://www.ncbi.nlm.nih.gov/pubmed/27488931>
188. Distler, F.A., *et al.* The Value of PSA Density in Combination with PI-RADS for the Accuracy of Prostate Cancer Prediction. *J Urol*, 2017. 198: 575.
<https://www.ncbi.nlm.nih.gov/pubmed/28373135>
189. Panebianco, V., *et al.* Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? *Eur Urol*, 2018. 74: 48.
<https://www.ncbi.nlm.nih.gov/pubmed/29566957>
190. Wang, R.S., *et al.* Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary? *Urology*, 2017. 102: 190.
<https://www.ncbi.nlm.nih.gov/pubmed/27845218>
191. Alberts, A.R., *et al.* Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. *Eur Urol*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/30082150>
192. Lee, S.M., *et al.* Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool. *Urol Oncol*, 2017. 35: 664.e11.
<https://www.ncbi.nlm.nih.gov/pubmed/28801025>
193. Mehrlivand, S., *et al.* A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification. *JAMA Oncol*, 2018. 4: 678.
<https://www.ncbi.nlm.nih.gov/pubmed/29470570>
194. Radtke, J.P., *et al.* Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. *Eur Urol*, 2017. 72: 888.
<https://www.ncbi.nlm.nih.gov/pubmed/28400169>
195. Truong, M., *et al.* Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy. *Cancer*, 2018. 124: 278.
<https://www.ncbi.nlm.nih.gov/pubmed/28976544>
196. van Leeuwen, P.J., *et al.* A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. *BJU Int*, 2017. 120: 774.
<https://www.ncbi.nlm.nih.gov/pubmed/28207981>
197. Wang, R., *et al.* Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients. *Clin Cancer Res*, 2017. 23: 3692.
<https://www.ncbi.nlm.nih.gov/pubmed/28143868>
198. Ericson, K.J., *et al.* Prostate cancer detection following diagnosis of atypical small acinar proliferation. *Can J Urol*, 2017. 24: 8714.
<https://www.ncbi.nlm.nih.gov/pubmed/28436357>

199. Epstein, J.I., *et al.* Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. *J Urol*, 2006. 175: 820.
<https://www.ncbi.nlm.nih.gov/pubmed/16469560>
200. Merrimen, J.L., *et al.* Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. *J Urol*, 2009. 182: 485.
<https://www.ncbi.nlm.nih.gov/pubmed/19524976>
201. Kronz, J.D., *et al.* High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. *Hum Pathol*, 2001. 32: 389.
<https://www.ncbi.nlm.nih.gov/pubmed/11331955>
202. Guo, C.C., *et al.* Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. *Mod Pathol*, 2006. 19: 1528.
<https://www.ncbi.nlm.nih.gov/pubmed/16980940>
203. Partin, A.W., *et al.* Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. *J Urol*, 2014. 192: 1081.
<https://www.ncbi.nlm.nih.gov/pubmed/24747657>
204. Moore, C.K., *et al.* Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. *J Urol*, 2005. 173: 70.
<https://www.ncbi.nlm.nih.gov/pubmed/15592031>
205. Walz, J., *et al.* High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. *Eur Urol*, 2006. 50: 498.
<https://www.ncbi.nlm.nih.gov/pubmed/16631303>
206. Moran, B.J., *et al.* Re-biopsy of the prostate using a stereotactic transperineal technique. *J Urol*, 2006. 176: 1376.
<https://www.ncbi.nlm.nih.gov/pubmed/16952636>
207. Donovan, J., *et al.* Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. *Health Technol Assess*, 2003. 7: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/12709289>
208. Eichler, K., *et al.* Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. *J Urol*, 2006. 175: 1605.
<https://www.ncbi.nlm.nih.gov/pubmed/16600713>
209. Shariat, S.F., *et al.* Using biopsy to detect prostate cancer. *Rev Urol*, 2008. 10: 262.
<https://www.ncbi.nlm.nih.gov/pubmed/19145270>
210. Aron, M., *et al.* Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. *BJU Int*, 2000. 85: 682.
<https://www.ncbi.nlm.nih.gov/pubmed/10759665>
211. Cuevas, O., *et al.* Significant ecological impact on the progression of fluoroquinolone resistance in *Escherichia coli* with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid. *J Antimicrob Chemother*, 2011. 66: 664.
<https://www.ncbi.nlm.nih.gov/pubmed/21172788>
212. Loeb, S., *et al.* Complications after prostate biopsy: data from SEER-Medicare. *J Urol*, 2011. 186: 1830.
<https://www.ncbi.nlm.nih.gov/pubmed/21944136>
213. Pepe, P., *et al.* Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. *Urology*, 2013. 81: 1142.
<https://www.ncbi.nlm.nih.gov/pubmed/23726443>
214. Pepdjonovic, L., *et al.* Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. *World J Urol*, 2017. 35: 1199.
<https://www.ncbi.nlm.nih.gov/pubmed/27987032>
215. von Knobloch, R., *et al.* Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: a prospective randomised trial. *Eur Urol*, 2002. 41: 508.
<https://www.ncbi.nlm.nih.gov/pubmed/12074792>
216. Adamakis, I., *et al.* Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream. *World J Urol*, 2004. 22: 281.
<https://www.ncbi.nlm.nih.gov/pubmed/14689224>
217. Bass, E.J., *et al.* Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. *Prostate Cancer Prostatic Dis*, 2017. 20: 311.
<https://www.ncbi.nlm.nih.gov/pubmed/28485391>

218. Meyer, A.R., *et al.* Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. *Urology*, 2018. 115: 8.
<https://www.ncbi.nlm.nih.gov/pubmed/29409845>
219. Kum, F., *et al.* Initial outcomes of local anaesthetic freehand transperineal biopsies in the outpatient setting. *BJU Int*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/30431694>
220. NCCN Clinical practice Guidelines in Oncology™: Prostate Cancer Early Detection, Version 2. 2015. 2015.
https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
221. Loeb, S., *et al.* Systematic review of complications of prostate biopsy. *Eur Urol*, 2013. 64: 876.
<https://www.ncbi.nlm.nih.gov/pubmed/23787356>
222. Giannarini, G., *et al.* Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. *Urology*, 2007. 70: 501.
<https://www.ncbi.nlm.nih.gov/pubmed/17688919>
223. Garcia C, *et al.* Does transperineal prostate biopsy reduce complications compared with transrectal biopsy? a systematic review and meta-analysis of randomised controlled trials. 2016. 195:4 SUPPL. 1 p. e328.
[https://www.jurology.com/article/S0022-5347\(16\)03167-0/pdf](https://www.jurology.com/article/S0022-5347(16)03167-0/pdf)
224. Linzer, D.G., *et al.* Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. *Urology*, 1996. 48: 757.
<https://www.ncbi.nlm.nih.gov/pubmed/8911521>
225. Pelzer, A.E., *et al.* Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project. *Eur Urol*, 2005. 48: 916.
<https://www.ncbi.nlm.nih.gov/pubmed/16126324>
226. Iczkowski, K.A., *et al.* Needle core length in sextant biopsy influences prostate cancer detection rate. *Urology*, 2002. 59: 698.
<https://www.ncbi.nlm.nih.gov/pubmed/11992843>
227. Van der Kwast, T., *et al.* Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). *Virchows Arch*, 2013. 463: 367.
<https://www.ncbi.nlm.nih.gov/pubmed/23918245>
228. Rogatsch, H., *et al.* Diagnostic effect of an improved preembedding method of prostate needle biopsy specimens. *Hum Pathol*, 2000. 31: 1102.
<https://www.ncbi.nlm.nih.gov/pubmed/11014578>
229. Novis, D.A., *et al.* Diagnostic uncertainty expressed in prostate needle biopsies. A College of American Pathologists Q-probes Study of 15,753 prostate needle biopsies in 332 institutions. *Arch Pathol Lab Med*, 1999. 123: 687.
<https://www.ncbi.nlm.nih.gov/pubmed/10420224>
230. Iczkowski, K.A. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. *Arch Pathol Lab Med*, 2006. 130: 835.
<https://www.ncbi.nlm.nih.gov/pubmed/16740037>
231. Reyes, A.O., *et al.* Diagnostic effect of complete histologic sampling of prostate needle biopsy specimens. *Am J Clin Pathol*, 1998. 109: 416.
<https://www.ncbi.nlm.nih.gov/pubmed/9535395>
232. Sauter, G., *et al.* Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. *Eur Urol*, 2016. 69: 592.
<https://www.ncbi.nlm.nih.gov/pubmed/26542947>
233. Cole, A.I., *et al.* Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. *J Urol*, 2016. 196: 405.
<https://www.ncbi.nlm.nih.gov/pubmed/26920466>
234. Kweldam, C.F., *et al.* Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. *Mod Pathol*, 2016. 29: 630.
<https://www.ncbi.nlm.nih.gov/pubmed/26939875>
235. Saeter, T., *et al.* Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study. *Prostate*, 2017. 77: 859.
<https://www.ncbi.nlm.nih.gov/pubmed/28240424>

236. Sebo, T.J., *et al.* Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. *Cancer*, 2001. 91: 2196.
<https://www.ncbi.nlm.nih.gov/pubmed/11391602>
237. Grossklauss, D.J., *et al.* Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. *J Urol*, 2002. 167: 2032.
<https://www.ncbi.nlm.nih.gov/pubmed/11956432>
238. Freedland, S.J., *et al.* Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. *J Urol*, 2004. 171: 2215.
<https://www.ncbi.nlm.nih.gov/pubmed/15126788>
239. Brimo, F., *et al.* Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. *Histopathology*, 2008. 53: 177.
<https://www.ncbi.nlm.nih.gov/pubmed/18752501>
240. Bangma, C.H., *et al.* Active surveillance for low-risk prostate cancer. *Crit Rev Oncol Hematol*, 2013. 85: 295.
<https://www.ncbi.nlm.nih.gov/pubmed/22878262>
241. Shore, N., *et al.* Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. *Curr Med Res Opin*, 2014. 30: 547.
<https://www.ncbi.nlm.nih.gov/pubmed/24320750>
242. Sommariva, S., *et al.* Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*, 2016. 69: 107.
<https://www.ncbi.nlm.nih.gov/pubmed/25481455>
243. Sehdev, A.E., *et al.* Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. *Hum Pathol*, 2001. 32: 494.
<https://www.ncbi.nlm.nih.gov/pubmed/11381367>
244. Ruijter, E.T., *et al.* Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. *J Pathol*, 1997. 183: 369.
<https://www.ncbi.nlm.nih.gov/pubmed/9422995>
245. Chan, N.G., *et al.* Pathological reporting of colorectal cancer specimens: a retrospective survey in an academic Canadian pathology department. *Can J Surg*, 2008. 51: 284.
<https://www.ncbi.nlm.nih.gov/pubmed/18815652>
246. Partin, A.W., *et al.* Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. *Urology*, 2001. 58: 843.
<https://www.ncbi.nlm.nih.gov/pubmed/11744442>
247. Harnden, P., *et al.* Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. *Lancet Oncol*, 2007. 8: 411.
<https://www.ncbi.nlm.nih.gov/pubmed/17466898>
248. Magi-Galluzzi, C., *et al.* International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. *Mod Pathol*, 2011. 24: 26.
<https://www.ncbi.nlm.nih.gov/pubmed/20802467>
249. Epstein, J.I., *et al.* Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. *J Urol*, 1993. 150: 135.
<https://www.ncbi.nlm.nih.gov/pubmed/7685422>
250. Marks, R.A., *et al.* The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. *Hum Pathol*, 2007. 38: 1207.
<https://www.ncbi.nlm.nih.gov/pubmed/17490720>
251. Sung, M.T., *et al.* Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. *Am J Surg Pathol*, 2007. 31: 311.
<https://www.ncbi.nlm.nih.gov/pubmed/17255778>
252. Aydin, H., *et al.* Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. *Urology*, 2004. 64: 551.
<https://www.ncbi.nlm.nih.gov/pubmed/15351591>
253. Ploussard, G., *et al.* The prognostic significance of bladder neck invasion in prostate cancer: is microscopic involvement truly a T4 disease? *BJU Int*, 2010. 105: 776.
<https://www.ncbi.nlm.nih.gov/pubmed/19863529>

254. Hoedemaeker, R.F., *et al.* Staging prostate cancer. *Microsc Res Tech*, 2000. 51: 423.
<https://www.ncbi.nlm.nih.gov/pubmed/11074612>
255. Stamey, T.A., *et al.* Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. *J Urol*, 2000. 163: 1155.
<https://www.ncbi.nlm.nih.gov/pubmed/10737486>
256. Epstein, J.I., *et al.* Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. *Scand J Urol Nephrol Suppl*, 2005: 34.
<https://www.ncbi.nlm.nih.gov/pubmed/16019758>
257. Kikuchi, E., *et al.* Is tumor volume an independent prognostic factor in clinically localized prostate cancer? *J Urol*, 2004. 172: 508.
<https://www.ncbi.nlm.nih.gov/pubmed/15247716>
258. van Oort, I.M., *et al.* Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. *World J Urol*, 2008. 26: 237.
<https://www.ncbi.nlm.nih.gov/pubmed/18265988>
259. van der Kwast, T.H., *et al.* International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. *Mod Pathol*, 2011. 24: 16.
<https://www.ncbi.nlm.nih.gov/pubmed/20818340>
260. Evans, A.J., *et al.* Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. *Am J Surg Pathol*, 2008. 32: 1503.
<https://www.ncbi.nlm.nih.gov/pubmed/18708939>
261. Chuang, A.Y., *et al.* Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: histologic features and pitfalls. *Am J Surg Pathol*, 2008. 32: 1201.
<https://www.ncbi.nlm.nih.gov/pubmed/18580493>
262. Sammon, J.D., *et al.* Risk factors for biochemical recurrence following radical perineal prostatectomy in a large contemporary series: a detailed assessment of margin extent and location. *Urol Oncol*, 2013. 31: 1470.
<https://www.ncbi.nlm.nih.gov/pubmed/22534086>
263. Iremashvili, V., *et al.* A Comprehensive Analysis of the Association Between Gleason Score at a Positive Surgical Margin and the Risk of Biochemical Recurrence After Radical Prostatectomy. *Am J Surg Pathol*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/30557174>
264. Smith, J.A., Jr., *et al.* Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. *J Urol*, 1997. 157: 902.
<https://www.ncbi.nlm.nih.gov/pubmed/9072596>
265. Mitterberger, M., *et al.* The value of three-dimensional transrectal ultrasonography in staging prostate cancer. *BJU Int*, 2007. 100: 47.
<https://www.ncbi.nlm.nih.gov/pubmed/17433033>
266. Sauvain, J.L., *et al.* Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. *Eur Urol*, 2003. 44: 21.
<https://www.ncbi.nlm.nih.gov/pubmed/12814671>
267. de Rooij, M., *et al.* Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. *Eur Urol*, 2016. 70: 233.
<https://www.ncbi.nlm.nih.gov/pubmed/26215604>
268. Jager, G.J., *et al.* Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. *AJR Am J Roentgenol*, 1996. 166: 845.
<https://www.ncbi.nlm.nih.gov/pubmed/8610561>
269. Cornud, F., *et al.* Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. *Radiology*, 2002. 224: 203.
<https://www.ncbi.nlm.nih.gov/pubmed/12091684>
270. Heijmink, S.W., *et al.* Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. *Radiology*, 2007. 244: 184.
<https://www.ncbi.nlm.nih.gov/pubmed/17495178>
271. Futterer, J.J., *et al.* Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. *Radiology*, 2005. 237: 541.
<https://www.ncbi.nlm.nih.gov/pubmed/16244263>

272. Wang, L., *et al.* Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. *Radiology*, 2004. 232: 133.
<https://www.ncbi.nlm.nih.gov/pubmed/15166321>
273. Poulakis, V., *et al.* Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage. *J Urol*, 2004. 172: 1306.
<https://www.ncbi.nlm.nih.gov/pubmed/15371829>
274. Schieda, N., *et al.* MRI assessment of pathological stage and surgical margins in anterior prostate cancer (APC) using subjective and quantitative analysis. *J Magn Reson Imaging*, 2017. 45: 1296.
<https://www.ncbi.nlm.nih.gov/pubmed/27726247>
275. Lim, C., *et al.* Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma. *J Magn Reson Imaging*, 2016. 43: 726.
<https://www.ncbi.nlm.nih.gov/pubmed/26303719>
276. Baco, E., *et al.* Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. *J Urol*, 2015. 193: 466.
<https://www.ncbi.nlm.nih.gov/pubmed/25150643>
277. Raskolnikov, D., *et al.* The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. *J Urol*, 2015. 194: 105.
<https://www.ncbi.nlm.nih.gov/pubmed/25623751>
278. D'Amico, A.V., *et al.* Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. *J Urol*, 2000. 164: 759.
<https://www.ncbi.nlm.nih.gov/pubmed/10953141>
279. Engelbrecht, M.R., *et al.* Patient selection for magnetic resonance imaging of prostate cancer. *Eur Urol*, 2001. 40: 300.
<https://www.ncbi.nlm.nih.gov/pubmed/11684846>
280. Abuzalouf, S., *et al.* Baseline staging of newly diagnosed prostate cancer: a summary of the literature. *J Urol*, 2004. 171: 2122.
<https://www.ncbi.nlm.nih.gov/pubmed/15126770>
281. Kiss, B., *et al.* Current Status of Lymph Node Imaging in Bladder and Prostate Cancer. *Urology*, 2016. 96: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/26966038>
282. Harisinghani, M.G., *et al.* Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. *N Engl J Med*, 2003. 348: 2491.
<https://www.ncbi.nlm.nih.gov/pubmed/12815134>
283. Hovels, A.M., *et al.* The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. *Clin Radiol*, 2008. 63: 387.
<https://www.ncbi.nlm.nih.gov/pubmed/18325358>
284. Gabriele, D., *et al.* Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. *World J Urol*, 2016. 34: 517.
<https://www.ncbi.nlm.nih.gov/pubmed/26276152>
285. Flanigan, R.C., *et al.* Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. *Urology*, 1996. 48: 428.
<https://www.ncbi.nlm.nih.gov/pubmed/8804497>
286. Tiguert, R., *et al.* Lymph node size does not correlate with the presence of prostate cancer metastasis. *Urology*, 1999. 53: 367.
<https://www.ncbi.nlm.nih.gov/pubmed/9933056>
287. Spevack, L., *et al.* Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. *Int J Radiat Oncol Biol Phys*, 1996. 34: 543.
<https://www.ncbi.nlm.nih.gov/pubmed/8621276>
288. Thoeny, H.C., *et al.* Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. *Radiology*, 2014. 273: 125.
<https://www.ncbi.nlm.nih.gov/pubmed/24893049>
289. von Eyben, F.E., *et al.* Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. *Nucl Med Commun*, 2014. 35: 221.
<https://www.ncbi.nlm.nih.gov/pubmed/24240194>
290. Van den Bergh, L., *et al.* Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. *Urol Oncol*, 2015. 33: 109 e23.
<https://www.ncbi.nlm.nih.gov/pubmed/25655681>

291. Schiavina, R., *et al.* Preoperative Staging With (11)C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. *Clin Genitourin Cancer*, 2018. 16: 305.
<https://www.ncbi.nlm.nih.gov/pubmed/29859737>
292. Pinaquy, J.B., *et al.* Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. *Prostate*, 2015. 75: 323.
<https://www.ncbi.nlm.nih.gov/pubmed/25393215>
293. Heck, M.M., *et al.* Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. *Eur J Nucl Med Mol Imaging*, 2014. 41: 694.
<https://www.ncbi.nlm.nih.gov/pubmed/24297503>
294. Budiharto, T., *et al.* Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. *Eur Urol*, 2011. 60: 125.
<https://www.ncbi.nlm.nih.gov/pubmed/21292388>
295. Maurer, T., *et al.* Current use of PSMA-PET in prostate cancer management. *Nat Rev Urol*, 2016. 13: 226.
<https://www.ncbi.nlm.nih.gov/pubmed/26902337>
296. Dias, A.H., *et al.* Prostate-Specific Membrane Antigen PET/CT: Uptake in Lymph Nodes With Active Sarcoidosis. *Clin Nucl Med*, 2017. 42: e175.
<https://www.ncbi.nlm.nih.gov/pubmed/28045734>
297. Froehner, M., *et al.* PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. *Case Rep Urol*, 2017. 2017: 1654231.
<https://www.ncbi.nlm.nih.gov/pubmed/28396816>
298. Jochumsen, M.R., *et al.* Benign Traumatic Rib Fracture: A Potential Pitfall on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Prostate Cancer. *Clin Nucl Med*, 2018. 43: 38.
<https://www.ncbi.nlm.nih.gov/pubmed/29076907>
299. Perera, M., *et al.* Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*, 2016. 70: 926.
<https://www.ncbi.nlm.nih.gov/pubmed/27363387>
300. Obek, C., *et al.* The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. *Eur J Nucl Med Mol Imaging*, 2017. 44: 1806.
<https://www.ncbi.nlm.nih.gov/pubmed/28624849>
301. van Leeuwen, P.J., *et al.* Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. *BJU Int*, 2017. 119: 209.
<https://www.ncbi.nlm.nih.gov/pubmed/27207581>
302. Uprimny, C., *et al.* 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. *Eur J Nucl Med Mol Imaging*, 2017. 44: 941.
<https://www.ncbi.nlm.nih.gov/pubmed/28138747>
303. Zhang, Q., *et al.* Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperativelymph node staging in patients with intermediate to high-riskprostate cancer. *J Transl Med*, 2017. 15: 230.
<https://www.ncbi.nlm.nih.gov/pubmed/29115970>
304. Tulsyan, S., *et al.* Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. *Nucl Med Commun*, 2017. 38: 1094.
<https://www.ncbi.nlm.nih.gov/pubmed/28957842>
305. Shen, G., *et al.* Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. *Skeletal Radiol*, 2014. 43: 1503.
<https://www.ncbi.nlm.nih.gov/pubmed/24841276>
306. Briganti, A., *et al.* When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. *Eur Urol*, 2010. 57: 551.
<https://www.ncbi.nlm.nih.gov/pubmed/20034730>
307. O'Sullivan, J.M., *et al.* Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. *BJU Int*, 2003. 92: 685.
<https://www.ncbi.nlm.nih.gov/pubmed/14616446>

308. Ayyathurai, R., *et al.* A study on staging bone scans in newly diagnosed prostate cancer. *Urol Int*, 2006. 76: 209.
<https://www.ncbi.nlm.nih.gov/pubmed/16601380>
309. Tateishi, U., *et al.* A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. *Ann Nucl Med*, 2010. 24: 523.
<https://www.ncbi.nlm.nih.gov/pubmed/20559896>
310. Evangelista, L., *et al.* Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. *Eur J Nucl Med Mol Imaging*, 2016. 43: 1546.
<https://www.ncbi.nlm.nih.gov/pubmed/26956538>
311. Brogsitter, C., *et al.* 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. *Eur J Nucl Med Mol Imaging*, 2013. 40 Suppl 1: S18.
<https://www.ncbi.nlm.nih.gov/pubmed/23579863>
312. Picchio, M., *et al.* [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. *Eur J Nucl Med Mol Imaging*, 2012. 39: 13.
<https://www.ncbi.nlm.nih.gov/pubmed/21932120>
313. Gutzeit, A., *et al.* Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. *Skeletal Radiol*, 2010. 39: 333.
<https://www.ncbi.nlm.nih.gov/pubmed/20205350>
314. Lecouvet, F.E., *et al.* Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? *Eur Urol*, 2012. 62: 68.
<https://www.ncbi.nlm.nih.gov/pubmed/22366187>
315. Pasoglou, V., *et al.* One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach? *Prostate*, 2014. 74: 469.
<https://www.ncbi.nlm.nih.gov/pubmed/24375774>
316. Corfield, J., *et al.* (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. *World J Urol*, 2018. 36: 519.
<https://www.ncbi.nlm.nih.gov/pubmed/29344682>
317. Roach, P.J., *et al.* The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. *J Nucl Med*, 2017.
<https://www.ncbi.nlm.nih.gov/pubmed/28646014>
318. Eiber, M., *et al.* 68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions? *Eur Urol*, 2016. 70: 938.
<https://www.ncbi.nlm.nih.gov/pubmed/27481174>
319. Hicks, R.J., *et al.* Seduction by sensitivity; reality, illusion or delusion? The challenge of assessing outcomes following PSMA-imaging selection of patients for treatment. *J Nucl Med*, 2017.
<https://www.ncbi.nlm.nih.gov/pubmed/28935839>
320. Hofman, M.S., *et al.* A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. *BJU Int*, 2018. 122: 783.
<https://www.ncbi.nlm.nih.gov/pubmed/29726071>
321. Smith, B.D., *et al.* Future of cancer incidence in the United States: burdens upon an aging, changing nation. *J Clin Oncol*, 2009. 27: 2758.
<https://www.ncbi.nlm.nih.gov/pubmed/19403886>
322. Arnold, M., *et al.* Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. *Eur J Cancer*, 2015. 51: 1164.
<https://www.ncbi.nlm.nih.gov/pubmed/24120180>
323. Liu, D., *et al.* Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. *J Urol*, 2012. 187: 1241.
<https://www.ncbi.nlm.nih.gov/pubmed/22335873>
324. Bill-Axelsson, A., *et al.* Radical prostatectomy or watchful waiting in early prostate cancer. *N Engl J Med*, 2014. 370: 932.
<https://www.ncbi.nlm.nih.gov/pubmed/24597866>

325. Kupelian, P.A., *et al.* Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. *J Clin Oncol*, 2002. 20: 3376.
<https://www.ncbi.nlm.nih.gov/pubmed/12177097>
326. Bubolz, T., *et al.* Treatments for prostate cancer in older men: 1984-1997. *Urology*, 2001. 58: 977.
<https://www.ncbi.nlm.nih.gov/pubmed/11744472>
327. Houterman, S., *et al.* Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. *Crit Rev Oncol Hematol*, 2006. 58: 60.
<https://www.ncbi.nlm.nih.gov/pubmed/16213153>
328. Ries LAG, M.D., Krapcho M *et al.* eds. SEER cancer Statistics Review, 1975-2005. 2008.
https://seer.cancer.gov/archive/csr/1975_2005/
329. Scosyrev, E., *et al.* Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. *Cancer*, 2012. 118: 3062.
<https://www.ncbi.nlm.nih.gov/pubmed/22006014>
330. Richstone, L., *et al.* Radical prostatectomy in men aged ≥ 70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. *BJU Int*, 2008. 101: 541.
<https://www.ncbi.nlm.nih.gov/pubmed/18257855>
331. Sun, L., *et al.* Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. *J Urol*, 2009. 182: 2242.
<https://www.ncbi.nlm.nih.gov/pubmed/19758616>
332. Hamilton, A.S., *et al.* Trends in the treatment of localized prostate cancer using supplemented cancer registry data. *BJU Int*, 2011. 107: 576.
<https://www.ncbi.nlm.nih.gov/pubmed/20735387>
333. Studenski, S., *et al.* Gait speed and survival in older adults. *Jama*, 2011. 305: 50.
<https://www.ncbi.nlm.nih.gov/pubmed/21205966>
334. Droz, J.P., *et al.* Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. *Eur Urol*, 2017. 72: 521.
<https://www.ncbi.nlm.nih.gov/pubmed/28089304>
335. Bellera, C.A., *et al.* Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. *Ann Oncol*, 2012. 23: 2166.
<https://www.ncbi.nlm.nih.gov/pubmed/22250183>
336. Albertsen, P.C., *et al.* Impact of comorbidity on survival among men with localized prostate cancer. *J Clin Oncol*, 2011. 29: 1335.
<https://www.ncbi.nlm.nih.gov/pubmed/21357791>
337. Tewari, A., *et al.* Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. *J Urol*, 2004. 171: 1513.
<https://www.ncbi.nlm.nih.gov/pubmed/15017210>
338. Parmelee, P.A., *et al.* Validation of the Cumulative Illness Rating Scale in a geriatric residential population. *J Am Geriatr Soc*, 1995. 43: 130.
<https://www.ncbi.nlm.nih.gov/pubmed/7836636>
339. Groome, P.A., *et al.* Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. *Cancer*, 2011. 117: 3943.
<https://www.ncbi.nlm.nih.gov/pubmed/21858801>
340. Charlson, M.E., *et al.* A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*, 1987. 40: 373.
<https://www.ncbi.nlm.nih.gov/pubmed/3558716>
341. Blanc-Bisson, C., *et al.* Undernutrition in elderly patients with cancer: target for diagnosis and intervention. *Crit Rev Oncol Hematol*, 2008. 67: 243.
<https://www.ncbi.nlm.nih.gov/pubmed/18554922>
342. Sachs, G.A., *et al.* Cognitive impairment: an independent predictor of excess mortality: a cohort study. *Ann Intern Med*, 2011. 155: 300.
<https://www.ncbi.nlm.nih.gov/pubmed/21893623>
343. Robinson, T.N., *et al.* Preoperative cognitive dysfunction is related to adverse postoperative outcomes in the elderly. *J Am Coll Surg*, 2012. 215: 12.
<https://www.ncbi.nlm.nih.gov/pubmed/22626912>
344. Borson, S., *et al.* The Mini-Cog as a screen for dementia: validation in a population-based sample. *J Am Geriatr Soc*, 2003. 51: 1451.
<https://www.ncbi.nlm.nih.gov/pubmed/14511167>

345. Oken, M.M., *et al.* Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*, 1982. 5: 649.
<https://www.ncbi.nlm.nih.gov/pubmed/7165009>
346. Katz, S., *et al.* Studies of Illness in the Aged. The Index of ADL: A Standardized Measure of Biological and Psychosocial Function. *JAMA*, 1963. 185: 914.
<https://www.ncbi.nlm.nih.gov/pubmed/14044222>
347. Lawton, M.P., *et al.* Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist*, 1969. 9: 179.
<https://www.ncbi.nlm.nih.gov/pubmed/5349366>
348. Stineman, M.G., *et al.* All-cause 1-, 5-, and 10-year mortality in elderly people according to activities of daily living stage. *J Am Geriatr Soc*, 2012. 60: 485.
<https://www.ncbi.nlm.nih.gov/pubmed/22352414>
349. Soubeyran, P., *et al.* Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. *PLoS One*, 2014. 9: e115060.
<https://www.ncbi.nlm.nih.gov/pubmed/25503576>
350. Carter, H.B., *et al.* Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. *J Urol*, 2007. 178: 2359.
<https://www.ncbi.nlm.nih.gov/pubmed/17936806>
351. Albertsen, P.C. Observational studies and the natural history of screen-detected prostate cancer. *Curr Opin Urol*, 2015. 25: 232.
<https://www.ncbi.nlm.nih.gov/pubmed/25692723>
352. Bruinsma, S.M., *et al.* Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. *Nat Rev Urol*, 2017. 14: 312.
<https://www.ncbi.nlm.nih.gov/pubmed/28290462>
353. Hamdy, F.C., *et al.* 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *N Engl J Med*, 2016. 375: 1415.
<https://www.ncbi.nlm.nih.gov/pubmed/27626136>
354. Thomsen, F.B., *et al.* Active surveillance for clinically localized prostate cancer--a systematic review. *J Surg Oncol*, 2014. 109: 830.
<https://www.ncbi.nlm.nih.gov/pubmed/24610744>
355. Tosoian, J.J., *et al.* Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. *J Clin Oncol*, 2015. 33: 3379.
<https://www.ncbi.nlm.nih.gov/pubmed/26324359>
356. van As, N.J., *et al.* Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. *Eur Urol*, 2008. 54: 1297.
<https://www.ncbi.nlm.nih.gov/pubmed/18342430>
357. Adamy, A., *et al.* Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. *J Urol*, 2011. 185: 477.
<https://www.ncbi.nlm.nih.gov/pubmed/21167529>
358. Soloway, M.S., *et al.* Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. *Eur Urol*, 2010. 58: 831.
<https://www.ncbi.nlm.nih.gov/pubmed/20800964>
359. Roemeling, S., *et al.* Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. *Eur Urol*, 2007. 51: 1244.
<https://www.ncbi.nlm.nih.gov/pubmed/17161520>
360. Khatami, A., *et al.* PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. *Int J Cancer*, 2007. 120: 170.
<https://www.ncbi.nlm.nih.gov/pubmed/17013897>
361. Klotz, L., *et al.* Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. *J Clin Oncol*, 2015. 33: 272.
<https://www.ncbi.nlm.nih.gov/pubmed/25512465>
362. Chodak, G.W., *et al.* Results of conservative management of clinically localized prostate cancer. *N Engl J Med*, 1994. 330: 242.
<https://www.ncbi.nlm.nih.gov/pubmed/8272085>
363. Sandblom, G., *et al.* Long-term survival in a Swedish population-based cohort of men with prostate cancer. *Urology*, 2000. 56: 442.
<https://www.ncbi.nlm.nih.gov/pubmed/10962312>

364. Johansson, J.E., *et al.* Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. *Lancet*, 1989. 1: 799.
<https://www.ncbi.nlm.nih.gov/pubmed/2564901>
365. Bill-Axelson, A., *et al.* Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med*, 2005. 352: 1977.
<https://www.ncbi.nlm.nih.gov/pubmed/15888698>
366. Adolfsson, J., *et al.* The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. *Eur Urol*, 2007. 52: 1028.
<https://www.ncbi.nlm.nih.gov/pubmed/17467883>
367. Jonsson, E., *et al.* Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. *Scand J Urol Nephrol*, 2006. 40: 265.
<https://www.ncbi.nlm.nih.gov/pubmed/16916765>
368. Lu-Yao, G.L., *et al.* Outcomes of localized prostate cancer following conservative management. *Jama*, 2009. 302: 1202.
<https://www.ncbi.nlm.nih.gov/pubmed/19755699>
369. Hayes, J.H., *et al.* Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. *Ann Intern Med*, 2013. 158: 853.
<https://www.ncbi.nlm.nih.gov/pubmed/23778902>
370. Wilt, T.J., *et al.* Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. *N Engl J Med*, 2017. 377: 132.
<https://www.ncbi.nlm.nih.gov/pubmed/22808955>
371. Steineck, G., *et al.* Quality of life after radical prostatectomy or watchful waiting. *N Engl J Med*, 2002. 347: 790.
<https://www.ncbi.nlm.nih.gov/pubmed/12226149>
372. Adolfsson, J. Watchful waiting and active surveillance: the current position. *BJU Int*, 2008. 102: 10.
<https://www.ncbi.nlm.nih.gov/pubmed/18422774>
373. Bill-Axelson, A., *et al.* Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. *N Engl J Med*, 2018. 379: 2319.
<https://www.ncbi.nlm.nih.gov/pubmed/30575473>
374. Yaxley, J.W., *et al.* Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. *Lancet*, 2016. 388: 1057.
<https://www.ncbi.nlm.nih.gov/pubmed/27474375>
375. Coughlin, G.D., *et al.* Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. *Lancet Oncol*, 2018. 19: 1051.
<https://www.ncbi.nlm.nih.gov/pubmed/30017351>
376. Albertsen, P.C., *et al.* Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. *Jama*, 1998. 280: 975.
<https://www.ncbi.nlm.nih.gov/pubmed/9749479>
377. Albertsen, P.C., *et al.* Statistical considerations when assessing outcomes following treatment for prostate cancer. *J Urol*, 1999. 162: 439.
<https://www.ncbi.nlm.nih.gov/pubmed/10411053>
378. Iversen, P., *et al.* Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. *J Urol*, 2004. 172: 1871.
<https://www.ncbi.nlm.nih.gov/pubmed/15540741>
379. Jacobs, B.L., *et al.* Use of advanced treatment technologies among men at low risk of dying from prostate cancer. *Jama*, 2013. 309: 2587.
<https://www.ncbi.nlm.nih.gov/pubmed/23800935>
380. Ramsay, C., *et al.* Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. *Health Technol Assess*, 2012. 16: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/23127367>
381. Allan, C., *et al.* Laparoscopic versus Robotic-Assisted Radical Prostatectomy for the Treatment of Localised Prostate Cancer: A Systematic Review. *Urol Int*, 2016. 96: 373.
<https://www.ncbi.nlm.nih.gov/pubmed/26201500>

382. Ilic, D., *et al.* Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. *Cochrane Database Syst Rev*, 2017. 9: CD009625.
<https://www.ncbi.nlm.nih.gov/pubmed/28895658>
383. Fossati, N., *et al.* The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. *Eur Urol*, 2017. 72: 84.
<https://www.ncbi.nlm.nih.gov/pubmed/28126351>
384. Cimino, S., *et al.* Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis. *Scand J Urol*, 2017. 51: 345.
<https://www.ncbi.nlm.nih.gov/pubmed/28644701>
385. Briganti, A., *et al.* Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. *Eur Urol*, 2012. 61: 480.
<https://www.ncbi.nlm.nih.gov/pubmed/22078338>
386. Gandaglia, G., *et al.* Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. *Eur Urol*, 2017. 72: 632.
<https://www.ncbi.nlm.nih.gov/pubmed/28412062>
387. Roach, M., 3rd, *et al.* Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys*, 1994. 28: 33.
<https://www.ncbi.nlm.nih.gov/pubmed/7505775>
388. Abdollah, F., *et al.* Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. *Int J Radiat Oncol Biol Phys*, 2012. 83: 624.
<https://www.ncbi.nlm.nih.gov/pubmed/22099031>
389. Dell'Oglio, P., *et al.* External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. *J Endourol*, 2014. 28: 416.
<https://www.ncbi.nlm.nih.gov/pubmed/24188052>
390. Hinev, A.I., *et al.* Validation of nomograms predicting lymph node involvement in patients with prostate cancer undergoing extended pelvic lymph node dissection. *Urol Int*, 2014. 92: 300.
<https://www.ncbi.nlm.nih.gov/pubmed/24480972>
391. Mattei, A., *et al.* The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. *Eur Urol*, 2008. 53: 118.
<https://www.ncbi.nlm.nih.gov/pubmed/17709171>
392. van der Poel, H.G., *et al.* Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. *BJU Int*, 2017. 120: 204.
<https://www.ncbi.nlm.nih.gov/pubmed/28188689>
393. Wit, E.M.K., *et al.* Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy. *Eur Urol*, 2017. 71: 596.
<https://www.ncbi.nlm.nih.gov/pubmed/27639533>
394. Bader, P., *et al.* Is a limited lymph node dissection an adequate staging procedure for prostate cancer? *J Urol*, 2002. 168: 514.
<https://www.ncbi.nlm.nih.gov/pubmed/12131300>
395. Passoni, N.M., *et al.* Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. *BJU Int*, 2014. 114: 503.
<https://www.ncbi.nlm.nih.gov/pubmed/24053552>
396. Steuber, T., *et al.* Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. *J Urol*, 2006. 175: 939.
<https://www.ncbi.nlm.nih.gov/pubmed/16469587>
397. Zorn, K.C., *et al.* External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. *J Endourol*, 2007. 21: 1345.
<https://www.ncbi.nlm.nih.gov/pubmed/18042028>
398. Beyer, B., *et al.* A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomy. *Eur Urol*, 2014. 66: 138.
<https://www.ncbi.nlm.nih.gov/pubmed/24411279>
399. Rud, E., *et al.* Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial? *Eur Urol*, 2015. 68: 487.
<https://www.ncbi.nlm.nih.gov/pubmed/25813692>

400. Kumar, S., *et al.* Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. *Cochrane Database Syst Rev*, 2006: CD006019.
<https://www.ncbi.nlm.nih.gov/pubmed/17054269>
401. Engel, J., *et al.* Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. *Eur Urol*, 2010. 57: 754.
<https://www.ncbi.nlm.nih.gov/pubmed/20106588>
402. Novara, G., *et al.* Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. *Eur Urol*, 2012. 62: 382.
<https://www.ncbi.nlm.nih.gov/pubmed/22749851>
403. Novara, G., *et al.* Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. *Eur Urol*, 2012. 62: 431.
<https://www.ncbi.nlm.nih.gov/pubmed/22749853>
404. Ficarra, V., *et al.* Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. *Eur Urol*, 2012. 62: 418.
<https://www.ncbi.nlm.nih.gov/pubmed/22749850>
405. Ficarra, V., *et al.* Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. *Eur Urol*, 2012. 62: 405.
<https://www.ncbi.nlm.nih.gov/pubmed/22749852>
406. Maffezzini, M., *et al.* Evaluation of complications and results in a contemporary series of 300 consecutive radical retropubic prostatectomies with the anatomic approach at a single institution. *Urology*, 2003. 61: 982.
<https://www.ncbi.nlm.nih.gov/pubmed/12736020>
407. Haglind, E., *et al.* Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. *Eur Urol*, 2015. 68: 216.
<https://www.ncbi.nlm.nih.gov/pubmed/25770484>
408. Burkhard, F.C., *et al.* The role of lymphadenectomy in prostate cancer. *Nat Clin Pract Urol*, 2005. 2: 336.
<https://www.ncbi.nlm.nih.gov/pubmed/16474786>
409. Ploussard, G., *et al.* Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications—a systematic review of the literature. *Eur Urol*, 2014. 65: 7.
<https://www.ncbi.nlm.nih.gov/pubmed/23582879>
410. Davis, J.W., *et al.* Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. *BJU Int*, 2011. 108: 993.
<https://www.ncbi.nlm.nih.gov/pubmed/21917102>
411. Briganti, A., *et al.* Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. *Eur Urol*, 2006. 50: 1006.
<https://www.ncbi.nlm.nih.gov/pubmed/16959399>
412. Ling, C.C., *et al.* From IMRT to IGRT: frontierland or neverland? *Radiother Oncol*, 2006. 78: 119.
<https://www.ncbi.nlm.nih.gov/pubmed/16413622>
413. Michalski, J.M., *et al.* Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. *JAMA Oncol*, 2018. 4: e180039.
<https://www.ncbi.nlm.nih.gov/pubmed/29543933>
414. Kuban, D.A., *et al.* Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? *Int J Radiat Oncol Biol Phys*, 2011. 79: 1310.
<https://www.ncbi.nlm.nih.gov/pubmed/20493642>
415. Zietman, A.L., *et al.* Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. *J Clin Oncol*, 2010. 28: 1106.
<https://www.ncbi.nlm.nih.gov/pubmed/20124169>
416. Viani, G.A., *et al.* Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. *Int J Radiat Oncol Biol Phys*, 2009. 74: 1405.
<https://www.ncbi.nlm.nih.gov/pubmed/19616743>
417. Peeters, S.T., *et al.* Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. *J Clin Oncol*, 2006. 24: 1990.
<https://www.ncbi.nlm.nih.gov/pubmed/16648499>
418. Beckendorf, V., *et al.* 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. *Int J Radiat Oncol Biol Phys*, 2011. 80: 1056.
<https://www.ncbi.nlm.nih.gov/pubmed/21147514>

419. Heemsbergen, W.D., *et al.* Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. *Radiother Oncol*, 2014. 110: 104.
<https://www.ncbi.nlm.nih.gov/pubmed/24246414>
420. Kalbasi, A., *et al.* Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. *JAMA Oncol*, 2015. 1: 897.
<https://www.ncbi.nlm.nih.gov/pubmed/26181727>
421. Zietman, A.L., *et al.* Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. *JAMA*, 2005. 294: 1233.
<https://www.ncbi.nlm.nih.gov/pubmed/16160131>
422. Peeters, S.T., *et al.* Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. *Int J Radiat Oncol Biol Phys*, 2005. 61: 1019.
<https://www.ncbi.nlm.nih.gov/pubmed/15752881>
423. Dearnaley, D.P., *et al.* The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN4772397). *Radiother Oncol*, 2007. 83: 31.
<https://www.ncbi.nlm.nih.gov/pubmed/17391791>
424. Kuban, D.A., *et al.* Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys*, 2008. 70: 67.
<https://www.ncbi.nlm.nih.gov/pubmed/17765406>
425. Matzinger, O., *et al.* Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. *Eur J Cancer*, 2009. 45: 2825.
<https://www.ncbi.nlm.nih.gov/pubmed/19682889>
426. Zapatero, A., *et al.* Risk-Adapted Androgen Deprivation and Escalated Three-Dimensional Conformal Radiotherapy for Prostate Cancer: Does Radiation Dose Influence Outcome of Patients Treated With Adjuvant Androgen Deprivation? A GICOR Study. *J Clin Oncol*, 2005. 23: 6561.
<https://www.ncbi.nlm.nih.gov/pubmed/16170164>
427. Zelefsky, M.J., *et al.* Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. *J Urol*, 2006. 176: 1415.
<https://www.ncbi.nlm.nih.gov/pubmed/16952647>
428. Vora, S.A., *et al.* Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*, 2007. 68: 1053.
<https://www.ncbi.nlm.nih.gov/pubmed/17398023>
429. Kupelian, P.A., *et al.* Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. *Int J Radiat Oncol Biol Phys*, 2007. 68: 1424.
<https://www.ncbi.nlm.nih.gov/pubmed/17544601>
430. Gomez-Iturriaga Pina, A., *et al.* Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged ≤ 55 years with favorable prostate cancer. *Urology*, 2010. 75: 1412.
<https://www.ncbi.nlm.nih.gov/pubmed/20035986>
431. Ishiyama, H., *et al.* Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. *Int J Radiat Oncol Biol Phys*, 2009. 75: 23.
<https://www.ncbi.nlm.nih.gov/pubmed/19243900>
432. Gelblum, D.Y., *et al.* Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*, 2000. 48: 119.
<https://www.ncbi.nlm.nih.gov/pubmed/10924980>
433. Lee, W.R., *et al.* Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy. *Cancer*, 2007. 109: 1506.
<https://www.ncbi.nlm.nih.gov/pubmed/17340591>
434. Zelefsky, M.J., *et al.* Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. *Int J Radiat Oncol Biol Phys*, 2000. 47: 1261.
<https://www.ncbi.nlm.nih.gov/pubmed/10889379>

435. Dearnaley, D.P., *et al.* Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. *Lancet Oncol*, 2014. 15: 464.
<https://www.ncbi.nlm.nih.gov/pubmed/24581940>
436. Fowler, J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. *Acta Oncol*, 2005. 44: 265.
<https://www.ncbi.nlm.nih.gov/pubmed/16076699>
437. Dasu, A., *et al.* Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients. *Acta Oncol*, 2012. 51: 963.
<https://www.ncbi.nlm.nih.gov/pubmed/22966812>
438. Dearnaley, D., *et al.* Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. *Lancet Oncol*, 2012. 13: 43.
<https://www.ncbi.nlm.nih.gov/pubmed/22169269>
439. Kuban, D.A., *et al.* Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer using Hypofractionation. *Int J Radiat Oncol Biol Phys*, 2010. 78: S58.
[http://www.redjournal.org/article/S0360-3016\(10\)01144-2/abstract](http://www.redjournal.org/article/S0360-3016(10)01144-2/abstract)
440. Pollack, A., *et al.* Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. *J Clin Oncol*, 2013. 31: 3860.
<https://www.ncbi.nlm.nih.gov/pubmed/24101042>
441. Aluwini, S., *et al.* Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. *Lancet Oncol*, 2015. 16: 274.
<https://www.ncbi.nlm.nih.gov/pubmed/25656287>
442. Lee, W.R., *et al.* Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. *J Clin Oncol*, 2016. 34: 2325.
<https://www.ncbi.nlm.nih.gov/pubmed/27044935>
443. Dearnaley, D., *et al.* Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol*, 2016. 17: 1047.
<https://www.ncbi.nlm.nih.gov/pubmed/27339115>
444. Aluwini, S., *et al.* Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. *Lancet Oncol*, 2016. 17: 464.
<https://www.ncbi.nlm.nih.gov/pubmed/26968359>
445. Incrocci, L., *et al.* Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol*, 2016. 17: 1061.
<https://www.ncbi.nlm.nih.gov/pubmed/27339116>
446. Catton, C.N., *et al.* Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. *J Clin Oncol*, 2017. 35: 1884.
<https://www.ncbi.nlm.nih.gov/pubmed/28296582>
447. Koontz, B.F., *et al.* A systematic review of hypofractionation for primary management of prostate cancer. *Eur Urol*, 2015. 68: 683.
<https://www.ncbi.nlm.nih.gov/pubmed/25171903>
448. Hocht, S., *et al.* Hypofractionated radiotherapy for localized prostate cancer. *Strahlenther Onkol*, 2017. 193: 1.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203817/>
449. Aluwini, S., *et al.* Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. *Radiat Oncol*, 2013. 8: 84.
<https://www.ncbi.nlm.nih.gov/pubmed/23570391>
450. Katz, A., *et al.* Stereotactic Body Radiation Therapy for Low-, Intermediate-, and High-Risk Prostate Cancer: Disease Control and Quality of Life at 6 Years. *Int J Radiat Oncol Biol Phys*, 2013. 87: S24.
[http://www.redjournal.org/article/S0360-3016\(13\)00738-4/abstract](http://www.redjournal.org/article/S0360-3016(13)00738-4/abstract)
451. Freeman, D., *et al.* Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial. *Front Oncol*, 2014. 4: 369.
<https://www.ncbi.nlm.nih.gov/pubmed/25657929>
452. Katz, A.J., *et al.* Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study. *Front Oncol*, 2014. 4: 301.
<https://www.ncbi.nlm.nih.gov/pubmed/25389521>

453. Bolla, M., *et al.* External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. *Lancet Oncol*, 2010. 11: 1066.
<https://www.ncbi.nlm.nih.gov/pubmed/20933466>
454. Pilepich, M.V., *et al.* Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. *Int J Radiat Oncol Biol Phys*, 2005. 61: 1285.
<https://www.ncbi.nlm.nih.gov/pubmed/15817329>
455. Roach, M., 3rd, *et al.* Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. *J Clin Oncol*, 2008. 26: 585.
<https://www.ncbi.nlm.nih.gov/pubmed/18172188>
456. D'Amico, A.V., *et al.* Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. *JAMA*, 2008. 299: 289.
<https://www.ncbi.nlm.nih.gov/pubmed/18212313>
457. Denham, J.W., *et al.* Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. *Lancet Oncol*, 2011. 12: 451.
<https://www.ncbi.nlm.nih.gov/pubmed/21440505>
458. Lawton, C.A., *et al.* An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. *Int J Radiat Oncol Biol Phys*, 2007. 69: 646.
<https://www.ncbi.nlm.nih.gov/pubmed/17531401>
459. Horwitz, E.M., *et al.* Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. *J Clin Oncol*, 2008. 26: 2497.
<https://www.ncbi.nlm.nih.gov/pubmed/18413638>
460. Bolla, M., *et al.* Duration of androgen suppression in the treatment of prostate cancer. *N Engl J Med*, 2009. 360: 2516.
<https://www.ncbi.nlm.nih.gov/pubmed/19516032>
461. Pisansky, T.M., *et al.* Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. *J Clin Oncol*, 2015. 33: 332.
<https://www.ncbi.nlm.nih.gov/pubmed/25534388>
462. Fossa, S.D., *et al.* Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. *Eur Urol*, 2016. 70: 684.
<https://www.ncbi.nlm.nih.gov/pubmed/27025586>
463. Fossa, S.D., *et al.* Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII). *ASCO Meeting Abstracts*, 2014. 32: 4.
http://ascopubs.org/doi/abs/10.1200/jco.2014.32.4_suppl.4
464. Warde, P., *et al.* Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. *Lancet*, 2011. 378: 2104.
<https://www.ncbi.nlm.nih.gov/pubmed/22056152>
465. Mason, M.D., *et al.* Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. *J Clin Oncol*, 2015. 33: 2143.
<https://www.ncbi.nlm.nih.gov/pubmed/25691677>
466. Mottet, N., *et al.* Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. *Eur Urol*, 2012. 62: 213.
<https://www.ncbi.nlm.nih.gov/pubmed/22502942>
467. Zelefsky, M.J., *et al.* Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. *Eur Urol*, 2011. 60: 1133.
<https://www.ncbi.nlm.nih.gov/pubmed/21889832>
468. Zapatero, A., *et al.* High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. *Lancet Oncol*, 2015. 16: 320.
<https://www.ncbi.nlm.nih.gov/pubmed/25702876>

469. Bolla, M., *et al.* Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. *J Clin Oncol*, 2016. 34: 1748. <https://www.ncbi.nlm.nih.gov/pubmed/26976418>
470. Gray, P.J., *et al.* Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. *Cancer*, 2013. 119: 1729. <https://www.ncbi.nlm.nih.gov/pubmed/23436283>
471. Sheets, N.C., *et al.* Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *Jama*, 2012. 307: 1611. <https://www.ncbi.nlm.nih.gov/pubmed/22511689>
472. Ash, D., *et al.* ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. *Radiother Oncol*, 2000. 57: 315. <https://www.ncbi.nlm.nih.gov/pubmed/11104892>
473. Martens, C., *et al.* Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. *Brachytherapy*, 2006. 5: 9. <https://www.ncbi.nlm.nih.gov/pubmed/16563992>
474. Crook, J.M., *et al.* Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. *J Clin Oncol*, 2011. 29: 362. <https://www.ncbi.nlm.nih.gov/pubmed/21149658>
475. Machtens, S., *et al.* Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. *World J Urol*, 2006. 24: 289. <https://www.ncbi.nlm.nih.gov/pubmed/16645877>
476. Grimm, P., *et al.* Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. *BJU Int*, 2012. 109 Suppl 1: 22. <https://www.ncbi.nlm.nih.gov/pubmed/22239226>
477. Potters, L., *et al.* Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. *Radiother Oncol*, 2004. 71: 29. <https://www.ncbi.nlm.nih.gov/pubmed/15066293>
478. Sylvester, J.E., *et al.* Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. *Int J Radiat Oncol Biol Phys*, 2011. 81: 376. <https://www.ncbi.nlm.nih.gov/pubmed/20864269>
479. Potters, L., *et al.* 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. *J Urol*, 2005. 173: 1562. <https://www.ncbi.nlm.nih.gov/pubmed/15821486>
480. Stone, N.N., *et al.* Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. *J Urol*, 2005. 173: 803. <https://www.ncbi.nlm.nih.gov/pubmed/15711273>
481. Zelefsky, M.J., *et al.* Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. *Int J Radiat Oncol Biol Phys*, 2007. 67: 327. <https://www.ncbi.nlm.nih.gov/pubmed/17084558>
482. Lawton, C.A., *et al.* Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). *Int J Radiat Oncol Biol Phys*, 2007. 67: 39. <https://www.ncbi.nlm.nih.gov/pubmed/17084551>
483. Stock, R.G., *et al.* Importance of post-implant dosimetry in permanent prostate brachytherapy. *Eur Urol*, 2002. 41: 434. <https://www.ncbi.nlm.nih.gov/pubmed/12074816>
484. Hoskin, P.J., *et al.* GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. *Radiother Oncol*, 2013. 107: 325. <https://www.ncbi.nlm.nih.gov/pubmed/23773409>
485. Galalae, R.M., *et al.* Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. *Int J Radiat Oncol Biol Phys*, 2002. 52: 81. <https://www.ncbi.nlm.nih.gov/pubmed/11777625>
486. Hoskin, P.J., *et al.* Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. *Radiother Oncol*, 2012. 103: 217. <https://www.ncbi.nlm.nih.gov/pubmed/22341794>
487. Pieters, B.R., *et al.* Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. *Radiother Oncol*, 2009. 93: 168. <https://www.ncbi.nlm.nih.gov/pubmed/19748692>

488. Hauswald, H., *et al.* High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. *Int J Radiat Oncol Biol Phys*, 2016. 94: 667.
<https://www.ncbi.nlm.nih.gov/pubmed/26443877>
489. Zamboglou, N., *et al.* High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. *Int J Radiat Oncol Biol Phys*, 2013. 85: 672.
<https://www.ncbi.nlm.nih.gov/pubmed/22929859>
490. Hoskin, P.J., *et al.* High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. *Radiother Oncol*, 2007. 84: 114.
<https://www.ncbi.nlm.nih.gov/pubmed/17531335>
491. Hoskin, P., *et al.* High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity. *Radiother Oncol*, 2014. 110: 268.
<https://www.ncbi.nlm.nih.gov/pubmed/24231242>
492. King, C.R., *et al.* Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. *Int J Radiat Oncol Biol Phys*, 2013. 87: 939.
<https://www.ncbi.nlm.nih.gov/pubmed/24119836>
493. Pagliarulo, V., *et al.* Contemporary role of androgen deprivation therapy for prostate cancer. *Eur Urol*, 2012. 61: 11.
<https://www.ncbi.nlm.nih.gov/pubmed/21871711>
494. Oefelein, M.G., *et al.* Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. *Urology*, 2000. 56: 1021.
<https://www.ncbi.nlm.nih.gov/pubmed/11113751>
495. Morote, J., *et al.* Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. *BJU Int*, 2009. 103: 332.
<https://www.ncbi.nlm.nih.gov/pubmed/19007366>
496. Pickles, T., *et al.* Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? *BJU Int*, 2012. 110: E500.
<https://www.ncbi.nlm.nih.gov/pubmed/22564197>
497. Klotz, L., *et al.* MP74-01 Nadir testosterone on ADT predicts for time to castrate resistant progression: a secondary analysis of the PR-7 intermittent vs continuous ADT trial. *J Urol*, 2014. 191: e855.
[https://www.jurology.com/article/S0022-5347\(14\)02593-2/pdf](https://www.jurology.com/article/S0022-5347(14)02593-2/pdf)
498. Desmond, A.D., *et al.* Subcapsular orchiectomy under local anaesthesia. Technique, results and implications. *Br J Urol*, 1988. 61: 143.
<https://www.ncbi.nlm.nih.gov/pubmed/3349279>
499. Scherr, D.S., *et al.* The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. *J Urol*, 2003. 170: 1703.
<https://www.ncbi.nlm.nih.gov/pubmed/14532759>
500. Klotz, L., *et al.* A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. *J Urol*, 1999. 161: 169.
<https://www.ncbi.nlm.nih.gov/pubmed/10037391>
501. Farrugia, D., *et al.* Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. *BJU Int*, 2000. 85: 1069.
<https://www.ncbi.nlm.nih.gov/pubmed/10848697>
502. Hedlund, P.O., *et al.* Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. *Scand J Urol Nephrol*, 2008. 42: 220.
<https://www.ncbi.nlm.nih.gov/pubmed/18432528>
503. Buble, G.J. Is the flare phenomenon clinically significant? *Urology*, 2001. 58: 5.
<https://www.ncbi.nlm.nih.gov/pubmed/11502435>
504. Collette, L., *et al.* Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. *Prostate*, 2001. 48: 29.
<https://www.ncbi.nlm.nih.gov/pubmed/11391684>
505. Klotz, L., *et al.* The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int*, 2008. 102: 1531.
<https://www.ncbi.nlm.nih.gov/pubmed/19035858>

506. Seidenfeld, J., *et al.* Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. *Ann Intern Med*, 2000. 132: 566.
<https://www.ncbi.nlm.nih.gov/pubmed/10744594>
507. Ostergren, P.B., *et al.* Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. *J Urol*, 2017. 197: 1441.
<https://www.ncbi.nlm.nih.gov/pubmed/27939836>
508. Crawford, E.D., *et al.* A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. *J Urol*, 2011. 186: 889.
<https://www.ncbi.nlm.nih.gov/pubmed/21788033>
509. Shore, N.D. Experience with degarelix in the treatment of prostate cancer. *Ther Adv Urol*, 2013. 5: 11.
<https://www.ncbi.nlm.nih.gov/pubmed/23372607>
510. Sciarra, A., *et al.* A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. *Medicine (Baltimore)*, 2016. 95: e3845.
<https://www.ncbi.nlm.nih.gov/pubmed/27399062>
511. Moffat, L.E. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. *Eur Urol*, 1990. 18 Suppl 3: 26.
<https://www.ncbi.nlm.nih.gov/pubmed/2151272>
512. Schroder, F.H., *et al.* Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. *Eur Urol*, 2004. 45: 457.
<https://www.ncbi.nlm.nih.gov/pubmed/15041109>
513. Smith, M.R., *et al.* Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. *J Clin Oncol*, 2004. 22: 2546.
<https://www.ncbi.nlm.nih.gov/pubmed/15226323>
514. Iversen, P. Antiandrogen monotherapy: indications and results. *Urology*, 2002. 60: 64.
<https://www.ncbi.nlm.nih.gov/pubmed/12231053>
515. Wadhwa, V.K., *et al.* Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. *BJU Int*, 2009. 104: 800.
<https://www.ncbi.nlm.nih.gov/pubmed/19338564>
516. Montgomery, R.B., *et al.* Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res*, 2008. 68: 4447.
<https://www.ncbi.nlm.nih.gov/pubmed/18519708>
517. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) summary of positive opinion for Erleada. 2018.
<https://www.ema.europa.eu/en/medicines/human/summaries-opinion/erleada>
518. Fahmy, W.E., *et al.* Cryosurgery for prostate cancer. *Arch Androl*, 2003. 49: 397.
<https://www.ncbi.nlm.nih.gov/pubmed/12893518>
519. Rees, J., *et al.* Cryosurgery for prostate cancer. *BJU Int*, 2004. 93: 710.
<https://www.ncbi.nlm.nih.gov/pubmed/15049977>
520. Han, K.R., *et al.* Third-generation cryosurgery for primary and recurrent prostate cancer. *BJU Int*, 2004. 93: 14.
<https://www.ncbi.nlm.nih.gov/pubmed/14678360>
521. Beerlage, H.P., *et al.* Current status of minimally invasive treatment options for localized prostate carcinoma. *Eur Urol*, 2000. 37: 2.
<https://www.ncbi.nlm.nih.gov/pubmed/10671777>
522. van der Poel H.G., *et al.* Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. *Eur Urol*, 2018. 74: 84.
<https://www.ncbi.nlm.nih.gov/pubmed/29373215>
523. Valerio, M., *et al.* New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. *Eur Urol*, 2017. 71: 17.
<https://www.ncbi.nlm.nih.gov/pubmed/27595377>
524. Ramsay, C.R., *et al.* Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*, 2015. 19: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/26140518>

525. Madersbacher, S., *et al.* High-energy shockwaves and extracorporeal high-intensity focused ultrasound. *J Endourol*, 2003. 17: 667.
<https://www.ncbi.nlm.nih.gov/pubmed/14622487>
526. Mouraviev, V., *et al.* Pathologic basis of focal therapy for early-stage prostate cancer. *Nat Rev Urol*, 2009. 6: 205.
<https://www.ncbi.nlm.nih.gov/pubmed/19352395>
527. Cooperberg, M.R., *et al.* Contemporary trends in low risk prostate cancer: risk assessment and treatment. *J Urol*, 2007. 178: S14.
<https://www.ncbi.nlm.nih.gov/pubmed/17644125>
528. Polascik, T.J., *et al.* Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. *Prostate*, 2008. 68: 1380.
<https://www.ncbi.nlm.nih.gov/pubmed/18543281>
529. Ahmed, H.U., *et al.* Will focal therapy become a standard of care for men with localized prostate cancer? *Nat Clin Pract Oncol*, 2007. 4: 632.
<https://www.ncbi.nlm.nih.gov/pubmed/17965641>
530. Eggener, S.E., *et al.* Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. *J Urol*, 2007. 178: 2260.
<https://www.ncbi.nlm.nih.gov/pubmed/17936815>
531. Crawford, E.D., *et al.* Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer. *Oncology (Williston Park)*, 2007. 21: 27.
<https://www.ncbi.nlm.nih.gov/pubmed/17313155>
532. Azzouzi, A.R., *et al.* Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol*, 2016.
<https://www.ncbi.nlm.nih.gov/pubmed/28007457>
533. Guillaumier, S., *et al.* A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. *Eur Urol*, 2018. 74: 422.
<https://www.ncbi.nlm.nih.gov/pubmed/29960750>
534. MacLennan, S., *et al.* A core outcome set for localised prostate cancer effectiveness trials. *BJU Int*, 2017. 120: E64.
<https://www.ncbi.nlm.nih.gov/pubmed/28346770>
535. Loeb, S., *et al.* Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. *Eur Urol*, 2015. 67: 619.
<https://www.ncbi.nlm.nih.gov/pubmed/25457014>
536. Ha, Y.S., *et al.* Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance. *Urology*, 2014. 84: 365.
<https://www.ncbi.nlm.nih.gov/pubmed/24925834>
537. Montironi, R., *et al.* Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. *Virchows Arch*, 2014. 465: 623.
<https://www.ncbi.nlm.nih.gov/pubmed/25316188>
538. Moreira, D.M., *et al.* Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study. *J Urol*, 2015. 194: 1258.
<https://www.ncbi.nlm.nih.gov/pubmed/25988518>
539. Morash, C., *et al.* Active surveillance for the management of localized prostate cancer: Guideline recommendations. *Can Urol Assoc J*, 2015. 9: 171.
<https://www.ncbi.nlm.nih.gov/pubmed/26225165>
540. Chen, R.C., *et al.* Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. *J Clin Oncol*, 2016. 34: 2182.
<https://www.ncbi.nlm.nih.gov/pubmed/29424578>
541. Satasivam, P., *et al.* Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance? *J Urol*, 2016. 195: 74.
<https://www.ncbi.nlm.nih.gov/pubmed/26192258>
542. Petrelli, F., *et al.* Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysis. *Urology*, 2016. 91: 136.
<https://www.ncbi.nlm.nih.gov/pubmed/26896733>

543. Klein, E.A., *et al.* A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *Eur Urol*, 2014. 66: 550.
<https://www.ncbi.nlm.nih.gov/pubmed/24836057>
544. Berg, K.D., *et al.* ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. *Eur Urol*, 2014. 66: 851.
<https://www.ncbi.nlm.nih.gov/pubmed/24630684>
545. Cantiello, F., *et al.* PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. *World J Urol*, 2016. 34: 485.
<https://www.ncbi.nlm.nih.gov/pubmed/26194612>
546. Schoots, I.G., *et al.* Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis. *BJU Int*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/29679430>
547. Klotz, L., *et al.* Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. *Eur Urol*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/30017404>
548. Schoots, I.G., *et al.* Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. *Eur Urol*, 2015. 67: 627.
<https://www.ncbi.nlm.nih.gov/pubmed/25511988>
549. Meng, X., *et al.* Role of prostate magnetic resonance imaging in active surveillance. *Transl Androl Urol*, 2017. 6: 444.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503957/>
550. Schoots, I.G., *et al.* Role of MRI in low-risk prostate cancer: finding the wolf in sheep's clothing or the sheep in wolf's clothing? *Curr Opin Urol*, 2017. 27: 238.
<https://www.ncbi.nlm.nih.gov/pubmed/28306604>
551. Sanguedolce, F., *et al.* Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter? *Clin Genitourin Cancer*, 2018. 16: 155.
<https://www.ncbi.nlm.nih.gov/pubmed/29198639>
552. Lai, W.S., *et al.* Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population. *Cancer*, 2017. 123: 1941.
<https://www.ncbi.nlm.nih.gov/pubmed/28140460>
553. Schoots, I.G. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? *Transl Androl Urol*, 2018. 7: 70.
<https://www.ncbi.nlm.nih.gov/pubmed/29594022>
554. Luzzago, S., *et al.* Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. *Urol Int*, 2018. 101: 56.
<https://www.ncbi.nlm.nih.gov/pubmed/29734177>
555. Thurtle, D., *et al.* Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. *BJU Int*, 2018. 122: 59.
<https://www.ncbi.nlm.nih.gov/pubmed/29438586>
556. Chang, E., *et al.* Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. *J Urol*, 2018. 199: 98.
<https://www.ncbi.nlm.nih.gov/pubmed/28728993>
557. Hamoen, E.H.J., *et al.* Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. *Eur Urol Focus*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/9331622>
558. Moore, C.M., *et al.* Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. *Eur Urol*, 2017. 71: 648.
<https://www.ncbi.nlm.nih.gov/pubmed/27349615>
559. Walton Diaz, A., *et al.* Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. *Urol Oncol*, 2015. 33: 202 e1.
<https://www.ncbi.nlm.nih.gov/pubmed/25754621>
560. Felker, E.R., *et al.* Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value. *J Urol*, 2016. 195: 1421.
<https://www.ncbi.nlm.nih.gov/pubmed/26674305>

561. Nassiri, N., *et al.* Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. *J Urol*, 2017. 197: 632.
<https://www.ncbi.nlm.nih.gov/pubmed/27639713>
562. Ross, A.E., *et al.* Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. *J Clin Oncol*, 2010. 28: 2810.
<https://www.ncbi.nlm.nih.gov/pubmed/20439642>
563. Thomsen, F.B., *et al.* Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study. *Ann Oncol*, 2016. 27: 460.
<https://www.ncbi.nlm.nih.gov/pubmed/26681677>
564. Klotz, L., *et al.* Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. *J Clin Oncol*, 2010. 28: 126.
<https://www.ncbi.nlm.nih.gov/pubmed/19917860>
565. Lam, T.B.L., *et al.* Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. *Eur Urol*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/30473433>
566. Loeb, S., *et al.* Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. *J Urol*, 2013. 190: 1742.
<https://www.ncbi.nlm.nih.gov/pubmed/23727309>
567. Studer, U.E., *et al.* Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). *Eur Urol*, 2008. 53: 941.
<https://www.ncbi.nlm.nih.gov/pubmed/18191322>
568. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. *Br J Urol*, 1997. 79: 235.
<https://www.ncbi.nlm.nih.gov/pubmed/9052476>
569. Musunuru, H.B., *et al.* Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. *J Urol*, 2016. 196: 1651.
<https://www.ncbi.nlm.nih.gov/pubmed/27569437>
570. Raldow, A.C., *et al.* Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. *JAMA Oncol*, 2015. 1: 334.
<https://www.ncbi.nlm.nih.gov/pubmed/26181182>
571. James, N.D., *et al.* Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. *Lancet*, 2016. 387: 1163.
<https://www.ncbi.nlm.nih.gov/pubmed/26719232>
572. Krauss, D., *et al.* Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. *Int J Radiat Oncol Biol Phys*, 2011. 80: 1064.
<https://www.ncbi.nlm.nih.gov/pubmed/20584576>
573. Kupelian, P.A., *et al.* Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. *Int J Radiat Oncol Biol Phys*, 2008. 71: 16.
<https://www.ncbi.nlm.nih.gov/pubmed/17996382>
574. Chang, K., *et al.* Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005. *Asian J Androl*, 2016. 18: 452.
<https://www.ncbi.nlm.nih.gov/pubmed/26323560>
575. van der Poel, H.G., *et al.* Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. *Eur Urol*, 2018. 74: 84.
<https://www.ncbi.nlm.nih.gov/pubmed/29373215>
576. Walsh, P.C. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. *J Urol*, 1997. 158: 1623.
<https://www.ncbi.nlm.nih.gov/pubmed/9302187>
577. Donohue, J.F., *et al.* Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. *J Urol*, 2006. 176: 991.
<https://www.ncbi.nlm.nih.gov/pubmed/16890678>
578. Bianco, F.J., Jr., *et al.* Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). *Urology*, 2005. 66: 83.
<https://www.ncbi.nlm.nih.gov/pubmed/16194712>

579. Walz, J., *et al.* A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *J Clin Oncol*, 2007. 25: 3576.
<https://www.ncbi.nlm.nih.gov/pubmed/17704404>
580. Eastham, J.A., *et al.* Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. *J Urol*, 2003. 170: 2292.
<https://www.ncbi.nlm.nih.gov/pubmed/14634399>
581. Vickers, A.J., *et al.* The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. *Lancet Oncol*, 2009. 10: 475.
<https://www.ncbi.nlm.nih.gov/pubmed/19342300>
582. Trinh, Q.D., *et al.* A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol*, 2013. 64: 786.
<https://www.ncbi.nlm.nih.gov/pubmed/23664423>
583. Pisansky, T.M., *et al.* Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. *Int J Radiat Oncol Biol Phys*, 1996. 34: 33.
<https://www.ncbi.nlm.nih.gov/pubmed/12118563>
584. Joniau, S., *et al.* Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. *Eur Urol*, 2015. 67: 319.
<https://www.ncbi.nlm.nih.gov/pubmed/24684960>
585. Loeb, S., *et al.* Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. *Urology*, 2007. 69: 1170.
<https://www.ncbi.nlm.nih.gov/pubmed/17572209>
586. Carver, B.S., *et al.* Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. *J Urol*, 2006. 176: 564.
<https://www.ncbi.nlm.nih.gov/pubmed/16813890>
587. Freedland, S.J., *et al.* Radical prostatectomy for clinical stage T3a disease. *Cancer*, 2007. 109: 1273.
<https://www.ncbi.nlm.nih.gov/pubmed/17315165>
588. Joniau, S., *et al.* Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. *Scand J Urol Nephrol*, 2012. 46: 164.
<https://www.ncbi.nlm.nih.gov/pubmed/22364377>
589. Johnstone, P.A., *et al.* Radical prostatectomy for clinical T4 prostate cancer. *Cancer*, 2006. 106: 2603.
<https://www.ncbi.nlm.nih.gov/pubmed/16700037>
590. Leibel, S.A., *et al.* The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. *Int J Radiat Oncol Biol Phys*, 1994. 28: 7.
<https://www.ncbi.nlm.nih.gov/pubmed/8270461>
591. Asbell, S.O., *et al.* Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. *Int J Radiat Oncol Biol Phys*, 1988. 15: 1307.
<https://www.ncbi.nlm.nih.gov/pubmed/3058656>
592. Pommier, P., *et al.* Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. *J Clin Oncol*, 2007. 25: 5366.
<https://www.ncbi.nlm.nih.gov/pubmed/18048817>
593. Lee, L.N., *et al.* Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. *Int J Radiat Oncol Biol Phys*, 2002. 52: 444.
<https://www.ncbi.nlm.nih.gov/pubmed/11872291>
594. Morris, W.J., *et al.* Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. *Int J Radiat Oncol Biol Phys*, 2017. 98: 275.
<https://www.ncbi.nlm.nih.gov/pubmed/28262473>
595. Rodda, S., *et al.* ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. *Int J Radiat Oncol Biol Phys*, 2017. 98: 286.
<https://www.ncbi.nlm.nih.gov/pubmed/28433432>
596. Yossepowitch, O., *et al.* Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. *J Urol*, 2007. 178: 493.
<https://www.ncbi.nlm.nih.gov/pubmed/17561152>
597. Bastian, P.J., *et al.* Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. *Cancer*, 2006. 107: 1265.
<https://www.ncbi.nlm.nih.gov/pubmed/16900523>

598. Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer (SPCG-15). 2014, U.S. National library of Medicine: NCT02102477.
<https://clinicaltrials.gov/ct2/show/NCT02102477>
599. Walz, J., *et al.* Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. *BJU Int*, 2011. 107: 765.
<https://www.ncbi.nlm.nih.gov/pubmed/20875089>
600. D'Amico, A.V., *et al.* Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. *J Clin Oncol*, 1999. 17: 168.
<https://www.ncbi.nlm.nih.gov/pubmed/10458230>
601. Spahn, M., *et al.* Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. *Eur Urol*, 2010. 58: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/20299147>
602. Zwergel, U., *et al.* Outcome of prostate cancer patients with initial PSA > or =20 ng/ml undergoing radical prostatectomy. *Eur Urol*, 2007. 52: 1058.
<https://www.ncbi.nlm.nih.gov/pubmed/17418938>
603. Magheli, A., *et al.* Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. *J Urol*, 2007. 178: 1311.
<https://www.ncbi.nlm.nih.gov/pubmed/17698095>
604. Gerber, G.S., *et al.* Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. *Eur Urol*, 1997. 32: 385.
<https://www.ncbi.nlm.nih.gov/pubmed/9412793>
605. Ward, J.F., *et al.* Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. *BJU Int*, 2005. 95: 751.
<https://www.ncbi.nlm.nih.gov/pubmed/15794776>
606. Moschini, M., *et al.* Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. *Eur Urol*, 2016. 69: 193.
<https://www.ncbi.nlm.nih.gov/pubmed/26264160>
607. James, N.D., *et al.* Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients With Newly-Diagnosed Non-Metastatic Prostate Cancer: Data From >690 Patients in the Control Arm of the STAMPEDE Trial. *Int J Radiat Oncol Biol Phys*, 2014. 90: S13.
[http://www.redjournal.org/article/S0360-3016\(14\)00746-9/abstract](http://www.redjournal.org/article/S0360-3016(14)00746-9/abstract)
608. Studer, U.E., *et al.* Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. *J Clin Oncol*, 2006. 24: 1868.
<https://www.ncbi.nlm.nih.gov/pubmed/16622261>
609. Hanks, G.E. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. *NCI Monogr*, 1988: 75.
<https://www.ncbi.nlm.nih.gov/pubmed/3050542>
610. Briganti, A., *et al.* Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. *Eur Urol*, 2009. 55: 261.
<https://www.ncbi.nlm.nih.gov/pubmed/18838212>
611. Schumacher, M.C., *et al.* Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. *Eur Urol*, 2008. 54: 344.
<https://www.ncbi.nlm.nih.gov/pubmed/18511183>
612. Abdollah, F., *et al.* More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. *Eur Urol*, 2015. 67: 212.
<https://www.ncbi.nlm.nih.gov/pubmed/24882672>
613. Pound, C.R., *et al.* Natural history of progression after PSA elevation following radical prostatectomy. *JAMA*, 1999. 281: 1591.
<https://www.ncbi.nlm.nih.gov/pubmed/10235151>
614. Aus, G., *et al.* Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort. *Eur Urol*, 2003. 43: 627.
<https://www.ncbi.nlm.nih.gov/pubmed/12767363>
615. Cheng, L., *et al.* Risk of prostate carcinoma death in patients with lymph node metastasis. *Cancer*, 2001. 91: 66.
<https://www.ncbi.nlm.nih.gov/pubmed/11148561>

616. Seiler, R., *et al.* Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. *J Urol*, 2014. 191: 1280.
<https://www.ncbi.nlm.nih.gov/pubmed/24262495>
617. Daneshmand, S., *et al.* Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. *J Urol*. 172: 2252.
<https://www.ncbi.nlm.nih.gov/pubmed/15538242>
618. Touijer, K.A., *et al.* Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. *Eur Urol*, 2014. 65: 20.
<https://www.ncbi.nlm.nih.gov/pubmed/23619390>
619. Thompson, I.M., *et al.* Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol*, 2009. 181: 956.
<https://www.ncbi.nlm.nih.gov/pubmed/19167731>
620. Bolla, M., *et al.* Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). *Lancet*, 2012. 380: 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/23084481>
621. Wiegel, T., *et al.* Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96-02/AUO AP 09/95 Trial. *Eur Urol*, 2014. 66: 243.
<https://www.ncbi.nlm.nih.gov/pubmed/24680359>
622. Stephenson, A.J., *et al.* Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol*, 2007. 25: 2035.
<https://www.ncbi.nlm.nih.gov/pubmed/17513807>
623. Wiegel, T., *et al.* Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. *Int J Radiat Oncol Biol Phys*, 2009. 73: 1009.
<https://www.ncbi.nlm.nih.gov/pubmed/18963539>
624. Iversen, P., *et al.* Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. *BJU Int*, 2010. 105: 1074.
<https://www.ncbi.nlm.nih.gov/pubmed/22129214>
625. Ghavamian, R., *et al.* Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pT_xN₊ prostate cancer: a matched comparison. *J Urol*, 1999. 161: 1223.
<https://www.ncbi.nlm.nih.gov/pubmed/10081874>
626. Messing, E.M., *et al.* Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. *Lancet Oncol*, 2006. 7: 472.
<https://www.ncbi.nlm.nih.gov/pubmed/16750497>
627. Abdollah, F., *et al.* Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. *J Clin Oncol*, 2014. 32: 3939.
<https://www.ncbi.nlm.nih.gov/pubmed/25245445>
628. Jegadeesh, N., *et al.* The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. *Cancer*, 2017. 123: 512.
<https://www.ncbi.nlm.nih.gov/pubmed/27859018>
629. Rusthoven, C.G., *et al.* The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. *Int J Radiat Oncol Biol Phys*, 2014. 88: 1064.
<https://www.ncbi.nlm.nih.gov/pubmed/24661660>
630. Ahlgren, G.M., *et al.* Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. *Eur Urol*, 2018. 73: 870.
<https://www.ncbi.nlm.nih.gov/pubmed/29395502>
631. Schweizer, M.T., *et al.* Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. *Cancer*, 2013. 119: 3610.
<https://www.ncbi.nlm.nih.gov/pubmed/23943299>
632. Ploussard, G., *et al.* Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. *J Urol*, 2013. 190: 1750.
<https://www.ncbi.nlm.nih.gov/pubmed/23643600>
633. Wiegel, T., *et al.* Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. *Int J Radiat Oncol Biol Phys*, 2015. 91: 288.
<https://www.ncbi.nlm.nih.gov/pubmed/25445556>

634. Moreira, D.M., *et al.* Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. *J Urol*, 2009. 182: 2250.
<https://www.ncbi.nlm.nih.gov/pubmed/19758614>
635. Moreira, D.M., *et al.* Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. *BJU Int*, 2010. 105: 1541.
<https://www.ncbi.nlm.nih.gov/pubmed/19912191>
636. Spratt, D.E., *et al.* Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. *Eur Urol*, 2018. 74: 107.
<https://www.ncbi.nlm.nih.gov/pubmed/29233664>
637. Preisser F, *et al.* Persistent PSA after radical prostatectomy and its impact on oncologic outcomes. *Eur Urol* 2019. prior to print.
638. Xiang, C., *et al.* Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience. *Urol Int*, 2018. 101: 47.
<https://www.ncbi.nlm.nih.gov/pubmed/29627830>
639. Rogers, C.G., *et al.* Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. *Cancer*, 2004. 101: 2549.
<https://www.ncbi.nlm.nih.gov/pubmed/15470681>
640. Ceci, F., *et al.* (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? *Eur J Nucl Med Mol Imaging*, 2015. 42: 1284.
<https://www.ncbi.nlm.nih.gov/pubmed/25975367>
641. Morigi, J.J., *et al.* Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. *J Nucl Med*, 2015. 56: 1185.
<https://www.ncbi.nlm.nih.gov/pubmed/26112024>
642. van Leeuwen, P.J., *et al.* (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. *BJU Int*, 2016. 117: 732.
<https://www.ncbi.nlm.nih.gov/pubmed/26683282>
643. Sanli, Y., *et al.* Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. *Ann Nucl Med*, 2017. 31: 709.
<https://www.ncbi.nlm.nih.gov/pubmed/28900854>
644. Mena, E., *et al.* Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. *Eur J Nucl Med Mol Imaging*, 2018. 45: 4.
<https://www.ncbi.nlm.nih.gov/pubmed/28894899>
645. Habl, G., *et al.* (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. *Prostate*, 2017. 77: 920.
<https://www.ncbi.nlm.nih.gov/pubmed/28317152>
646. Schmidt-Hegemann, N.S., *et al.* Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. *Radiat Oncol*, 2018. 13: 37.
<https://www.ncbi.nlm.nih.gov/pubmed/29499730>
647. Choo, R., *et al.* Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. *Int J Radiat Oncol Biol Phys*, 2009. 75: 407.
<https://www.ncbi.nlm.nih.gov/pubmed/19211197>
648. Gandaglia, G., *et al.* Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. *Eur Urol*, 2017. 72: 910.
<https://www.ncbi.nlm.nih.gov/pubmed/28622831>
649. Garcia-Barreras, S., *et al.* Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy. *Clin Transl Oncol*, 2018. 20: 1004.
<https://www.ncbi.nlm.nih.gov/pubmed/29243074>
650. Lohm, G., *et al.* Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. *World J Urol*, 2013. 31: 423.
<https://www.ncbi.nlm.nih.gov/pubmed/22460203>

651. Ploussard, G., *et al.* Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. *World J Urol*, 2014. 32: 1331.
<https://www.ncbi.nlm.nih.gov/pubmed/24270970>
652. Fossati, N., *et al.* Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. *Eur Urol*, 2017.
<https://www.ncbi.nlm.nih.gov/pubmed/28779974>
653. Guerif, S.G., *et al.* The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy. *J Clin Oncol*, 2017. 35: 16.
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.6_suppl.16
654. Amling, C.L., *et al.* Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? *J Urol*, 2001. 165: 1146.
<https://www.ncbi.nlm.nih.gov/pubmed/11257657>
655. Toussi, A., *et al.* Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? *J Urol*, 2016. 195: 1754.
<https://www.ncbi.nlm.nih.gov/pubmed/26721226>
656. Stephenson, A.J., *et al.* Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. *J Clin Oncol*, 2006. 24: 3973.
<https://www.ncbi.nlm.nih.gov/pubmed/16921049>
657. Roach, M., 3rd, *et al.* Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys*, 2006. 65: 965.
<https://www.ncbi.nlm.nih.gov/pubmed/16798415>
658. Jackson, W.C., *et al.* Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. *Eur Urol*, 2018. 74: 413.
<https://www.ncbi.nlm.nih.gov/pubmed/29306514>
659. Choueiri, T.K., *et al.* Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. *Cancer*, 2010. 116: 1887.
<https://www.ncbi.nlm.nih.gov/pubmed/20162710>
660. Freiburger, C., *et al.* Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival. *Radiat Oncol*, 2017. 12: 98.
<https://www.ncbi.nlm.nih.gov/pubmed/28615058>
661. Royce, T.J., *et al.* Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol*, 2017. 3: 652.
<https://www.ncbi.nlm.nih.gov/pubmed/28097317>
662. Tilki, D., *et al.* External Validation of the EAU BCR risk groups to predict metastasis and mortality after Radical Prostatectomy in a European Cohort. Prior to print 2019.
663. Zagars, G.K., *et al.* Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. *Radiother Oncol*, 1997. 44: 213.
<https://www.ncbi.nlm.nih.gov/pubmed/9380819>
664. Rouviere, O., *et al.* Imaging of prostate cancer local recurrences: why and how? *Eur Radiol*, 2010. 20: 1254.
<https://www.ncbi.nlm.nih.gov/pubmed/19921202>
665. Beresford, M.J., *et al.* A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. *Clin Oncol (R Coll Radiol)*, 2010. 22: 46.
<https://www.ncbi.nlm.nih.gov/pubmed/19948393>
666. Gomez, P., *et al.* Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? *BJU Int*, 2004. 94: 299.
<https://www.ncbi.nlm.nih.gov/pubmed/15291855>
667. Kane, C.J., *et al.* Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. *Urology*, 2003. 61: 607.
<https://www.ncbi.nlm.nih.gov/pubmed/12639656>
668. Evangelista, L., *et al.* Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. *Clin Nucl Med*, 2013. 38: 305.
<https://www.ncbi.nlm.nih.gov/pubmed/23486334>

669. Fanti, S., *et al.* PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. *Eur J Nucl Med Mol Imaging*, 2016. 43: 55.
<https://www.ncbi.nlm.nih.gov/pubmed/26450693>
670. Fuccio, C., *et al.* Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. *Ann Nucl Med*, 2010. 24: 485.
<https://www.ncbi.nlm.nih.gov/pubmed/20544323>
671. Fuccio, C., *et al.* Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. *Eur J Radiol*, 2012. 81: e893.
<https://www.ncbi.nlm.nih.gov/pubmed/22621862>
672. Treglia, G., *et al.* Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. *Clin Chem Lab Med*, 2014. 52: 725.
<https://www.ncbi.nlm.nih.gov/pubmed/24310773>
673. Castellucci, P., *et al.* Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging 11C-Choline PET/CT Scan Before Salvage Radiation Therapy? *J Nucl Med*, 2014. 55: 1424.
<https://www.ncbi.nlm.nih.gov/pubmed/24935990>
674. Mitchell, C.R., *et al.* Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. *J Urol*, 2013. 189: 1308.
<https://www.ncbi.nlm.nih.gov/pubmed/23123372>
675. Soyka, J.D., *et al.* Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*, 2012. 39: 936.
<https://www.ncbi.nlm.nih.gov/pubmed/22415598>
676. Ceci, F., *et al.* Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. *Eur J Nucl Med Mol Imaging*, 2014. 41: 2222.
<https://www.ncbi.nlm.nih.gov/pubmed/25182750>
677. Beer, A.J., *et al.* Radionuclide and hybrid imaging of recurrent prostate cancer. *Lancet Oncol*, 2011. 12: 181.
<https://www.ncbi.nlm.nih.gov/pubmed/20599424>
678. Beheshti, M., *et al.* Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. *Eur J Nucl Med Mol Imaging*, 2008. 35: 1766.
<https://www.ncbi.nlm.nih.gov/pubmed/18465129>
679. Nanni, C., *et al.* (18)F-FACBC (anti-1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. *Eur J Nucl Med Mol Imaging*, 2016. 43: 1601.
<https://www.ncbi.nlm.nih.gov/pubmed/26960562>
680. Bach-Gansmo, T., *et al.* Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. *J Urol*, 2017. 197: 676.
<https://www.ncbi.nlm.nih.gov/pubmed/27746282>
681. Afshar-Oromieh, A., *et al.* Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*, 2014. 41: 11.
<https://www.ncbi.nlm.nih.gov/pubmed/24072344>
682. Caroli, P., *et al.* (68)Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. *Eur J Nucl Med Mol Imaging*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/29922948>
683. Farolfi, A., *et al.* (68)Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. *Eur J Nucl Med Mol Imaging*, 2018.
<https://www.ncbi.nlm.nih.gov/pubmed/29905907>
684. Emmett, L., *et al.* Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET. *J Nucl Med*, 2017.
<https://www.ncbi.nlm.nih.gov/pubmed/28747524>
685. Bluemel, C., *et al.* 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. *Clin Nucl Med*, 2016. 41: 515.
<https://www.ncbi.nlm.nih.gov/pubmed/29269569>

686. Verburg, F.A., *et al.* Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. *Eur J Nucl Med Mol Imaging*, 2016. 43: 397.
<https://www.ncbi.nlm.nih.gov/pubmed/26563121>
687. Giesel, F.L., *et al.* Intraindividual Comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. *J Nucl Med*, 2018. 59: 1076.
<https://www.ncbi.nlm.nih.gov/pubmed/29269569>
688. Eiber, M., *et al.* Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. *J Magn Reson Imaging*, 2011. 33: 1160.
<https://www.ncbi.nlm.nih.gov/pubmed/21509875>
689. Liauw, S.L., *et al.* Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. *Int J Radiat Oncol Biol Phys*, 2013. 85: 378.
<https://www.ncbi.nlm.nih.gov/pubmed/22717242>
690. Linder, B.J., *et al.* Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. *Can J Urol*, 2014. 21: 7283.
<https://www.ncbi.nlm.nih.gov/pubmed/24978358>
691. Kitajima, K., *et al.* Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. *J Nucl Med*, 2014. 55: 223.
<https://www.ncbi.nlm.nih.gov/pubmed/24434294>
692. Donati, O.F., *et al.* Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? *Radiology*, 2013. 268: 440.
<https://www.ncbi.nlm.nih.gov/pubmed/23481164>
693. Abd-Alazeez, M., *et al.* Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images. *Prostate Cancer Prostatic Dis*, 2015. 18: 128.
<https://www.ncbi.nlm.nih.gov/pubmed/25644248>
694. Alonzo, F., *et al.* Detection of locally radio-recurrent prostate cancer at multiparametric MRI: Can dynamic contrast-enhanced imaging be omitted? *Diagn Interv Imaging*, 2016. 97: 433.
<https://www.ncbi.nlm.nih.gov/pubmed/26928245>
695. Ceci, F., *et al.* 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. *Eur J Nucl Med Mol Imaging*, 2014. 41: 878.
<https://www.ncbi.nlm.nih.gov/pubmed/24346416>
696. De Vischere, P. The role of imaging in patients with early recurrent prostate cancer: systematic review. *Eur Urol Oncol* 2018. Article in Press.
[https://euoncology.europeanurology.com/article/S2588-9311\(18\)30170-6/fulltext](https://euoncology.europeanurology.com/article/S2588-9311(18)30170-6/fulltext)
697. Boorjian, S.A., *et al.* Radiation therapy after radical prostatectomy: impact on metastasis and survival. *J Urol*, 2009. 182: 2708.
<https://www.ncbi.nlm.nih.gov/pubmed/19836762>
698. Stish, B.J., *et al.* Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. *J Clin Oncol*, 2016. 34: 3864.
<https://www.ncbi.nlm.nih.gov/pubmed/27480153>
699. Pfister, D., *et al.* Early salvage radiotherapy following radical prostatectomy. *Eur Urol*, 2014. 65: 1034.
<https://www.ncbi.nlm.nih.gov/pubmed/23972524>
700. Siegmann, A., *et al.* Salvage radiotherapy after prostatectomy - what is the best time to treat? *Radiother Oncol*, 2012. 103: 239.
<https://www.ncbi.nlm.nih.gov/pubmed/22119375>
701. Ohri, N., *et al.* Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. *Eur J Cancer*, 2012. 48: 837.
<https://www.ncbi.nlm.nih.gov/pubmed/21945099>
702. Trock, B.J., *et al.* Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. *Jama*, 2008. 299: 2760.
<https://www.ncbi.nlm.nih.gov/pubmed/18560003>

703. Boorjian, S.A., *et al.* Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. *Eur Urol*, 2011. 59: 893.
<https://www.ncbi.nlm.nih.gov/pubmed/21388736>
704. Bartkowiak, D., *et al.* Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. *Acta Oncol*, 2018: 57: 362.
<https://www.ncbi.nlm.nih.gov/pubmed/28816074>
705. Soto, D.E., *et al.* Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. *Int J Radiat Oncol Biol Phys*, 2012. 82: 1227.
<https://www.ncbi.nlm.nih.gov/pubmed/21549519>
706. Tendulkar, R.D., *et al.* Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. *J Clin Oncol*, 2016. 34: 3648.
<https://www.ncbi.nlm.nih.gov/pubmed/27528718>
707. Sweeney, C., *et al.* The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). *J Natl Cancer Inst*, 2015. 107: djv261.
<https://www.ncbi.nlm.nih.gov/pubmed/26409187>
708. Xie, W., *et al.* Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. *J Clin Oncol*, 2017. 35: 3097.
<https://www.ncbi.nlm.nih.gov/pubmed/28796587>
709. Jackson, W.C., *et al.* Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. *Pract Radiat Oncol*, 2014. 4: 99.
<https://www.ncbi.nlm.nih.gov/pubmed/24890350>
710. Shipley, W., *et al.* Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. *N Eng J Med*, 2017. 376: 417.
<https://www.nejm.org/doi/full/10.1056/NEJMoa1607529>
711. Carrie, C., *et al.* Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. *Lancet Oncol*, 2016. 17: 747.
<https://www.ncbi.nlm.nih.gov/pubmed/27160475>
712. Spratt, D.E., *et al.* A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. *Eur Urol*, 2018. 73: 156.
<https://www.ncbi.nlm.nih.gov/pubmed/28716370>
713. Gandaglia, G., *et al.* Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. *Eur Urol*, 2018. 73: 512.
<https://www.ncbi.nlm.nih.gov/pubmed/29229176>
714. Michalski, J.M., *et al.* Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*, 2010. 76: 361.
<https://www.ncbi.nlm.nih.gov/pubmed/19394158>
715. Poortmans, P., *et al.* Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. *Radiother Oncol*, 2007. 84: 121.
<https://www.ncbi.nlm.nih.gov/pubmed/17706307>
716. Wiltshire, K.L., *et al.* Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. *Int J Radiat Oncol Biol Phys*, 2007. 69: 1090.
<https://www.ncbi.nlm.nih.gov/pubmed/17967303>
717. Sassowsky, M., *et al.* Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10. *Int J Radiat Oncol Biol Phys*, 2013. 87: 534.
<https://www.ncbi.nlm.nih.gov/pubmed/23972722>
718. Gay, H.A., *et al.* Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. *Int J Radiat Oncol Biol Phys*, 2012. 83: e353.
<https://www.ncbi.nlm.nih.gov/pubmed/22483697>
719. Ramey, S.J., *et al.* Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. *Eur Urol*, 2018. 74: 99.
<https://www.ncbi.nlm.nih.gov/pubmed/29128208>

720. Pisansky, T.M., *et al.* Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. *Int J Radiat Oncol Biol Phys*, 2016. 96: 1046.
<https://www.ncbi.nlm.nih.gov/pubmed/27745980>
721. King, C.R. The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis. *Radiother Oncol*, 2016. 121: 199.
<https://www.ncbi.nlm.nih.gov/pubmed/27863963>
722. Fossati, N., *et al.* Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *Eur Urol*, 2016. 69: 728.
<https://www.ncbi.nlm.nih.gov/pubmed/26497924>
723. Fossati, N., *et al.* Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. *Eur Urol*, 2017. 71: 886.
<https://www.ncbi.nlm.nih.gov/pubmed/27484843>
724. Abugharib, A., *et al.* Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. *J Urol*, 2017. 197: 662.
<https://www.ncbi.nlm.nih.gov/pubmed/27614333>
725. Fiorino, C., *et al.* Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in \geq PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. *Int J Radiat Oncol Biol Phys*, 2016. 96: 333.
<https://www.ncbi.nlm.nih.gov/pubmed/27497691>
726. Ghadjar, P., *et al.* Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. *J Clin Oncol*, 2015. 33: 4158.
<https://www.ncbi.nlm.nih.gov/pubmed/26527774>
727. Ghadjar, P., *et al.* Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. *Radiother Oncol*, 2018. 126: 257.
<https://www.ncbi.nlm.nih.gov/pubmed/29103826>
728. Goenka, A., *et al.* Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. *Eur Urol*, 2011. 60: 1142.
<https://www.ncbi.nlm.nih.gov/pubmed/21855208>
729. Ost, P., *et al.* High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. *Eur Urol*, 2011. 60: 842.
<https://www.ncbi.nlm.nih.gov/pubmed/21514039>
730. Buscariollo, D.L., *et al.* Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. *Pract Radiat Oncol*, 2017. 7: e125.
<https://www.ncbi.nlm.nih.gov/pubmed/28274403>
731. Hwang, W.L., *et al.* Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. *JAMA Oncol*, 2018. 4: e175230.
<https://www.ncbi.nlm.nih.gov/pubmed/29372236>
732. Heidenreich, A., *et al.* [Radical salvage prostatectomy : Treatment of local recurrence of prostate cancer after radiotherapy]. *Urologe A*, 2008. 47: 1441.
<https://www.ncbi.nlm.nih.gov/pubmed/18806991>
733. Ahlering, T.E., *et al.* Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. *J Urol*, 1992. 147: 900.
<https://www.ncbi.nlm.nih.gov/pubmed/1538492>
734. Zincke, H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. *J Urol*, 1992. 147: 894.
<https://www.ncbi.nlm.nih.gov/pubmed/1538491>
735. Lerner, S.E., *et al.* Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. *J Urol*, 1995. 154: 1103.
<https://www.ncbi.nlm.nih.gov/pubmed/7543608>
736. Rogers, E., *et al.* Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. *J Urol*, 1995. 153: 104.
<https://www.ncbi.nlm.nih.gov/pubmed/7526002>
737. Garzotto, M., *et al.* Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. *J Urol*, 1998. 159: 950.
<https://www.ncbi.nlm.nih.gov/pubmed/9474190>

738. Vaidya, A., *et al.* Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. *J Urol*, 2000. 164: 1998.
<https://www.ncbi.nlm.nih.gov/pubmed/11061900>
739. Stephenson, A.J., *et al.* Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. *J Urol*, 2004. 172: 2239.
<https://www.ncbi.nlm.nih.gov/pubmed/15538239>
740. Heidenreich, A., *et al.* [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy]. *Urologe A*, 2006. 45: 474.
<https://www.ncbi.nlm.nih.gov/pubmed/16465521>
741. Heidenreich, A., *et al.* Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. *Eur Urol*, 2010. 57: 437.
<https://www.ncbi.nlm.nih.gov/pubmed/19303197>
742. Chade, D.C., *et al.* Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. *Eur Urol*, 2012. 61: 961.
<https://www.ncbi.nlm.nih.gov/pubmed/22280856>
743. Sanderson, K.M., *et al.* Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. *J Urol*, 2006. 176: 2025.
<https://www.ncbi.nlm.nih.gov/pubmed/17070244>
744. Leonardo, C., *et al.* Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. *Int J Urol*, 2009. 16: 584.
<https://www.ncbi.nlm.nih.gov/pubmed/19453762>
745. Chade, D.C., *et al.* Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *Eur Urol*, 2011. 60: 205.
<https://www.ncbi.nlm.nih.gov/pubmed/21420229>
746. Mandel, P., *et al.* Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. *BJU Int*, 2016. 117: 55.
<https://www.ncbi.nlm.nih.gov/pubmed/25711672>
747. Gotto, G.T., *et al.* Impact of prior prostate radiation on complications after radical prostatectomy. *J Urol*, 2010. 184: 136.
<https://www.ncbi.nlm.nih.gov/pubmed/20478594>
748. Ward, J.F., *et al.* Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. *J Urol*, 2005. 173: 1156.
<https://www.ncbi.nlm.nih.gov/pubmed/15758726>
749. Philippou, Y., *et al.* Comparative Oncologic and Toxicity Outcomes of Salvage Radical Prostatectomy Versus Nonsurgical Therapies for Radiorecurrent Prostate Cancer: A Meta-Regression Analysis. *Eur Urol Focus*, 2016. 2: 158.
<https://www.ncbi.nlm.nih.gov/pubmed/28723532>
750. Ismail, M., *et al.* Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. *BJU Int*, 2007. 100: 760.
<https://www.ncbi.nlm.nih.gov/pubmed/17662081>
751. Pisters, L.L., *et al.* Salvage prostate cryoablation: initial results from the cryo on-line data registry. *J Urol*, 2008. 180: 559.
<https://www.ncbi.nlm.nih.gov/pubmed/18554664>
752. Pisters, L.L., *et al.* Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. *J Urol*, 2009. 182: 517.
<https://www.ncbi.nlm.nih.gov/pubmed/19524984>
753. Bahn, D.K., *et al.* Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. *Clin Prostate Cancer*, 2003. 2: 111.
<https://www.ncbi.nlm.nih.gov/pubmed/15040872>
754. Williams, A.K., *et al.* Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. *Eur Urol*, 2011. 60: 405.
<https://www.ncbi.nlm.nih.gov/pubmed/21185115>
755. Spiess, P.E., *et al.* A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. *BJU Int*, 2010. 106: 194.
<https://www.ncbi.nlm.nih.gov/pubmed/19922545>
756. Cespedes, R.D., *et al.* Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. *J Urol*, 1997. 157: 237.
<https://www.ncbi.nlm.nih.gov/pubmed/8976261>

757. Mouraviev, V., *et al.* Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. *Eur Urol*, 2012. 61: 1204.
<https://www.ncbi.nlm.nih.gov/pubmed/22421081>
758. Pisters, L.L., *et al.* The efficacy and complications of salvage cryotherapy of the prostate. *J Urol*, 1997. 157: 921.
<https://www.ncbi.nlm.nih.gov/pubmed/9072600>
759. Ahmad, I., *et al.* Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer. *PLoS One*, 2013. 8: e69243.
<https://www.ncbi.nlm.nih.gov/pubmed/23950886>
760. Chen, C.P., *et al.* Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. *Int J Radiat Oncol Biol Phys*, 2013. 86: 324.
<https://www.ncbi.nlm.nih.gov/pubmed/23474112>
761. Burri, R.J., *et al.* Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*, 2010. 77: 1338.
<https://www.ncbi.nlm.nih.gov/pubmed/20138442>
762. Gomez-Veiga, F., *et al.* Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. *BJU Int*, 2012. 109 Suppl 1: 17.
<https://www.ncbi.nlm.nih.gov/pubmed/22239225>
763. Yamada, Y., *et al.* A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. *Brachytherapy*, 2014. 13: 111.
<https://www.ncbi.nlm.nih.gov/pubmed/24373762>
764. Lee, B., *et al.* Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. *Int J Radiat Oncol Biol Phys*, 2007. 67: 1106.
<https://www.ncbi.nlm.nih.gov/pubmed/17197119>
765. Moman, M.R., *et al.* Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. *Brachytherapy*, 2010. 9: 119.
<https://www.ncbi.nlm.nih.gov/pubmed/19850536>
766. Colombel M, *et al.* Clinical results of the prostate HIFU project. *Eur Urol Suppl*, 2006: 491.
[https://www.eusupplements.europanurology.com/article/S1569-9056\(06\)00023-6/abstract](https://www.eusupplements.europanurology.com/article/S1569-9056(06)00023-6/abstract)
767. Gelet, A., *et al.* Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. *J Endourol*, 2000. 14: 519.
<https://www.ncbi.nlm.nih.gov/pubmed/10954310>
768. Gelet, A., *et al.* Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. *Urology*, 2004. 63: 625.
<https://www.ncbi.nlm.nih.gov/pubmed/10037389>
769. Uchida, T., *et al.* High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. *BJU Int*, 2011. 107: 378.
<https://www.ncbi.nlm.nih.gov/pubmed/21265984>
770. Berge, V., *et al.* Health-related quality of life after salvage high-intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer. *Int J Urol*, 2011. 18: 646.
<https://www.ncbi.nlm.nih.gov/pubmed/21771102>
771. Crouzet, S., *et al.* Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. *BJU Int*, 2017. 119: 896.
<https://www.ncbi.nlm.nih.gov/pubmed/28063191>
772. Karnes, R.J., *et al.* Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. *J Urol*, 2015. 193: 111.
<https://www.ncbi.nlm.nih.gov/pubmed/25150640>
773. Suardi, N., *et al.* Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. *Eur Urol*, 2015. 67: 299.
<https://www.ncbi.nlm.nih.gov/pubmed/24571959>
774. Tilki, D., *et al.* Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. *J Urol*, 2015. 193: 484.
<https://www.ncbi.nlm.nih.gov/pubmed/25180792>

775. Rigatti, P., *et al.* Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. *Eur Urol*, 2011. 60: 935.
<https://www.ncbi.nlm.nih.gov/pubmed/21840116>
776. Ost, P., *et al.* Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. *Eur Urol*, 2015. 67: 852.
<https://www.ncbi.nlm.nih.gov/pubmed/25240974>
777. Rischke, H.C., *et al.* Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. *Strahlenther Onkol*, 2015. 191: 310.
<https://www.ncbi.nlm.nih.gov/pubmed/25326142>
778. Ploussard, G., *et al.* Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. *J Urol*, 2015. 194: 983.
<https://www.ncbi.nlm.nih.gov/pubmed/25963190>
779. van den Bergh, R.C., *et al.* Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. *Eur Urol*, 2016. 69: 802.
<https://www.ncbi.nlm.nih.gov/pubmed/26691493>
780. Duchesne, G.M., *et al.* Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. *Lancet Oncol*, 2016. 17: 727.
<https://www.ncbi.nlm.nih.gov/pubmed/27155740>
781. Siddiqui, S.A., *et al.* Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. *J Urol*, 2008. 179: 1830.
<https://www.ncbi.nlm.nih.gov/pubmed/18353378>
782. Crook, J.M., *et al.* Intermittent androgen suppression for rising PSA level after radiotherapy. *N Engl J Med*, 2012. 367: 895.
<https://www.ncbi.nlm.nih.gov/pubmed/22931259>
783. Levine, G.N., *et al.* Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. *Circulation*, 2010. 121: 833.
<https://www.ncbi.nlm.nih.gov/pubmed/20124128>
784. O'Farrell, S., *et al.* Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer. *J Clin Oncol*, 2015. 33: 1243.
<https://www.ncbi.nlm.nih.gov/pubmed/25732167>
785. James, N.D., *et al.* Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). *Eur Urol*, 2015. 67: 1028.
<https://www.ncbi.nlm.nih.gov/pubmed/25301760>
786. Glass, T.R., *et al.* Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. *J Urol*, 2003. 169: 164.
<https://www.ncbi.nlm.nih.gov/pubmed/12478127>
787. Gravis, G., *et al.* Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. *Eur Urol*, 2015. 68: 196.
<https://www.ncbi.nlm.nih.gov/pubmed/25277272>
788. Gravis, G., *et al.* Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. *Eur Urol*, 2016. 70: 256.
<https://www.ncbi.nlm.nih.gov/pubmed/26610858>
789. Sweeney, C.J., *et al.* Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *N Engl J Med*, 2015. 373: 737.
<https://www.ncbi.nlm.nih.gov/pubmed/26244877>
790. Kyriakopoulos, C.E., *et al.* Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHARTED Trial. *J Clin Oncol*, 2018. 36: 1080.
<https://www.ncbi.nlm.nih.gov/pubmed/29384722>

791. Gravis, G., *et al.* Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHARTED and GETUG-AFU15 Studies. *Eur Urol*, 2018. 73: 847.
<https://www.ncbi.nlm.nih.gov/pubmed/29475737>
792. Parker, C.C., *et al.* Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *Lancet*, 2018. 392: 2353.
<https://www.ncbi.nlm.nih.gov/pubmed/30355464>
793. Hussain, M., *et al.* Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). *J Clin Oncol*, 2006. 24: 3984.
<https://www.ncbi.nlm.nih.gov/pubmed/16921051>
794. Harshman, L.C., *et al.* Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. *J Clin Oncol*, 2018. 36: 376.
<https://www.ncbi.nlm.nih.gov/pubmed/29261442>
795. Fizazi, K., *et al.* Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*, 2017. 377: 352.
<https://www.ncbi.nlm.nih.gov/pubmed/28578607>
796. Kunath, F., *et al.* Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. *Cochrane Database Syst Rev*, 2014. 6: CD009266.
<https://www.ncbi.nlm.nih.gov/pubmed/24979481>
797. Niraula, S., *et al.* Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. *J Clin Oncol*, 2013. 31: 2029.
<https://www.ncbi.nlm.nih.gov/pubmed/23630216>
798. Sciarra, A., *et al.* A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy? *Eur Urol*, 2014. 65: 905.
<https://www.ncbi.nlm.nih.gov/pubmed/23838638>
799. Botrel, T.E., *et al.* Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. *BMC Urol*, 2014. 14: 9.
<https://www.ncbi.nlm.nih.gov/pubmed/24460605>
800. Brungs, D., *et al.* Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*, 2014. 17: 105.
<https://www.ncbi.nlm.nih.gov/pubmed/24686773>
801. Magnan, S., *et al.* Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol*, 2015. 1: 1261.
<https://www.ncbi.nlm.nih.gov/pubmed/26378418>
802. Hussain, M., *et al.* Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med*, 2013. 368: 1314.
<https://www.ncbi.nlm.nih.gov/pubmed/23550669>
803. Hussain, M., *et al.* Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. *J Clin Oncol*, 2016. 34: 280.
<https://www.ncbi.nlm.nih.gov/pubmed/26552421>
804. Verhagen, P.C., *et al.* Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. *World J Urol*, 2014. 32: 1287.
<https://www.ncbi.nlm.nih.gov/pubmed/24258313>
805. Calais da Silva, F., *et al.* Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Urooncological Group. *Eur Urol*, 2014. 66: 232.
<https://www.ncbi.nlm.nih.gov/pubmed/23582949>
806. Tsai, H.T., *et al.* Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. *J Urol*, 2017. 197: 1251.
<https://www.ncbi.nlm.nih.gov/pubmed/27993663>
807. Hershman, D.L., *et al.* Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. *JAMA Oncol*, 2016. 2: 453.
<https://www.ncbi.nlm.nih.gov/pubmed/26720308>

808. Abrahamsson, P.A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. *Eur Urol*, 2010. 57: 49.
<https://www.ncbi.nlm.nih.gov/pubmed/19683858>
809. Nair, B., *et al.* Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. *Cochrane Database Syst Rev*, 2002: CD003506.
<https://www.ncbi.nlm.nih.gov/pubmed/11869665>
810. Eisenberger, M.A., *et al.* Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *N Engl J Med*, 1998. 339: 1036.
<https://www.ncbi.nlm.nih.gov/pubmed/9761805>
811. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. *Lancet*, 2000. 355: 1491.
<https://www.ncbi.nlm.nih.gov/pubmed/10801170>
812. Schmitt, B., *et al.* Maximal androgen blockade for advanced prostate cancer. *Cochrane Database Syst Rev*, 2000: CD001526.
<https://www.ncbi.nlm.nih.gov/pubmed/10796804>
813. Akaza, H., *et al.* Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. *Cancer*, 2009. 115: 3437.
<https://www.ncbi.nlm.nih.gov/pubmed/19536889>
814. Vale, C.L., *et al.* Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. *Lancet Oncol*, 2016. 17: 243.
[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(15\)00489-1/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00489-1/fulltext)
815. Gravis, G., *et al.* Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2013. 14: 149.
<https://www.ncbi.nlm.nih.gov/pubmed/23306100>
816. Smith, T.J., *et al.* Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*, 2015. 33: 3199.
<https://www.ncbi.nlm.nih.gov/pubmed/26169616>
817. Sydes, M.R., *et al.* Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. *Ann Oncol*, 2018. 29: 1235.
<https://www.ncbi.nlm.nih.gov/pubmed/29529169>
818. Wallis, C.J.D., *et al.* Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. *Eur Urol*, 2018. 73: 834.
<https://www.ncbi.nlm.nih.gov/pubmed/29037513>
819. Vale, C.L., *et al.* What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. *Ann Oncol*, 2018. 29: 1249.
<https://www.ncbi.nlm.nih.gov/pubmed/29788164>
820. Boeve, L.M.S., *et al.* Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. *Eur Urol*, 2018. S0302: 30658.
<https://www.ncbi.nlm.nih.gov/pubmed/30266309>
821. Ost, P., *et al.* Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. *J Clin Oncol*, 2018. 36: 446.
<https://www.ncbi.nlm.nih.gov/pubmed/29240541>
822. Eisenhauer, E.A., *et al.* New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*, 2009. 45: 228.
<https://www.ncbi.nlm.nih.gov/pubmed/19097774>
823. Smith, M.R., *et al.* Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. *J Clin Oncol*, 2005. 23: 2918.
<https://www.ncbi.nlm.nih.gov/pubmed/15860850>
824. Smith, M.R., *et al.* Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. *Cancer*, 2011. 117: 2077.
<https://www.ncbi.nlm.nih.gov/pubmed/21523719>

825. Crawford, E.D., *et al.* Challenges and recommendations for early identification of metastatic disease in prostate cancer. *Urology*, 2014. 83: 664.
<https://www.ncbi.nlm.nih.gov/pubmed/24411213>
826. Hussain, M., *et al.* Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*, 2018. 378: 2465.
<https://www.ncbi.nlm.nih.gov/pubmed/29949494>
827. Smith, M.R., *et al.* Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med*, 2018. 378: 1408.
<https://www.ncbi.nlm.nih.gov/pubmed/29420164>
828. Hussain, M., *et al.* Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. *J Clin Oncol*, 1994. 12: 1868.
<https://www.ncbi.nlm.nih.gov/pubmed/8083710>
829. Taylor, C.D., *et al.* Importance of continued testicular suppression in hormone-refractory prostate cancer. *J Clin Oncol*, 1993. 11: 2167.
<https://www.ncbi.nlm.nih.gov/pubmed/8229130>
830. Petrylak, D.P., *et al.* Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med*, 2004. 351: 1513.
<https://www.ncbi.nlm.nih.gov/pubmed/15470214>
831. Berthold, D.R., *et al.* Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. *J Clin Oncol*, 2008. 26: 242.
<https://www.ncbi.nlm.nih.gov/pubmed/18182665>
832. Tannock, I.F., *et al.* Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*, 2004. 351: 1502.
<https://www.ncbi.nlm.nih.gov/pubmed/15470213>
833. Ryan, C.J., *et al.* Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*, 2013. 368: 138.
<https://www.ncbi.nlm.nih.gov/pubmed/23228172>
834. Rathkopf, D.E., *et al.* Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). *Eur Urol*, 2014. 66: 815.
<https://www.ncbi.nlm.nih.gov/pubmed/24647231>
835. Ryan, C.J., *et al.* Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*, 2015. 16: 152.
<https://www.ncbi.nlm.nih.gov/pubmed/25601341>
836. Beer, T.M., *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*, 2014. 371: 424.
<https://www.ncbi.nlm.nih.gov/pubmed/24881730>
837. Kantoff, P.W., *et al.* Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *J Clin Oncol*, 2010. 28: 1099.
<https://www.ncbi.nlm.nih.gov/pubmed/20100959>
838. Kantoff, P.W., *et al.* Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*, 2010. 363: 411.
<https://www.ncbi.nlm.nih.gov/pubmed/20818862>
839. Small, E.J., *et al.* Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol*, 2006. 24: 3089.
<https://www.ncbi.nlm.nih.gov/pubmed/16809734>
840. Roviello, G., *et al.* Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. *Medicine (Baltimore)*, 2016. 95: e4636.
<https://www.ncbi.nlm.nih.gov/pubmed/27787354>
841. Graff, J.N., *et al.* Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. *Ann Oncol*, 2016. 27: 286.
<https://www.ncbi.nlm.nih.gov/pubmed/26578735>

842. Evans, C.P., *et al.* The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer. *Eur Urol*, 2016. 70: 675.
<https://www.ncbi.nlm.nih.gov/pubmed/27006332>
843. Alunkal, J.J., *et al.* Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. *Clin Genitourin Cancer*, 2017. 15: 610.
<https://www.ncbi.nlm.nih.gov/pubmed/28344102>
844. Shore, N.D., *et al.* Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. *Lancet Oncol*, 2016. 17: 153.
<https://www.ncbi.nlm.nih.gov/pubmed/26774508>
845. Beer, T.M., *et al.* Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. *Eur Urol*, 2017. 71: 151.
<https://www.ncbi.nlm.nih.gov/pubmed/27477525>
846. Scher, H.I., *et al.* Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol*, 2016. 34: 1402.
<https://www.ncbi.nlm.nih.gov/pubmed/26903579>
847. Armstrong, A.J., *et al.* Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. *Clin Cancer Res*, 2010. 16: 203.
<https://www.ncbi.nlm.nih.gov/pubmed/20008841>
848. Italiano, A., *et al.* Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. *Eur Urol*, 2009. 55: 1368.
<https://www.ncbi.nlm.nih.gov/pubmed/18706755>
849. Horgan, A.M., *et al.* Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. *J Geriatr Oncol*, 2014. 5: 119.
<https://www.ncbi.nlm.nih.gov/pubmed/24495703>
850. Kellokumpu-Lehtinen, P.L., *et al.* 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. *Lancet Oncol*, 2013. 14: 117.
<https://www.ncbi.nlm.nih.gov/pubmed/23294853>
851. Fizazi, K., *et al.* Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*, 2012. 13: 983.
<https://www.ncbi.nlm.nih.gov/pubmed/22995653>
852. de Bono, J.S., *et al.* Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med*, 2011. 364: 1995.
<https://www.ncbi.nlm.nih.gov/pubmed/21612468>
853. Parker, C., *et al.* Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med*, 2013. 369: 213.
<https://www.ncbi.nlm.nih.gov/pubmed/23863050>
854. Bahl, A., *et al.* Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. *Ann Oncol*, 2013. 24: 2402.
<https://www.ncbi.nlm.nih.gov/pubmed/23723295>
855. de Bono, J.S., *et al.* Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet*, 2010. 376: 1147.
<https://www.ncbi.nlm.nih.gov/pubmed/20888992>
856. Scher, H.I., *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*, 2012. 367: 1187.
<https://www.ncbi.nlm.nih.gov/pubmed/22894553>
857. Scher, H.I., *et al.* Clinical trials in relapsed prostate cancer: defining the target. *J Natl Cancer Inst*, 1996. 88: 1623.
<https://www.ncbi.nlm.nih.gov/pubmed/8931606>
858. Sartor, A., *et al.* Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). *J Clin Oncol* 2016. 34: Abstract 5006.
http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.5006

859. Eisenberger, M., *et al.* Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. *J Clin Oncol*, 2017. 35: 3198.
<https://www.ncbi.nlm.nih.gov/pubmed/28809610>
860. Resnick, M.J., *et al.* Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. *J Clin Oncol*, 2015. 33: 1078.
<https://www.ncbi.nlm.nih.gov/pubmed/25667275>
861. Hoskin, P., *et al.* Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. *Lancet Oncol*, 2014. 15: 1397.
<https://www.ncbi.nlm.nih.gov/pubmed/25439694>
862. European Medicines Agency (EMA). EMA restricts use of prostate cancer medicine Xofigo. 2018.
<https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo>
863. Smith, M.R., *et al.* ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with mCRPC. ESMO Congress Oct 19-23, 2018, Munich, Germany, 2018.
<https://www.urotoday.com/conference-highlights/esmo-2018/esmo-2018-prostate-cancer/107706-esmo-2018-era-223-a-phase-3-trial-of-radium-223-in-combination-with-abiraterone-acetate-and-prednisone-prednisolone-for-the-treatment-of-asymptomatic-or-mildly-symptomatic-chemotherapy-naive-patients-with-bone-predominant-mcrpc.html>
864. de Bono, J.S., *et al.* Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. *Eur Urol*, 2017. 71: 656.
<https://www.ncbi.nlm.nih.gov/pubmed/27402060>
865. Badrising, S., *et al.* Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. *Cancer*, 2014. 120: 968.
<https://www.ncbi.nlm.nih.gov/pubmed/24382803>
866. Zhang, T., *et al.* Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. *Expert Opin Pharmacother*, 2015. 16: 473.
<https://www.ncbi.nlm.nih.gov/pubmed/25534660>
867. Antonarakis, E.S., *et al.* AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N Engl J Med*, 2014. 371: 1028.
<https://www.ncbi.nlm.nih.gov/pubmed/25184630>
868. Attard, G., *et al.* Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. *J Clin Oncol*, 2018. 36: 2639.
<https://www.ncbi.nlm.nih.gov/pubmed/30028657>
869. Mateo, J., *et al.* DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *N Engl J Med*, 2015. 373: 1697.
<https://www.ncbi.nlm.nih.gov/pubmed/26510020>
870. Clarke, N., *et al.* Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*, 2018. 19: 975.
<https://www.ncbi.nlm.nih.gov/pubmed/29880291>
871. Le, D.T., *et al.* PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*, 2015. 372: 2509.
<https://www.ncbi.nlm.nih.gov/pubmed/26028255>
872. Gillessen, S., *et al.* Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol*, 2015. 26: 1589.
<https://www.ncbi.nlm.nih.gov/pubmed/27141017>
873. Aggarwal, R., *et al.* Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. *Eur Urol Oncol*, 2018. 1: 78.
<https://www.sciencedirect.com/science/article/pii/S2588931118300191>
874. Payne, H., *et al.* Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. *Urol Oncol*, 2011. 29: 593.
<https://www.ncbi.nlm.nih.gov/pubmed/20060331>

875. Pezaro, C.J., *et al.* Visceral disease in castration-resistant prostate cancer. *Eur Urol*, 2014. 65: 270.
<https://www.ncbi.nlm.nih.gov/pubmed/24295792>
876. Ohlmann C, *et al.* Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy. *Eur Urol Suppl* 2006. 5: abstract #289.
http://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.4682
877. Gillessen, S., *et al.* Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol*, 2018. 73: 178.
<https://www.ncbi.nlm.nih.gov/pubmed/28655541>
878. Esper, P.S., *et al.* Supportive care in the patient with hormone refractory prostate cancer. *Semin Urol Oncol*, 1997. 15: 56.
<https://www.ncbi.nlm.nih.gov/pubmed/9050140>
879. Dy, S.M., *et al.* Evidence-based standards for cancer pain management. *J Clin Oncol*, 2008. 26: 3879.
<https://www.ncbi.nlm.nih.gov/pubmed/18688056>
880. Hartsell, W.F., *et al.* Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst*, 2005. 97: 798.
<https://www.ncbi.nlm.nih.gov/pubmed/15928300>
881. Hoskin, P., *et al.* A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. *J Natl Cancer Inst*, 2015. 107.
<https://www.ncbi.nlm.nih.gov/pubmed/26242893>
882. Frankel, B.M., *et al.* Percutaneous vertebral augmentation: an elevation in adjacent-level fracture risk in kyphoplasty as compared with vertebroplasty. *Spine J*, 2007. 7: 575.
<https://www.ncbi.nlm.nih.gov/pubmed/17905320>
883. Dutka, J., *et al.* Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases. *Ortop Traumatol Rehabil*, 2003. 5: 276.
<https://www.ncbi.nlm.nih.gov/pubmed/18034018>
884. Frankel, B.M., *et al.* Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. *Neurosurgery*, 2007. 61: 531.
<https://www.ncbi.nlm.nih.gov/pubmed/17881965>
885. Marco, R.A., *et al.* Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. *J Bone Joint Surg Am*, 2000. 82: 642.
<https://www.ncbi.nlm.nih.gov/pubmed/10819275>
886. Saad, F., *et al.* A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst*, 2002. 94: 1458.
<https://www.ncbi.nlm.nih.gov/pubmed/12359855>
887. Fizazi, K., *et al.* Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet*, 2011. 377: 813.
<https://www.ncbi.nlm.nih.gov/pubmed/21353695>
888. Smith, M.R., *et al.* Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. *Lancet*, 2012. 379: 39.
<https://www.ncbi.nlm.nih.gov/pubmed/22093187>
889. Stopeck, A.T., *et al.* Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer*, 2016. 24: 447.
<https://www.ncbi.nlm.nih.gov/pubmed/26335402>
890. Aapro, M., *et al.* Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. *Ann Oncol*, 2008. 19: 420.
<https://www.ncbi.nlm.nih.gov/pubmed/17906299>
891. Medication-Related Osteonecrosis of the Jaws, S. Otto, Editor. 2015, Springer-Verlag Berlin Heidelberg.
892. Rice, S.M., *et al.* Depression and Prostate Cancer: Examining Comorbidity and Male-Specific Symptoms. *Am J Mens Health*, 2018. 12: 1864.
<https://www.ncbi.nlm.nih.gov/pubmed/29957106>
893. van Stam, M.A., *et al.* Prevalence and correlates of mental health problems in prostate cancer survivors: A case-control study comparing survivors with general population peers. *Urol Oncol*, 2017. 35: 531.e1.
<https://www.ncbi.nlm.nih.gov/pubmed/28457651>

894. Horwitz, E.M., *et al.* Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. *J Urol*, 2005. 173: 797.
<https://www.ncbi.nlm.nih.gov/pubmed/15711272>
895. Stamey, T.A., *et al.* Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. *J Urol*, 1989. 141: 1076.
<https://www.ncbi.nlm.nih.gov/pubmed/2468795>
896. Shen, S., *et al.* Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. *J Urol*, 2005. 173: 777.
<https://www.ncbi.nlm.nih.gov/pubmed/15711268>
897. Eisenberg, M.L., *et al.* Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. *Eur Urol*, 2010. 57: 622.
<https://www.ncbi.nlm.nih.gov/pubmed/19375843>
898. Teeter, A.E., *et al.* Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. *J Urol*, 2018. 199: 713.
<https://www.ncbi.nlm.nih.gov/pubmed/28870860>
899. Grivas, N., *et al.* Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up. *J Clin Lab Anal*, 2018: e22693.
<https://www.ncbi.nlm.nih.gov/pubmed/30365194>
900. Ray, M.E., *et al.* PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. *Int J Radiat Oncol Biol Phys*, 2006. 64: 1140.
<https://www.ncbi.nlm.nih.gov/pubmed/16198506>
901. Hancock, S.L., *et al.* Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. *J Urol*, 1995. 154: 1412.
<https://www.ncbi.nlm.nih.gov/pubmed/7544843>
902. Oefelein, M.G., *et al.* The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. *J Urol*, 1995. 154: 2128.
<https://www.ncbi.nlm.nih.gov/pubmed/7500474>
903. Doneux, A., *et al.* The utility of digital rectal examination after radical radiotherapy for prostate cancer. *Clin Oncol (R Coll Radiol)*, 2005. 17: 172.
<https://www.ncbi.nlm.nih.gov/pubmed/15901001>
904. Chaplin, B.J., *et al.* Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. *Eur Urol*, 2005. 48: 906.
<https://www.ncbi.nlm.nih.gov/pubmed/16126322>
905. Warren, K.S., *et al.* Is routine digital rectal examination required for the followup of prostate cancer? *J Urol*, 2007. 178: 115.
<https://www.ncbi.nlm.nih.gov/pubmed/17499293>
906. Brockman, J.A., *et al.* Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. *Eur Urol*, 2015. 67: 1160.
<https://www.ncbi.nlm.nih.gov/pubmed/25301759>
907. Eggener, S.E., *et al.* Predicting 15-year prostate cancer specific mortality after radical prostatectomy. *J Urol*, 2011. 185: 869.
<https://www.ncbi.nlm.nih.gov/pubmed/21239008>
908. Bryce, A.H., *et al.* Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. *Prostate Cancer Prostatic Dis*, 2017. 20: 221.
<https://www.ncbi.nlm.nih.gov/pubmed/28117385>
909. Muoio, B., *et al.* The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature. *Int J Biol Markers*, 2018. 33: 10.
<https://www.ncbi.nlm.nih.gov/pubmed/28885659>
910. Hong, P., *et al.* Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis. *Asian J Androl*, 2018. 20: 561.
<https://www.ncbi.nlm.nih.gov/pubmed/30084431>
911. Giridhar, K.V., *et al.* Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis*, 2018. 21: 431.
<https://www.ncbi.nlm.nih.gov/pubmed/29858590>

912. Beer, T.M., *et al.* The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. *Cancer*, 2006. 107: 489.
<https://www.ncbi.nlm.nih.gov/pubmed/16804926>
913. Daniell, H.W. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. *Urology*, 2001. 58: 101.
<https://www.ncbi.nlm.nih.gov/pubmed/11502461>
914. Miller, P.D., *et al.* Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. *Br J Urol*, 1992. 70: 295.
<https://www.ncbi.nlm.nih.gov/pubmed/1384920>
915. Iacovelli, R., *et al.* The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. *Clin Genitourin Cancer*, 2018. 16: e645.
<https://www.ncbi.nlm.nih.gov/pubmed/29339044>
916. Conde, F.A., *et al.* Risk factors for male osteoporosis. *Urol Oncol*, 2003. 21: 380.
<https://www.ncbi.nlm.nih.gov/pubmed/14670549>
917. Hamdy, R.C., *et al.* Algorithm for the management of osteoporosis. *South Med J*, 2010. 103: 1009.
<https://www.ncbi.nlm.nih.gov/pubmed/20818296>
918. Higano, C.S. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. *Urol Oncol*, 2003. 21: 392.
<https://www.ncbi.nlm.nih.gov/pubmed/14670551>
919. Kanis, J.A., *et al.* Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. *Osteoporos Int*, 2008. 19: 1395.
<https://www.ncbi.nlm.nih.gov/pubmed/18751937>
920. Cianferotti, L., *et al.* The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. *Oncotarget*, 2017. 8: 75646.
<https://www.ncbi.nlm.nih.gov/pubmed/29088899>
921. Thomas, H.R., *et al.* Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. *Clin Genitourin Cancer*, 2018. 16: 313.
<https://www.ncbi.nlm.nih.gov/pubmed/29866496>
922. Padhani, A.R., *et al.* Rationale for Modernising Imaging in Advanced Prostate Cancer. *Eur Urol Focus*, 2017. 3: 223.
<https://www.ncbi.nlm.nih.gov/pubmed/28753774>
923. Lecouvet, F.E., *et al.* Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. *Eur J Cancer*, 2014. 50: 2519.
<https://www.ncbi.nlm.nih.gov/pubmed/25139492>
924. Ulmert, D., *et al.* A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. *Eur Urol*, 2012. 62: 78.
<https://www.ncbi.nlm.nih.gov/pubmed/22306323>
925. Padhani, A.R., *et al.* METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. *Eur Urol*, 2017. 71: 81.
<https://www.ncbi.nlm.nih.gov/pubmed/27317091>
926. Bourke, L., *et al.* Survivorship and Improving Quality of Life in Men with Prostate Cancer. *Eur Urol* 68(3):374-83., 2015.
<https://www.ncbi.nlm.nih.gov/pubmed/25941049>
927. Carlsson, S., *et al.* Surgery-related complications in 1253 robot-assisted and 485 open retropubic radical prostatectomies at the Karolinska University Hospital, Sweden. *Urology*, 2010. 75: 1092.
<https://www.ncbi.nlm.nih.gov/pubmed/20022085>
928. Ficarra, V., *et al.* Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. *Eur Urol*, 2009. 55: 1037.
<https://www.ncbi.nlm.nih.gov/pubmed/19185977>
929. Rabbani, F., *et al.* Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy. *Eur Urol*, 2010. 57: 371.
<https://www.ncbi.nlm.nih.gov/pubmed/19945779>
930. Resnick, M.J., *et al.* Long-term functional outcomes after treatment for localized prostate cancer. *N Engl J Med*, 2013. 368: 436.
<https://www.ncbi.nlm.nih.gov/pubmed/23363497>

931. Parekh, A., *et al.* Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. *Urology*, 2013. 81: 130. <https://www.ncbi.nlm.nih.gov/pubmed/23273077>
932. Msezane, L.P., *et al.* Bladder neck contracture after robot-assisted laparoscopic radical prostatectomy: evaluation of incidence and risk factors and impact on urinary function. *J Endourol*, 2008. 22: 377. <https://www.ncbi.nlm.nih.gov/pubmed/18095861>
933. Chiong, E., *et al.* Port-site hernias occurring after the use of bladeless radially expanding trocars. *Urology*, 2010. 75: 574. <https://www.ncbi.nlm.nih.gov/pubmed/19854489>
934. Haglind, E., *et al.* Corrigendum re: "Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial" [*Eur Urol* 2015;68:216-25]. *Eur Urol*, 2017. 72: e81. <https://www.ncbi.nlm.nih.gov/pubmed/28552613>
935. Park, B., *et al.* Comparison of oncological and functional outcomes of pure versus robotic-assisted laparoscopic radical prostatectomy performed by a single surgeon. *Scand J Urol*, 2013. 47: 10. <https://www.ncbi.nlm.nih.gov/pubmed/22835035>
936. Donovan, J.L., *et al.* Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. *N Engl J Med*, 2016. 375: 1425. <https://www.ncbi.nlm.nih.gov/pubmed/27626365>
937. Barocas, D.A., *et al.* Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. *JAMA*, 2017. 317: 1126. <https://www.ncbi.nlm.nih.gov/pubmed/28324093>
938. Wallis, C.J., *et al.* Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. *BMJ*, 2016. 352: i851. <https://www.ncbi.nlm.nih.gov/pubmed/26936410>
939. Budaus, L., *et al.* Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. *Eur Urol*, 2012. 61: 112. <https://www.ncbi.nlm.nih.gov/pubmed/22001105>
940. Nguyen, P.L., *et al.* Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. *Eur Urol*, 2014: 67(5):825. <https://www.ncbi.nlm.nih.gov/pubmed/25097095>
941. Donovan, K.A., *et al.* Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. *Cancer*, 2015. 121: 4286. <https://www.ncbi.nlm.nih.gov/pubmed/26372364>
942. Cherrier, M.M., *et al.* Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. *Psychooncology*, 2009. 18: 237. <https://www.ncbi.nlm.nih.gov/pubmed/18636420>
943. Alibhai, S.M., *et al.* Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. *Cancer*, 2017. 123: 237. <https://www.ncbi.nlm.nih.gov/pubmed/27583806>
944. Herr, H.W., *et al.* Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. *J Urol*, 2000. 163: 1743. <https://www.ncbi.nlm.nih.gov/pubmed/10799173>
945. Potosky, A.L., *et al.* Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. *J Clin Oncol*, 2001. 19: 3750. <https://www.ncbi.nlm.nih.gov/pubmed/11533098>
946. Iversen, P., *et al.* Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. *J Urol*, 2000. 164: 1579. <https://www.ncbi.nlm.nih.gov/pubmed/11025708>
947. Iversen, P., *et al.* Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. *BJU Int*, 2001. 87: 47. <https://www.ncbi.nlm.nih.gov/pubmed/11121992>
948. Boccardo, F., *et al.* Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. *J Clin Oncol*, 1999. 17: 2027. <https://www.ncbi.nlm.nih.gov/pubmed/10561254>
949. Walker, L.M., *et al.* Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. *Clin Genitourin Cancer*, 2013. 11: 375. <https://www.ncbi.nlm.nih.gov/pubmed/23891497>

950. Elliott, S., *et al.* Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. *J Sex Med*, 2010. 7: 2996.
<https://www.ncbi.nlm.nih.gov/pubmed/20626600>
951. de Voogt, H.J., *et al.* Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. *J Urol*, 1986. 135: 303.
<https://www.ncbi.nlm.nih.gov/pubmed/2935644>
952. Irani, J., *et al.* Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flashes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. *Lancet Oncol*, 2010. 11: 147.
<https://www.ncbi.nlm.nih.gov/pubmed/19963436>
953. Sloan, J.A., *et al.* Methodologic lessons learned from hot flash studies. *J Clin Oncol*, 2001. 19: 4280.
<https://www.ncbi.nlm.nih.gov/pubmed/11731510>
954. Moraska, A.R., *et al.* Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. *J Support Oncol*, 2010. 8: 128.
<https://www.ncbi.nlm.nih.gov/pubmed/20552926>
955. Frisk, J., *et al.* Two modes of acupuncture as a treatment for hot flashes in men with prostate cancer--a prospective multicenter study with long-term follow-up. *Eur Urol*, 2009. 55: 156.
<https://www.ncbi.nlm.nih.gov/pubmed/18294761>
956. Smith, M.R., *et al.* Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. *J Urol*, 2006. 175: 136.
<https://www.ncbi.nlm.nih.gov/pubmed/16406890>
957. Cree, M., *et al.* Mortality and institutionalization following hip fracture. *J Am Geriatr Soc*, 2000. 48: 283.
<https://www.ncbi.nlm.nih.gov/pubmed/10733054>
958. Saylor, P.J., *et al.* Metabolic complications of androgen deprivation therapy for prostate cancer. *J Urol*, 2009. 181: 1998.
<https://www.ncbi.nlm.nih.gov/pubmed/19286225>
959. Gonnelli, S., *et al.* Obesity and fracture risk. *Clin Cases Miner Bone Metab*, 2014. 11: 9.
<https://www.ncbi.nlm.nih.gov/pubmed/25002873>
960. Sieber, P.R., *et al.* Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. *J Urol*, 2004. 171: 2272.
<https://www.ncbi.nlm.nih.gov/pubmed/15126801>
961. Wadhwa, V.K., *et al.* Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. *BJU Int*, 2011. 107: 1923.
<https://www.ncbi.nlm.nih.gov/pubmed/20950306>
962. Higano, C., *et al.* Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. *Urology*, 2004. 64: 1182.
<https://www.ncbi.nlm.nih.gov/pubmed/15596194>
963. Nobes, J.P., *et al.* A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. *BJU Int*, 2012. 109: 1495.
<https://www.ncbi.nlm.nih.gov/pubmed/21933330>
964. Grundy, S.M., *et al.* Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*, 2005. 112: 2735.
<https://www.ncbi.nlm.nih.gov/pubmed/16157765>
965. Braga-Basaria, M., *et al.* Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. *J Clin Oncol*, 2006. 24: 3979.
<https://www.ncbi.nlm.nih.gov/pubmed/16921050>
966. Cheung, A.S., *et al.* Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. *Endocr Relat Cancer*, 2014. 21: R371.
<https://www.ncbi.nlm.nih.gov/pubmed/25056176>
967. Smith, M.R., *et al.* Sarcopenia during androgen-deprivation therapy for prostate cancer. *J Clin Oncol*, 2012. 30: 3271.
<https://www.ncbi.nlm.nih.gov/pubmed/22649143>
968. Saigal, C.S., *et al.* Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. *Cancer*, 2007. 110: 1493.
<https://www.ncbi.nlm.nih.gov/pubmed/17657815>

969. Lu-Yao, G., *et al.* Changing patterns in competing causes of death in men with prostate cancer: a population based study. *J Urol*, 2004. 171: 2285.
<https://www.ncbi.nlm.nih.gov/pubmed/15126804>
970. Keating, N.L., *et al.* Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. *J Natl Cancer Inst*, 2010. 102: 39.
<https://www.ncbi.nlm.nih.gov/pubmed/19996060>
971. Efsthathiou, J.A., *et al.* Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. *Eur Urol*, 2008. 54: 816.
<https://www.ncbi.nlm.nih.gov/pubmed/18243498>
972. Jones, C.U., *et al.* Radiotherapy and short-term androgen deprivation for localized prostate cancer. *N Engl J Med*, 2011. 365: 107.
<https://www.ncbi.nlm.nih.gov/pubmed/21751904>
973. Nguyen, P.L., *et al.* Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. *Jama*, 2011. 306: 2359.
<https://www.ncbi.nlm.nih.gov/pubmed/22147380>
974. Bourke, L., *et al.* Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? *Br J Cancer*, 2013. 108: 9.
<https://www.ncbi.nlm.nih.gov/pubmed/23321508>
975. Blankfield, R.P. Androgen deprivation therapy for prostate cancer and cardiovascular death. *JAMA*, 2012. 307: 1252; author reply 1252.
<https://www.ncbi.nlm.nih.gov/pubmed/22453560>
976. Bosco, C., *et al.* Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. *Eur Urol*, 2015. 68: 386.
<https://www.ncbi.nlm.nih.gov/pubmed/25484142>
977. Nguyen, P.L., *et al.* Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. *Int J Radiat Oncol Biol Phys*, 2012. 82: 1411.
<https://www.ncbi.nlm.nih.gov/pubmed/21708431>
978. Tsai, H.K., *et al.* Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. *J Natl Cancer Inst*, 2007. 99: 1516.
<https://www.ncbi.nlm.nih.gov/pubmed/17925537>
979. Albertsen, P.C., *et al.* Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. *Eur Urol*, 2014. 65: 565.
<https://www.ncbi.nlm.nih.gov/pubmed/24210090>
980. Gilbert, S.E., *et al.* Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. *Br J Cancer*, 2016. 114: 401.
<https://www.ncbi.nlm.nih.gov/pubmed/26766737>
981. Bourke, L., *et al.* Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*, 2015: 69(4):693.
<https://www.ncbi.nlm.nih.gov/pubmed/26632144>
982. Ahmadi, H., *et al.* Androgen deprivation therapy: evidence-based management of side effects. *BJU Int*, 2013. 111: 543.
<https://www.ncbi.nlm.nih.gov/pubmed/23351025>
983. Meng, F., *et al.* Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. *BMC Cancer*, 2016. 16: 180.
<https://www.ncbi.nlm.nih.gov/pubmed/26940836>
984. Nead, K.T., *et al.* Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. *J Clin Oncol*, 2016. 34: 566.
<https://www.ncbi.nlm.nih.gov/pubmed/26644522>
985. Bennett, D., *et al.* Factors influencing job loss and early retirement in working men with prostate cancer-findings from the population-based Life After Prostate Cancer Diagnosis (LAPCD) study. *J Cancer Surviv*, 2018. 12: 669.
<https://www.ncbi.nlm.nih.gov/pubmed/30058009>
986. Borji, M., *et al.* Positive Effects of Cognitive Behavioral Therapy on Depression, Anxiety and Stress of Family Caregivers of Patients with Prostate Cancer: A Randomized Clinical Trial. *Asian Pac J Cancer Prev*, 2017. 18: 3207.
<https://www.ncbi.nlm.nih.gov/pubmed/29281868>
987. Bourke, L., *et al.* A qualitative study evaluating experiences of a lifestyle intervention in men with prostate cancer undergoing androgen suppression therapy. *Trials*, 2012. 13: 208.
<https://www.ncbi.nlm.nih.gov/pubmed/23151126>

988. Berruti, A., *et al.* Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. *J Urol*, 2000. 164: 1248.
<https://www.ncbi.nlm.nih.gov/pubmed/10992374>
989. Carlin, B.I., *et al.* The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. *Cancer*, 2000. 88: 2989.
<https://www.ncbi.nlm.nih.gov/pubmed/10898342>
990. Smith, D.P., *et al.* Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. *BMJ*, 2009. 339: b4817.
<https://www.ncbi.nlm.nih.gov/pubmed/19945997>
991. Taylor, K.L., *et al.* Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. *J Clin Oncol*, 2012. 30: 2768.
<https://www.ncbi.nlm.nih.gov/pubmed/22734029>
992. Cella, D.F., *et al.* The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol*, 1993. 11: 570.
<https://www.ncbi.nlm.nih.gov/pubmed/8445433>
993. Esper, P., *et al.* Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. *Urology*, 1997. 50: 920.
<https://www.ncbi.nlm.nih.gov/pubmed/9426724>
994. Groenvold, M., *et al.* Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. *J Clin Epidemiol*, 1997. 50: 441.
<https://www.ncbi.nlm.nih.gov/pubmed/9179103>
995. van Andel, G., *et al.* An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. *Eur J Cancer*, 2008. 44: 2418.
<https://www.ncbi.nlm.nih.gov/pubmed/18774706>
996. Wei, J.T., *et al.* Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. *Urology*, 2000. 56: 899.
<https://www.ncbi.nlm.nih.gov/pubmed/11113727>
997. Szymanski, K.M., *et al.* Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. *Urology*, 2010. 76: 1245.
<https://www.ncbi.nlm.nih.gov/pubmed/20350762>
998. Litwin, M.S., *et al.* The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med Care*, 1998. 36: 1002.
<https://www.ncbi.nlm.nih.gov/pubmed/9674618>
999. Giesler, R.B., *et al.* Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. *Qual Life Res*, 2000. 9: 645.
<https://www.ncbi.nlm.nih.gov/pubmed/11236855>
1000. Potosky, A.L., *et al.* Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. *J Natl Cancer Inst*, 1999. 91: 1719.
<https://www.ncbi.nlm.nih.gov/pubmed/10528021>
1001. Giberti, C., *et al.* Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. *World J Urol*, 2009. 27: 607.
<https://www.ncbi.nlm.nih.gov/pubmed/19455340>
1002. Giberti, C., *et al.* Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer. *Can J Urol*, 2017. 24: 8728.
<https://www.ncbi.nlm.nih.gov/pubmed/28436359>
1003. Lardas, M., *et al.* Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. *Eur Urol*, 2017. 72: 869.
<https://www.ncbi.nlm.nih.gov/pubmed/28757301>
1004. Giesler, R.B., *et al.* Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention. *Cancer*, 2005. 104: 752.
<https://www.ncbi.nlm.nih.gov/pubmed/15986401>
1005. Anderson, C.A., *et al.* Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev*, 2015. 1: CD001843.
<https://www.ncbi.nlm.nih.gov/pubmed/25602133>

1006. Chen, Y.C., *et al.* Surgical treatment for urinary incontinence after prostatectomy: A meta-analysis and systematic review. *PLoS One*, 2017. 12: e0130867.
<https://www.ncbi.nlm.nih.gov/pubmed/28467435>
1007. Pavlovich, C.P., *et al.* Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. *BJU Int*, 2013. 112: 844.
<https://www.ncbi.nlm.nih.gov/pubmed/23937708>
1008. Philippou, Y.A., *et al.* Penile rehabilitation for postprostatectomy erectile dysfunction. *Cochrane Database Syst Rev*, 2018. 10: CD012414.
<https://www.ncbi.nlm.nih.gov/pubmed/30352488>
1009. Hatzimouratidis K, *et al.*, EAU Guidelines on Male Sexual Dysfunction, In: EAU Guidelines, E.G. Office, Editor. 2018.
<https://uroweb.org/guideline/male-sexual-dysfunction/>
1010. Dieperink, K.B., *et al.* The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients. *Br J Cancer*, 2013. 109: 3005.
<https://www.ncbi.nlm.nih.gov/pubmed/24169342>
1011. Galvao, D.A., *et al.* Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. *J Clin Oncol*, 2010. 28: 340.
<https://www.ncbi.nlm.nih.gov/pubmed/19949016>
1012. Bourke, L., *et al.* Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. *Eur Urol*, 2014. 65: 865.
<https://www.ncbi.nlm.nih.gov/pubmed/24119318>
1013. Cella, D., *et al.* Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. *Value Health*, 2009. 12: 124.
<https://www.ncbi.nlm.nih.gov/pubmed/18647260>
1014. Smith, M.R., *et al.* Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. *J Urol*, 2003. 169: 2008.
<https://www.ncbi.nlm.nih.gov/pubmed/12771706>
1015. Michaelson, M.D., *et al.* Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. *J Clin Oncol*, 2007. 25: 1038.
<https://www.ncbi.nlm.nih.gov/pubmed/17369566>
1016. Migliorati, C.A., *et al.* Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. *Lancet Oncol*, 2006. 7: 508.
<https://www.ncbi.nlm.nih.gov/pubmed/16750501>
1017. Wadhwa, V.K., *et al.* Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. *BJU Int*, 2010. 105: 1082.
<https://www.ncbi.nlm.nih.gov/pubmed/19912210>
1018. Smith, M.R., *et al.* Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med*, 2009. 361: 745.
<https://www.ncbi.nlm.nih.gov/pubmed/19671656>

10. CONFLICT OF INTEREST

All members of the EAU – EANM - ESTRO – ESUR – SIOG Prostate Cancer Guidelines working panel have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: <http://www.uroweb.org/guidelines/>.

This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

11. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2.

If a publisher and/or location is required, include:

EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>

References to individual guidelines should be structured in the following way:

Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.

